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Early psychosis is a high-risk period for suicide. Of concern, suicide rates in psychosis 
have increased over recent years. Several risk factors have been established, including being 
male, white, recent loss, previous suicide attempts, depression, illegal drug use and 
agitation/restlessness.  
Although insight has been consistently associated with positive outcomes in psychosis, 
concerns have been voiced regarding the potential link between insight and increased 
suicidality. Thus, this thesis commences with a literature review on this topic, which reported 
mixed results and methodological limitations in previous studies, which were addressed in 
this investigation.  
Real-world data on suicides by patients with schizophrenia from the South London 
and Maudsley NHS Foundation Trust are also presented, which supports further the necessity 
for this work. 
Data from three large cohorts of first-episode psychosis (FEP) patients from the UK 
(n=112-181) and Spain (n=397) were analysed to ascertain the role of multiple insight 
dimensions (illness recognition, symptoms relabelling, awareness of the social consequences 
and awareness of the need for treatment) in risk for suicidal behaviour. Although bivariate 
analyses showed significant relationships between insight levels and risk of suicidal 
behaviour, only previous suicide attempts and depression, both of which were linked with 
insight, survived the multivariate analyses, hence emerging as the main predictors of suicidal 
behaviour. In other words, suicidal history and depression appear to explain the apparent 
association of insight with suicide risk in psychosis. 
Hence, no evidence was found supporting a direct relationship between insight and 
suicidal behaviour in early psychosis despite common assertions to the contrary, which has 
implications on clinical practice and future research. Insight, which is linked with better 
outcomes, does not increase suicidality. Guidelines should therefore prioritise improving 
insight interventions (e.g. talking therapies or antipsychotics) from first presentation with 
psychosis and future studies may examine whether this reduces suicide rates.    
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Chapter 1 - General introduction 
 ‘There is but one truly serious philosophical problem and that is suicide’. 
The Myth of Sisyphus, Camus A. (1942)  
(trans. from French: Le Mythe de Sisyphe by O’Brien, J. (1955) 
 
In ‘The Myth of Sisyphus’, Camus suggests that suicide amounts to a confession that 
life is not worth living (the basis of a common question asked to patients in routine clinical 
practice). In other words, Camus linked suicide with what he called the ‘absurd’, i.e. the 
meaninglessness of life. Can peoples’ lives change to become more meaningful? Is suicide 
preventable? In short, the answer has to be ‘yes’ (WHO, 2016), otherwise, why would anyone 
bother investigating the topic further?    
Although every year almost one million people end their lives across the world - it has 
become one of the three leading causes of death in the most economically productive age 
group (15-44 years) (WHO, 2016) - suicide has received relatively little attention in medical 
research. For example, a simple search on Medline accessed on 15 May 2016 by using five 
‘Medical Subject Headings’, including suicide, yielded the following results, graphically 
shown in figure 1.1. below: 
Figure 1.1. Medline search for the following Medical Subject Headings: 'cancer', 













One potential reason for this disparity is that from a historical perspective, suicide was 
still a criminal offence in many countries until relatively recent times; for instance, suicide was 
only decriminalised in the UK in 1961 (UK Government, 1961).  Indeed, in contemporary 
society suicide is still prosecuted (at least in theory) in up to 23 countries (WHO, 2016). Also, 
the public used to consider suicide a sin, although no religion, including Islam and 
Christianity, specifically condemns suicide (Berrios, 1996). On the other hand, suicide is still 
accepted as a normal behaviour by some minorities such as the Jaina Sect in India and The 
Yurubas in Nigeria (Berrios, 1996). Moreover, ethnic differences in risk of self-harm and 
suicide have been consistently found both in the UK (see Al-Sharifi et al., 2015) and in other 
countries (e.g. McKenzie et al., 2012), which in psychosis appear to be mediated by factors 
such as religion, cultural appraisals of illness and social aspects (Upthegrove et al., 2013). 
Thus, suicide research in psychosis should consider the influence of cultural-related variables 
by cross-comparing findings from samples from different countries and backgrounds, which 
is the approach taken by this investigation, which includes psychosis patients from the UK 
(diverse ethnicities, including ethnic minorities, with different religions) and Spain (Caucasian 
white people, mainly Christian). See chapters 4-8 for further details.   
 
Figure 1.2. Suicide Act 1961 (Taken from UK Government, 1961) 
 
Hence, in my opinion the limited research on suicide to date seems to be related to 
issues around stigma (not only stigma towards mental health in general, but particularly 
towards suicide), including stigma from colleagues within the medical field. In addition, the 
funding support for research in mental health is scant when compared with other disciplines, 




What is the role of psychiatry in suicide prevention?  
Psychological autopsy studies have revealed that about 90% of people who killed 
themselves had a mental disorder (Arsenault-Lapierre et al., 2004), which accounts for up to 
47-74% of the population attributable fraction (Cavanagh et al., 2003), with depression and 
psychotic disorders the most common diagnoses found in suicide completers (Arsenault-
Lapierre et al., 2004). With regard to psychosis, the early stages of the illness have been 
consistently found to be the highest risk period (e.g. Palmer et al., 2005), and I will discuss this 
in more detail throughout this thesis. However, others argue that suicide in schizophrenia 
might be a rational act in some individuals (Hewitt et al., 2010), which was also Bleuler’s view 
quoted below (Bleuler, 1911).   
Thus, this chapter begins with some information on the concept of psychosis, with a 
focus on early psychosis. Then, the next section reviews the definition of suicidal behaviour, 
including suicide attempts and suicide completion, and summarises the epidemiology of 
suicide both in the general population and in psychosis. In keeping with this, chapter 3 
provides new clinical data on suicide in patients with schizophrenia spectrum disorders who 
received secondary mental healthcare in the South London and Maudsley NHS Foundation 
Trust. The third section of this chapter deals with insight from a historical/conceptual 
perspective and also, it presents some of the measures which will be used in this thesis. Then, 
in chapter 2 I formulate the specific research question of this thesis and I explain its clinical 
relevance, including an updated systematic literature review on this topic. In addition, I 
postulate my a priori responses to this question, i.e. the hypotheses which will be tested with 
data from two first-episode psychosis (FEP) samples (presented in chapters 4-7), before 
drawing a reasoned conclusion as discussed in chapter 8.  
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1.1. – Psychosis 
1.1.a. – History 
Clinicians, including those who work in areas other than mental health, often receive 
referrals or reports in which a patient is described as ‘psychotic’ or suffering from ‘psychosis’. 
From this, the clinician immediately becomes aware that the patient suffers from a severe 
mental disorder with a range of symptoms which can be explained, but never understood, as 
Jaspers stated in 1913 (Jaspers, 1913). 
Psychosis (from the Greek, ‘any illness of the mind’) was first coined by the Austrian 
poet and physician Ernst von Feuchterlesben in his 1845 publication ‘The Principles of Medical 
Psychology’ to describe a wide range of mental disturbances characterized by ‘a confusion 
between the self and the world’, i.e. ‘a confusion between the body and the mind’.  
Over the second half of the 19th century, several contributions from French and 
German schools to better understanding psychosis resulted in the categorical classification of 
psychotic disorders developed by Emil Kraepelin (1856-1925) in 1896. Thus, Kraepelin 
clinically observed that his patients could be classified into what he determined were two 
different, mutually exclusive, categories. Thus, those who suffered from three previously 
described nosological entities, namely Démence précoce (Morel, 1809-1873), catatonia 
(Kahlbaum, 1828-1899) and hebephrenia (Hecker, 1843-1909), were reported to have a similar 
deteriorating course of the illness with poor early outcomes. Subsequently, Kraepelin 
combined these three syndromes into a single disease entity which he coined dementia praecox, 
meaning ‘senility of the young’. On the other hand, those patients with the so-called manic-
depressive illness presented with a remitting-relapsing condition which included periods of full 
recovery and a favourable long-term prognosis (Kraepelin, 1896).  
In the first decades of the 20th century, when no effective psychiatric medication was 
available, most therapies for mental disorders were based on emerging ideas from Freud’s 
psychoanalysis. Thus, another German-speaking Swiss psychiatrist, Eugen Bleuler (1857-
1939), who was highly influenced by psychoanalysis via two of his trainees, Adolf Meyer and 
Carl Gustav Jung, attempted to explain the psychotic phenomenology observed on his 
institutionalised patients through the interpretation of their experiences of the self, thus 
coining the term schizophrenia (from Greek, ‘split mind’). Given the severity of their symptoms 
and the lack of effective treatments at that point, Bleuler took a more psychodynamic 
approach in order to alleviate their suffering. Like Kraepelin, Bleuler argued that dementia 
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praecox, or "group of the schizophrenias", was fundamentally a physical disease process 
characterized by exacerbations and remissions. Although Bleuler agreed that no one was ever 
completely "cured" of schizophrenia, he believed that the overall prognosis was not uniformly 
grim. Bleuler listed four primary symptoms of schizophrenia, which were traditionally taught 
to medical students as the four “As”, namely Autism, Ambivalence, loosening of Associations 
and inappropriate Affect. Bleuler’s son, Manfred Bleuler, considered that the main 
contribution made by his father to the problem of schizophrenia(s) was “to favour the study of 
what was going on ‘psychodynamically’ in a schizophrenic patient.’’ (Bleuler, 1983).  
Later in life, Kraepelin himself raised concerns about the limitations of his 
dichotomous classification (Kraepelin, 1920): 
“No experienced psychiatrist will deny that there are an alarmingly large number of cases in 
which it seems impossible, in spite of the most careful observation, to make a firm diagnosis… 
Nevertheless it is becoming increasingly clear that we cannot distinguish satisfactorily between these 
two illnesses and this brings home the suspicion that our formulation of the problem may be incorrect.”  
However, Kraepelin’s chief pupil, Carl Wernicke (1848-1905), mainly focused on 
neurology, particularly on aphasia. Wernicke postulated a ‘theory of disjunction’, that is, an 
interruption of the connections between neural systems to explain psychopathology. This led 
to him receiving criticism from Karl Jaspers (1883-1969) who labelled Wernicke a ‘brain 
mythologist’. At age 28 Jaspers wrote his seminal contribution to psychiatry, General 
Psychopathology (Jaspers, 1913), a comprehensive description of mental symptoms from a 
phenomenological perspective. Unfortunately, Wernicke died prematurely and he did not 
have many students of psychiatry. Only Kleist took up his ideas, which were widened further 
by Karl Leonhard (1904-1988), a pupil of Kleist. Thus, the so-called ‘Wernicke- Kleist 
Leonhard’ School developed a classification of endogenous psychoses originally published in 
1957 (Leonhard, 1979), which included up to five categories (phasic psychoses, cycloid 
psychoses, unsystematic schizophrenias, systematic schizophrenias and childhood onset 
schizophrenias), each of which had a number of different subtypes. Interestingly, findings 
from genetics based on twin studies (Franzek & Beckmann, 1998) appear to provide further 
support for this first classification of psychoses from a dimensional approach. Also, a recent 
study demonstrated the Leonhard’s Classification to have a higher degree of familial 
aggregation than the DSM-IV-TR (APA, 2000) or ICD-10 (WHO, 1993), which may be therefore 




After the Second World Ward and the “euthanasia” era in Germany, from which 
Leonhard himself saved many patients, German psychiatry became discredited and turned 
towards more psychodynamic approaches such as psychoanalysis. In addition, the relative 
isolation of Leonhard during the latter part of his life in East Germany, after the partition of 
Germany in 1961, prevented the Wernicke-Kleist-Leonhard School’s contributions from 
receiving much attention in Western countries. However, the first lines written by Leonhard in 
the seventh edition of his ‘classification of endogenous psychoses’ may still explain the 
relatively low success from decades of neurobiological research on psychoses (Leonhard, 
1979): 
“…Lack of success in clinical etiological research in my opinion is the result of the fact that 
endogenous psychoses have been roughly divided into only two forms. In this way a majority or even a 
multitude of disorders have been lumped together and therefore no uniform aetiology could of course be 
found….”    
Another German psychiatrist, Kurt Schneider (1887-1967), who had been Jaspers’ 
pupil, highlighted the organic origin of all types of psychoses in his 1946 Clinical 
Psychopathology (see Schneider, 1959). In addition, Schneider listed a group of symptoms, 
which were found to be highly specific, but not pathognomonic, of schizophrenia as opposed 
to other psychoses (Peralta & Cuesta, 1999). These were called ‘first-rank’ symptoms (see table 
1.1. below) and as a whole, they concern the inability to identify the boundaries between the 
self and the non-self. The first-rank symptoms have been highly influential on the current 
classifications of mental disorders, such as the International Classification of Diseases (10th 
edition) (ICD-10) and the Diagnostic and Statistical Manual of Mental Disorders (DSM), 5th 
edition, (DSM-5) (APA, 2013). 
 
     Table 1.1. Schneider’s first-rank symptoms 
Hearing thoughts spoken aloud 
Hallucinations: third-person, somatic or in the form of a commentary 
Thought withdrawal, thought insertion or thought broadcasting 
Delusional perception 
Feelings or actions experienced as made or influenced by external agents 
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The value of the term ‘psychosis’ is that it is a more inclusive category than 
‘schizophrenia’, yet it implies serious impairment. More recently, the term ‘schizophrenia 
spectrum disorders’ has been widely accepted due to its broader meaning and less 
stigmatising connotations, which also tends to include those patients with schizoaffective 
disorder. 
 
1.1.b. – Current classification of psychotic disorders 
As detailed above, Kraepelin and Schneider have significantly influenced the current 
international classifications of psychotic disorders in ICD-10 and DSM-5. However, there are 
some minor differences between these two approaches, which are typically used in Europe 
and America, respectively. Thus, while the ICD-10 criteria put more emphasis on the 
Schneiderian first-rank symptoms, the DSM-5 approach is more focused on the duration of 
symptoms and their impact on psychosocial functioning. Main diagnostic categories of DSM-5 
psychotic disorders are listed in table 1.2. below and the specific diagnostic criteria for 
schizophrenia are shown in box 1.1.  
 
Table 1.2. Main diagnostic categories of DSM-5 psychoses (APA, 2013) 
- Schizophrenia 
- Schizoaffective disorder 
- Schizophreniform disorder 
- Delusional disorder 
- Brief psychotic disorder 
- Catatonia 
- Attenuated Psychosis Syndrome and Shared Psychotic Disorder 
- Bipolar I Disorder (with psychotic features) 
- Bipolar II Disorder (with psychotic features) 
- Cyclothymic Disorder (with psychotic features) 
- Major depressive disorder (with psychotic features) 
- Psychotic disorder due to a general medical condition 
- Alcohol-induced psychosis 
- Other substance-induced psychosis 
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Box 1.1 – DSM-5 diagnosis of schizophrenia 
A. Characteristic symptoms: Two (or more) of the following, each present for a significant 
portion of time during a 1-month period (or less if successfully treated): 
--delusions 
--hallucinations 
--disorganized speech (e.g. frequent derailment or incoherence)  
--grossly disorganized or catatonic behaviour  
--negative symptoms, i.e., affective flattening, alogia, or avolition  
Note: At least two of the five symptoms must be present for at least one month. One of the two 
symptoms must be delusions, hallucinations, or disorganized speech.  
B. Social/occupational dysfunction: The level of functioning, including areas such as work, 
interpersonal relations, or self-care, is markedly below the level achieved prior to the onset (or 
when the onset is in childhood or adolescence, failure to achieve expected level of 
interpersonal, academic, or occupational achievement). 
C. Duration: Continuous signs of the disturbance persist for at least 6 months. This 6-month 
period must include at least 1 month of symptoms (or less if successfully treated) that meet 
Criterion A (i.e. active-phase symptoms) and may include periods of prodromal or residual 
symptoms. During these prodromal or residual periods, the signs of the disturbance may be 
manifested by only negative symptoms or two or more symptoms listed in Criterion A present 
in an attenuated form (e.g. odd beliefs, unusual perceptual experiences). 
D. Schizoaffective and Mood Disorder exclusion: Schizoaffective Disorder and Mood Disorder 
With Psychotic Features have been ruled out because either (1) no Major Depressive Episode, 
Manic Episode, or Mixed Episode have occurred concurrently with the active-phase 
symptoms; or (2) if mood episodes have occurred during active-phase symptoms, their total 
duration has been brief relative to the duration of the active and residual periods. 
E. Substance/general medical condition exclusion: The disturbance is not due to the direct 
physiological effects of a substance (e.g. a drug of abuse, a medication) or a general medical 
condition. 
F. Relationship to an Autism Spectrum Disorder or Communication Disorder: If there is a history of 
Autistic Disorder or another Communication Disorder, the additional diagnosis of 
Schizophrenia is made only if prominent delusions or hallucinations are also present for at 
least a month (or less if successfully treated). 
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1.1.c. – Dimensions vs. Categories. What are the symptoms of psychosis? 
In keeping with the Leonhard’s model of psychoses proposed in 1957 (see Leonhard, 
1979), recent research has suggested that the phenomenology of psychotic disorders, including 
first presentation with psychosis (Peralta et al., 2013), may be better conceptualized by several 
symptom dimensions (van Os, 1997; Peralta & Cuesta, 2001; Demjaha et al., 2009), namely 
positive (e.g. delusions and hallucinations), negative (e.g. apathy, blunted affect, social 
isolation), disorganization (e.g. loosening of association, derailment, flight of ideas), mania 
(e.g. elation, euphoria, overfamiliarity, disinhibition) and depression (e.g. low mood, 
anhedonia) (Peralta & Cuesta, 2001; Demjaha et al., 2009), and catatonia, agitation and lack of 
insight (Peralta & Cuesta, 2001).  
Of particular interest to this investigation is the concept of depression in psychosis. 
Although Kraepelin (1896) had considered schizophrenia to be a ‘non-affective’ psychosis, 
recent research suggests otherwise (e.g. Peralta et al., 2013). Thus, up to three pathways have 
been proposed to link depression with schizophrenia: i) depression as intrinsic to psychosis; ii) 
depression as a psychological reaction to the diagnosis (which links with my main research 
question, as explained below); and iii) depression in psychosis in relation to childhood 
trauma, i.e. as confounder since childhood trauma is associated with psychosis (Trotta et al., 
2015) and depression (for a review, see Bebbington et al., 2005; Upthegrove et al., 2016).  
Also, despite findings from neurobiological research supporting a dimensional model 
of psychoses (Craddock & Owen, 2010), the official international classifications ICD-10 and 
DMS-5 are still based on the ‘first’ Kraepelinian dichotomy. Thus, schizophrenia and affective 
psychoses are still mutually exclusive diagnoses (see box 1.1. above).  
 
1.1.d. – Psychosis and schizophrenia 
Although from a historical point of view, schizophrenia represents the paradigm of 
psychotic disorders, caution should be taken when using these two terms interchangeably. 
Thus, it should be noted that schizophrenia does not necessarily equate to psychosis and vice 
versa.  However, research and treatment focused on a broader concept of psychosis has 
several advantages. Specifically, recent research findings from genetics suggest that psychotic 
disorders are overlapping, rather than separate entities (Owen et al., 2011). Also, diagnosis can 
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change within the psychosis spectrum over time, although schizophrenia is usually found to 
have the highest stability (e.g. Bromet et al., 2005). 
In order to briefly discuss the aetiology of psychotic disorders as part of this chapter, 
most of the research findings presented below come from studies on schizophrenia. Indeed, 
research on psychosis and schizophrenia is often treated as interchangeable despite being 
based on different concepts. Moreover, this lack of distinction in many studies may explain, to 
some degree, the conflicting results when investigating what causes ‘psychosis’. 
 
1.1.e. – Aetiology 
What causes psychosis? A biopsychosocial disorder 
Despite a very significant number of research projects looking at the neurobiology of 
psychosis, particularly schizophrenia, over the last few decades, no single factor has been 
directly linked with the origin of the condition. Current evidence suggests that the onset of 
psychosis appears to be the result of a combination of biological, psychological and social 
factors and complex interactions between them, which I will briefly discuss in the subsections 
below. 
 
1.1.e.1. – Genetics 
The greatest single risk factor for psychosis, particularly schizophrenia, is a having a 
close relative affected by the condition. Indeed, family, twin and adoption studies found that 
the prevalence of schizophrenia rises according to the degree of the affected relative up to over 
40% in identical twins (Tsuang et al., 1991; Cardno et al., 1999). While this has contributed to a 
significant interest in identifying the so-called ‘schizophrenia gene’, it also suggests that other 
non-heritable external factors may be related to the aetiology of the disorder. 
Four major findings have emerged from genetics research in psychosis. First, given 
that the identical twin of a schizophrenic has over 50% chance of escaping the illness, genetics 
does not seem to the be the whole story (Gottesman & Shields, 1982). Second, even though no 
one questions the genetic component of schizophrenia, no single ‘schizophrenia gene’ has 
been found. Rather, multiple individually rare mutations, each of which has a small effect size, 
altering genes in neurodevelopmental pathways appear to contribute to schizophrenia (Walsh 
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et al., 2008). Thus, up to 108 defined loci have been linked with schizophrenia (Ripke et al., 
2014), which will probably increase further in the years to come. Third, Genome-Wide 
Association studies have confirmed the lack of specificity of genetic risk for schizophrenia 
with regard to bipolar affective disorder (Craddock & Owen, 2010). Finally, copy number 
variants, which are submicroscopic deletions and duplications of segments of 
deoxyribonucleic acid that are important sources of individual genomic variation through 
complex regulation-expression mechanisms, were found to be associated with a range of 
neurodevelopmental disorders such as autism spectrum disorders, intellectual disability and 
attention-deficit hyperactivity disorder (ADHD) (Owen et al., 2011) as well as psychosis, from 
which two conclusions can be drawn. First, this finding provides further support for the 
neurodevelopmental hypothesis of schizophrenia postulated by Weinberger (Weinberger, 
1986), Murray and Lewis (Murray & Lewis, 1987) almost three decades ago. Second, consistent 
with Leonhard’s classification of psychoses, it seems that we should view the functional 
psychoses as members of a group of related and overlapping syndromes that result in part 
from a combination of genetic and environmental effects on brain development (Owen et al., 
2011).  
 
1.1.e.2. – Neurochemistry 
After the serendipitous discovery of the antipsychotic properties of chlorpromazine by 
Delay & Deniker in 1952 and by linking the observations that dopamine agonists could induce 
psychotic symptoms and that antipsychotics tended to cause Parkinson’s Disease-like side-
effects, Carlsson and Lindqvist formulated the so-called dopamine hypothesis of schizophrenia 
(Carlsson & Lindqvist, 1963), for which Carlsson was awarded the Nobel Prize for Medicine 
and Physiology in 2000.  
Briefly, the dopamine hypothesis of schizophrenia implies that the illness arises from 
hyperactivity of the mesolimbic dopaminergic system and that the blockade of the dopamine 
D2 receptor is most strongly associated with antipsychotic activity (Carlsson & Lindqvist, 
1963). The role of dopamine in psychosis has also been demonstrated in at–high-risk-of-
psychosis patients (Howes et al., 2011). However, the mechanism of action of clozapine, an 
atypical antipsychotic indicated for the management of treatment-resistant schizophrenia 
despite relatively weak anti-dopamine activity, suggests that other neurotransmitter systems 
such as serotonin may be involved in the pathophysiology of psychosis (Meltzer, 1989). Over 
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the last two decades additional neurotransmitters such as glutamate, GABA and acetylcholine 
have attracted attention from researchers as promising new pharmacological targets (Girgis & 
Abi-Dargham, 2012). 
 
1.1.e.3. - Brain abnormalities 
In 1976 a study using computed tomography revealed that the cerebral ventricles of 
patients with schizophrenia were significantly enlarged (Johnstone et al., 1976). Since these 
abnormalities were present in early stages of the illness, they were thought to be the result of 
early events of aetiological importance, i.e. neurodevelopmental problems (Murray & Lewis, 
1987). Further neuroimaging research, by using MRI in patients with first-episode 
schizophrenia (Leung et al., 2011), confirmed these findings, which were also replicated by 
recent neuroimaging studies with adolescents presenting with very-early-onset psychosis 
(Pina-Camacho et al., 2016) and in individuals at-high-risk of psychosis (McKechanie et al., 
2016). However, in contrast to the deteriorating conceptualisation of schizophrenia based on 
the first clinical observations made by Kraepelin, the neuroimaging changes observed in the 
schizophrenic brain do not appear to progress over the course of the illness, consistent with 
the better outcomes achieved by today’s patients with psychosis (e.g. Morgan et al., 2014), 
which has led to speculation about ‘the myth of schizophrenia as a progressive brain disease’ (see 
Zipursky et al., 2013).   
   
1.1.e.4. – Early environmental factors - pregnancy and birth complications 
The anatomical brain abnormalities and the neurochemical dysfunction found in 
patients with schizophrenia which has been described above appear to be the result of very 
early damage to the brain (Murray & Lewis, 1987). In keeping with this, birth weight, 
premature birth and perinatal hypoxia are associated with an increased risk of schizophrenia 
in adulthood (Cannon et al., 2002). More recent findings from neurobiology appear to provide 
further support for the neurodevelopmental theory of schizophrenia (Fatemi & Folsom, 2009). 
Moreover, paternal age, obstetric complications and cannabis use were reported to be the 
strongest non-genetic contributing factors to schizophrenia (Matheson et al., 2011).   
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1.1.e.5. – Late environmental factors - drugs use, social factors and life events  
Almost half a century ago, amphetamines were reported to induce a psychotic state 
with some, but not all, schizophrenia symptoms (Connell, 1958). However, these patients 
usually achieve full remission within a relatively short period of time, even without treatment. 
More recently, cannabis has been strongly associated with an earlier onset of schizophrenia 
and poorer long-term outcomes (see Marconi et al., 2016). Specifically, an analysis with data 
from the Genetics and Psychosis Study, which was also used in this thesis (Chapter 4 and 
Chapter 6), revealed that smoking the high-potency subtype of cannabis known as skunk, 
which only has Delta-9-Tetrahydrocannabinol without cannabidiol (Potter et al., 2008), 
particularly at early ages, significantly increases the risk of early onset first-episode psychosis 
(Di Forti et al., 2009), which may explain up to 25% of psychosis cases at a population level (Di 
Forti et al., 2015). 
In addition, the results from the Aetiology and Ethnicity in Schizophrenia and Other 
Psychoses (AESOP) study, which revealed that the risk of psychosis was associated with 
ethnicity, being particularly increased in Black African-Caribbean people (Fearon et al., 2006), 
and with urbanicity (Kirkbride et al., 2008) led to proposal of a ‘sociodevelopmental’ model of 
psychosis (Morgan et al., 2010a). Furthermore, the negative impact of childhood adversity on 
outcomes of patients with psychosis has been the subject of a recent meta-analysis (Trotta et 
al., 2015).     
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1.1.f. – Treatment 
Since the serendipitous discovery of chlorpromazine over half a century ago (Delay & 
Deniker, 1952), almost all antipsychotic drugs have dopamine D2 receptor (DRD2) blocking 
effects. Although the first-generation antipsychotics (FGA) successfully managed psychosis, 
particularly positive symptoms, the strong dopamine blockade was associated with significant 
side-effects such as extrapyramidal symptoms and hyperprolactinemia. The so-called second-
generation antipsychotics (SGA), also known as atypical, of which clozapine is the most potent, 
binds and affects not only DRD2 but also other neurotransmitter receptors, such as serotonin 
receptors 2 (5HT-2R) (Meltzer, 1989), which is therefore a challenge to the dopamine 
hypothesis of schizophrenia (Carlsson & Lindqvist, 1963).  
Although the SGA can be effective in the treatment of psychotic symptoms with fewer 
movement disorders, they carry a higher risk of cardio-metabolic side-effects than FGA 
(Lieberman et al., 2005). Choice of antipsychotic should be individualised and consider the 
patient’s and carers’ views (NICE, 2015). Clozapine is effective in around 60% of patients who 
were previously treatment refractory (Meltzer, 2013). Clozapine was also demonstrated to 
reduce suicide risk in patients with schizophrenia and schizoaffective disorders (Meltzer et al., 
2003; Bourgeois et al., 2004). However, clinicians still hesitate about its initiation (Patel, 2012), 
which tends to occur ‘too late’ (Howes et al., 2012) because of concerns about neutropenia and 
practical monitoring issues. 
Psychological treatments have been endorsed by the UK National Institute for Health 
and Care Excellence (NICE) guidelines (NICE, 2015), which recommend that all patients with 
schizophrenia should be offered cognitive behavioural therapy (CBT) and family intervention 
in addition to antipsychotic drugs (NICE, 2015). 
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1.1.g. – Outcome 
The term psychosis, particularly schizophrenia, is inevitably associated with a 
deteriorating disorder and poor outcome, which originates from the work of Kraepelin, who 
investigated the course of the illness in severely psychotic patients admitted to a long-term 
institution in Germany during the 19th century, that is, when pharmacological treatments were 
unavailable.  
However, some clinicians today still hold this view, which may be the result of a 
variation of the well-known hospital (selection) bias. Thus, those patients remaining in care 
are those with the most severe forms of the illness, which the clinician will consider the 
natural outcome of the syndrome. These patients tend to receive a diagnosis of schizophrenia 
based on poor outcome, which is consistent with the 6-month criterion for schizophrenia in 
the DSM-5 (DSM-5) detailed above (Box 1.1.). On the other hand, such a diagnosis tends to be 
avoided in those subjects who get discharged from services (i.e., unlike a patient diagnosed 
with ‘FEP’, someone with ‘schizophrenia’ is less likely to get discharged from secondary 
mental healthcare). Hence, there is a tautological issue here with regard to the association of 
schizophrenia with poor outcome (for further details, see van Os et al., 2012).  
An alternative approach to better understand the outcome of ‘psychosis’ is to follow-
up all the incident cases who present with a first-episode of psychosis over a prolonged period 
of time (5-10 years) within a geographically defined catchment area. This approach was taken 
by the AESOP-10 study, which reported better long-term outcomes for FEP patients in 
comparison with the previous literature (Morgan et al., 2014), although the study findings 
may not generalise to other settings and countries.  
39 
 
1.1.h. – First episode of psychosis 
First episode psychosis (FEP) is a clinical term used to indicate that an individual has 
presented with psychosis for the first time, i.e. there is no evidence of previous psychotic 
symptoms or treatments for psychosis. Given the above broad definition of ‘psychosis’, one 
can imagine that the concept of FEP encompasses a wide range of patients with varying 
presentations and diagnoses.  
Over the last few decades there has been a growing interest in using FEP samples for 
research on psychosis. Regardless of the specific research subject (neurobiological aetiology, 
cognition, or outcomes, including suicide), using such a sample minimises biases associated 
with chronicity, such as the duration of the illness, the effects of hospitalisation or exposure to 
medication.  
The definition of ‘FEP’ I used in this thesis is the experience of one or more psychotic 
symptoms for at least 7 days, which does not resolve by treatment within that time. These 
criteria are based on the WHO 10-country study (Jablensky et al., 1992) and have been 
previously used by our group (e.g. Kirkbride et al., 2006). 
 
1.2. – Suicidal behaviour 
1.2.a. – Concept and terms 
Suicidal behaviour, which can be used interchangeably with the term ‘suicidal act’, 
encompasses both ‘suicide attempts’ and ‘suicides’, i.e. suicide completions. Most research 
groups use the standard suicidology nomenclature provided by O’Carroll and colleagues in 
their 1996 consensus paper (O’Carroll et al., 1996).  
Thus, ‘suicide attempt’ is defined as ‘a potentially self-injurious behaviour with a 
nonfatal outcome, for which there is evidence (either explicit or implicit) that the person 
intended to kill him/herself’. A suicide attempt may or may not result in injuries. ‘Suicide’ 
(completion), just suicide thereafter, was defined as ‘Death from injury, poisoning, or 
suffocation where there is evidence (either explicit or implicit) that the injury was self-inflicted 
and that the decedent intended to kill him/herself’ (O’Carroll et al., 1996).    
In other words, ‘suicidal behaviour’ is defined in terms of just two core elements: self-
infliction and intent. The outcome, i.e. fatal (or death) and non-fatal, distinguishes suicide 
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from suicide attempts, respectively. For the purposes of this thesis, I will use the broader 
concept of suicidal behaviour. However, while in chapter 3 I will report the findings from a 
sample of patients with schizophrenia spectrum disorder who took their lives, i.e. ‘suicides’, in 
chapters 4-7 I will investigate the associations of insight (and other baseline variables) with 
‘suicidal behaviour’, i.e. including suicide attempts and suicides, in two cohorts of patients 
with FEP.  
In the UK, in order to certify the cause of death as suicide a coroner is required to 
provide evidence of suicide intent ‘beyond reasonable doubt’. In particular, the coroner must 
feel satisfied i) that the injury was self-inflicted (i.e. there was no evidence of any third party 
involvement) and ii) that the person had intent to die (either explicitly, i.e. a suicide note, or 
implicitly, for instance, the evidence provided by the last treating psychiatrist). As a result, a 
number of suicides are recorded as ‘open verdicts’ or ‘undetermined cause of death’ (Linsley 
et al., 2001). Subsequently, most suicide research groups in the UK include both categories of 
death when investigating suicide, which is widely accepted.  
Some groups, however, support the notion of a ‘suicidal spectrum’ ranging from 
suicidal ideation to suicide completion, with decreasing prevalence and increasing lethality 
(Bebbington et al., 2010). Thus, although a previous suicide attempt is the strongest predictor 
of further suicide attempts (Sokero et al., 2005) and completed suicide (Coryell & Young, 
2005), only about 10% of suicide attempters go on to take their lives (Runeson et al., 2010). 
Moreover, between 60% and 90% of suicide completers do not have suicidal antecedents 
(Isometsa & Lonnqvist, 1998). Hence, there are grounds to consider that suicide attempters 
and completers are different, albeit related, populations, as recently shown by Giner et al., 
(2013), which represents a major challenge for suicide research as explained below. However, 
no such differences between suicide attempters and completers were found in patients with 
psychosis (Innamorati et al., 2008; Giner et al., 2013). In particular, both studies directly 
compared suicide attempters with suicide completers in order to examine a wide range of 
variables which could potentially distinguish both groups, i.e. suicide attempters from 
completers. Interestingly, the prevalence of schizophrenia and related disorders did not differ 
across groups, which suggests that in patients with psychosis there is no such distinction 
between suicide attempters and completers. While this may be questionable, particularly in 
other non-psychotic psychiatric and non-psychiatric populations (de Leon et al.., 2015), it 
provides support for the methodology used in this thesis to investigate the role of insight in 
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suicidal behaviour, including suicide attempts and suicides, in patients with FEP detailed in 
chapters 4, 5, 6 and 7.    
On the other hand, as alluded to above, worldwide suicide research leaders have 
recently voiced concerns about the limitation of generalising findings from suicide attempters 
to suicide completers, who should be considered as the ‘outliers’ (from a statistical point of 
view) of ‘suicidal groups’ in studies on suicide. Indeed, this may partially explain the widely 
recognised inability to predict risk of suicide both in clinical practice and in research (de Leon 
et al., 2015).   
 
1.2.b. – Suicide in the general population: epidemiology, methods and risk factors 
Every year almost one million people die from suicide around the world. In 1998, 
suicide constituted 1.8% of the total disease burden; this is estimated to rise to 2.4% by 2020. 
Specifically, 804,000 suicides were reported across the world in 2012 (WHO, 2016), which 
indicates an annual global age-standardized suicide rate of 11.4 per 100,000 inhabitants with 
significant differences between genders as follows: 15.0 for males and 8.0 for females (WHO, 
2016).  
In the UK, there were 106,629 suicides in the general population over 1996-2013, an 
average of 4,477 per year, i.e. 11.9/100,000/year. However, only between one-quarter and one-
third of these individuals had been in contact with mental health services during the 12 
months preceding suicide (NCISH, 2015). 
 Of note, suicide has become especially concerning among young people, representing 
one of the three leading causes of death in the most economically productive age group (15-44 
years) and the second leading cause of death in 15-19 year olds (WHO, 2016), which is also the 
age-group at highest risk of psychosis (e.g. Palmer et al., 2005; Dutta et al., 2010). 
Suicide is a public health problem in all regions of the world. However, it should be 
noted that 75% of suicides occur in low- and middle-income countries (WHO, 2016) where 
investment in research is limited (Lopez-Castroman et al., 2015a). Furthermore, in up to 23 
low-income countries there are no data available on suicide at all (WHO, 2016). 
Although the World Health Organization (WHO) Mental Health Action Plan 2013-2020 
set up a global target of reducing the suicide rate by 10% by 2020, which is in line with a 
previously formulated plan from the UK Department of Health (DoH, 1999), to date only 28 
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countries have reported having a national suicide prevention strategy (WHO, 2016). 
Moreover, suicide prevention strategies have yielded mixed results so far (Hawton and van 
Heeringen, 2009) and suicide rates in patients under secondary mental healthcare in the UK 
have remained unchanged in the UK for the past five years (NCISH, 2015).  
Common methods of suicide include hanging, which is the most common in the UK 
(NCISH, 2015), self-poisoning and jumping from a height, which vary across country and 
gender depending on the availability (Hawton & van Heeringen, 2009). For instance, firearms 
are ubiquitous in the USA and the high level of firearm ownership has been directly 
associated with an increased risk of firearm-related mortality (Bangalore & Messerli, 2013), 
including suicide (Kposowa et al., 2016). In keeping with this, reducing access to lethal 
methods was linked with decreased suicide rates as demonstrated by the coal-gas story in the 
UK in the 60s, i.e. the reduced suicide rates in the UK following the decrease in the proportion 
of CO in the domestic gas in the 60s, which used to be a common suicide method (Kreitman, 
1976), which was also replicated later in the UK (e.g. Bennewith et al., 2007) and in other 
countries (e.g. Gunnell et al., 2007). 
With regard to risk factors for suicide in the general population, genetic loading, 
personality characteristics (impulsivity, aggression), restricted foetal growth and perinatal 
circumstances, early traumatic life events, neurobiological disturbances, psychiatric and 
physical disorders, psychosocial crisis, availability of methods and exposure to models of 
suicide (e.g. Mann et al., 1999) have been linked with suicide (Hawton & van Heeringen, 
2009). By far the strongest risk factor for suicide is a previous suicide attempt (WHO, 2016).  
From a more historical perspective, suicide can be also conceptualized as a social 
phenomenon (Durkheim, 1897), which is supported by recent research showing an association 
between suicide and migration, ethnicity and social disadvantage (McKenzie et al., 2012). In 
keeping with Durkheim’s theories, over the last century there has been an increased suicide 
rate in times of economic recession, including the current recession which commenced in 2007, 
as demonstrated by a recent systematic review, which I co-authored (Oyesanya et al., 2015).  
From a psychodynamic point of view, the main contribution to understanding suicide 
at an individual level was made by Karl Menninger (1938). Briefly, according to 
psychoanalysis, suicide is the consequence of a misdirection of the instinct for survival, a 




In 1999, Mann and colleagues proposed a stress-diathesis suicide model (Mann et al., 
1999), which while subject to criticism (de Leon et al., 2015), is still widely accepted. 
Specifically, this model suggests that suicidal behaviour is the result of the effect of a stressor, 
including psychiatric disorders and psychosocial crises, on people with the underlying 
diathesis, i.e. hopelessness and impulsivity. Findings from neurobiological research appear to 
provide some support for this model, particularly regarding the role of serotonergic and 
noradrenergic systems and the ventromedial prefrontal cortex in suicide (Mann, 2003).   
 
1.2.c. – Suicide in psychosis: epidemiology, methods and risk factors 
Interestingly, in the last paragraph of his 1911 seminal work ‘Dementia Praecox or the 
Group of schizophrenias’ Bleuler made a first comment on the very violent suicidal acts observed 
in patients with schizophrenia(s), who were chronically symptomatic due to the lack of 
effective treatments at that time: 
“The most serious of all schizophrenia symptoms is the suicidal drive.” (Bleuler, 1911). Of 
relevance to the following chapters of this thesis, such comment continues as follows: 
“I am even taking this opportunity to state clearly that our present-day social system demands 
great, and entirely inappropriate cruelty from the psychiatrist in this respect. People are being forced to 
continue to live a life that has become unbearable for them for valid reasons; this alone is bad enough. 
However, it is even worse, when life is made increasingly intolerable for these patients by using every 
means to subject them to constant humiliating surveillance. Most of our worst restraining measures 
would be unnecessary, if we were not duty-bound to preserve the patient’s lives which, for them as well 
for doctors, are only of negative value. If all this would, at least, serve some purpose! However, like 
Savage, I am convinced, that in schizophrenia is this very surveillance which awakes, increases and 
maintains the suicidal drive. Only in exceptional cases would any of our patients commit suicide, if 
were permitted to do as they wished. And even if a few more killed themselves – does this reason justify 
the fact that we torture hundreds of patients and aggravate their disease? At the present time, we 
psychiatrists are burdened with the tragic responsibility to do our utmost to bring about a change in 
these views in the near future” (Bleuler, 1911).   
There is, indeed, a relationship between Bleuler’s conceptualization of schizophrenic 
patients’ lives, which according to him were not worth living any longer, and Camus’ views of 
suicide (see the first paragraph of the chapter). It should be noted, however, that Bleuler’s 
patients were pharmacologically untreated and therefore, symptomatically very unwell.  
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Indeed, schizophrenia and related disorders have been associated with higher 
mortality and shorter life expectancy than the general population (Brown, 1997), which also 
seems to have widened over the last few decades (Saha et al., 2007). Suicide represents a major 
cause of premature death among this group of patients (Brown, 1997; Saha et al., 2007; Dutta et 
al., 2012), with a current estimated ‘lifetime risk’ of 2-5% (Palmer et al., 2005; Dutta et al., 
2010), which, while lower than the previously quoted estimate of 10% (Miles, 1977; Caldwell & 
Gottesman, 1999), remains unacceptably high. Also, following a FEP, risk of suicidal 
behaviour has been estimated to be up to 3% for suicide completion (SC) and 18% for suicide 
attempts (SA) over a 5-year follow-up period (Clarke et al., 2006).  
In the light of the currently estimated lifetime suicide risk of 2-5% (Palmer et al., 2005; 
Dutta et al., 2010) in schizophrenia spectrum disorders in comparison to the classically quoted 
“10%” (Miles, 1977; Caldwell & Gottesman, 1999), one may conclude that the ‘lifetime risk’ of 
suicide in schizophrenia has decreased over the past few decades. However, the difference in 
these figures is because proportionate mortality (PM) is quoted, which is the percentage of the 
dead who died by suicide (10%) instead of case fatality (CF), which is the percentage of the 
original sample who died by suicide, i.e. 2-5% % (Palmer et al., 2005; Dutta et al., 2010). Since 
most suicides occur in early stages of the psychotic illness and all the subjects will die at some 
point (the later they die, the more likely they will do so from non-suicide causes), PM 
overestimates the real lifetime suicide risk. Similarly, CF may underestimate lifetime suicide 
risk since some suicides occur even two decades after first presentation with psychosis (Dutta 
et al., 2010). Palmer and colleagues conducted a meta-analysis of 61 studies which found CF to 
more accurately estimate the real lifetime risk of suicide in schizophrenia, which was reported 
to be 5.6% in schizophrenia (Palmer et al., 2005).  
In the UK between 2003-2013, 3,066 patients (i.e. those in contact with psychiatric, drug 
and alcohol, child and adolescent or learning disabilities services within 12 months of their 
death) with a primary diagnosis of schizophrenia and related disorders died from suicide, i.e. 
approximately 17% of patient suicides (NCISH, 2015), which is in line with a previous meta-
analysis of psychological autopsy studies (Arsenault-Lapierre et al., 2004). Of concern, in the 
UK there has been a steady rise in the number of suicides by patients with schizophrenia since 




Figure 1.3. Number of suicides by patients with schizophrenia in England over 
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The epidemiological evidence that suicidal behaviour is a major complication of 
schizophrenia spectrum disorders provides an impetus for the development of programmes 
for suicide prevention in this group of patients, already a core focus of mental health policies 
in the United Kingdom (DoH, 1999) and a priority within the World Health Organization 
Mental Health Action Plan 2013-2020 (WHO, 2013). 
With regard to suicide method, patients with schizophrenia have been reported to 
frequently use violent / physical methods, particularly jumping from a height or in front of a 
train (Dutta et al., 2010; Nielssen et al., 2010; Lopez-Morinigo et al., 2014b; Lopez-Morinigo et 
al., 2016), which was also replicated in samples of suicide attempters (e.g. Baca-Garcia et al., 
2005b). This has implications for suicide prevention as restricting access to methods has been 
demonstrated to reduce suicide rates at a population level (Kreitman, 1976; Bennewith et al., 
2007; Hawton & van Heeringen, 2009; WHO, 2016). The commonly used violent methods by 
patients with schizophrenia who attempt to take their lives irrespective of outcome (Baca-
Garcia et al., 2005) and the lack of sociodemographic and clinical differences between suicide 
attempters and completers with schizophrenia and psychotic disorders (Innamorati et al., 
2008; Giner et al., 2013) allowed me to analyse both groups together as detailed in the 
methodology sections of chapters 4, 5, 6 and 7 where further details in this respect are 
provided.   
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A meta-analysis carried out by Hawton and colleagues (2005) showed statistical 
significance for the following risk factors of suicide in schizophrenia: being male, white, living 
alone, recent loss, hopelessness, agitation/restlessness, low self-esteem, fear of mental 
disintegration, poor compliance, previous suicide attempt and suicidal ideation, depression, 
drug misuse, presence of impulsivity and a family history of depression. Reduced risk was 
associated with hallucinations in this meta-analysis (Hawton et al., 2005). Interestingly, no 
statistically significant association was found between insight and suicide which is discussed 
thoroughly in chapter 2. In addition, the number of previous admissions (Popovic et al., 2014), 
self-devaluation and insomnia (Pompili et al., 2011) were linked with suicide risk in psychosis. 
Interestingly, prior suicidal ideation has been found to be relatively uncommonly reported in 
patients with psychosis who later take their own lives (Bakst et al., 2009), which represents a 
real challenge in the clinical setting.  
Suicide in schizophrenia and psychotic disorders usually occurs in the early stages of 
the disorder (e.g. Dutta et al., 2010, Lopez-Morinigo et al., 2014b; confirmed by a meta-analysis 
(Palmer et al., 2005)). The loss of lives in this young population and the number of years of life 
lost are a clear impetus for this thesis. 
In keeping with this, suicide risk factors have been investigated in FEP samples, and 
have been the subject of two systematic reviews (Pompili et al., 2011; Challis et al., 2013; 
Nordentoft et al., 2015) and a meta-analysis (Challis et al., 2013). This has revealed that a 
history of self-harm, is associated with a fourfold increased risk, while suicidal ideation, 
greater insight, alcohol and substances misuse,  younger age at onset and at first treatment, 
depressed mood and the duration of untreated psychosis all increased suicide risk to a lesser 
extent after first contact with mental health services.  
Of note, although greater insight was associated with an increased risk of self-harm, in 
the 2013 Challis et al. meta-analysis of FEP studies (Challis et al., 2013), the effect size was 
rather small (OR=1.64, 95% CI 1.23-2.56), which was consistent with the seminal Hawton et al. 
meta-analysis of schizophrenia patients conducted in 2005 (Hawton et al., 2005) reporting a 
non-significant association (OR=2.04, 95% CI 0.54-7.74). In other words, while the above 
results suggest that insight may increase suicide risk in psychosis, it seems that if such an 
association existed, it would appear to be mediated by other variables.  
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1.3. – Insight 
1.3.a. – History  
To a large extent, the history of insight mirrors the history of psychiatry, i.e. the history 
of insanity, relabelled as psychosis by Ernst von Feuchterlesben in 1845 (see section 1.1.a. for 
further details).  
Until the early nineteenth century the concept of insanity, as proposed by Hobbes and 
Locke, was based on the presence of delusions, which were ‘insightless’ by definition (see 
Berrios, 1996). Accordingly, physicians did not pay much attention to the, at that time, non-
existent concept of insight. However, it was lawyers, who were interested in challenging ‘total’ 
insanity, who raised the issue of ‘awareness of illness’; thus, resulting in the new concept of 
‘partial’ insanity which at that time had two meanings: 
 Intermittent: periods of madness alternated with lucid intervals. Under the current 
UK law, particularly in accordance with the Mental Capacity Act (MCA, 2005), this 
intermittent partial insanity would be, to some degree, equivalent to the current 
medico-legal concept of capacity as ‘time’-dependent. 
 Incomplete: madness affecting one region of the psyche, i.e. monomanias, which were 
defined further by the French School (Esquirol, Pinel, Falret, Baillarger) in terms of 
Faculty Psychology. Of relevance to the focus in my thesis, the concept of insight 
appeared to be first described at the same time as the definition of an ‘emotional’ 
insanity (which would be known as ‘depression’ in today’s psychiatry). As detailed 
below, insight has been consistently associated with depression: the greater the 
insight, the lower the mood (e.g. Mintz et al., 2003). Whether insight can also lead to 
suicidal behaviour in patients with psychosis is a central question of this thesis.  
The concept of a ‘partial’ madness challenged the previously unquestioned 
‘insightlessness’, which allowed for the existence of an insanity which, to paraphrase 
Baillarger, ‘was aware of itself’ (Berrios, 1996). 
In addition, this ongoing debate among the alienists in the second half of the 
nineteenth century incorporated new concepts into psychiatry, such as consciousness 
(awareness), introspection, self and subjectivity. Given that the psychological concept of 
consciousness was mainly understood as a form of perception, not surprisingly the term 
‘insight’ (i.e. an inner eye) was taken to refer to the above complex concepts. According to 
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Berrios, the first ever clinical usage of the term ‘insightlessness’ dates back to 1893 by Krafft-
Ebing: ‘in chronic insanity, when delusions have become organized and defect has ensued, the 
patient is absolutely insightless to his disease’ (Berrios, 1996). 
In spite of the apparent link between lack of insight and psychosis, neither Kraepelin 
nor Bleuler paid much attention to the concept of insight, which was revived thanks to the 
seminal contributions made by Jaspers (1913), Lewis (1934) and Conrad (1958). Thus, Jaspers, 
who had suffered from a chronic pulmonary disease since his childhood, linked ‘insight’ to the 
patient’s self and the knowledge of self-existence with a focus on the attitude, i.e. what is 
implicit (for instance, attending the relevant appointments) rather than what is explicit (‘I have 
schizophrenia’). From the Maudsley Hospital in London, Lewis (1934) defined insight as a 
‘correct attitude to a morbid change in one self’’ (Lewis, 1934). From a more phenomenological 
perspective, Conrad (1958) described the onset and progression of psychotic symptoms in 
patients with schizophrenia in relation to ‘insight’ impairment, although he did not use the 
term insight as such.   
Finally, since the publication of a seminal paper by David in 1990 (David, 1990) there 
has been a growing interest in ‘insight’, mainly in psychosis but also in other psychiatric 
conditions, including the publication of two textbooks (Amador & David, 1998; Markova, 




1.3.b. – Definition  
The term insight only exists in English and it does not have translation into Latin 
languages. The Oxford English Dictionary provides up to three definitions of insight, the third 
of which applies to ‘psychology’:  
i) Internal sight, mental vision or perception, discernment; in early use 
sometimes, Understanding, intelligence, wisdom. 
ii) The fact of penetrating with the eyes of the understanding into the inner 
character or hidden nature of things; a glimpse or view beneath the surface; the 
faculty or power of thus seeing. 
iii) Psychology: In studies of behaviour and learning, the sudden perception of the 
solution to a problem or difficulty; applied to animals, giving an indication of 
their capacity for ideas and reasoning.  
The three definitions listed above link with the broader concept of insight used in the 
field of psychiatry. However, even a combination of the above definitions cannot capture the 
complexity of understanding i) that someone has an illness, ii) that such illness is mental and  
iii) the consequent attitude towards such ‘mental illness’, including treatment compliance.  
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1.3.c. – Multidimensional model of insight 
In 1990 David proposed that insight is not a unitary, ‘all-or-nothing’ phenomenon but 
is composed of three different, albeit overlapping dimensions – (i) the recognition that one has 
a mental illness, (ii) the ability to relabel unusual mental events (such as delusions and 
hallucinations) as pathological, and (iii) compliance with treatment (David, 1990): 
Awareness of illness – This insight dimension is not the same as accepting a label of 
‘psychosis’ or ‘schizophrenia. Rather, this factor evaluates the ability of a patient to recognise 
an emotional or psychological change (‘something is going wrong’) which appears to point to 
a mental illness.  
Ability to recall psychotic experiences as pathological – This factor relates to the awareness 
of having had psychotic symptoms and the ability to attribute such psychotic symptoms to a 
mental illness. For instance, a patient with (stabilised) schizophrenia may recall commanding 
voices, yet be unable to attribute such experiences to their mental illness. This distinction 
between awareness and attribution was elaborated further by Amador (1991).   
Awareness of the need for treatment – This insight domain is strongly associated with 
compliance. However, ‘awareness of the need for treatment’ represents a broader concept that 
comprises both an explicit attitude towards psychiatric treatment, including pharmacological 
and non-pharmacological interventions, and the implicit behaviour (for instance, how many 
sessions or appointments the patient fails to attend). 
Indeed, patients present with different degrees of each insight domain, as illustrated 
by the clinical vignettes shown in figure 1.4 below based on David’s model (1990): 
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Figure 1.4. Diagram showing clinical vignettes concerning the main components of 




More specifically, while a small proportion of patients present with complete lack of 
insight, the vast majority of people present with ‘partial’ insight levels, as graphically 
demonstrated by this study from our group with a sample of relatively stable and well-
functioning patients with schizophrenia and schizoaffective disorder who were participating 
in a clinical trial (Wiffen et al., 2010): 
 
Figure 1.5. Venn diagram showing the percentage of stable patients in the early 
stages of schizophrenia demonstrating good levels of each dimension of insight. 




1.3.d. – Insight and psychosis 
So far I have discussed the concept and definition of insight ‘in psychosis’ because the 
term always refers to insight into something. Moreover, the object of insight may affect the 
concept of insight itself (Markova & Berrios, 1992).  
From a historical perspective I have shown that the concept of (lack of) insight in 
psychosis was intrinsically linked with madness, which was relabelled as psychosis in the 
nineteenth century. Hence, it is not surprising that most research on insight has focused on 
insight in ‘psychosis’, particularly schizophrenia (for a review, see the aforementioned second 
edition of ‘Insight and Psychosis’ by Amador & David, 2004).  
Indeed, the International Pilot Study of Schizophrenia conducted by the World Health 
Organization in 1973 reported that up to 97% of patients had insight deficits (Carpenter et al., 
1973). Later on, with multidimensional approaches, lower prevalences of lack of insight in 
samples of psychotic patients were reported (e.g. Amador et al., 1994; Wiffen et al., 2010). In 
addition, patients with schizophrenia were found to have lower levels of insight than those 
with affective psychoses (Amador et al., 1994). More recently, ‘poor insight’ has been 
described as a discriminating feature of schizophrenia (Arango & Amador, 2011). The 
question therefore arises: what underlies lack of insight in schizophrenia and related 
disorders? This forms the context for section 1.3.f. below. In order to investigate the origin of 
impaired insight in psychosis, insight needs to be ‘measured’ appropriately (see section 1.3.e).       
In addition to psychosis, insight into other psychiatric conditions has recently attracted 
interest, such as mood disorders (Ghaemi & Rosenquist, 2004), eating disorders 
(Konstantakopoulos et al., 2011), as well as neuropsychiatric disorders (David et al., 2012). 
Furthermore, about one-quarter of patients suffering from chronic physical health conditions 
do not take their medication as prescribed (Cramer & Rosenheck, 1998), although some 
authors suggest that insight into a medical illness is phenomenologically different from 
awareness of mental illness (e.g. Lysaker et al., 2009). Interestingly from a clinician 
perspective, ‘we all believe that our patients have above average adherence (it’s the other person’s 
patients who have the problem)’ (David, 2010).     
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1.3.e. – Measuring insight 
Early literature on insight in psychosis relied on patients’ narrative descriptions of 
their beliefs around their mental illness. While this approach offers a rich view about a 
patient’s self-assessment, it cannot be replicated for research purposes. As a result, 
investigators began to design interviews in which insight could be ‘scored’, which initially 
resulted in patients being classified as having ‘good’ or ‘poor’ insight. One example of this 
measurement of insight might be the Present State Examination (Wing et al., 1974).  
Later on, semi-structured scored interviews were validated to measure insight. The 
first such measure was The Insight and Treatment Attitudes Questionnaire (ITAQ) developed 
by McEvoy and colleagues in 1989 (McEvoy et al., 1989). The ITAQ is an 11-item questionnaire 
which assesses patients’ attitudes or beliefs about whether they have a mental illness and 
whether they need treatment. While an advance in the assessment of insight, this scale does 
not capture other domains of insight which are currently believed to constitute this complex 
construct. In essence, the ITAQ still measures insight from a unidimensional perspective. 
Thus, in keeping with the multidimensional models of insight proposed by David 
(1990) and Amador (1991), two scales were validated to measure insight multidimensionally.  
In 1993 Amador (Amador et al., 1993) developed the Scale to assess Unawareness of 
Mental Disorder (SUMD). In addition to the independent assessment of awareness and 
attribution, the SUMD distinguishes current and past awareness of i) having a mental 
disorder, ii) the effects of medication, iii) the social consequences of the illness, and iv) the 
specific signs and symptoms.  The shortened version of the Scale to Assess Unawareness of 
Mental Disorder (SUMD) (Amador et al., 1994), which provides scores on three insight 
dimensions: insight into mental illness, insight into need for treatment, and insight into the 
social consequences of the illness, was used to measure insight in chapter 7 of this thesis. Of 
note, this scale assesses unawareness of illness, i.e. the higher the score (which ranges from 0 
to 5), the poorer the insight.    
The Schedule for Assessment of Insight (David, 1990), including an Expanded version 
(SAI-E) (Kemp & David, 1997), is an 11-item semi-structured interview easily applicable to 
clinical practice (Sanz et al., 1998) that provides several separate insight scores based on 
David’s model (David, 1990): awareness of mental illness, relabelling of psychotic symptoms 
as abnormal and treatment compliance. A further item assessing ‘hypothetical contradiction’ 
was added to the original scale, which refers to a patients’ reaction if someone were to deny 
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their psychotic experiences. This item was found to be part of the ‘symptoms relabelling’ 
dimension according to a factor analysis (Morgan et al., 2010b), which is also replicated in 
chapter 5 of this thesis. The three factors can be summed to create a total score. The SAI-E also 
includes items to assess compliance with medications, and a 7-point overall compliance item, 
to be scored by the patient’s primary nurse or carer. The scale is available in appendix 5. Also, 
the SAI-E has been recently validated in Spanish as a result of a collaboration study, which I 
co-authored (Soriano-Barceló et al., 2016).   
Further insight assessments commonly used in research include self-reports such as 
the Birchwood Insight Scale (Birchwood et al., 1994), the Markova and Berrios’ Insight Scale 
(Markova & Berrios, 1992), which actually evaluates insight domains close to the so-called 
‘cognitive insight’ (Beck et al., 2004), and the specific insight item of two large scales of general 
psychopathology such as the Positive and Negative Symptoms Scale (PANSS) (Kay et al., 
1987) and the Manual for the Assessment and Documentation of Psychopathology (AMDP 
System) (Guy & Ban, 1982). 
With regard to the SAI-E, it was found to have a high correlation with both the ITAQ 
and, more weakly, with the Markova and Berrios’s Scale, (Sanz et al., 1998), and this is 
detailed in table 1.3. below.    
 
Table 1.3. Concurrent validity of SAI-E. Pearson’s correlation coefficients between 
SAI-E and other insight scales. Taken from Sanz et al. (1998) 
 ITAQ PANSS SAI M&B - a M&B – b 
SAI-E 0.845*** 0.895*** 0.97*** 0.466** 0.410* 
* p<0.05; ** p<0.01; *** p<0.001 
ITAQ: Insight and Treatment Attitudes Questionnaire (McEvoy et al., 1989);  
PANSS: Positive And Negative Syndrome Scale (Kay et al., 1987); 
SAI: Schedule for the Assessment of Insight (David, 1990); 
M&B: Markova and Berrios’ Insight Scale (Markova & Berrios, 1992); 
SAI-E: Schedule for the Assessment of Insight, expanded version (Kemp & David, 1997). 
 
Given the number of instruments available to measure insight, the investigator 
designing a study in which an insight assessment needs to be included may wonder which 
scale he/she should use for such a research project. In Table 1.4. below I summarise the 
attributes of the scales, which may be of help to guide the above decision. In particular, 
moving from left to right I have highlighted the advantages of a multidimensional assessment 
of insight.  
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Table 1.4. Insight dimensions assessed by scales 
Dimensions of insight  PSE PANSS ITAQ SUMD SAI-E 
Awareness of having a mental disorder √ √ √ √ √ 
Relabelling psychotic symptoms correctly    √ √ 
Awareness of the social consequences     √ √ 
Awareness of the need for treatment    √ √ 
PSE: Present State Examination (Wing et al., 1994); PANSS: Positive and Negative Syndrome Scale (Kay et al., 1987)  
ITAQ: Insight and Treatment Attitude Questionnaire (McEvoy et al., 1989)  
SUMD: Scale to assess Unawareness of Mental Disorder (Amador et al., 1993) 
SAI-E: Schedule for Assessment of Insight, expanded version (Kemp & David, 1997) 
 
1.3.f. – Why do patients with psychosis lack insight? 
As detailed above, patients with psychotic disorders (Amador et al., 1994), particularly 
schizophrenia (Carpenter et al., 1973, Arango & Amador, 2011), tend to deny having a mental 
illness and treatment non-compliance is the rule rather than the exception (e.g. Lieberman et 
al., 2005). In order to explain what underlies lack of insight in psychosis, psychological 
(Lysaker et al., 2007), psychopathological (Cuesta & Peralta, 1994) and neuropsychological 
(Aleman et al., 2006) theories have been proposed.  
From a psychological perspective, ‘lack of insight’ is viewed as having a function in 
terms of being protective or preserving self-esteem (Cooke et al., 2005). It is therefore intuitive 
to think that too much insight might be undesirable.  
Cuesta & Peralta and colleagues, however, failed to link lack of insight with other 
psychopathological symptoms or neurocognitive deficits in different samples of patients with 
psychotic disorders (Cuesta & Peralta, 1994; Cuesta et al., 2000; Cuesta et al., 2011), which led 
them to suggesting that lack of insight in psychosis may be conceptualised as a primary 
symptom of the illness in a Bleulerian sense (Cuesta & Peralta, 1994).   
In addition, neurocognitive deficits in psychosis in relation to impaired insight have 
been investigated for the last three decades (Amador et al., 1991) given the clinical similarities 
with so-called ‘anosognosia’ in neurological diseases (Babinski, 1914). The relationship 
between lack of insight and neurocognitive deficits was also the subject of a systematic review 
in 2004 (Morgan & David, 2004) and a meta-analysis encompassing 35 studies in 2006 (Aleman 
et al., 2006), which found a small, but significant, relationship between poor insight in 
psychosis and general cognition, and slightly larger with executive functions as assessed by 
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the Wisconsin Card Sorting Test (WCST). More recently, a study conducted by our group, 
which I co-authored, found verbal memory to predict insight in FEP above and beyond the 
effects of general cognition (i.e. intelligence quotient, IQ) (Wiffen et al., 2012). However, 
percentages of variance on insight dimensions explained by verbal memory (although 
statistically significant) were very low (Wiffen et al., 2012), in line with the results from the 
aforementioned meta-analysis (Aleman at al., 2006). Hence, there are grounds to consider that 
other variables may affect insight.  
In particular, metacognition, which is defined as ‘thinking about one’s and others’ 
thinking’ (Frith, 1992), and particularly the so-called ‘cognitive insight’ (Beck et al., 2004), has 
recently attracted interest from research on insight, including a seminal textbook (Dimaggio & 
Lysaker, 2010). Interestingly, verbal memory was also associated with cognitive insight in two 
FEP studies (Lepage et al., 2008; Buchy et al., 2010). 
In keeping with a neurological basis of insight in psychosis, a number of neuroimaging 
studies have investigated brain ‘regions of interest’. Although results have been mixed to date 
(see David et al., 2012), prefrontal areas seem to emerge as the key area where complex neural 
circuitries, rather than specific anatomical brain regions, might underpin clinical insight in 
psychosis (e.g. Shad et al., 2006; Morgan et al., 2010b; Antonius et al., 2011; Bergé et al., 2011; 
see David et al., 2012 for a review) as well as cognitive insight (Orfei et al., 2013). 
Of importance, the fourth revision (text reviewed) of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM), published by the American Psychiatric Association in 
2000 described lack of insight in patients with schizophrenia as follows (APA, 2000): 
‘A majority of individuals with schizophrenia lack insight regarding the fact that they have a 
psychotic illness. Evidence suggests that poor insight is a manifestation of the illness itself, rather than 
a coping strategy. It may be comparable to the lack of awareness of neurological deficits seen in a stroke, 
termed anosognosia. This symptom predisposes the individual to noncompliance with treatment and has 
been predictive of…increased number of involuntary hospital admissions, poorer psychosocial 




In addition, premorbid personality (Campos et al., 2011; Cuesta et al., 2011; Ritsner & 
Blumenkrantz, 2007; Lysaker et al., 1999), premorbid adjustment (Ayesa-Arriola et al., 2011; 
Wiffen et al., 2012; Debowska et al., 1998; Keshavan et al., 2004), education level (Wiffen et al., 
2010) and duration of untreated psychosis (DUP) (Ayesa-Arriola et al., 2011; Cuesta et al., 
2011; Saravanan et al., 2010) have been reported to contribute to insight in FEP. Interestingly, a 
significant association was found between insight and psychopathology by a meta-analysis 
formed of 40 studies (Mintz et al., 2003), although the percentage of variance explained by 
symptom severity was low (less than 7%), thus suggesting that other factors may play a more 
relevant role in insight.  While both positive and negative symptoms showed a negative 
relationship with insight, as expected, depression was the only psychopathological dimension 
that positively correlated with insight (Mintz et al., 2003), i.e. the greater the insight, the more 
severe the depression. A further meta-analysis of 59 studies carried out in 2015 (Belvederi et 
al., 2015) showed a small (effect size r=0.14-0.17), but significant, association of depression 
with illness awareness and symptoms relabelling. On the other hand, neither insight into the 




1.3.g. – Can insight be improved? 
Insight has been demonstrated to be a dynamic phenomenon, which can evolve over 
the course of the illness, showing a tendency to improve in the first stages of psychosis (Wiffen 
et al., 2010; Campos et al., 2011; Cuesta et al., 2011, Quee et al., 2011). However, ‘lack of 
insight’ has also been shown to have trait-like qualities (Wiffen et al., 2010), which led to 
speculation that insight may be, to some extent, determined on first presentation with 
psychosis (Cuesta et al., 2011). Hence, it seems that insight may have both trait- and state-like 
properties (Wiffen et al., 2010). However, a 3-year follow-up FEP study with the sample used 
in chapter 7 of this thesis revealed that lack of insight in FEP appears to behave as a trait of the 
illness, which may also be determined from first contact with services (Ayesa-Arriola & 
Lopez-Morinigo, 2014). 
With regard to therapeutic interventions for lack of insight in psychotic disorders, a 
meta-analysis in 2013 found small non-significant effects for cognitive-behavioural therapy 
(CBT) and psychoeducation, although only five studies met the inclusion criteria for each of 
the above therapies (Pijnenborg et al., 2013). However, larger effects emerged from those 
studies in which a combination of different treatments, including medication, was delivered to 
participants (Guo et al., 2010; Fung et al., 2011). In keeping with this, a secondary analysis of 
data from the European First-episode Schizophrenia Trial (EUFEST) study reported treatment 
with antipsychotics to be associated with significant insight improvement over the first three 
months after which insight improvement was no longer significant (Pijnenborg et al., 2015).    
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1.3.h. – Insight and clinical outcomes 
Is insight always ‘good’? 
Insight has been consistently linked with better long-term outcomes in psychotic 
disorders, including improved compliance, reduced number of hospitalizations and better 
psychosocial functioning (e.g. David et al., 1995; McEvoy, 2004; Lincoln et al., 2007). Hence, 
the direction of the associations between insight and outcome appears to be positive, the 
greater the insight the better the outcome, which highlights the importance of further research 
on interventions into lack of insight in psychosis (see section 1.3.g. above). 
However, an inverse association of insight with depression (better insight, worse 
depression) has been consistently demonstrated as shown by a meta-analysis (Mintz et al., 
2003) summarised in figure 1.6. below. This so-called ’Insight Paradox’ (Lysaker et al., 2007) 
has recently been subjected to a meta-analysis (Belvederi et al., 2015), which revealed that 
while recognition of mental illness and symptom relabelling were linked with depression, 
treatment compliance did not show such an association. Moreover, as many clinicians hold, 
too much insight (into such a devastating condition) may lead patients to depression, 
demoralization, and even suicide (Drake & Cotton, 1986), although the latter has not been 
confirmed yet (Restifo et al., 2009), which forms the context for the next section and the 
research work presented in this thesis. 
 




















1.3.i. – Criticisms of insight 
Given the aforementioned relationship between insight and depression (e.g. Mintz et 
al., 2003) and the subsequent negative effect of insight on patients’ self-esteem, even though 
this association appears to be much more complex (see Ghaemi & Rosenquist, 2004; and 
Belvederi et al., 2015 for reviews), not surprisingly insight has received much criticism since 
the seminal contribution made by David in 1990 (David, 1990).  
Thus, this article (David, 1990) was followed by two Lancet editorials arguing ‘against 
insight’. The first one, with no authors listed and published in the same year (1990), compared 
insight with a ‘full confession leading to absolution’ and insight was considered to be ‘academically 
nourishing but clinically sterile’. A second Lancet editorial in 1993 described insight (assessment) 
as a confrontation between the doctor (or therapist) and the patient (Joyce, 1993). In keeping 
with these views, Perkins & Moodley (1993) claimed that judging a patient as lacking insight 
was a form of ‘Eurocentric’ arrogance from doctors, that is, the only ones who know the 
correct way to label an illness (Perkins & Moodley, 1993). Despite such an antipsychiatry 
approach, it is undeniable that cultural factors such as the construction of the concept of 
illness, including psychosis, play a significant part in the complex concept of insight (for a 
review, see Kirmayer et al., 2004), as do attitudes of family members (Gigante et al., 2004). In 
addition, expressed emotion by carers, which is highly influenced by culture too, contributes 
to negative outcomes in patients with a FEP such as the so-called ‘post-psychotic depression’, 
hence suggesting the importance of family interventions, also taking into account cultural 
issues, early in the course of the illness (Upthegrove et al., 2013).  
From a more personal perspective as researcher and clinician, it seems that the main 
criticism of insight in research comes from the categorisation of patients as ‘lacking insight’ 
rather than understanding each individual’s view of his/her illness. Although it is true that 
clinical research is about investigating distributions of variables across ‘groups’ in relation to 
outcomes, current insight scales such as the SAI-E (Kemp & David, 1997) do take into account 
cultural aspects of the subject when rating his/her insight levels.  
After this general introduction to psychosis, suicidal behaviour and insight, chapter 2 
continues with a summary of previous research on the relationship between insight and 
suicide risk in psychosis.  
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Chapter 2 – The role of insight in suicidal behaviour in 
psychosis: previous research 
 
2.1. – Introduction 
In 1952 the first antipsychotic, chlorpromazine was serendipitously discovered by two 
French psychiatrists, Delay and Deniker (Delay & Deniker, 1952). For the first time in the 
history of psychiatry, (positive) psychotic symptoms could be alleviated to a large extent, 
which significantly contributed to the ‘de-institutionalisation’ of patients and the 
commencement of community psychiatry (Thornicroft & Bebbington, 1989).  
Paradoxically, such a successful change in the management of psychosis was 
accompanied by an increase in recorded rates of suicide in schizophrenia, from 0.5-2% in the 
late 19th century and early years of the 20th century (Stephens et al., 1999; Healy et al., 2006) to 
5-10% over the last few decades (Caldwell & Gottesman, 1990; Palmer et al., 2005), which is 
illustrated in figure 2.1. below, although epidemiological research from Scandinavian 
countries found a decrease in suicide rates in patients with schizophrenia after 
deinstitutionalisation (Heilä et al., 2005; Rantanen et al., 2009).      












Is insight a risk or a protective factor for suicidal behaviour in early psychosis? 
This subheading summarises the main research question of this investigation. In order 
to answer this research question, I will analyse data from three cohorts of FEP patients, which 
are presented in chapters 4, 5, 6 and 7 before reaching a conclusion based on all the data which 
is detailed in chapter 8.  
The aforementioned seminal meta-analysis conducted by Hawton and colleagues in 
2005 found no statistically significant association between insight and risk of suicide in 
schizophrenia, although the odds-ratio (OR) was 2.04 with a wide confidence interval (95%, CI 
0.54-7.74), suggesting that insight may still be a risk factor (Hawton et al., 2005). A more recent 
meta-analysis of eight FEP studies replicated such a relationship, with an OR of 1.64 (95%CI 
1.23-2.56).  Indeed, it is commonly believed amongst clinicians that insight into illness in 
patients with schizophrenia might lead to a sense of hopelessness, demoralisation, depression 
and sometimes suicide, which is also supported by some research conducted in the 1980s 
(Drake & Cotton, 1986), although not replicated recently (Restifo et al., 2009). Nevertheless, 
insight has been consistently associated with low mood in schizophrenia (Mintz et al., 2003; 
Nair et al., 2014; Belvederi et al., 2015).  
In chapter 1 (section 1.3.c.) I argued that insight is not an ‘all-or-none’ concept (David, 
1990). Rather, a multidimensional model of insight has been consistently replicated (Amador 
& David, 2004). Accordingly, a first step may be to reformulate my research question as 
follows:  
Which dimensions of insight (if any) behave as risk factors of suicidal behaviour in early 
psychosis and which dimensions (if any) are protective? 
 Interestingly, Hawton et al’s meta-analysis (Hawton et al., 2005) considered insight 
and compliance separately and found a significant odds-ratio for poor compliance (OR=3.75 
95% CI 2.20-6.37) as a risk factor for suicide, which was consistent with later studies (e.g. Lui, 
2009). Hence, there are grounds to speculate that better insight might reduce suicide risk via 
improved compliance.  
I proposed that the inconsistency of results concerning the role of insight in developing 
suicidal behaviours in patients with schizophrenia and related disorders as revealed by 
Hawton et al.’s meta-analysis may relate to: a) methodological differences between studies; b) 
the complexity of the concept of insight; c) assessment of insight using scales that attempt to 
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measure it from a unidimensional perspective; and d) the extent to which potential 
confounders and other possible mediating factors such as feelings of hopelessness and 
depression are taken into account (Lopez-Morinigo et al., 2012). 
 
2.2. – Systematic review of previous literature 
Given the above inconclusive findings with regard to my research topic, in the early 
stages of my PhD studies I conducted an updated systematic review of ‘insight, suicide and 
schizophrenia’ by including all the relevant articles published on PubMed up until June 2010 
which resulted in a peer-reviewed publication (Lopez-Morinigo et al., 2012). Of note, this 
publication was followed by increased and fruitful research interest in this area, including a 
further systematic review focused on ‘insight and suicidal behaviour’ in first-episode 
schizophrenia (Melle & Barrett, 2012). 
More specifically, since the publication of my systematic review (Lopez-Morinigo et 
al., 2012), two cross-sectional studies with samples of schizophrenia patients (Kao & Liu, 2011; 
Yan et al., 2013) and two FEP studies have reported data on the association of insight with 
suicidal behaviour (Upthegrove et al., 2014; Barrett et al., 2015), including a meta-analysis of 8 
FEP studies with information on this subject (Challis et al., 2013). In this review I have not 
included a publication from our group (Ayesa-Arriola et al., 2015) since data from this study 
are analysed further in chapter 7. Also, there has been a growing research interest in the 
relationship between insight and depression both in schizophrenia (e.g. Misdrahi et al., 2014) 
and in FEP (e.g. Upthegrove et al., 2014), which has been subjected to a recent meta-analysis 
(Belvederi et al., 2015).   
Thus, in order to systematically examine the role of insight in schizophrenia and risk of 
suicidal behaviours, initially I conducted a PubMed review of papers that assessed both 
insight and suicidality, in samples of patients with schizophrenia spectrum disorders during 
the period January 1977- June 2010, which was published in 2012 (Lopez-Morinigo et al., 
2012). For this thesis, I also updated the above search in June 2016, including not only PubMed 
but also two further databases namely PsycInfo and Embase since papers related to my PhD 
topic may have been published in non-medical journals or in the ‘grey’ literature outside 
Medline.   
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I decided to limit the search to this period (as far back as 1977) to ensure that the 
studies included would be based on similar definitions of schizophrenia and related disorders 
such as schizoaffective disorders, i.e. only criteria from ICD-9 (WHO, 1977) and DSM-III 
(APA, 1980) onwards were considered valid.  Thus, all the articles finally selected would be 
using a similar concept of schizophrenia spectrum.  
The search strategy utilised ‘Medical Subjects Headings’ (MeSH headings) and 
keywords (“suicid*”, “self-harm*”, “schizophr*”, “psychos*”, “psychot*”, “illness*”, 
“insight*”, “awareness*” and “consciousness*”) with extensive use of cross-referencing. The 
only initial search limitation was by English language. This preliminary search yielded 1,193 
references.  The following selection criteria were applied to the abstracts: 
 Sample size of more than 10 patients. 
 Age: 16-65 years. 
 Diagnosis: ‘Schizophrenia spectrum disorders’, encompassing Schizophrenia, 
Schizoaffective Disorder according to either ICD-9 (APA, 1977), or ICD-10 (WHO, 
1993), or DSM-III (APA, 1980), DSM-III-R (APA, 1987) or DSM-IV-TR definitions (APA, 
2000); or first-psychosis episode (FEP) according to the DSM-IV-TR criteria (APA, 
2000). 
 Insight assessments, including simple dichotomous measurements (i.e. 
‘absent/present’) had to be included. 
 Data available concerning suicide attempts (SA) and/or suicide completions (SC).  
 Outpatient status of patients during the observation period (i.e. not institutionalised 
patients).  
 In case of replication studies by the same group, only the latest one - with the largest 
sample size - was included. 
 Although data derived from clinical trials (e.g. Bourgeois et al., 2004) was included 
(given the lack of evidence concerning the influence of any particular antipsychotic 
drug on insight), psychotherapeutic intervention studies were excluded.  
 References from selected articles were also hand-searched and they were included in 




Initially, a meta-analysis was attempted with the data available. However, this 
approach was not feasible owing to the methodological differences between the studies, such 
as the insight assessment, the illness stage of participants, the study design (cross-sectional vs. 
prospective) and the lack of consistent quantitative data required for meta-analysis.  
Therefore, I chose to conduct a narrative review of the selected articles, using a semi-
quantitative approach.  
The initial search yielded a total of 1,193 papers, namely 563 PubMed articles, 134 from 
PsycINFO and 496 references emerged from EMBASE. The abstracts were screened against the 
above selection criteria by two researchers independently (JDLM RRR, see Lopez-Morinigo et 
al., 2012). Thus, 20 studies were finally included in the review.    
These were divided into those showing a positive association between the ‘classic’ 
insight dimension (i.e. recognition of having a mental illness) and risk of suicide: the greater 
the level of insight, the higher the risk of suicide (Table 2.1); and those studies that did not 
show such association, which meant that there was either an inconclusive association or that 
insight represented a protective factor: the greater the insight, the lower the risk of suicide 
(Table 2.2). This lack of conclusiveness with regard to such a clinically relevant potential 
association led me to conducting further data-based research which is presented in chapters 4-
7 of this thesis.  
The six positive association studies (Table 2.1) represent a total sample size of 2,606 
patients. Also, three of them reported follow-up data (Crumlish et al., 2005; Gonzalez, 2008; 
Robinson et al., 2009), comprising 1,771 patients with a mean 1.6 year follow-up 
(approximately 1,825 person-years).  
The fourteen negative studies, i.e. they failed to find an association of insight with 
suicide risk, (Table 2.2) represented a total sample size of 2,996 patients. Of note, five of them 
had a prospective design (Yen et al., 2002; Bourgeois et al., 2004; Acosta et al., 2009; Bakst et al., 
2009; Robinson et al., 2010). These five studies comprise 1,366 patients, followed-up for a mean 
of 3.5 years (approximately 4,842 person-years). Of interest, 27 completed suicides were 
reported. Thus, a case fatality (CF) of 1.30% was estimated (27 in 1,366). A mean risk of suicide 




2.2.a. – Positive association studies (see Table 2.1) 
Four studies with FEP patients (Crumlish et al., 2005; Foley et al., 2008; Harvey et al., 
2008; Robinson et al., 2009) were identified and up to 12.6% of these patients had made a SA 
before the index episode.  
Also, three studies had a cross-sectional design (Harvey et al., 2008; Foley et al., 2008; 
Schennach-Wolff et al., 2009). Colleagues from our group, who analysed a subsample of the 
Aetiology and Ethnicity in Schizophrenia and Other Psychoses (AESOP) cohort (presented in 
chapters 5 and 6), reported a significant positive association between a background of self-
harm and higher scores on both overall insight and the recognition of illness, which were 
measured using the multidimensional SAI-E (Kemp & David, 1997), during the first 
presentation with psychosis, while no significant correlations between compliance and a 
history of self-harm were found (Harvey et al., 2008). In keeping with this, a cross-sectional 
FEP study from Dublin (Republic of Ireland) (Foley et al., 2008) with 107 patients found 
insight, which was assessed through a self-rater-based scale such as the Birchwood Insight 
Scale (BIS) (Birchwood et al., 1994), to be the only significant factor associated with a history of 
previous suicide attempts, which was present in a small group of 10 patients (9% of the 
sample). Assessing insight from a unidimensional approach with the insight item of the 
Positive and Negative Syndrome Scale for Schizophrenia (PANSS) (Kay et al., 1987), similar 
findings were reported by Schennach-Wolff and colleagues (Schennach-Wolff et al., 2009) in a 
sample of 339 patients with schizophrenia spectrum disorders, among whom 75 (22%) had 
made a SA before the index episode. At discharge, suicidal patients showed a significantly 
lower score on the PANSS insight item (greater insight), means: 2.0 vs. 2.4, respectively.  
Among these six positive studies, only Robinson and colleagues (Robinson et al., 2009) 
reported data about suicide completions: six deaths by suicide recorded in their sample of 661 
FEP patients, who had been followed-up over two years. A CF of 0.9% was consequently 
obtained. Insight was qualitatively assessed with the insight item from the Early Psychosis 
Prevention and Intervention Centre (EPPIC) interview (unidimensionally as absent, partial or 
full). Among those who made a SA over the follow-up (57 cases, 8.6%), a lower proportion 
had presented lack of insight (42%) at baseline compared to the non-suicidal group (64%). In 
this case, lack of insight at baseline appeared to show a protective effect on the development of 
suicidal behaviours.  
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In the study by Crumlish and colleagues (Crumlish et al., 2005), 101 patients with FEP 
were followed-up over four years during which over a third of the initial sample made at least 
one SA. Interestingly, insight (assessed by self-reports and the PANSS item) improved over 
the follow-up and its assessment at 6 months predicted a suicidal event up to four years later.  
Similar findings were reported from a prospective study with a larger sample of 1,009 
more chronic schizophrenia patients by Gonzalez (Gonzalez, 2008). Among the 67 patients 
who made a SA over the 6-month follow-up (6.6% of the sample), a high proportion of them 




Table 2.1. Insight as an apparent risk factor for suicide 
Studies N initial 
 
Design 
(if P, FU) 
N at FU (%) Age 










Harvey, 2008 496 C NA 30 ± 10 FEP, 
ICD-10 
SAI-E NA 56 (11.3)  
NA 
Previous SA associated with overall insight and 
illness recognition, not with compliance. 
Foley, 2008 107 C NA 30 ± 11 FEP, 
DSM-IV-TR 
BIS NA 10 (9) NA Illness recognition linked with previous SA. 
Schennach, 2009  339 C NA 34 ± 11 Sch spectrum, 
DSM-IV 
PANSS NA 75 
(22.1) 
NA Those with previous SA showed greater insight. 
Crumlish, 2005  101 
 




NA NA 20 
(19.8) 
Insight improved over the FU and its assessment at 
6-month FU predicted developing a SA up to 4 
years later. 
Robinson, 2009 661 
 








A lower proportion of suicide attempters over FU 
lacked insight at baseline. 
Gonzalez, 2008 1009 
 






111 (11.1) Those who made a SA over the FU, a high 
proportion had recognized having a mental illness 
at baseline. 
TOTAL/MEANS 2713 1.6y 1109 (62.6) 32.85   0.9 14.9% 10.61%  
N: Sample size. n: number. P: Prospective. C: Cross-sectional. FU: Follow-up. SD: Standardized deviation CF: Case-fatality. SA: Suicide attempt. FEP: First-Episode Psychosis. pFEP: prior to FEP. ICD: 
International Classification of Diseases. NA: Not available (or not applicable). Sch: Schizophrenia. Schform: Schizophreniform. DSM: Diagnostic and Statistical Manual of Mental Disorders.  DSM-IV-
TR: Fourth Edition of DSM. y: years. SA pFEP: Number and percentage of SA prior to the FEP. SA-FU: Number and percentage of SA during the follow-up. SAI-E: Scale for Assessment of Insight, 
expanded version (Kemp & David, 1997). IS: Insight Scale (Birchwood et al., 1994). PANSS: Positive and Negative Syndrome Scale for schizophrenia (Kay et al., 1987). EPPIC: Early Psychosis and 
Intervention Centre intake mental state examination.  
70 
 
2.2.b. – Negative studies (see Table 2.2) 
The first study to test the association between insight, conceptualized as a 
multidimensional phenomenon, and suicide in a sample of patients with schizophrenia was 
carried out by Amador and colleagues in 1996 (Amador et al., 1996). In this multicenter study, 
218 schizophrenia patients were recruited (mean age: 34 years). Forty-nine of them (22.5%) had 
reported a SA in the past. After administering the SUMD (Amador et al., 1991), neither general 
awareness of having a mental disorder, nor awareness of the need for treatment nor awareness 
of the social consequences of the illness were significantly different between the suicidal and 
the non-suicidal group (bivariate analyses by Chi-square tests). A significant association 
between awareness of some symptoms - delusions, asociality, anhedonia and blunted affect - 
was found in the bivariate analysis, but these correlations were not replicated by the 
multivariate regression model (Amador et al., 1996). 
Previously, Hu and colleagues (Hu et al., 1991) had carried out a post-mortem study 
with a group of 42 patients who had died by suicide and two more control groups. No 
significant differences in terms of presence-absence of insight were found in the comparative 
analyses between the cited groups (Hu et al., 1991).  
Two negative studies deserve special consideration since both showed similar findings 
with contrasting study designs: a cross-sectional study (Kim et al., 2003) and a prospective 
study (Bourgeois et al., 2004). In the cross-sectional study (Kim et al., 2003) insight was 
assessed with the Hamilton Scale item (Hamilton, 1960) through the authors’ transformation of 
the depression insight item in a sample of 333 schizophrenia patients with a high risk of 
previous suicidality (up to 60% of the sample). The multivariable regression analysis not only 
failed to demonstrate an association between insight and a suicidal history, but also showed 
hopelessness as the only factor correlating with previous suicidality. This finding was 
replicated in a prospective study with a larger sample size (980 patients) (Bourgeois et al., 
2004). However, the sample was part of clinical trial and so while they represented a high-risk 
group, they were closely monitored. Indeed, only eight patients completed suicide over the 2-
year follow-up, which would represent a CF of 0.81%, although nearly half the initial sample 
had to be hospitalized and thereby risk of exhibiting a suicidal behaviour was diminished. 
Interestingly, insight improved during the follow-up while risk of suicide decreased. 
More recently, four cross-sectional studies failed to find any relationship between 
insight and risk of suicide, including three samples of patients with schizophrenia and 
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schizoaffective disorder (Restifo et al., 2009; Salgado et al., 2010; Yan et al., 2013) and FEP study 
(Barrett et al., 2010a). Thus, Restifo and colleagues (Restifo et al., 2009) had demonstrated 
bivariate correlations between insight (assessed as present or absent) and previous suicidal 
behaviour (present in over a third of their sample of 174 patients), which was no longer 
significant when multivariable analyses were undertaken. In line with this, despite using a 
multidimensional assessment of insight such as the SUMD (Salgado et al., 2010) or the ITAQ 
(Yan et al., 2013), no significant associations of insight with previous suicidal history emerged 
from the analyses. Similarly, Barrett and colleagues (Barrett et al., 2010a) did not find 
significant differences between the suicidal group (a quarter of the sample) and the non-
suicidal group with regard to insight scores on the PANSS item.  
Four other negative studies presented a longitudinal design (Yen et al., 2002; Bakst et 
al., 2009; Acosta et al., 2009; Robinson et al., 2010). In Taiwan, Yen and colleagues (Yen et al., 
2002) reported the lack of significant associations between any of the insight dimensions, 
assessed from a multidimensional approach with the SAI-E (Kemp & David, 1997), and the 
development of suicidal events during the one-year follow-up of a sample composed of 74 
patients. However, 12 patients were hospitalized and another four were lost to follow-up.  
Acosta and colleagues (Acosta et al., 2009) conducted a study with 73 inpatients, 57 of 
whom were followed-up up one year after discharge. No significant differences were found 
between the suicidal group (36.9% of the initial sample) and the non-suicidal one with regard 
to the level of awareness of having a mental illness, which was measured with the first three 
items of the SUMD (Amador et al., 1993). 
More recently, two longitudinal studies with samples of FEP were published (Bakst et 
al., 2009; Robinson et al., 2010). While Bakst and colleagues (Bakst et al., 2009) reported a 
percentage of SA of 12.3% (initial sample: 529 patients) over a 4-year follow up; the Robinson’s 
group (Robinson et al., 2010) followed-up a smaller sample (413 patients) but with longer 
follow-up (7.4 years) and found a higher risk of SA (21.6%). In neither the bivariate analysis 
(Bakst et al., 2009) nor the multivariate model (Robinson et al., 2010) were correlations found 
between insight (assessed in both cases unidimensionally) and risk of suicide. 
Interestingly, a large epidemiological study from Beijing (China) with urban 
schizophrenia patients (Yan et al., 2013) revealed quality of life, urbanicity and having a major 
medical condition to be the strongest risk factors associated with having a lifetime history of 
suicide attempts versus those without, while there were no between-groups differences in 
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terms of insight levels, measured with the ITAQ (McEvoy et al., 1989). These findings were 
replicated in a sample of 50 schizophrenia patients from Spain (Salgado et al., 2010) who were 
cross-sectionally evaluated with the SUMD (Amador et al., 1993). In keeping with this, a cross-
sectional study conducted in Istanbul (Turkey) (Evren & Evren, 2004) of 60 patients with 
schizophrenia spectrum disorders reported bivariate associations of total insight scores, as 
measured by the SAI-E (Kemp & David, 1997), with lifetime suicide attempts. However, the 
multivariable logistic regression models failed to replicate these associations, while depression 
(as risk factor) and negative symptoms (as protective factor) emerged as the main variables 
related to suicidal antecedents. Also, in another report from Taiwan with 104 patients with 
schizophrenia spectrum disorders (Kao & Liu, 2011) bivariate associations were found for two 
insight domains, namely insight into illness and insight into need for treatment, which were 
measured with the Self-Appraisal of Illness Questionnaire (SAIQ) (Marks et al., 2000). 
However, only insight into need for treatment survived the multivariable regression models 
which also showed hopelessness and previous hospitalizations to be associated with a history 
of suicidal behavior.  
In addition, a recent 1-year follow-up FEP, which did not meet the above selection 
criteria since ‘suicidality’ had been measured with the Calgary Depression Scale for 
Schizophrenia (CDSS) (Addington et al., 1992) rather than reporting on real suicide attempts, 
found that those who gained insight over the 1-year follow-up had lower scores on suicidality 
at that point (Barrett et al., 2015).   
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Table 2.2. Insight as an apparent protective factor or with an inconclusive role in the risk of suicide 
Studies N initial 
 
Design 
(if P, FU) 
N at FU 
(%) 
Age 











Hu, 1991 42 Cases- 
Controls 




NA NA NA Post-mortem study of schizophrenic patients who had died by suicide. No 
differences on insight compared with a control group 
Amador, 1996 218 C NA 34.3 ± 11 Schizophr, 
DSM-III-R 
SUMD NA 49 
(22.5) 
NA Awareness of some symptoms -delusions, anhedonia, asociality and 
blunted affect- was associated in bivariate analyses. 
No insight dimension survived the multivariable regression model. 






32.9 ± 10 Schizophr, 
DSM-IV 
SAI-E 1.35 NA NA None of insight dimensions associated with suicide risk over FU 
Kim, 2003 333 C NA 35.1 ± 9 Schizophr, 
DSM-III-R, 
HAM-D NA 200 
(60.0) 
NA Multivariable regression analysis failed to demonstrate an association 
between insight and previous SA.  Hopelessness the strongest predictor 






37.1 ± 10 Schizophr, 
Schizoaffec 
DSM-IV 




Insight improved during the FU while risk of suicide decreased. 
Hopelessness was the strongest predictor of suicidality. 
Evren, 2004 60 C NA 39.2 ± 10.1 Schizohr, 
SCAN 
SAI-E NA 27 
(45) 
NA Insight scores did not survive multivariable regression models, which 
found depression and negative symptoms to be related to suicidality 






29.2 ± 9 FEP, 
DSM-III-R 




Bivariate analyses did not show insight as a predictive factor of suicidality. 






NA Multivariable analyses: no correlations between insight and risk of suicide. 
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N: Sample size. n: number. P: Prospective. C: Cross-sectional. FU: Follow-up. SD: Standardized deviation CF: Case-fatality. SA: Suicide attempt. FEP: First-Episode Psychosis. pFEP: prior to FEP. ICD: 
International Classification of Diseases. NA: Not available (or not applicable). Sch: Schizophrenia. Schform: Schizophreniform. DSM: Diagnostic and Statistical Manual of Mental Disorders.  DSM-IV-
TR: Fourth Edition of DSM. y: years. SA pFEP: Number and percentage of SA prior to the FEP. SA-FU: Number and percentage of SA during the follow-up. SAI-E: Scale for Assessment of Insight, 
expanded version (Kemp & David, 1997). . IS: Insight Scale (Birchwood et al., 1994). PANSS: Positive and Negative Syndrome Scale for schizophrenia (Kay et al., 1987). EPPIC: Early Psychosis and 
Intervention Centre intake mental state examination. ITAQ: Insight and Treatment Attitudes Questionnaire (McEvoy et al., 1989). SAIQ: Self-Appraisal of Illness Questionnaire (Marks et al., 2000). 
Barrett, 2010a 170 C NA 27.2 ± 8 FEP, 
DSM-IV 
PANSS item NA 44 
(25.9) 
NA No differences in insight between patients with/without previous SA. 
















Multivariable analyses: no association between insight at baseline and 
suicidality over the FU. 












 None of insight dimensions was associated with a higher risk of suicide 
over 1-y FU. Hopelessness as the strongest predictor. 
Salgado, 2010 50 C NA NA Schizophr, 
Schizoaff, 
DSM-IV 
SUMD NA NA NA No correlation between insight and suicide risk. 
Kao & Liu, 2011 104 C NA 40.5 ± 14.5 Schizophr, 
Schizoaff, 
DSM-IV 
SAIQ NA 51 
(49) 
NA Insight into illness did not survive the multivariable models, while insight 
into the need for treatment was linked with lifetime suicide attempts 
Yan, 2013 540 C NA 42.8 ± 8.9 Schizophr ITAQ NA 65 
(12) 




3750 3.5y 1366 
(66.0) 





2.3. – Inconsistency of the results and directions for future research  
In the light of the above systematic review, four methodological issues appear to 
contribute to the mixed results concerning the association of insight with suicide risk in 
patients with schizophrenia and other psychotic disorders (Lopez-Morinigo et al., 2012).  
First, an explanation for the above inconsistent results may relate to selection bias, to 
which cross-sectional studies are subject. For example, insight may have been seen to be a risk 
factor for suicide due to the presence of a suicide attempt in the past in patients with 
reasonable insight (Gonzalez, 2008; Foley et al., 2008; Harvey et al., 2008; Acosta et al., 2009; 
Bakst et al., 2009). However, the presence of a SA in the past actually could represent an 
independent variable which may influence the levels of insight at the time of assessment. In 
other words, a psychotic patient who had made a SA before his/her acute episode, when 
asked whether he/she may have a mental illness (as part of the insight assessment), may be 
more likely to give a positive response, in contrast to those who had not developed such 
behaviour. Whether the patient is attributing the SA or the psychotic symptoms to what 
he/she calls ‘mental illness’ could not be inferred from his/her response, i.e. the insight 
assessment, particularly if insight was assessed in a simple unidimensional or dichotomous 
fashion.  
Second, another problem affecting cross-sectional studies is recall bias - where patients 
are relied upon to give previous instances of SA. A more insightful patient may be more likely 
to remember and report such episodes plus such events, which of course are likely to be 
distressing,  and they may also be more readily recalled if the current mood state is low 
(Gonzalez, 2008; Foley et al., 2008; Harvey et al., 2008; Acosta et al., 2009). This also links with 
the aforementioned relationship between insight and depression, which indeed deserves 
further theoretical debate (Belvederi et al., 2015). 
Third, another methodological aspect to highlight concerns the assessment of insight. 
Only 6 (out of 20) studies in this review (Amador et al., 1996; Yen et al., 2002; Evren & Evren, 
2004; Harvey et al., 2008; Acosta et al., 2009; Salgado et al., 2010) used a validated 
multidimensional scale to assess insight, which encompasses both the SAI-E (Kemp & David, 
1997) and the SUMD (Amador et al., 1993). One of them was positive (Harvey et al., 2008), but 
this was a cross-sectional study (thus subject to both selection and recall biases) and also, one 
of the main insight dimensions (treatment compliance) was not associated with greater 
suicidality. These different results, according to the scale used, seem consistent with Hawton et 
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al.’s meta-analysis (Hawton et al., 2005), which reported poor compliance to be a significant 
risk factor for suicide, whilst failing to find a robust association between insight and suicide. 
Therefore, it is possible that some dimensions of insight may be associated with increasing 
suicide risk, while others are not (Amador et al., 1996; Yen et al., 2002; Acosta et al., 2009).  
Fourth, the statistical analyses need to be considered when drawing conclusions from 
these studies. For example, insight lost its significant association with greater risk of suicide, 
which had been reached by the bivariate analyses, after conducting multiple regression 
analysis in at least six studies (Kim et al., 2003; Bourgeois et al., 2004; Evren et al., 2004; Bakst et 
al., 2009; Robinson et al., 2010; Kao & Liu, 2011). Interestingly, multivariable regression 
analyses tended to find depression as the main contributor to suicide risk (e.g. Baskt et al., 
2009; Restifo et al., 2009; Barrett et al., 2010a). 
In summary, cross-sectional studies (subject to both selection and recall biases) with 
unidimensional scales that do not carry out multivariable analyses may have a tendency to 
show false positive associations between insight and a greater suicide risk.  
Hence, further research studies examining this clinically relevant question, namely the 
potential link between insight and suicide risk in psychosis, need to consider the following 
methodological aspects. First, larger sample sizes are required since suicide attempts, and 
especially suicides, represent rare phenomena. Second, longer follow-up periods from the first 
psychotic episode are necessary in order to capture a sufficient number of suicidal events that 
facilitates further statistical analyses and account needs to be taken of attrition. Although 
methodologically challenging, insight should be reassessed over the follow-up in order to 
capture its dynamicity and how insight changes influence suicide risk. Third, insight should be 
assessed with a validated multidimensional scale such as the SAI-E (Kemp & David, 1997) and 
SUMD (Amador et al., 1991). These methodological issues were considered when designing 
this investigation (see chapters 4-7). In addition, the possibility that service structure and other 
study variables may modify suicide risk should be acknowledged. 
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2.4. – Aims of this thesis  
i. To describe the demographic characteristics of those patients with schizophrenia 
spectrum disorder (SSD) from the South London and Maudsley NHS Foundation Trust 
(SLaM) presenting between 2007 and 2013 who completed suicide (chapter 3). 
ii. To compare these SSD suicide completers with i) non-SSD suicide completers; and ii) 
non-suicide completers with SSD; in terms of demographic and clinical variables, 
service use-related factors, suicide methods, the Health of the Nation Outcome Scale 
(HoNOS) and risk assessment ratings (chapter 3). 
iii. To describe the risk of suicide in two prospectively ascertained cohorts of patients 
(aged: 18-65 years) admitted to the SLaM wards with a FEP and followed up over a 
median of 7 years (chapters 4 and 5), and in the combined sample (chapter 6) 
ascertained in the same manner. 
iv. To analyse whether particular dimensions of insight - awareness of having a mental 
illness, ability to relabel symptoms as pathological and treatment compliance - act as 
risk or protective factors for suicidal behaviours in the above FEP cohorts within the 
follow-up, whilst adjusting the analyses for a range of putative demographic and 
clinical variables that may mediate the relationship between insight domains and risk 
of suicide (chapters 4, 5, 6). 
v. To describe the risk of suicide in a prospectively ascertained cohort of 397 FEP patients 
(aged: 18-65 years) from Santander (Spain) and followed-up over 3 years (chapter 7). 
vi. To analyse whether particular dimensions of insight - awareness of having a mental 
illness, awareness of the social consequences of the illness and treatment compliance - 
act as risk or protective factors for suicidal behaviours within the follow-up, whilst 
adjusting the analyses for a range of putative demographic and clinical variables that 
may mediate the relationship between insight domains and risk of suicide (chapter 7). 
vii. To cross-compare the findings from these two cohorts of FEP patients, including a 
comparison with previous literature, in order to determine the role of insight in the risk 
of suicidal behaviours in early psychosis (chapter 8).  
78 
 
2.5. – Hypotheses 
Based on the above review of previous literature and my own clinical experience, with 
regard to the role of insight dimensions in risk of suicidal behaviour after first presentation 
with psychosis, generally speaking I hypothesised that there will be differences amongst the 
different domains. In particular, I postulated that: 
Hypothesis 1 (H1): Recognition of mental illness increases risk. 
Hypothesis 2 (H2): Symptom relabeling is linked with greater risk. 
Hypothesis 3 (H3): Awareness of the social consequences of the illness is associated with 
increased risk.  
Hypothesis 4 (H4): However, regarding hypotheses 1, 2 and 3 above, the relationships 
between the above insight dimensions and risk of suicidal behaviour in psychosis will 
be confounded by depression and previous suicide attempts, both of which will be 
linked with both insight levels at first presentation with psychosis and suicidal 
behaviour risk over the follow-up periods.  
Hypothesis 5 (H5): Awareness of need for treatment will (directly) reduce suicide risk.   
Hypothesis 6 (H6): Overall insight will not be significantly associated with increased (or 




Figure 2.2. Hypothesised model to be tested in this thesis  







Chapter 3  – Suicide completion by patients with 
schizophrenia in secondary mental healthcare. Data from the 
South London and Maudsley (SLaM) Biomedical Research 
Centre (BRC) Case Register 
 
3.1. – Introduction 
This chapter describes the epidemiology of suicide completion in patients with 
schizophrenia spectrum disorders (SSD) who received care under secondary mental health 
services from the South London and Maudsley NHS Foundation Trust. 
I identified a population of secondary mental healthcare users who completed suicide 
over the study period (2007-2013) from the SLaM case register, which is linked to national 
mortality data.  
First, I conducted a comparison study in order to investigate demographic and clinical 
differences, including service use-related factors and the Health of the Nation Outcome Scale 
(HoNOS) (Wing et al., 1994) and risk assessment ratings, between those patients with and 
without SSD receiving secondary mental healthcare who completed suicide (Lopez-Morinigo 
et al., 2014b).  
Second, I carried out a case-control study aimed to examine specific risk factors for 
suicide in patients with SSD (Lopez-Morinigo et al., 2016). Specifically, I compared those 
subjects with SSD who completed suicide, i.e. ‘cases’, with a group of unmatched ‘controls’, i.e. 
individuals with SSD drawn from the same register who did not end their lives in this way. In 
addition, I tested whether there was a relationship between disengagement, which is linked to 
lack of insight (Amador & David, 2004), and risk of suicide completion.  
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3.2. – Background 
As detailed in chapter 1, suicide is a serious international public health problem. Every 
year almost one million people die by suicide around the world (WHO, 2014). Of note, suicide 
has become especially concerning among young people as one of the three leading causes of 
death in the most economically productive age group (15-44 years) and the second leading 
cause of death in 15-19 year olds (Patton et al., 2009). Since 2008, suicide prevention has 
become a major priority within the World Health Organization mental health policies (WHO, 
2008). However, suicide prevention strategies have yielded mixed results so far (Hawton & 
van Heeringen, 2009). Moreover, suicide rates in the UK have remained unchanged over the 
past five years (NCISH, 2015). 
Recent literature on suicide seems to support a ‘suicidal spectrum’ ranging from 
suicidal ideation to suicide completion, with decreasing prevalence and increasing lethality 
(Bebbington et al., 2010). However, suicide attempters and suicide completers appear to be two 
different, although overlapping, populations (Innamorati et al., 2008; Giner et al., 2013). 
Nevertheless, these differences between suicide attempters and completers have not been 
replicated in patients with SSD (Innamorati et al., 2008; Giner et al. 2013).   
With regard to suicide completion, psychological autopsy studies have revealed that 
about 90% of people who killed themselves had a ‘psychiatric disorder’ (Arsenault-Lapierre et 
al., 2004), contributing to 47-74% of the population risk of suicide, with half of suicide 
completers meeting criteria for depression (Cavanagh et al., 2003; Hawton et al., 2003). 
Therefore, the presence of a psychiatric condition appears to be the strongest known risk factor 
for suicide (Cavanagh et al., 2003).  It could therefore be envisaged that better management of 
mental disorders might reduce suicide rates. More specifically, secondary mental health 
services may play a crucial role in ‘suicide prevention’ (WHO, 2013).  
While a list of risk factors have been strongly associated with ‘suicidal behaviour’, it 
remains unclear the extent to which ‘known’ risk factors vary across psychiatric diagnoses 
(Arsenault-Lapierre et al., 2004). In particular, a better understanding of associations between 
risk factors and diagnoses may lead to the development and implementation of diagnosis-
driven suicide prevention strategies in secondary mental health services (Lopez-Morinigo et 
al., 2014b). For instance, limiting access to suicide methods has been demonstrated to reduce 
suicide rates at a population level (e.g. Kreitman, 1976; Bennewith et al., 2007). However, it 
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remains unclear whether there are specific associations of psychiatric diagnoses with suicide 
completion methods (Nielssen et al., 2010).  
Suicide has been found to be the largest single cause of excess mortality in 
schizophrenia (Brown, 1997; Saha et al., 2007), particularly in early psychosis (Dutta el al., 
2010). However, the rate of suicide in schizophrenia has been recently reported to be lower, 
from 2% (Dutta et al., 2010) to 5% (Palmer et al., 2005), than the previously quoted figure of 
10% (Miles, 1977; Caldwell & Gottesman, 1990). 
While some recognised general suicide risk factors have been replicated in 
schizophrenia patients such as being male, living alone and hopelessness; specific suicide risk 
factors, such as lower treatment adherence, have also been linked to schizophrenia (Hawton et 
al., 2005).  Patients with schizophrenia tend not to report suicidal ideation (Bakst et al., 2009), 
which is a common suicide risk factor for most other psychiatric conditions (Hawton & van 
Heeringen, 2009).  Also, suicide risk assessment in schizophrenia remains under-utilized 
(Pedersen et al., 2014).  It therefore seems that the classic suicide prevention model has been 
less helpful in schizophrenia spectrum disorders than in other diagnoses. Specific suicide 
completion characteristics in patients with schizophrenia and related disorders in comparison 
to other diagnoses have not been investigated fully. 
Over the last two decades the UK Department of Health has aimed to reduce suicides 
at a national level (DoH, 1984). In keeping with this, structured clinical risk assessments were 
strongly recommended by the UK NICE guidelines in 2004 (NICE, 2004) and widely used. 
However, more recent reviews of the NICE guidelines have voiced concerns about the limited 
role of risk assessment tools and scales in the clinical management of the patients (NICE, 2011). 
Moreover, a recent meta-analysis showed that risk scales are of little use for predicting repeat 
self-harm in suicide attempters (Quinlivan et al., 2016). However, the extent to which these 
instruments can predict suicide risk in patients with schizophrenia spectrum disorders (SSD) 
receiving secondary mental healthcare has not been sufficiently examined (Pedersen et al., 
2014). Moreover, concerns have been voiced regarding the role of risk assessment in 
preventing suicide in patients with schizophrenia (Large & Ryan, 2014). Also, it remains 
poorly understood what specific factors evaluated by the risk assessment lead patients with 
schizphrenia under the care of mental health services to take their own lives. 
First, I aimed to investigate differences across diagnoses (SSD vs. non-SSD) in a sample 
of patients receiving secondary mental healthcare from teams supervised by Consultant 
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Psychiatrists (i.e. not those treated solely by general practitioners (family physicians) in 
primary care) in South-East London who went on to die from suicide. Sociodemographic and 
clinical variables, including HoNOS and ‘risk assessment’ ratings and ‘service use’-related 
factors, and suicide methods were compared between patients with and without schizophrenia 
spectrum disorders (SSD) who all died by suicide. I am the principal author of a peer-reviewed 
paper summarising the findings (Lopez-Morinigo et al., 2014b). 
Second, I investigated potential predictors of suicide completion in patients with SSD 
receiving secondary mental healthcare. Sociodemographic and clinical variables, including 
HoNOS and ‘risk assessment’ ratings and ‘service use’-related factors, were compared between 
patients with SSD who died by suicide and unmatched controls drawn from the same case 
register, i.e. subjects with SSD who did not complete suicide in the same time frame.  
Specifically, I tested whether early first contact with services, being male, white, single and 
unemployed, living alone, depression and related variables, particularly hopelessness and 
suicidal ideation, and suicidal history are associated with increased risk of suicide completion 
in patients with SSD under secondary mental healthcare. Also, I postulated that engagement 
with services, which is associated with insight (Amador & David, 2004), would reduce suicide 
risk in patients with SSD under secondary mental healthcare, in keeping with the fifth 
hypothesis of this PhD research project (H5) listed in chapter 2 (section 2.5.). This analysis 
resulted in a further peer-reviewed publication of which I am the principal author (Lopez-
Morinigo et al., 2016). 
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3.3. – Aims and objectives  
3.3.a. – Descriptive aims and objectives 
 To describe the demographic characteristics of those patients with 
schizophrenia spectrum disorder (SSD) presenting between 2007 and 2013 
who completed suicide. 
 To compare patients with/without SSD who took their lives. 
 To compare methods of suicide across groups and describe unascertainable 
causes of death. 
 To compare patients with SSD who died from suicide with those who did not. 
 
3.3.b. – Analytical aims and objectives 
 To calculate differences in demographic and clinical variables, including the 
Health of the Nation Outcome Scale (HoNOS) and risk assessment ratings, 
between patients with and without SSD who took their lives. 
 To calculate differences in suicide methods across suicide completers 
with/without SSD. 
 To calculate differences in demographic and clinical variables, including 
HoNOS and risk assessment ratings, between patients with SSD who 
completed suicide and those with SSD who did not. 
 To investigate independent risk factors for suicide. Specifically, to assess the 
inter-relationships between factors associated with suicide completion. 
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3.4. – Methods 
3.4.a – Sample information 
The sample comes from the South London and Maudsley (SLaM) Biomedical Research 
Centre (BRC) Case Register. SLaM is an NHS Trust which provides secondary mental health 
care to four boroughs in South-East London (UK): Lambeth, Southwark, Lewisham and 
Croydon. Approximately 1.23 million inhabitants reside in this geographic catchment area, 
which as a whole was found to be comparable with other populations of London in terms of 
age, gender, education and socio-economic status distributions (Stewart et al., 2009; Perera et 
al., 2016).  
Fully-electronic health records have been in use across all SLaM services since 2006, 
and in 2007-08 the Clinical Record Interactive Search (CRIS) system was built which renders 
de-identified copies of these available for research use with appropriate governance structures 
(Stewart et al., 2009). Under UK law, anonymised data can be analysed without prior consent, 
and CRIS has received ethical approval in this respect as a data resource for secondary 
analyses from the Oxfordshire Research Ethics Committee C (reference: 08/H0606/71+5) (see 
appendix 1) currently accessing data on over 250,000 patients.  
This Research Ethics approval also covers the pseudonymised linkage between CRIS 
data and those from the Office for National Statistics (ONS) in January 2014 (ONS, 2014), 
which registers all deaths in the UK and the official cause of death, including suicide and the 
method of suicide according to ICD-10 classification (ICD-10). 
In particular, those patients who were ‘active’ to SLaM (i.e. had at least one face-to-face 
contact with a clinical member of staff) before 31st December 2013 and had died by suicide 
(according to the death certificate details obtained from ONS (ONS, 2014)) over the period 
from 1st January 2007 to 31st December 2013 were included. Those with an ‘undetermined 
cause of death’ (ICD-10 Y codes) (ICD-10) were included in the suicide group because in the 
UK most ‘open verdicts’ are very likely to be deaths by suicide since the coroner, who under 
UK law certifies the official cause of death, is required to provide evidence of suicide intent 
‘beyond reasonable doubt’ (Linsley et al., 2001).  
In addition, for the case-control study I selected those suicide completers with a 
primary diagnosis of schizophrenia spectrum disorders (ICD-10 codes F2). Five ‘controls’ were 
selected per ‘case’, although this was not a randomisation algorithm. Thus, for each patient 
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who completed suicide the five individuals with a primary diagnosis of SSD who were 
assessed by a SLaM member of the staff after the date of first contact with services of the index 
case were taken from SLaM BRC CRIS. The controls were unmatched for demographic or 
clinical variables to allow investigation of between-groups differences.   
 
3.4.b. – Measures 
3.4.b.1. – Demographic and clinical variables 
Date of birth, gender, ethnicity, and marital and employment status are compulsory 
fields in the source clinical records system and were analysed.  
Social deprivation was estimated with the ‘Index of Multiple Deprivation’ (IMD). In 
particular, area-level deprivation scores were available through an anonymous link created in 
CRIS between lower super output area residence code of the latest permanent address (a 
geographic unit comprising approximately 400 households) and summary data for that area 
from 2001 UK Census output. The Index of Multiple Deprivation is derived from seven 
domains: income, employment, health, education, housing and services, crime and 
environment (ONS, 2007). 
In addition, the type of the last antipsychotic recorded (classic oral, atypical oral, 
clozapine, depot) and use of antidepressants (yes/no) over the study period were analysed. 
Also, patient legal status under the UK Mental Health Act 1983 (Amended 2007) (DoH, 
2008) was considered. I investigated whether being subject to a ‘Community Treatment Order’ 
(CTO) (DoH, 2008) was associated with risk of suicide completion in patients with SSD. 
 
3.4.b.2. – Diagnosis 
ICD-10 diagnoses (WHO, 1993) were made by the treating consultant psychiatrist. As a 
result, those patients who were just seen on one occasion such as a single presentation to A&E 
or one outpatient appointment were more likely not to be diagnosed as reported below. For 
analyses described in the first section of results, categories were hierarchically created from 
ICD-10 codes (WHO, 1993). Thus, only one of the following exclusive diagnostic categories 
were recorded if the patient had received more than one ICD-10 primary diagnosis: ‘F2’ – 
‘schizophrenia spectrum disorder’ (SSD); ‘F31 and F32.3’ – ‘Affective Psychosis’; ‘F32.1, F32.2, 
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F33, F34 and F4’ – ‘Mood disorder/Neuroses’; ‘F0 and F1’ – ‘Organic/Drugs’; ‘F5, F6 and the 
remaining categories’ were grouped as ‘All other diagnoses’. Other patients were labelled as 
‘Diagnosis Unknown’ because they either had a F99 or Z71.1 ICD-10 diagnosis or no diagnosis 
was recorded. Patients with two or more ICD-10 (WHO, 1993) primary diagnoses over time 
were included in only one of the above categories according to a diagnostic hierarchy.  For 
instance, a patient with two primary ICD-10 diagnoses such as F2 and F0 was classified as SSD. 
Whilst many patients with SSD have other comorbidities such as cannabis misuse (e.g. Morgan 
et al., 2010a), given the higher stability of schizophrenia diagnosis over time (Bromet et al., 
2005), we chose this category as the first in our hierarchical system.  This allowed me to create 
two clinically meaningful categories to compare: those patients with SSD and those with non-
SSD.    
 
3.4.b.3. – Cause of death, suicide ascertainment and suicide method 
Suicide method was ascertained from that recorded in the ONS Certificate of Death 
(ONS, 2014). ICD-10 codes (WHO, 1993) of the official cause of death (ONS, 2014) and the 
following groups were considered: poisoning – X64; hanging – X70; drowning - X71; cutting - 
X78; jumping (either from high place or in front of a vehicle) - X80, X81; suicide by unspecified 
means – X84; and undetermined cause of death – Y10-34.  
Of note, there were also deaths from natural causes in the control group. ICD-10 codes 
of cause of death were recorded and nine categories were created as follows: i) neoplasms 
(C259-900); ii) diseases of the endocrine system (E141-149); iii) organic mental disorders (F03-
09); iv) diseases of the nervous system  (G060-409); v) diseases of the circulatory system (I119-
850); vi) diseases of the respiratory system (J180-459); vii) diseases of the digestive system 
(K709-859); viii) diseases of the genitourinary system (N390); and ix) other ill-defined and 








3.4.b.4. – Health of the Nation Outcome Scale (HoNOS) 
The Health of the Nation Outcome Scale (HoNOS) has been a widely used outcome 
measure in British mental health services since its introduction in the 1990s.  It has been 
reported to be a reliable and valid instrument to assess clinical outcomes, and to have easy 
applicability to clinical settings (Wing et al., 1994). HoNOS is formed of 12 items which assess 
psychopathological symptoms, alcohol/drugs use, cognitive performance and social needs. 
Each item is scored on a Likert scale from 0 (absent) to 4 (maximum severity), and the 12 scores 
are summed to create total scores, i.e. the higher the score, the more complex/severe the case. 
The last HoNOS score recorded was used for this study.  
 
3.4.b.5. – Risk assessment 
‘Full risk assessment’ is a compulsory target across the Trust when ‘high risk’ is 
deemed from a ‘brief risk assessment’, which is mandatory for all active cases.  All patients 
who have been seen on at least one occasion by a member of the staff have a ‘brief risk 
assessment’ documented, which is a narrative record of the patient’s risk: i) to self; ii) to others 
and iii) from others. If the patient is deemed at ‘high’ risk in any of these domains, a ‘full risk 
assessment’ needs to be completed, which consists of a structured assessment taking the form 
of present/absent tick-boxes enquiring about widely recognised risk factors for three major 
clusters: suicide, violence and self-neglect. For this study, only suicide risk assessment was 
taken into account, which is composed of 15 items. Positive responses can be summed to create 
total scores, i.e. the higher the score the greater the suicide risk (Wu et al., 2012). The most 
recent full risk assessment was considered for these analyses.  
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3.4.c. – Statistical analysis 
First, distributions of continuous variables were inspected by histograms and 
parametric and non-parametric tests were used in order to examine differences across the 
above ‘diagnostic categories’ with regard to demographic and clinical variables. Post-hoc 
analyses investigated inter-groups differences. This analysis was also conducted to compare 
those patients with SSD who died from suicide with: i) those non-SSD patients who ended 
their lives; and ii) those patients with SSD who did not take their lives (i.e. ‘controls’ in both 
analyses).  
People dying from suicide with/without SSD were compared in the following respects: 
i) on demographic and clinical variables using student t tests, Mann-Whitney U tests and Chi-
square tests, as appropriate; ii) on suicide methods, calculating odds ratios and adjusting for 
age at the time of death and ethnicity; iii) on HoNOS, where completed, both individual 
HoNOS item (Mann-Whitney-U) and total scores (student t-test); iv) on full risk assessment 
ratings (Chi-square tests were used for individual items and t-test compared total scores across 
groups). Again, those subjects with SSD who took their lives were compared with the two 
control groups in the above respects. 
In addition, receiver operating characteristic (ROC) curves (Hanley & McNeil, 1982) 
were plotted to assess the performance, namely sensitivity and specificity, of risk assessment 
total scores to predict suicide in patients with SSD. Also, the prevalence of suicide in 
schizophrenia (5%) (Palmer et al., 2005) was used to estimate the positive and negative 
predictive values.   
Finally, binary logistic regression models were built to investigate predictors of suicide 
completion. Those statistically significant variables from the above univariate analyses 
concerning ‘cases and controls’ were added to a first binary logistic regression model. A final 
regression model was conducted with the independent variables that remained significant. 
Odds Ratios (ORs) and 95% Confidence Intervals (CIs) were calculated. Specifically, the 
percentage of variance on the dependent variable (i.e. suicide completion) explained by each 
model (through the Nagelkerke R2), the percentage of individuals correctly classified across 
groups (suicide completers and non-suicide completers) and the individual contribution of 
each independent variable to the model (ORs, 95%CIs) were investigated. 
All analyses were conducted using SPSS version 22.0 (SPSS Inc, Chicago, Il, USA). 
90 
 
3.5. – Results 
Of 120,216 SLaM ‘active’ service users until the 31st December 2011, 308 who died by 
suicide over 2007-2011 were identified from the SLaM BRC CRIS and 54 subjects with SSD 
(17.5%) died from suicide over the period 2007-2011, who were compared with 254 non-SSD 


















SSD: Schizophrenia spectrum disorder 
54 (17.5%) 
SSD 









Figure 3.1. Flow chart of CRIS patients. Comparison study between suicide 
completers with/without SSD 
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Of 242,227 SLaM ‘active’ service users until 31st December 2013, 635 suicides were 
identified from the SLaM BRC CRIS. Of these individuals, 96 patients (15.1%) had a 
schizophrenia spectrum disorder (F2-ICD10) diagnosis. Those who died before 1st January 2007 
(n=25) were removed from the analyses since full electronic records before 2007 were 
unavailable. Therefore, 71 individuals with SSD who took their lives over 2007-2013 were 
compared with 355 subjects with SSD without this outcome (controls) from the SLaM BRC 




































SSD suicide completers 
(cases) 
355 
SSD non-suicide completers  
(controls) 
s 
Figure 3.2. Flow chart of CRIS patients until 2013. Case-control study between suicide 
completers with SSD (cases) and patients with SSD who did not die from suicide (controls) 
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3.5.a. – Comparison study of suicide completers: SSD vs. non-SSD 
3.5.a.1. – Sociodemographic and clinical characteristics 
 Sociodemographic and clinical characteristics are compared between those with and 
without SSD in Table 3.1. No diagnostic differences were observed in gender; however, age at 
the time of suicide was younger in those with SSD than the remainder. There were significant 
group differences in ethnicity across suicide completers’ diagnoses with Black ethnicity more 
frequent in patients presenting with SSD. IMD scores were higher in SSD compared to the 
remainder.  
Of note, SSD cases had received longer duration of care from the Trust teams (1294 vs. 
81 days) and had been seen by a member of the staff substantially more recently before the 






















 Means ± SD   
Age at death 42.7 ± 14.0 39.3 ± 11.9 43.5 ± 14.4  0.04 
Deprivation (IMD) 28.0 ± 13.7 32.1 ± 11.4 27.1 ± 14.0  0.01 
 N (%)   
Gender (males) 211 (68.5) 38 (70.3) 173 (68.1) 1.11 (0.58-2.11) 0.87 
Ethnicity      
     White 187 (60.7) 26 (48.4) 161 (63.4) 0.54 (0.30-0.97) 0.04 
     Black 36 (11.7) 20 (37.0) 16 (6.3) 8.75 (4.14-18.5) <0.01 
     Others 85 (27.6) 8 (14.8) 77 (30.3) 0.40 (0.18-0.88) 0.02 
First language English 147 (47.7) 34 (62.9) 113 (44.5) 2.12 (1.15-3.88) 0.01 
 Medians (days)   
Length of service contact 184 1294 81  <0.01 
Last face-to-face to death 70 10 146  <0.01 
SSD: schizophrenia spectrum disorder. OR: Odds Ratio. CI: Confidence Interval. SD: Standard deviation.   IMD: Index of Multiple 
Deprivation (ONS, 2007) 
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3.5.a.2. – Suicide method 
As shown in Table 3.2., ‘hanging’ was the most common suicide method in the sample 
overall (131, 42.5%). SSD suicide cases had more frequently utilized ‘jumping’, while ‘hanging’ 
was significantly more frequent among the remainder.  There were no suicides by firearms. 
 
Table 3.2. Suicide method: schizophrenia spectrum disorder (SSD) vs. non-SSD 




























































































3.5.a.3. – Health of the Nation Outcome Scale (HoNOS) 
116 suicide completers (37.6%) had at least one HoNOS completed. Completion rates 
differed across diagnoses: 83.3% of those with SSD; 35.0% of the remainder (OR=12.9, 95%CI 
6.0-27.7, p<0.001). On individual items, patients with SSD scored significantly higher on 
‘hallucinations & delusions’, while subjects with non-SSD had higher scores on ‘depressed 
mood’ and ‘self-injury’ (Table 3.3).  
 
Table 3.3. Health of the Nation Outcome Scale (HoNOS): Individual items 
 and total scores in SSD and non-SSD suicide completers 
 SSD 
n=45 
(45/54 = 83.3%) 
non-SSD 
n=69 
(69/254 = 35.0%) 
p-value 
Individual items    
  Agitated behaviour 0.44 0.51 0.65 
  Self-injury 0.18 1.03 <0.01 
  Drinking & Drugs 0.71 0.70 0.92 
  Cognitive Problems 0.31 0.59 0.30 
  Physical Illness 0.82 0.68 0.99 
  Halluc./Delus. 1.22 0.29 <0.01 
  Depressed Mood 0.89 1.80 <0.01 
  Other mental issues 1.38 1.65 0.64 
  Relationship 1.07 1.17 0.80 
  Daily living 0.87 0.87 0.90 
  Living 0.67 0.59 0.76 
  Occupational 0.96 0.78 0.70 
Total score 9.55 10.52 0.41 
 SSD: schizophrenia spectrum disorder 
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3.5.a.4. - Full risk assessment 
As described in Table 3.4., only 40 suicide completers (13%) had at least one full risk 
assessment completed: 19 SSD (35.2%) vs. 21 non-SSD (8.3%) (OR=6.0, 95%CI 2.9-12.3, p<0.01). 
Mean ± SD total scores were lower in SSD (4.1 ± 2.9) compared to non-SSD (6.2 ± 2.2; t=-2.65, 
p=0.01). With regard to individual items, patients who had SSD receiving a full risk assessment 
were less likely to be recorded as having ‘suicidal ideation’, ‘hopelessness’, ‘lack of control 
over life’, ‘impulsivity’ or a ‘significant loss’; while ‘disengagement’ was more common in 
individuals with SSD at borderline statistical significance. 
 

















Individual items      
Suicidal History 26 (65) 11 (57.9) 15 (71.4) 0.55 (0.15-2.05) 0.37 
Lethal Method 15 (37.5) 5 (26.3) 10 (47.6) 0.39 (0.10-1.49) 0.16 
Plan to end life 8 (20) 2 (10.5) 6 (28.6) 0.29 (0.05-1.68) 0.15 
Suicidal ideation 16 (40) 4 (21) 12 (57.1) 0.2 (0.05-0.81) 0.03 
Hopelessness 18 (45) 4 (21) 14 (66.6) 0.13 (0.03-0.55) <0.01 
Distress 17 (42.5) 7 (36.8) 10 (47.6) 0.64 (0.18-2.27) 0.49 
No control of life 15 (37.5) 4 (21) 11 (52.4) 0.24 (0.06-0.98) 0.04 
Alcohol/Drugs 11 (27.5) 7 (36.8) 4 (19.0) 2.47 (0.59-10.40) 0.21 
Impulsivity 18 (45) 5 (26.3) 13 (61.9) 0.22 (0.06-0.84) 0.03 
Living alone 18 (45) 8 (42.1) 10 (47.6) 0.80 (0.23-2.80) 0.73 
Poor physical health 9 (22.5) 4 (21) 5 (23.8) 0.85 (0.19-3.79) 0.83 
Significant loss 18 (45) 5 (26.3) 13 (61.9) 0.22 (0.06-0.84) 0.03 
Disengagement 9 (22.5) 7 (36.8) 2 (9.5) 5.54 (0.98-31.25) 0.06 
Recent Discharge  11 (27.5) 5 (26.3) 6 (28.6) 0.89 (0.22-3.59) 0.87 
Family History 0 0 (0) 0 (0) n/a n/a 
Total score  4.11 ± 2.88 6.24 ± 2.19  0.01 
SSD: schizophrenia spectrum disorder. OR: Odds Ratio. CI: Confidence Interval 
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3.5.b. – Case-control study: suicide completers with SSD vs. non-suicidal SSD patients 
As alluded to above, of 242,227 SLaM ‘active’ service users until the 31st December 
2013, 635 suicides were identified from the SLaM BRC CRIS. Of these 635 subjects who took 
their lives, 96 patients (15.11%) had a diagnosis within the schizophrenia spectrum (F2-ICD10). 
Those who died before 1st January 2007 (n=25) were removed from the analyses since full 
electronic records before 2007 were unavailable. Thus, 71 suicide completers and 355 controls 
matched for diagnosis were drawn from the SLaM BRC CRIS. 
 
3.5.b.1. - Sociodemographic and clinical characteristics of the sample 
Sociodemographic and clinical characteristics of the whole sample are presented in 
Table 3.5, including comparisons across groups.  
Specifically, while age at first referral did not differ across groups, suicidal patients 
were significantly younger at the time of first contact with services than controls (34.5 ± 12.6 
vs. 39.2 ± 15.2, t=-2.43, p=0.01). Also, when compared with those controls who died from 
natural causes (n=25), age at death remained significantly younger in the suicidal group (38.5 ± 
13.2 vs. 63.2 ± 17.6, t=-6.40, p<0.01).  
There was a higher male predominance in cases compared to controls (OR=2.07, 95%CI 
1.18-3.65, p=0.01). However, no group differences in marital status, employment or ethnicity 
























OR (95% CI) p-value 
Age at first referral (years) 33.9 ± 21.2 30.3 ± 21.1 34.6 ± 21.2  0.12 
Age at first contact (years) 38.4 ± 14.9 34.5 ± 12.6 39.2 ± 15.2  0.01 
Age at death (years) 44.9 ± 18.0 38.5 ± 13.2 63.2 ± 17.6*  <0.01 
Gender (males) 254 (59.6) 52 (73.2) 202 (56.9) 2.07 (1.18-3.65) 0.01 
Marital status (unmarried) 387 (90.8) 66 (92.9) 321 (90.4) 1.36 (0.51-3.60) 0.65 
Unemployed 182 (87.1) 28 (82.3) 154 (88.0) 0.64 (0.24-1.72) 0.40 
Ethnicity      
  White 189 (44.4) 33 (46.5) 156 (43.9) 1.17 (0.66-1.85) 0.70 
  Black  165 (38.7) 25 (35.2) 140 (39.4) 0.83 (0.49-1.42) 0.59 
  South-Asian 24 (5.6) 5 (7.0) 19 (5.3) 1.34 (0.48-3.71) 0.57 
  Others 27 (6.3) 4 (5.6) 23 (6.4) 0.86 (0.29-2.57) 0.79 
Social Deprivation (IMD) 31.9 ± 11.3 30.2 ± 12.2 32.3 ± 11.1  0.18 





3.5.b.2. - Service use-related factors 
As detailed in Table 3.6., suicide completers were seen by a member of the staff within 
a shorter period of time from the first referral than controls (medians: 20 vs. 133 days, 
respectively), although this difference did not reach significance (p=0.12). Suicide completers 
had received significantly shorter duration of care from the Trust teams (medians-days: 1283 
vs. 2517, p<0.01) than controls and a number of cases had been seen by a member of the staff 
very shortly before the suicide event (median=10 days). 
No significant differences in terms of type of last antipsychotic medication prescribed 
or use of antidepressants emerged from the analyses. Also, the percentage of subjects under 





































Length from referral  
to first contact (median, days)  
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20 133  0.12 
Length of service contact  
(median, days) 
2255 1283 2517  <0.01 
Last face-to-face to death 
(median, days) 
16* 10 63*  0.05 
Last hospital discharge to death 
(median, days) 
233* 161 571*  0.24 
Antipsychotic      
   Oral classic 10 (2.3) 2 (2.8) 8 (2.2) 1.15  
(0.24-5.58) 
0.70 
   Oral atypical 200 (46.9) 38 (53.5) 162 (45.6) 1.27 
(0.65-2.49) 
0.51 
   Clozapine 24 (5.6) 2 (2.8) 22 (6.2) 0.39 
(0.09-1.72) 
0.27 
   Depot 80 (18.8) 12 (16.9) 68 (19.1) 0.75 
(0.37-1.52) 
0.49 
Antidepressant 76 (17.8) 16 (22.5) 60 (16.9) 1.43 
(0.77-2.66) 
0.31 
SCT 18 (4.2) 3 (4.2) 15 (4.2)  1.00 
*including those who died from natural causes (n=41) and suicide completers (n=71).  
SCT: Supervised Community Treatment. OR: Odds Ratio. CI: Confidence Interval 
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3.5.b.3. - Cause of death and suicide method 
As shown in Table 3.7., there were 25 deaths from natural causes amongst controls, 
being diseases of the circulatory system (n=6) the most common natural cause of death.  
With regard to suicide completers, hanging (n=14) and jumping (n=13) were the most 
common suicide methods. Twenty-six individuals received an open verdict (undetermined 
cause of death).  There were no suicides by firearms. 
 
Table 3.7. Cause of death - ICD-10 codes 
Natural cause 25 
   Neoplasms (C259-710) 3 
   Endocrine system (E141-149) 2 
   Mental disorders (F019-209) 3 
   Nervous System (G060-409) 2 
   Circulatory System (I119-850) 6 
   Respiratory System (J180-449) 3 
   Digestive system (K709-859) 2 
   Genitourinary system (N390) 3 
   Unspecified causes of mortality (R99) 1 
Unnatural causes 71 
   Hanging (X70) 14 
   Jumping (X81, X81) 13 
   Poisoning (X60) 4 
   Drowning (X71) 4 
   Cutting (X78) 2 
   Unspecified means (X84) 8 







3.5.b.4 - Health of the Nation Outcome Scale (HoNOS) 
61 suicide completers (85.9%) and 315 controls (88.7%) had at least one HoNOS 
completed. Completion rates did not significantly differ across groups (p=0.54). As detailed in 
Table 3.8. below, neither HoNOS total score nor did individual items significantly differ 
between groups.   
 
Table 3.8. Health of the Nation Outcome Scale (HoNOS): Individual items and 
total scores comparison in suicide completers (cases) and non-suicide completers 
with SSD (controls) 











Individual items    p-value 
Agitated behaviour 0.55 0.39 0.58 0.50 
Self-injury 0.15 0.20 0.14 0.25 
Drinking & Drugs 0.55 0.57 0.54 0.81 
Cognitive Problems 0.58 0.39 0.62 0.09 
Physical Illness 0.97 0.79 1.00 0.23 
Hallucinations/Delusions 1.16 1.11 1.17 0.96 
Depressed Mood 0.82 0.90 0.80 0.93 
Other mental problems 1.34 1.41 1.32 0.62 
Relationship problems 1.05 1.02 1.06 0.87 
Daily living 0.96 0.97 0.96 0.98 
Living conditions  0.63 0.82 0.59 0.73 
Occupational problems 1.02 1.03 1.02 0.63 







3.5.b.5. - Full risk assessment 
As shown in Table 3.9., 31 suicide completers (43.6%) and 214 controls (60.3%) had at 
least one full risk assessment completed (OR=0.51, 95%CI 0.30-0.85, p=0.01).  
Mean ± SD total scores were lower in suicide completers than controls: 3.19 ± 2.17 vs. 
4.52 ± 2.98 (t=3.39, p=0.02), respectively. Differences in individual items are detailed in Table 
2.10. Specifically, the following items were significantly associated with an increased risk of 
suicide completion as follows: ‘suicidal history’ (OR=4.42, 95%CI 2.01-9.65, p<0.01), ‘previous 
use of violent method’ (OR=3.37, 95%CI 1.47-7.74, p=0.01), ‘suicidal ideation’ (OR=3.57, 95%CI 
1.40-9.07, p=0.01) and ‘recent hospital discharge ’ (OR=2.71, 95%CI 1.17-6.28, p=0.04). 
Table 3.9. Full Risk Assessment: Completion rates, individual items and total 

















Individual items      
Suicidal history 69 (28.2) 18 (58.1) 51 (23.8) 4.42 (2.01-9.65) <0.01 
Violent method 41 (16.7) 11 (35.5) 30 (14.0) 3.37 (1.47-7.74) <0.01 
Plan to end life 9 (3.7) 3 (9.7) 6 (2.8) 3.71 (0.88-15.69) 0.09 
Suicidal ideation 27 (11.0) 8 (25.8) 19 (8.9) 3.57 (1.40-9.07) 0.01 
Hopelessness 26 (10.6) 6 (19.3) 20 (9.3) 2.33 (0.85-6.35) 0.11 
Distress 71 (29.0) 11 (35.5) 60 (28.0) 1.41 (0.64-3.12) 0.40 
No control of life 50 (20.4) 10 (32.2) 40 (18.7) 2.07 (0.90-4.74) 0.09 
Alcohol/Drugs 78 (31.8) 14 (45.1) 64 (29.9) 1.93 (0.90-4.15) 0.10 
Impulsivity 81 (33.1) 11 (35.5) 70 (32.7) 1.13 (0.51-2.49) 0.84 
Living alone 95 (38.8) 10 (32.2) 85 (39.7) 0.72 (0.32-1.61) 0.55 
Poor physical health 71 (29.0) 5 (16.1) 66 (30.8) 0.43 (0.16-1.17) 0.14 
Significant loss 63 (25.7) 9 (29.0) 54 (25.2) 1.21 (0.53-2.79) 0.66 
Disengagement 91 (37.1) 14 (45.2) 77 (36.0) 1.46 (0.68-3.13) 0.33 
Recent discharge 42 (17.1) 10 (32.2) 32 (15.0) 2.71 (1.17-6.28) 0.04 
Family history 9 (3.7) 0 (0) 9 (4.2) n/a 0.62 
Total score 3.3 ± 2.3 4.5 ± 2.9 3.1 ± 2.2  0.02 
SSD: schizophrenia spectrum disorder. OR: Odds Ratio. CI: Confidence Interval 
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ROC curve analyses for risk assessment total scores (see figure 3.3 below) found the 
most optimal cut-off point to be 3-4, with a sensitivity of 0.58 and specificity of 0.57. The area 
under the curve was 0.63 (95%CI 0.51-0.74), which is shown in figure 1 below. If we assume 
that the prevalence of suicide in these patients is 5% (Palmer et al., 2005), the positive 
predictive value was 0.06, while the negative predictive value was 0.96. 
 









3.5.b.6. - Multivariable binary logistic regression models 
Age at first contact with services, gender and four items from the risk assessment, 
namely suicidal history, use of violent method, suicidal ideation and recent discharge from 
hospital, which had been significantly associated with suicide completion in the above 
univariate analyses, were added to the model (see Table 3.10).  
However, only age at first presentation (OR=0.94, 95%CI 0.90-0.98, p<0.01), suicidal 
history (OR=4.07, 95%CI 1.80-9.18, p<0.01) and suicidal ideation (OR=3.06, 95%CI 1.14-8.20, 
p=0.03) survived as significant predictors of suicide completion. The final binary logistic 
regression model shown in table 3.11 (χ2=29.771, df=3, p<0.01) explained 21.5% (Nagelkerke 
R2) of the variance on suicide completion and overall correctly classified 86.5% of the subjects. 
Specifically, 98.6% of non-suicides and 3.2% of suicides were predicted by the model. 
 
Table 3.10. Multivariable regression model: suicide completion as the dependent variable 
 B SE Wald p OR 95% CI 
Age at first contact -0.06 0.02 8.84 <0.01 0.94 0.90 - 0.98 
Gender 0.32 0.46 0.47 0.49 1.37 0.55 - 3.41 
Suicidal history 1.20 0.56 4.60 0.03 3.31 1.11 - 9.89 
Violent method 0.32 0.61 0.28 0.59 1.38 0.42 - 4.55 
Suicidal ideation 1.11 0.52 4.54 0.03 3.03 1.09 - 8.39 
Recent hospital discharge  0.80 0.48 2.79 0.09 2.23 0.87 - 5.72 
Model χ2=33.599, df=6, p<0.001.  
 
   Table 3.11. Final regression model: suicide completion as the dependent variable 
 B SE Wald p OR 95% CI 
Age at first contact -0.06 0.02 9.31 <0.01 0.94 0.90 - 0.98 
Suicidal history 1.40 0.41 11.42 <0.01 4.07 1.80 - 9.18 
Suicidal ideation 1.12 0.50 4.94 0.03 3.06 1.14 - 8.20 
  Model χ2=29.771, df=3, p<0.001 
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3.6. – Discussion 
3.6.a. – Principal findings 
In a large clinical case register sourced from electronic mental health records linked to a 
national death certification database, I investigated characteristics of patients with SSD dying 
from suicide. First, I compared these subjects with those patients without SSD who took their 
lives. Second, I conducted a case-control study in order to examine potential predictors of 
suicide in SSD, including engagement, which is related to insight, by comparing subjects with 
SSD who completed suicide with those individuals with SSD who did not complete suicide in 
the same time frame.  
Thus, a population of secondary mental healthcare users who completed suicide over 
the study period (2007-2013) was identified from our case register. Nearly one in five of the 
suicide completers had been diagnosed with schizophrenia spectrum disorders (SSD), which is 
approximately double that in previous reports (Arsenault-Lapierre et al., 2004), although this 
may reflect the high prevalence of psychotic disorders in South-East London (Fearon et al., 
2006). 
When suicide completers with/without SSD were compared, I found that SSD patients 
were more likely to have full risk assessment and HoNOS documented than non-SSD subjects. 
However, the classic risk factors evaluated by these instruments were significantly more 
common in non-SSD patients (Lopez-Morinigo et al., 2014b). This led me to designing the 
second study in which I compared SSD patients who took their lives (cases) with controls, i.e. 
SSD patients who did not end their lives (Lopez-Morinigo et al., 2016).  
Thus, early first contact with mental health services, suicidal history and suicidal 
ideation were associated with suicide completion. Owing to low frequency and lack of 
statistical power, suicide completion in SSD is not a predictable occurrence, with only 21.5% of 
the variance explained by the final regression model, yet older age at first contact with mental 
health services and lack of both suicidal history and suicidal ideation are useful protective 
markers indicative of those less likely to end their own lives.  As postulated, disengagement 
increased risk of suicide, although this relationship did not reach statistical significance 
(Lopez-Morinigo et al., 2016).  
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3.6.b. – Sociodemographic and clinical variables 
Several differences were found in sociodemographic characteristics between SSD and 
other diagnoses. Specifically, those subjects with SSD died at a younger age, they tended to be 
more commonly of Black origin and they were more socially deprived than non-SSD suicide 
completers, which replicated previous findings in our catchment area with non-suicide 
samples (Kirkbride et al., 2008; Aschan et al., 2013). Thus, while some previous studies have 
shown an association between psychosis and Black ethnicity (Fearon et al., 2006), other groups 
have raised concerns regarding a diagnostic bias towards psychosis in Black people (Gara et 
al., 2012; McKenzie, 2012). However, previous studies from our group, which carefully 
considered the above potential bias in the methodology, revealed a link between Black 
Ethnicity, social deprivation and psychosis in our catchment area (Morgan et al., 2010a). 
Hence, the findings concerning differences between patients with and without SSD who died 
by suicide in terms of social deprivation and ethnicity might reflect specific sociodemographic 
characteristics of our population irrespective of such a fatal outcome despite previous 
literature showing a relationship between ethnicity and suicide (McKenzie, 2012; Al-Sharifi et 
al., 2015).   
In keeping with the above, the case-control study revealed that those subjects with SSD 
who died by suicide had their first contact with mental health services at a younger age than 
SSD controls, which is consistent with previous studies showing an increased suicide risk in 
early psychosis (e.g. Dutta, 2010), although late onset behaved as a risk factor in an 
epidemiological study from Taiwan (Kuo et al., 2005). Moreover, when suicide completers 
were compared with those controls who died from natural causes (see Table 3.5.), these 
controls were found to have a significantly longer life expectancy, 63 vs. 38 years, thus 
providing further support for suicide prevention in early psychosis. Regarding gender, I 
replicated an increased risk of suicide completion in males (Hu et al., 1991; De Hert et al., 2001; 
Sinclair et al., 2004; Kuo et al., 2005; Hawton, 2005).  
Of relevance, neither being unemployed nor unmarried was associated with increased 
suicide risk, which was, however, consistent with a previous meta-analysis (Hawton et al., 
2005).  Also, despite previous literature showing a relationship between ethnicity and suicide 
(Hawton et al., 2005; McKenzie et al., 2012; Al-Sharifi et al., 2015), I failed to replicate such an 
association. However, it should be noted that being single, unemployed and of Black ethnicity 
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are characteristics of a majority of people with psychosis living in south-east London (Fearon 
et al., 2006; Kirkbride et al., 2008). 
 
3.6.c. – Suicide method 
With regard to suicide method, I found that while hanging was the most common 
suicide method in the whole sample, patients with SSD were more likely to have used 
‘jumping’ (from an height or in front of a vehicle) to take their lives, consistent with previous 
literature on suicide completion and methodology (Hawton & van Heeringen, 2009; Nielssen 
et al., 2010; McGirr et al., 2006; McGirr & Turecki, 2008).  
Hence, in line with previous literature (Hu et al., 1991; De Hert et al., 2001; McGirr et 
al., 2006; McGirr & Turecki, 2008; Hawton et al., 2009; Nielssen et al., 2010; Dutta et al., 2010), I 
replicated that hanging and jumping (from an height or in front of a vehicle) were the most 
common suicide methods in patients with SSD, although patients with SSD were reported to 
kill themselves by taking overdoses in Finland (Heilä, 1997). Of note, no suicides by firearms 
were identified in the study, which is in line with previous reports from the UK (e.g. Dutta et 
al., 2010) and other European countries (e.g. De Hert et al., 2001), thus reflecting the restrictions 
to firearms access compared with the USA. It should be noted that firearms are ubiquitous in 
the USA and the high level of firearm ownership has been directly associated with an 
increased risk of firearm-related mortality (Bangalore & Messerli, 2013), including suicide 
(Kposowa et al., 2016). 
In keeping with this, limiting availability of lethal methods has been demonstrated to 
reduce suicide rates at a population level (Kreitman, 1976; Hawton & van Heeringen, 2009). 
Also, restricting access to suicide hotspots such as heights through safety barriers (e.g. 
(Bennewith et al., 2007) and railway lines by installing platform edge doors (Law et al., 2009) 
has been reported to reduce overall suicide rates at such places (Cox et al., 2013). Hence, 
installing physical barriers in bridges, tall buildings and railway stations, particularly when 
placed near psychiatric hospitals, given our replication finding concerning the increased 
suicide risk after discharge, may prevent patients with SSD from suicide (Lopez-Morinigo, 
2014b). Although restricting access to means of hanging appears to be more challenging, such a 
planned method requires a longer period of time during which these individuals may be 
identified through welfare checks or Home Treatment Team visits.       
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3.6.d. – Health of the Nation Outcome Scale (HoNOS) and risk assessment ratings 
Of relevance, it seems that clinicians deem patients who have SSD at greater risk of 
suicide than other patients and they are therefore more likely to have received a full risk 
assessment, as well as having a higher likelihood of HoNOS completion, which is relatively in 
contrast to previous literature (Pedersen et al., 2014). However, the above instruments may 
have been completed due to concerns raised regarding other risks such as violence and/or self-
neglect. Interestingly, known suicide risk factors, which are evaluated by these tools, tended to 
be less commonly recorded as present in those who have SSD than in subjects with non-SSD. 
Also, the predictive models were of little value to identify those individuals with SSD who 
completed suicide (as explained below).  
 
3.6.d.1. – Health of the Nation Outcome Scale (HoNOS) 
With regard to HoNOS items in our sample of suicide completers, while symptoms 
severity such as depressed mood and ‘hallucinations & delusions’ differed across diagnostic 
groups, as expected, interestingly ‘social needs’, ‘cognitive deficits’ or ‘alcohol/drugs 
problems’ did not (significantly) vary between suicide completers with SSD and without SSD. 
In this regard, it could be speculated that the care package provided to these patients by the 
Trust succeeded in meeting their complex social needs and accordingly the most recent 
HoNOS scores regarding social needs did not reveal differences across the above diagnostic 
categories. An alternative explanation might be that there are no associations between 
(met/unmet) social needs, psychiatric diagnosis and suicidality. In keeping with this, the case-
control study failed to find these relationships.  
 
3.6.d.2. – Risk assessment 
Interestingly, known suicide risk factors tended to be less commonly recorded as 
present in those who have SSD than in subjects with non-SSD. Of relevance, disengagement 
was found to be (significantly) more frequent in SSD than non-SSD suicide completers, 
however. Despite the above, half of suicide completers with a SSD had been seen by a member 
of the staff shortly before such a fatal outcome, which is in line with previous studies showing 
the relative inability of clinicians to predict imminent suicide risk in individuals with SSD 
under their care (Heilä et al., 1997; Tarrier et al., 2006).  
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Of note, SSD controls were more likely to have a full risk assessment documented than 
suicide completers, which was relatively in contrast to previous literature (Pedersen et al., 
2014). Alternatively, this difference may have been due to the longer care received by non-
suicidal subjects. Also, a full risk assessment may have been completed due to concerns raised 
regarding other clusters of risk such as violence and/or self-neglect (Wu et al., 2012), as 
alluded to above. Moreover, recording of risk assessment has been reported to be, to some 
extent, circular. Specifically, some data from risk assessments following self-harm are more 
likely to be recorded if episodes result in a specialist assessment (Kapur et al., 2008). 
In line with our hypotheses and previous research (Hu et al., 1991; De Hert et al., 2001; 
Sinclair et al., 2004; Hawton et al., 2005; Dutta et al., 2010) I replicated the role of suicidal 
history and suicidal ideation (Hawton et al., 2005; Popovic et al., 2014), previous use of a 
violent method and recent hospital discharge (NCISH, 2015) in suicide risk in psychosis. These 
factors were, however, more common in patients with non-SSD who died by suicide. 
Moreover, no associations of hopelessness, impulsivity, alcohol/drugs misuse, living alone or 
significant losses with suicide completion were found in line with previous literature in suicide 
and psychosis (McGirr et al., 2006; Dutta et al., 2011). Also, most of suicide completers with 
SSD did not have most of the factors evaluated by the risk assessment with the exception of 
‘suicidal history’. Hence, suicide in SSD may represent a challenge to the classic suicide model 
(Mann et al., 1999), particularly regarding the role of hopelessness (Beck et al., 1990) and 
impulsivity (Mann et al., 1999; Baca-Garcia et al., 2005a).  
In addition, the ROC curves showed that risk assessment total scores performed poorly 
in terms of sensitivity, specificity and positive predictive value, while the test had a very high 
negative predictive value, which is in full agreement with a recent systematic review of risk 
assessment scales for predicting repeat self-harms in suicide attempters (Quinlivan et al., 2016). 
Of relevance, a history of disengagement was found to be present in nearly half of the 
suicide completers with SSD, which was a non-significantly higher proportion than in non-SSD 
patients. However, most of suicides in the SSD group occurred shortly after having been seen 
by a member of the staff, which is in line with previous studies showing the relative inability 
of clinicians to predict imminent suicide risk in individuals with SSD under their care (Hu et 




3.6.e. – Service use-related factors 
In terms of mental health services use-related factors, those who completed suicide, 
were also more likely to have a suicide history, as discussed below, tended to have a shorter 
interval between the referral and first contact with services. These findings are in full 
agreement with two previous first-episode psychosis studies which suggest that suicidal 
behaviour preceding first contact with services appears to shorten the duration of untreated 
psychosis (DUP), which in both studies was reported to be a high-risk period, leading the 
patient to receive psychiatric attention earlier (Upthegrove et al., 2010; Lopez-Morinigo et al., 
2014a). Moreover, psychotic symptoms in adolescents appear to be a clinical marker for future 
suicidal behaviour both in the general population (Kelleher et al., 2012; Kelleher et al., 2013) 
and in clinical samples (Kelleher et al., 2014). 
Also, the duration of care was significantly shorter in those who died from suicide 
compared to non-suicidal patients but this is most likely the consequence of suicide bringing 
care to a halt. More importantly, I replicated the high suicide risk during the immediate period 
after hospitalization (Hu et al., 1991; Sinclair et al., 2004; Heilä et al., 1997; De Hert et al., 2001; 
NCISH et al., 2015). In particular, half of our suicide completers took their lives over the 6-
month period after being discharged from a psychiatric ward. Hence, close monitoring over 
that period of time should be strongly recommended (Popovic et al., 2014; NCISH, 2015).   
There have been recommendations on the use of antidepressants (Siris, 2000; Siris et al., 
2001; Sinclair et al., 2004) and depot antipsychotics (Sinclair et al., 2004) for suicide prevention 
in schizophrenia and related disorders. However, our findings do not provide further support 
for these guidelines. Similarly, in spite of the anti-suicidal properties of clozapine (eg. Meltzer 
et al., 2003; Bourgeois et al., 2004), I was unable to show a particular benefit for this drug. 
These results were in line with previous case-control studies (De Hert et al., 2001; Kuo et al., 
2005), which all may have lacked sufficient statistical power to test the role of the above 
interventions in suicide prevention in psychosis.  
Also, receiving community mental healthcare under restriction in accordance with the 
UK Mental Health Act 1983 (Amended 2007) (DoH, 2008), which is known as Community 
Treatment Order (CTO), did not appear to prevent patients with SSD from suicide. These 
findings seem to be consistent with the UK National Confidential Inquiry into Suicide and 
Homicide 2015 report (NCISH, 2015). In particular, there were 42 suicides in patients subject to 
a community treatment order (CTO) between 2009 and 2013 in England. Moreover, the suicide 
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rate was significantly higher in CTO patients (2.0 per 1,000 CTOs in 2009-2012) than in the 
general population (9.4/100,000-year), as expected, since CTO patients are selected for risk on 
hospital discharge. Indeed, 19 of the 42 deaths (45%) occurred within 3 months of hospital 
discharge, which is a high-risk period (Hawton et al., 2005), as replicated by our findings. In 
addition, 6 patients who died from suicide while subject to a CTO had been non-adherent with 
drug treatment in the month before death and 9 had missed the last appointment with 
services; 2 had both refused treatment and missed the last appointment. Therefore, 31% of 
those who died from suicide were not receiving care as intended despite CTO powers, which 
suggests that gaining insight, rather than legal restrictions, may improve engagement with 
services, thus reducing suicide risk.     
Although a recent randomized controlled trial (RCT) showed that CTO did not reduce 
the number of readmissions over a 12-month follow-up in patients with psychotic disorders 
(Rugkåsa et al., 2015), no data on suicidal behaviour were reported. Hence, further research in 
this controversial area is warranted in order to clarify whether CTOs can help to tackle suicide 
in SSD.  However, a randomized controlled trial aimed to answer such a research question 
raises ethical issues since in the above study (Rugkåsa et al., 2015) patients in the control group 
were not receiving care voluntarily but under Section 17 of the UK Mental Health Act (DoH, 
2008). In other words, the RCT to clarify this matter would have to compare patients under 
CTO with high-risk subjects (hence, probably fulfilling criteria for CTO according to the 












3.6.f. – Strengths and limitations 
This study focused on the rare outcome of suicide completion. Moreover, by using a 
large case register linked to national mortality data all those patients with a diagnosis of SSD 
who were receiving secondary mental healthcare in our catchment area and died by suicide 
over 2007-2013 were included in the study with the only exception of those who completed 
suicide outside the UK. Of note, most of patients were followed-up over a prolonged period 
(median=6.17years). Since only a small proportion of patients living in South-East London 
receive private mental health care, the sample is likely to be representative. In addition, a wide 
range of demographic and clinical variables, including service use-related factors and specific 
scales such as HoNOS and ‘risk assessment’, were analysed.  
However, these results should be considered in the light of several limitations. First, the 
sample was formed of secondary mental health services users living in south-east London, an 
inner-urban area, and results may not generalise to people receiving mental health input from 
primary care or those in rural areas. Second, HoNOS and risk assessment ratings were not 
available for a number of participants. Also, I can speculate that those patients who had 
HoNOS and risk assessment completed were deemed ‘at-high-risk’ by their clinical teams. In 
addition, although just the last HoNOS and risk assessment were considered for the analyses, 
risk factors evaluated by those instruments may have changed from that point to death. Hence, 
the findings regarding HoNOS and risk assessment ratings should be interpreted with caution. 
Also, it should be noted that a wide range of variables have been taken over a prolonged 
period of time, which also varies across the study patients, who ranged from having one single 
assessment to several years under secondary mental healthcare, thus reflecting the real-world 
nature of our data. Finally, other non-tested variables such as premorbid personality (Giner et 




3.6.g. – Implications and directions for future research 
Risk of suicide completion in patients with SSD appears to be highly unpredictable. In 
particular, early first contact with mental health services, previous suicidal history and suicidal 
ideation were found to be the strongest predictors of suicide completion in patients with SSD, 
which is in line with recent recommendations to tackle suicide in schizophrenia (Popovic et al., 
2014). However, given the low predictive value of our model to identify suicide completers, 
which was also consistent with the short time from last contact with a mental health 
professional to dying from suicide, no suicide prevention strategies at an individual level can 
be drawn from our findings.  
Also, nearly half of the suicide completers had a history of disengagement with 
services, although the differences did not reach significance. Hence, there are grounds to 
consider that insight, which has been associated with adherence (Amador & David, 2004), 
might be a protective factor for suicide in schizophrenia spectrum disorders via increased 
compliance and engagement, which has been demonstrated to reduce suicide rate both in early 
psychosis (Barrett et al., 2015) and mixed samples (Sinclair et al., 2004; Hawton et al., 2005) 
despite common assertions to the contrary (see (Lopez-Morinigo et al., 2012)). 
In addition, stigma, which prevents patients from receiving proper care (Alonso et al., 
2007), may play a relevant role in suicide risk in patients with SSD who disengage from 
secondary mental health services (Thornicroft & Mansella, 2013). Nevertheless, more research 
is needed to test whether anti-stigma campaigns can reduce suicide rates both at a population 
level and in high-risk groups such as mental health service users with SSD.  
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3.7 – Chapter Summary 
In line with our hypotheses, early first contact with mental health services, suicidal 
history and suicidal ideation were associated with suicide completion. Owing to low frequency 
and lack of statistical power, suicide completion in SSD is not a predictable occurrence, with 
only 21.5% of the variance explained by the final regression model, yet older age at first contact 
with mental health services and lack of both suicidal history and suicidal ideation are useful 
protective markers indicative of those less likely to end their own lives.   
Interestingly, disengagement from services was found to be a risk factor for suicide 
completion in patients with SSD. Hence, there are grounds to consider that insight may reduce 
suicide risk in patients with SSD via improved adherence, which is in line with the PhD 
hypotheses detailed in chapter 2 (section 2.5), particularly H5.   
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Chapter 4 - Suicidal behaviour in early psychosis. Findings 
from the Genetics and Psychosis (GAP) study (London, UK) 
 
4.1. – Introduction 
This chapter describes the predictors of suicidal behaviour in a 3-year follow-up first-
episode psychosis (FEP) cohort from London (UK). In particular, the role of three insight 
dimensions - recognition of having a mental illness, symptom relabelling and awareness of the 
need for treatment - in suicidal acts (including suicide attempts and suicide completion) over 
the follow-up period was investigated. Also, these analyses were adjusted for a set of 
demographic and clinical variables, which may mediate/confound the above relationships and 
therefore influence the rate of suicidal acts. 
Some of the analyses presented below have been published as a peer-reviewed article, 
namely the influence of suicidal history on insight levels at first presentation with psychosis 
(Lopez-Morinigo et al., 2014a). However, for the purposes of this thesis I have focused on 
suicidal events ‘after’ first presentation with psychosis, thus considering survival to a first 
suicide attempt (including suicide completions) over the follow-up period in relation to insight 
levels at baseline.  
 
4.2. - Background 
The rate of suicide in schizophrenia has been recently reported to be approximately 5% 
(Palmer et al., 2005). More recently, a large epidemiological study with a cohort of FEP patients 
(n=2,783) who were followed-up over 10 years has estimated this risk at 1.9% (Dutta et al., 
2010). While these figures are lower than the previously quoted estimate of 10% (Miles, 1977; 
Caldwell & Gottesman, 1990), suicide risk in schizophrenia and related disorders remains 
unacceptably high, representing the largest single cause of excess mortality in schizophrenia 
(Brown, 1997; Saha et al., 2007; Dutta et al., 2012). Moreover, between 15-26% of FEP patients 
have made at least one suicide attempt by their first treatment contact and 2–11% attempt to 
end their lives over the first year after treatment onset (Melle et al., 2006). Yet, it remains 
unknown the number of patients with an undiagnosed first episode of psychosis who take 
their lives within the context of the onset of a psychotic illness.  
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A seminal meta-analysis by Hawton and colleagues published in 2005 summarised 
suicide risk factor studies in schizophrenia. Of note, previous depressive disorder, previous 
suicide attempts, drug misuse, agitation or motor restlessness, fear of mental disintegration 
and recent loss were reported to be the most robust risk factors. Interestingly, compliance with 
treatment was demonstrated to reduce suicide risk (Hawton et al., 2005; Qin et al., 2006). In 
keeping with the above, a more recent systematic review in first-episode psychosis (Pompili et 
al., 2011) revealed that suicide risk factors in psychosis are stage-related. 
Regarding risk changes over time, some studies showed that the periods of the highest 
risk of suicide in FEP patients are shortly before and after hospitalization (Melle et al., 2006; 
Harvey et al., 2008: Ayesa-Arriola et al., 2015). One study (Flanagan & Compton, 2012) found 
that nearly one-quarter of patients endorsed a history of suicidal ideation in the two weeks 
prior to first admission and they should also be carefully monitored at initiating treatment and 
over the early stages of the course of the psychotic illness. However, it should be pointed out 
that such a history may influence clinicians in the decision to admit and hence this observation 
is somewhat circular.  
Studies testing the role of insight in risk of suicide in psychosis have attracted interest 
although so far results are inconclusive (Hawton et al., 2005; Pompili et al., 2011; Lopez-
Morinigo et al., 2012; Melle & Barrett, 2012;). Insight has been suggested to increase suicide 
risk, particularly in early psychosis, due to the so-called ‘demoralization syndrome’ (Drake & 
Cotton, 1986), a notion widely held amongst clinicians. Briefly, those patients who are more 
aware of having such a devastating illness, i.e. those with greater insight, would tend to 
become depressed and develop feelings of hopelessness, including a potential increased risk of 
suicide. On the other hand, denial of illness and subsequent poor compliance with treatment 
was found to increase suicide risk in schizophrenia (Hawton et al., 2005). Hence, there are 
grounds to consider that insight, which is linked with compliance (Amador & David, 2004), 
may reduce suicide risk via improved adherence.  
Also, it could be argued that suicidal behaviours preceding first presentation with 
psychosis, which is the strongest predictor of further suicidal events (Hawton et al., 2005; 
Pompili et al., 2011), may affect insight levels at that point. As detailed in chapter 2, a few 
cross-sectional studies conclude that insight is a risk factor for suicide on the basis that those 
patients with greater insight had a higher prevalence of previous suicidal acts than those with 
poorer insight (Harvey et al., 2008; Gonzalez, 2008; Schennach-Wolff et al., 2009). This is taken 
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to support notions that acquiring insight may damage self-esteem and lead to depression 
(Drake & Cotton, 1986; Restifo et al., 2009). However, such results may be subject to both 
selection and recall bias (Lopez-Morinigo et al., 2012). Furthermore, applying the temporality 
criterion of causality (Hill, 1965) may lead me to suggest that, on the contrary, suicidal 
behaviours preceding FEP may influence later insight at first presentation, either directly or 
through some mediating variables. To my knowledge, only my 2014 study (Lopez-Morinigo et 
al., 2014a), which is presented in this chapter, has investigated the potential influence of 
suicidal acts preceding FEP on insight dimensions at first presentation (at baseline). 
Thus, in this chapter I will present research (now published: Lopez-Morinigo et al., 
2014a) concerning the association of previous suicidal history with multiple insight dimensions 
at first contact with services using data from the Genetics and Psychosis (GAP) study, which 
recruited a sample of incidence cases with a FEP. In particular, I hypothesised that FEP 
patients with a past history of suicidal behaviour would have a greater ‘awareness of mental 
illness’ and ’symptom relabelling’ at first presentation than non-suicidal FEP patients.  This is 
because prior suicidal events might have been a consequence of certain psychotic symptoms 
such as distress or hallucinations and therefore a suicidal history might help these patients to 
more easily recall at the time of insight assessment such psychotic phenomena and the 
(potential) illness underlying them. On the other hand, ‘compliance’ should be less associated 
with such antecedents since suicidal patients have a tendency to be less open to receiving 
external help, i.e. they tend to try and deal with problems themselves.  
Next I will present the results of having followed-up this FEP cohort over a median 
period of 3 years in order to ascertain the influence of each insight domain on later risk of 
suicidal behaviours, including suicide attempts (SA) and suicide completions (SC), i.e. to test 




4.3. - Aims and Objectives 
4.3.a. – Descriptive aims and objectives 
 To describe the distribution of insight dimensions according to the outcome of 
suicidal behaviours, including both suicide attempts and suicide completions. 
 
4.3.b. – Analytical aims and objectives 
 To investigate whether there is an association between a history of suicidal 
behaviours before first presentation with psychosis and insight levels at that time of 
first assessment.  
 To adjust the above analyses for a set of potential confounders in order to 
determine independent predictors of insight at baseline, including the role of 
previous suicidal history.  
 To calculate the case fatality of this FEP sample over the 3-year follow-up period. 
 To identify the risk factors associated with suicidal behaviours in a FEP cohort over 
a 3-year follow-up period. 
o And to determine whether there is an association of insight levels with risk 
of suicidal behaviours over the 3-year follow-up.  
 To test for potential interactions between insight dimensions and other clinical and 
demographic variables related to risk of suicidal behaviour. 
 To formulate a model, based on a multivariable Cox regression analysis of the 
above baseline variables, including insight dimensions, for predicting suicidal 





4.4. - Method 
4.4.a. – Participants, study design, setting and follow-up 
The data for this part of the thesis are derived from the National Institute of Health 
Research Biomedical Research Centre (NIHR BRC) Genetics and Psychosis (GAP) study. All 
patients aged 18-65 years who presented with a FEP to the South London and Maudsley NHS 
Foundation Trust, which provides secondary mental healthcare to four boroughs in South-East 
London (Southwark, Lambeth, Lewisham and Croydon), were approached within the first 
week of admission. In total, N=252 incidence FEP patients met GAP inclusion criteria and 
agreed to take part in the study (i.e. approximately 44% of those who were approached). Those 
who had been administered the expanded version of the Schedule for the Assessment of 
Insight (Kemp and David, 1997; Sanz et al., 1998) at the study inception (n=112) were included 
in this study.  
The GAP study obtained ethical approval from the local research ethics committees and 
participants provided written informed consent.  
Inclusion criteria were fulfilling ICD-10 (WHO, 1993) criteria for psychosis (codes F20-
F29 and F30-32 with psychotic features) according to the clinical team, including assessment by 
at least one senior psychiatrist. Exclusion criteria were moderate to severe learning disabilities 
as defined by ICD-10 (WHO, 1993), poor English fluency (i.e. the participant would require an 
interpreter), a history of previous contact with health services (GP or Psychiatric) for psychosis 
and a known organic cause of psychosis. In addition, given the specific aims of this thesis, only 
those patients with an insight assessment at baseline through the Schedule for Assessment of 
Insight – Expanded version (SAI-E) (Kemp & David, 1997) could be included.  
The GAP study, which first started in 2004, has a cross sectional case-control design 
and investigates a wide variety of potential risk factors, biological markers, physical health 
measures, psychological, psychopathological, neurocognitive and socio-demographic 
differences between patients presenting to psychiatric services for the first time with psychosis 






Box 4.1. – GAP study battery summary 
Fasting blood sample (esp. investigating DNA, proteomics, glucose levels, transcriptomics) 
and physical health measures.  
Questionnaires (focusing on childhood experiences, stress, physical health, drug use). 
Measures of psychopathology (including the PANSS and others). 
Salivary cortisol sampling. 
Brain scan (structural and functional MRI, Diffusion Tensor Imaging). 
Neuropsychological battery. 
  
Screening was carried out through a variety of channels to ensure the maximum level 
of recruitment and minimise selection bias. Researchers took a weekly list of all new 
admissions to SLaM wards which may assess or treat psychotic patients, and screened 
patients’ clinical notes to assess for suitability. This was supplemented with regular 
communication with doctors, nurses and healthcare assistants on the wards. The study aimed 
to approach patients presenting with a functional psychosis within the catchment area. This 
was done as soon as possible after admission (and no more than 6 months after their first 
contact with services). This involved regular updates from ward teams regarding new patients, 
and appropriate patients usually being approached first by a member of staff, before the 
research team contacted them.  Recruitment from wards was supplemented with recruitment 
from community teams and home treatment teams (<10% of patients) where resources were 
available to cover these.  
Once a patient was deemed to be suitable and after checking with the ward team that it 
would not be detrimental to the patient or of undue risk to the researcher, participants would 
be approached, invited to participate in the study and given information and consent sheets. If 
patients were willing and able to give informed consent, they would read through the consent 
form, confirm that they fully understood the study, were assured that they could drop out at 
any time without giving any reason and sign the forms. Some patients would be approached 
on several occasions to ensure they had fully understood the information. If patients asked not 
to be approached again, this was, of course, honoured. 
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Once a patient consented, assessments were carried out as quickly as possible in the 
minimum necessary number of visits, taking into account the attention span and availability of 
the patient. Assessments were either carried out on the ward, at the team base or at the 
patient’s home. 
All recruitment and assessments were carried out by trained psychologists or 
psychiatrists and under the overall supervision of senior researchers and principal 
investigators. One of those assessments consisted of an interview using the Schedule for the 
Assessment of Insight – Expanded version (SAI-E) (Kemp & David, 1997), which is detailed 
below. The patients who took part in the SAI-E interview formed the subsample for this thesis.  
In order to obtain suicide-related information on each patient at 3 years (minimum 
follow-up period based on power calculations reported in section 4.4.c.1. below), all cases were 
traced through a procedure performed by several GAP researchers which included contacting 
the patient via a phone call and/or a letter and contacting the GP. Also, data from this cohort 
were linked with the Office for National Statistics (ONS), which in the UK records the official 
cause of death by using ICD-10 codes.  
 
4.4.b. – Measures 
4.4.b.1. – Premorbid, sociodemographic and clinical variables 
Information was obtained from patients, relatives and medical records in the GAP 
study. This included sex, age at admission, age at onset and duration of untreated psychosis 
(DUP), which was estimated from the patient’s medical notes with the Nottingham Onset 
Schedule (Singh et al., 2005). The time from the date of the first continuous psychotic symptom 
(lasting at least a week) to the date of commencing on antipsychotic medication (having taken 
75% of doses within the following month) was taken. 
Other sociodemographic variables collected were: level of education, relationship 
status (“married” vs. “unmarried”), living status (“alone” vs. “other”), employment status 
(“employed”, “student” or “unemployed”), cannabis use (yes/no) and alcohol use (yes/no). In 
particular, all participants were asked about their use of illicit drugs and those who reported 
ever using cannabis were interviewed using the Cannabis Experience Questionnaire (see Di 




4.4.b.2. – Insight 
The Schedule for Assessment of Insight – Expanded version (SAI-E) (Kemp & David, 
1997) was used to evaluate insight. This is a semi-structured interview easily applicable to 
clinical practice (Sanz et al., 1998) that provides several separate insight scores based on 
David’s model (David, 1990): ‘awareness of mental illness’, ‘relabelling of psychotic symptoms 
as abnormal’ and ‘compliance’. Researchers were trained by the scale author demonstrating 
good inter-rater reliability (Morgan et al., 2010b). Of note, the SAI-E was found to strongly 
correlate with other insight scales, including the Scale to Assess Unawareness of Mental 
Disorder (SUMD) (Sanz et al., 1998), which was used in chapter 7 (Santander cohort). This 
allowed cross-comparison of the findings from these two cohorts, which are presented in the 
general discussion (Chapter 8).  
 
4.4.b.3. – Neurocognitive tests 
The National Adult Reading Test (NART) (Nelson & Willison, 1991) was used to 
evaluate the premorbid Intelligence Quotient (IQ). Also, the short version of the Wechsler 
Adult Intelligence Scale Revised (WAIS-R, Wechsler, 1981) provided an accurate estimate of 
the current IQ (full scale). 
Executive function was assessed by the Trail Making Test (Reitan, 1958), which 
involves connecting numbers (Trails A) or alternating numbers and letters (Trails B). The time 
(in seconds) taken to complete the task was the dependent variable. Subtracting time to 
complete Trails A from Trails B gives an overall measure of executive function, after having 
controlled for the effect of processing speed. 
 
4.4.b.4. – Psychopathological symptoms 
With regard to psychopathology, in the GAP study five psychopathological dimensions 
were measured with the Positive and Negative Symptoms Scale for Schizophrenia (PANSS, 
Kay et al., 1987) based on a previous systematic review of PANSS factor analyses (Wallwork et 
al., 2012): positive (items P1, P3, P5 and G9), negative (items N1, N2, N3, N4, N6 and G7), 
disorganization (items P2, N5 and G11), mania (items P4, P7, G8 and G14) and depression 
(items G2, G3 and G6).  
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4.4.b.5. – Suicide attempts information 
Suicidal behaviours were taken from medical records and defined as ‘any potentially 
self-injurious behaviour for which the person intended to kill himself/herself’ (O'Carroll et al., 
1996). In particular, any suicidal act before first contact with psychiatric services and any 
further suicidal behaviours were registered, which included suicide attempts and suicide 
completions. Information on suicidal behaviour was available for the entire sample.  
In addition, I identified all occurrences of death and emigration in the cohort over the 
follow-up period via a person-tracing procedure conducted by the Office for National Statistics 
(ONS) for England and Wales and the General Register Office (GRO) for Scotland using name, 
sex, date of birth, and last known address. For all identified deaths, principal underlying 
causes of death were determined according to the International Classification of Diseases, 10th 
revision (ICD-10), as recorded on copies of death certificates obtained from ONS. I classified as 
‘suicides’ those subjects with the following ICD-10 codes of death according to the ONS: X60–
X84 and Y10–Y34. Of note, in the UK most ‘open verdicts’ (ICD-10 codes Y10–Y34) are likely to 
be suicides since the coroner, who under UK law certifies the cause of death, needs to provide 
evidence (of suicide) ‘beyond reasonable doubt’ (Linsley et al., 2001).  
 
4.4.c – Statistical analysis 
The Statistical Package for Social Science version 22.0 (SPSS Inc., Chicago, IL, USA) was 
used for performing the statistical analyses. Descriptive analyses and comparison of patient 
characteristics, including the aforementioned demographic and clinical variables, were 
undertaken using chi-square, t-tests and Mann-Whitney U tests as appropriate.  
First, predictors of insight dimensions at baseline were investigated through binary 
logistic regression models in order to precisely test the influence of suicidal history on insight 
levels after adjusting the analyses for potential mediating variables.  
Second, all patients were entered into a survival analysis with the end date being the 
date of first suicide attempt (or suicide completion where appropriate) or the censoring point, 
i.e. either the date on which the patient was last known to be alive or the end of the follow-up 
study period, which commenced at the time of discharge from hospital or after first contact to 
services in those patients who were not admitted at first presentation.  
125 
 
Risk of suicide over the follow-up period was calculated by considering the proportion 
of patients who died from suicide of the total initial sample size (i.e. those who were lost to 
follow-up were included in the denominator), which is known as case-fatality (Palmer et al., 
2005). 
Survival analyses (Kaplan-Meier Curves and log-rank tests) were performed to 
compare time from hospital discharge, or first appointment for those outpatients who did not 
require hospitalization, to first suicidal event or the censoring point as appropriate with insight 
levels at baseline. Participants were censored as non-attempters at the time of the last face-to-
face assessment with a member of staff. Unlike binary logistic regression, survival analyses 
capture the dynamics of suicide/non-suicide status which, indeed, can change over the course 
of the illness. For instance, a suicide attempt that occurs early should be accounted for 
differently from a later suicidal event. Equally, a non-suicide attempter who is lost to follow-
up in an early phase should not be considered in the same way as those non-suicide attempters 
who completed the follow-up. This methodology was chosen to overcome the limitation from 
the vast majority of previous studies, which used logistic regression. 
In addition, multivariable Mandel-Cox regression models (Cox, 1972) were built up in 
order to investigate survival in relation to baseline insight variables, whilst adjusting the 
analyses for potential mediating/confounding demographic and clinical variables. 
All of the above analyses were two-tailed and significance level was set at 5%. 
 
4.4.c.1. – Power calculations 
I used the stpower logrank command of STATA 11.0 for Windows (StataCorp LP, USA) 
to conduct the power calculations pertaining to insight variables. 
Thus, the FEP cohort presented in this chapter was followed-up over a period ranging 
from 3 to 6 years. Based on previous FEP studies, it is expected that at the end of the follow-up 
at least 20% of the initial sample size will have made one suicide attempt (e.g. Robinson et al., 
2010), including 2-5% of suicides (Dutta et al., 2010; Palmer et al., 2005).  Given that the mean 
SAI-E score for FEP patients is around 13/28 with a standard deviation of around 6 (e.g. 
Morgan et al., 2010), a difference of 2 points (e.g. 13 vs 15) between suicide attempters and non-
attempters, which is considered to be clinically meaningful (Kemp & David, 1998), is 
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equivalent to an effect size of 0.33 with a two-tailed alpha set at 5%. Under these assumptions I 
will have 62.5% power to detect such 2-point difference in this sample (n=112). 
 
4.5. – Results 
4.5.a. – Baseline demographic and clinical characteristics of the sample 
The sample comprised 112 GAP participants. The sociodemographic and clinical 
characteristics of the whole sample, including the number of patients with information 
available on each variable, and differences between those with/without suicide attempts (SA) 
prior to first presentation are presented in Tables 4.1 and Table 4.2 below. 
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Table 4.1. GAP: Baseline demographic and clinical characteristics of the sample and 











n = 22 
(19.6%) 
Without 
previous SA  
n = 90 
(80.3%) 
Statistic p-value 
Age at first contact, years  112 (100) 29.4 ± 9.2 27.8 ± 5.8 29.8 ± 5.8 T = -1.2 0.21 
Gender, males 112 (100) 73 (65.2) 13 (59.0) 60 (66.6) Χ2  = 0.5 0.50 
Level of education 110 (98.2)      
    No qualifications  18 (66.4) 4 (18.2) 14 (15.9) Χ2  = 0.1 0.79 
    GCSE  23 (20.9) 5 (22.7) 18 (20.4) Χ2  = 0.1 0.81 
    Further  42 (38.2) 7 (31.8) 35 (39.8) Χ2  = 0.5 0.50 
    University  27 (24.5) 6 (27.3) 21 (23.8) Χ2  = 0.1 0.74 
Unmarried 111 (99.1) 84 (75.7) 16 (72.7) 68 (76.4) Χ2  = 0.1 0.72 
Living alone 111 (99.1) 40 (36.0) 11 (50.0) 29 (32.5) Χ2  = 2.3 0.13 
Unemployed 110 (98.2) 69 (62.7) 10 (45.4) 59 (67.0) Χ2  = 3.5 0.06 
Ethnicity 111 (99.1)      
    White  29 (26.1) 9 (40.9) 20 (22.5) Χ2  = 3.1 0.08 
    Black  49 (44.1) 6 (27.2) 43 (48.3) Χ2  = 3.2 0.07 
    Other  33 (29.7) 7 (31.8) 26 (29.2) Χ2  = 0.1 0.81 
DUP: days, median 111 (99.1) 42 36 60 U 0.85 
Diagnosis (ICD-10) 111 (99.1)      
    Schizophrenia spectrum  86 (77.5) 15 (71.4) 71 (78.9) Χ2  = 0.5 0.46 
    Mania with psychosis  16 (14.4) 3 (14.3) 13 (14.4) Χ2  = 0.0 0.98 
    Psychotic depression  9 (8.1) 3 (14.3) 6 (6.6) Χ2  = 1.3 0.25 
Cannabis use 89 (79.5)      
    Use  81 (72.3) 18 (81.8) 63 (70.0) Χ2  = 1.2 0.27 
    Abuse/dependence  41 (46.1) 7 (38.9) 34 (47.9) Χ2  = 0.50 0.50 
Alcohol 90 (80.3)      
    Use  68 (75.6) 14 (87.5) 54 (72.9) Χ2  = 1.5 0.22 
    Abuse/dependence  29 (32.2) 6 (26.0) 23 (31.1) Χ2  = 0.2 0.62 
GAP: Genetics and Psychosis Study. SA: suicide attempts (prior to first presentation). 
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4.5.b. – Insight 
4.5.b.1. – Values and scores distribution 
The insight total scores and insight dimensions levels are summarised in table 4.2. In 
particular, the mean, standard deviation (SD), median and range of scores for recognition of 
illness, symptoms relabeling, treatment compliance and the total insight are presented. 
Kolmogorov-Smirnov tests confirmed normal distribution for the insight scores except 
compliance, which was skewed towards better compliance but which resembled normality 
sufficiently (see figure 4.1 below) so parametric tests were used. 
 




Mean ± SD Median Min - Max K-S test 
Recognition 112 (100) 4.9 ± 3.3 5.0 0 – 10 0.11 
Relabelling 103 (91.9) 4.9 ± 3.4 4.9 0 – 12 0.15 
Compliance 108 (96.4) 3.7 ± 1.8 4.0 0 - 6 0.02 
Total insight 100 (89.3) 13.6 ± 7.3 13.6 1 – 28 0.30 
GAP: Genetics and Psychosis Study. SD: Standard deviation. K-S: Kolmogorov-Smirnov Test 
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Figure 4.1. Insight distributions across the GAP sample 
GAP: Genetics and Psychosis Study 
 
4.5.b.2. – Correlations between insight dimensions 
All insight dimensions showed significant (p<0.01) and positive correlations between 
themselves. Recognition of illness and treatment compliance showed the weakest correlation 
(r=0.42), while relabelling and recognition had the strongest correlation (r=0.75). All these 
correlations are presented in table 4.3 below.  
 
Table 4.3. GAP: Correlation matrix* of theoretical  
insight dimensions (N=112) 
 Recognition Relabelling Compliance 
Recognition  0.75 0.42 
Relabelling 0.75  0.48 
Compliance 0.42 0.48  
GAP: Genetics and Psychosis Study 




4.5.b.3. – Factor analysis 
An exploratory factor analysis with Varimax rotation was performed in order to assess 
the degree of similarity between these data and the 3-factor model proposed by David (David, 
1990). However, our factor analysis yielded two factors with eigenvalues over 1. These factors 
explained 47.4% and 12.9% of the variance, so in total 60.3% of the variance. 
A separate factor analysis was conducted in which 3 factors were forcibly retained in 
keeping with previous studies (e.g. Morgan et al., 2010b). However, the solution that emerged 
was even less satisfactory than the 2-factor solution. Hence, the original 3-factor structure was 
not replicated in this sample. In particular, the ‘relabelling’ component did not emerge as an 
independent third factor and it was captured by the ‘recognition’ factor. 
 
Table 4.4. GAP: Factor loadings following a varimax rotation on the SAI-E 
 Rotated component Matrix* 
  Factors 
SAI-E item Insight dimensions 1 2 
1  0.71 0.03 
2  0.83 -0.00 
3 Recognition 0.76 0.19 
4  0.80 0.07 
5  0.72 0.09 
6  0.54 0.51 
7  0.80 0.13 
8 Relabeling 0.73 0.30 
9  0.60 0.25 
10  -0.03 0.86 
11 Compliance 0.17 0.77 
Initial eigenvalues  5.22 1.42 
Variance explained (%)  47.4 12.9 
GAP: Genetics and Psychosis Study 
Extraction Method: Principal Component Analysis 
Rotation Method: Varimax with Kaiser Normalization 




4.5.c. – Differences between patients with/without previous suicide attempts in insight 
levels, psychopathology and neurocognitive variables 
Illness recognition and symptoms relabeling were found to be significantly higher in 
those with SA before first presentation than in those subjects without such antecedents as 
detailed in table 4.5 below. In addition, the depression score was higher in the suicidal group 
than in those without such antecedents, although the difference only did not reach statistical 
significance (p=0.08). Also, there were no significant differences between groups in terms of 






Table 4.5. GAP: Differences in insight, psychopathology and neurocognitive variables 













Insight scores       
Recognition 112 (100)  n=22 n=90   
  4.9 ± 3.3 6.2 ± 2.7 4.7 ± 3.3 t = 2.0 p=0.05 
Relabelling 103 (91.9)  n=21 n=82   
  4.9 ± 3.4 6.4 ± 3.1 4.5 ± 3.4 t = 2.2 p=0.03 
Compliance 108 (96.4)  n=21 n=87   
  3.7 ± 1.8 4.3 ± 1.8 3.6 ± 1.8 t = 1.6 p=0.11 
Total Insight 100 (89.2)  n=20 n=80   
  13.6 ± 7.3 16.8 ± 6.4 12.8 ± 7.4 t = 2.2 p=0.03 
Psychopathology 109 (97.3)  n=21 n=88   
Positive   9.2 ± 4.4 8.7 ± 4.3 9.3 ± 4.4 U 0.47 
Negative   11.9 ± 6.1 12.0 ± 5.6 11.9 ± 6.2 U 0.95 
Disorganization  6.4 ± 2.7 5.5 ± 2.3 6.6 ± 2.8 U 0.37 
Mania  5.4 ± 2.2 4.8 ± 1.1 5.5 ± 2.4 U 0.98 
Depression  7.2 ± 3.2 8.3 ± 3.5 6.9 ± 3.0 t = 1.7 0.08 
Premorbid IQ 90 (80.3)  n=18 n=72   
Verbal  87.9 ± 11.3 88.9 ± 11.1 87.7 ± 11.4 t = 0.4 0.67 
Performance  94.7 ± 10.6 96.5 ± 7.2 94.3 ± 11.3 t = 0.8 0.42 
Full  90.5 ± 10.6 91.9 ± 9.6 90.1 ± 10.8 t = 0.6 0.52 
IQ (WAIS-III) 92 (82.1)  n=18 n=74   
  88.4 ± 25.3 93.9 ± 14.1 87.1 ± 27.3 t = 1.0 0.31 
TMT-A (seconds) 92 (82.1)  n=18 n=74   
  47.0 ± 20.9 41.6 ± 17.1 48.3 ± 21.7 t = -1.2 0.23 
TMT-B (seconds) 86 (76.8)  n=18 n=68   
  119.5 ± 74.0 97.7 ± 56.1 125.2 ± 77.4 t = -1.4 0.16 
TMT-B-A (seconds) 86 (76.8)  n=18 n=68   
  71.8 ± 62.4 60.3 ± 49.6 74.8 ± 65.4 t = -0.8 0.38 
GAP: Genetics and Pychosis Study. SA: Suicide attempts (prior to first presentation/contact)  IQ: Intelligence Quotient. WAIS-III: Wechsler 
Adult Intelligence Scale Revised (Wechsler, 1981).  TMT: Trail Making test (Reitan, 1958).  
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4.5.d. – Bivariate analyses: relationships between insight dimensions and baseline 
demographic and clinical characteristics of the sample 
I performed exploratory analyses in order to investigate potential relationships 
between insight levels and a set of demographic variables, such as age at first contact, gender, 
education level, marital, living and employment status and ethnicity. However, only gender 
and ethnicity revealed significant differences in insight levels. In particular, females showed a 
higher level of recognition (6.0 ± 3.2 vs. 4.4 ± 3.2, p=0.01) and total insight (15.9 ± 7.1 vs. 12.4 ± 
7.3, p=0.02) than males and those of White ethnicity had significantly higher levels of 
compliance than the two remaining groups, i.e. Black people and ‘other ethnicity’ (4.5 ± 1.7 vs. 




















Table 4.6. GAP: Baseline demographic data and insight levels 
 Recognition Relabelling Compliance Total insight 
Age at first contact n = 112 n = 103 n = 108 n = 100 
 r=-0.09 r = -0.13 r = -0.04 r =-0.08 
 p=0.32 r = 0.17 p = 0.63 p = 0.15 
Gender n = 112 n = 103 n = 108 n = 100 
Males 4.4 ± 3.2 4.6 ± 3.2 3.6 ± 1.8 12.4 ± 7.3 
Females 6.0 ± 3.2 5.6 ± 3.7 4.1 ± 1.7 15.9 ± 7.1 
 t=-2.4, p=0.01 t=-1.4, p=0.15 t=-1.4, p=0.16 t=-2.3, p=0.02 
Level of education n=110 n=101 n=106 n=98 
No qualifications 3.9 ± 2.9 4.1 ± 3.1 4.1 ± 1.8 11.6 ± 6.8 
≥ GCSE 5.2 ± 3.3 5.0 ± 3.4 3.7 ± 1.8 14.0 ± 7.4 
 t=-1.5, p=0.15 t=-1.0, p=0.31 t=0.7, p=0.48 t=-1.2, p=0.23 
Marital status n=111 n=102 n=107 n=99 
Unmarried 4.8 ± 3.4 4.7 ± 3.4 3.7 ± 1.8 13.2 ± 7.5 
Married 5.3 ± 2.9 5.5 ± 3.5 3.8 ± 1.7 14.6 ± 6.5 
 t=-0.7, p=0.47 t=-0.99, p=0.32 t=-0.1, p=0.89 t=-0.7, p=0.43 
Living status n=111 n=102 n=107 n=99 
Alone 5.2 ± 3.4 5.2 ± 3.4 3.6 ± 1.8 14.0 ± 7.7 
With others 4.8 ± 3.2 4.7 ± 3.4 3.8 ± 1.7 13.2 ± 7.1 
 t=0.7, p=0.45 t=0.7, p=0.48 t=-0.6, p=0.52 t=-0.5, p=0.60 
Employment status n=111 n=102 n=107 n=99 
Unemployed 4.6 ± 6.3 4.4 ± 3.3 3.5 ± 1.7 12.4 ± 7.2 
Employed 5.5 ± 3.2 5.9 ± 3.4 4.2 ± 1.8 15.6 ± 7.1 
 t=-1.5, p=0.14 t=-2.2, p=0.03 t=-1.9, p=0.06 t=-2.1, p=0.04 
Ethnicity n=111 n=102 n=107 n=99 
White 6.6 ± 3.2 6.2 ± 3.5 4.5 ± 1.7* 16.5 ± 7.7 
Black 4.4 ± 3.2 4.2 ± 3.0 3.5 ± 1.7 12.4 ± 6.5 
Others 4.7 ± 3.3 4.9 ± 3.6 3.5 ± 1.8 13.1 ± 7.9 
 F=2.4, p=0.09 F=2.7, p=0.06 F=3.4, p=0.04 F=2.6, p=0.08 




With regard to baseline clinical characteristics of the sample such as DUP, diagnosis 
and alcohol and illicit drugs use/abuse/dependence, several significant differences emerged 
from the bivariate analyses which are shown in table 4.7 below.  
DUP was dichotomised into two groups by splitting the sample through the median 
since the distribution of DUP values was skewed. Thus, all insight scores were significantly 
lower in those with a long (>42 days) DUP, i.e. the longer the DUP, the poorer the insight. 
In terms of diagnosis, those subjects with psychotic depression showed significantly 
greater levels of insight than those with schizophrenia spectrum disorders and mania with 
psychosis.  
In addition, drugs users were found to have greater levels of illness recognition and 
symptom relabelling than those who never took illicit drugs. 
Other non-significant differences are presented in table 4.7 below. 
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Table 4.7. GAP: Baseline clinical characteristics and insight dimensions 
 Recognition Relabelling Compliance Total Insight 
DUP n=111 n=102 n=107 n=99 
   < 42 days 5.5 ± 3.1 5.8 ± 3.2 4.1 ± 1.6 15.4 ± 6.7 
   > 42 days 4.3 ± 3.3 4.0 ± 3.3 3.4 ± 1.8 11.7 ± 7.4 
 t=-2.0, p=0.04 t=-2.6, p<0.01 t=-2.2, p=0.03 t=-2.6, p=0.01 
     
Diagnosis n=111 n=102 n=108 n=100 
   Schizophrenia 4.6 ± 3.3 4.7 ± 3.2 3.8 ± 1.8 13.1 ± 7.0 
   Mania 4.5 ± 3.2 4.0 ± 3.6 3.0 ± 1.8 11.3 ± 7.7 
   Depression* 8.8 ± 1.1 8.7 ± 2.7 5.2 ± 0.9 22.8 ± 3.4 
 F=7.5, p<0.01 F=6.3, p<0.01 F=4.6, p=0.01 F=8.1, p<0.01 
     
Alcohol n=90 n=86 n=87 n=84 
   Use 5.5 ± 3.3 5.4 ± 3.6 4.0 ± 1.8 14.9 ± 7.4 
   non-use 4.4 ± 2.5 4.2 ± 2.6 3.6 ± 1.8 11.9 ± 5.9 
 t=1.5, p=0.13 t=1.6, p=0.11 t=0.9, p=0.36 t=1.6, p=0.10 
   Abuse/dep 5.7 ± 3.2 5.9 ± 3.2 4.2 ± 1.6 15.8 ± 7.3 
   non-abuse/dep 5.0 ± 3.1 4.7 ± 3.4 3.8 ± 1.8 13.4 ± 7.1 
 t=0.9, p=0.32 t=1.6, p=0.10 t=1.2, p=0.23 t=1.4, p=0.17 
     
Drugs n=112 n=103 n=108 n=100 
   Use 5.4 ± 3.2 5.4 ± 3.5 3.8 ± 1.8 14.5 ± 7.5 
   non-use 3.9 ± 3.1 3.7 ± 2.9 3.7 ± 1.6 11.4 ± 6.6 
 t=2.3, p=0.02 t=2.2, p=0.02 t=0.4, p=0.69 t=1.9, p=0.06 
   Abuse 5.3 ± 3.6 5.6 ± 3.4 3.9 ± 1.8 15.0 ± 7.9 
   non-abuse/dep 5.0 ± 3.2 4.9 ± 3.6 3.8 ± 1.9 13.4 ± 7.6 
 t=0.3, p=0.73 t=0.8, p=0.40 t=0.4, p=0.69 t=0.9, p=0.36 
GAP: Genetics and Psychosis Study. DUP: Duration of untreated psychosis 
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I also conducted correlation analyses between insight scores and psychopathological 
dimensions and neurocognitive variables, which are detailed in table 4.8 below, and revealed 
several significant differences. With regard to psychopathology, disorganization correlated 
negatively with all insight scores except compliance (p<0.01), while mania showed negative 
significant correlations with the four insight scores. 
Interestingly, depression showed very significant positive correlations with all insight 
dimensions (p<0.01) except compliance, which correlated positively with negative symptoms 
(r=0.22, p=0.03) and negatively with mania (r=-0.21, p=0.03). Finally, full premorbid IQ 
showed a positive significant correlation with recognition (r=0.22, p=0.03) and TMT-B was 
significantly associated with recognition (r-0.21, p=0.04) and relabeling (r=-0.26, p=0.02), i.e. 






Table 4.8. GAP: Correlations between insight levels, psychopathology measures and cognition 
 Recognition Relabelling Compliance Total Insight 
 n r p n r p n r p n r p 
Positive 109 -0.25 0.01 101 -0.28 0.01 105 -0.08 0.41 98 -0.24 0.01 
Negative 109 -0.00 0.96 101 0.06 0.53 105 0.22 0.03 98 0.10 0.35 
Disorganization 108 -0.33 <0.01 100 -0.28 <0.01 104 -0.05 0.61 97 -0.28 <0.01 
Mania 109 -0.21 0.03 101 -0.26 0.01 105 -0.21 0.03 98 -0.24 0.02 
Depression 109 0.32 <0.01 101 0.27 0.01 105 0.17 0.08 98 0.33 <0.01 
Premorbid IQ 90 0.22 0.03 85 0.18 0.09 87 -0.00 0.96 83 0.14 0.19 
IQ (WAIS-III) 92 0.09 0.39 86 0.11 0.29 89 0.03 0.75 84 0.07 0.53 
TMT-A (seconds) 92 -0.18 0.07 86 -0.13 0.24 89 0.02 0.84 84 -0.13 0.24 
TMT-B (seconds) 86 -0.21 0.04 81 -0.26 0.02 83 0.00 0.99 79 -0.19 0.08 
TMT B-A (seconds) 86 -0.16 0.15 81 -0.20 0.07 83 0.00 0.95 79 -0.15 0.20 
GAP: Genetics and Psychosis Study. IQ: Intelligence Quotient. WAIS: Wechsler Adult Revised Intelligence Scale (Wechsler, 1981). TMT: Trail Making Test (Reitan, 1958) 
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4.5.e. – Regression on recognition of illness 
A hierarchical linear regression model (by using ‘enter’ method, i.e. all the variables 
were initially entered the model) was carried out to reassess the association of previous SA 
with illness recognition after controlling for gender, ethnicity, DUP, diagnosis of ‘psychotic 
depression’ and drugs use. In addition, I included two more blocks of variables into the model 
with those neurocognitive and psychopathological variables which had emerged significant 
from the bivariate analyses to determine predictors of illness recognition. Thus, only a 
diagnosis of depression remained significant (p<0.01), while disorganization showed a trend 
(p=0.08). This model explained 38% of the variance on recognition. 
Table 4.9. GAP: Regression on recognition 
 B SE p R2 Change p-change 
Block 1:     0.084 0.03 
   Gender -0.76 0.66 0.26   
   White 0.58 0.76 0.44   
Block 2:    0.038 0.07 
   DUP (> 42 days) -0.98 0.61 0.11   
Block 3:     0.122 <0.01 
   Depression (dx) 2.7 1.1 0.01   
Block 4:    0.044 0.04 
   Drugs 1.23 0.74 0.10   
Block 5:    0.003 0.57 
   Suicidal history 0.12 0.72 0.86   
Block 6:    0.012 0.56 
   Full premorbid IQ 0.02 0.03 0.59   
   TMT-B 0.00 0.01 0.46   
Block 7:    0.075 0.10 
   Positive -0.05 0.08 0.55   
   Disorganization -0.23 0.13 0.08   
   Mania -0.07 0.18 0.70   
   Depression 0.19 0.12 0.11   
GLOBAL R2    0.38  
GAP: Genetics and Psychosis Study. DUP: Duration of untreated psychosis. dx: diagnosis.  
IQ: Intelligence Quotient. TMT: Trail Making Test (Reitan, 1958) 
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4.5.f. – Regression on relabelling of symptoms 
A hierarchical linear regression model (by using ‘enter’ method as explained above) 
was carried out to reassess the association of previous SA with symptoms relabelling after 
controlling for the effects of unemployment, DUP, diagnosis of ‘psychotic depression’ and 
drugs use, since they all were significantly associated with relabelling in the bivariate analyses.  
I also added two more blocks of variables to the model with those neurocognitive and 
psychopathological linked with relabelling. DUP (p=0.02), a diagnosis of depression (p<0.01) 
and drugs use (p=0.04) survived as significant predictors of relabelling. This final model 
accounted for 31% of the variance on relabelling of symptoms.  
 
Table 4.10. GAP: Regression on relabelling 
 B SE p R2 Change p-change 
Block 1:     0.031 0.13 
   Unemployment -1.25 0.74 0.09   
Block 2:    0.068 0.02 
   DUP (> 42 days) -1.67 0.70 0.02   
Block 3:     0.170 <0.01 
   Depression (dx) 4.61 1.27 <0.01   
Block 4:    0.069 <0.01 
   Drugs 1.74 0.82 0.04   
Block 5:    0.000 0.85 
   Suicidal history -0.10 0.88 0.902   
Block 6:    0.002 0.66 
   TMT-B -0.00 0.00 0.74   
Block 7:    0.039 0.40 
   Positive 0.02 0.08 0.79   
   Disorganization -0.16 0.09 0.11   
   Mania -0.09 0.20 0.65   
   Depression 0.11 0.13 0.42   
GLOBAL R2    0.31  
GAP: Genetics and Psychosis Study. DUP: Duration of untreated psychosis. dx: diagnosis.  




4.5.g. – Regression on treatment compliance 
A hierarchical linear regression model (which used ‘enter’ method) was carried out to 
assess potential predictors of treatment compliance. Since the relationship between suicidality 
and compliance had not reached significance, suicidal history was not included into the model. 
Thus, being white (p=0.02), DUP (p=0.04), a diagnosis of psychotic depression (p<0.01) and 
manic symptoms severity (p=0.03) predicted compliance, although the model only explained a 
22% of the variance on this insight domain.  
 
Table 4.11. GAP: Regression on compliance 
 B SE p R2 Change p-change 
Block 1:     0.055 0.02 
   White 0.83 0.37 0.02   
Block 2:    0.044 0.03 
   DUP (> 42 days) -0.67 0.32 0.04   
Block 3:    0.065 <0.01 
   Depression (dx) 1.39 0.57 0.02   
Block 4:    0.054 0.04 
   Negative 0.03 0.03 0.20   
   Mania -0.15 0.07 0.03   
GLOBAL R2    0.22  











4.5.h. – Regression on total insight 
A hierarchical linear regression model (by using ‘enter’ method) was carried out to 
reassess the association of previous SA with total insight after controlling for the effects of 
gender, unemployment, DUP, diagnosis of ‘psychotic depression’ and several 
psychopathological dimensions such as positive, disorganization, mania and depression, 
which all had been associated with total insight. In addition, in order to determine the 
predictors of recognition of illness, I included one more block with three psychopathological 
dimensions such as disorganization, mania and depression into the model. Thus, DUP (p=0.03) 
and a diagnosis of depression (p<0.01) emerged as significant predictors of total insight. In 
particular, this model accounted for up to 31% of the variance on total insight.  
 
Table 4.12. GAP: Regression on total insight 
 B SE p R2 Change p-change 
Block 1:     0.087 0.01 
    Gender -1.23 1.40 0.36   
    Unemployment -1.41 1.39 0.31   
Block 2:    0.064 0.01 
    DUP -2.89 1.31 0.03   
Block 3:     0.110 <0.01 
    Depression (dx) 7.28 2.47 <0.01   
Block 4:    0.012 0.23 
    Previous SA -1.05 1.66 0.53   
Block 5:    0.040 0.30 
    Positive -0.04 0.17 0.80   
    Disorganization -0.36 0.27 0.19   
    Mania -0.26 0.32 0.42   
    Depression 0.17 0.22 0.44   
GLOBAL R2    0.31  




4.5.i. – Suicidal behaviours over the 3-year follow-up period 
In total, 32 subjects (28.5%) made at least one suicide attempt either prior to first contact 
with services or over the follow-up. Eighteen individuals (16.1%) attempted to take their lives 
over the follow-up, 8 of whom (7.1%) did so both before and after first presentation to services. 
6 patients made two suicide attempts over the follow-up period and 3 subjects died from 
suicide over the 3-year that period, which yielded a case fatality of 3/112=2.7%. This is 
summarized in figure 4.2.  
In particular, 18 follow-up suicide attempters, including 3 suicide completers, and 94 
non-suicide attempters were compared through Kaplan-Meier survival analyses and Cox 
Regression models with regard to baseline insight levels, whilst adjusting the analyses for a set 
of demographic and clinical variables. Of note, the median time from first contact to first 
suicide attempt was 1 year, as shown by the Kaplan-Meier Curve below (Figure 4.2.).  
Also, most of the suicidal acts occurred shortly after the last appointment with a SLaM 
member of the staff. The median of this time was 8 days for the first attempt (n=18) and 6.5 
days for the second attempt (n=6). Also, the three suicides occurred within 10 days, 17 days 
and almost three months after last face-to-face contact with the staff, respectively.    
 
Figure 4.1. Kaplan-Meier Survival Curve showing time to first suicide attempt over 


























GAP: Genetics and Psychosis Study. FEP: First-episode psychosis. CF: case-fatality  
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Figure 4.2. Flow chart of suicidal events in the GAP study 
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SUICIDE COMPLETIONS 
(CF = 3/112=2.7%) 
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4.5.j. – Suicide methods 
As detailed in figure 4.4., above, there were 24 suicidal events over the follow-up. Thus, 
poisoning (n=10) and cutting (n=6) were the most common suicide methods. Also, there were 
suicide attempts by violent methods such as jumping (n=4), which included jumping from a 
height or in front of a train. There were no suicide attempts by firearms. 
Also, 3 subjects ended their lives, who were all males. One suicide completer with 
bipolar affective disorder was found dead at home after taking an overdose of medication 
within the context of a depressive relapse. Another individual, who suffered from 
schizophrenia, set fire at his home two weeks after disengaging from the team and possibly 
discontinuing medication. Finally, one subject jumped from a height locally.      
 
 
Table 4.13. GAP: Suicide methods 
Method Events (n=24) 
Poisoning* 10 
Cutting him/herself 8 
Jumping* 4 
Hanging 1 
Setting a fire* 1 
GAP: Genetics and Psychosis Study 








4.5.k. – Risk factors for suicidal behaviour over the follow-up 
Univariate analyses concerning demographic, clinical and symptom-related variables, 
including insight, are presented below in tables 4.14, 4.15 and 4.16, respectively.  
 
Table 4.14. GAP: Univariate analysis: log-rank tests of equality of survival distributions 
for the demographic variables 







Gender Male 11.7 12 0.03 0.86 
 Female 6.3 6   
Age at first contact <28 9.8 14 4.01 0.04 
 >28 8.2 4   
Education level No qualifications 2.8 4 1.58 0.66 
 GCSE 3.5 4   
 Higher 6.5 7   
 University 4.2 2   
Marital status Unmarried 12.9 14 0.49 0.48 
 Married 4.1 3   
Living status Alone 6.1 11 4.46 <0.01 
 Not alone 10.9 6   
Employment status Unemployed 10.7 9 1.01 0.32 
 Employed 6.3 8   
Ethnicity White 4.4 7 2.34 0.31 
 Black 7.5 6   
 Other 5.0 4   
 








Table 4.15. GAP: Univariate analysis: log-rank tests of equality of survival distributions for 
the clinical variables 







Previous SA Absent 14.5 10 10.06 <0.01 
 Present 3.5 8   
DUP <42 8.6 10 0.72 0.40 
 >42 8.4 7   
Diagnosis Schizophrenia 13.9 17 3.24 0.19 
 Mania 2.5 1   
 Depression 1.4 0   
Drugs use Absent 4.9 3 0.98 0.32 
 Present 13.0 15   
Alcohol use Absent 3.2 2 0.97 0.32 
 Present 9.8 13   
 
GAP: Genetics and Psychosis Study. SA: Suicide attempts (before first contact).  
DUP: Duration of untreated psychosis. 
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Table 4.16. GAP: Cox regression analyses for neurocognitive, psychopathological 
and insight-related variables 
Risk factor RR 95% CI p-value 
Neurocognition    
    Full premorbid IQ 0.95 0.91 - 1.00 0.09 
    TMT-B-A 0.83 0.99 – 1.01 0.83 
Psychopathology    
    Positive 1.02 0.91 – 1.15 0.70 
    Negative 1.06 0.99 – 1.14 0.10 
    Disorganization 0.98 0.82 – 1.17 0.83 
    Mania 0.83 0.59 – 1.16 0.20 
    Depression 1.07 0.92 – 1.14 0.37 
Insight    
    Recognition of illness 1.09 0.94 – 1.26 0.24 
    Symptoms relabeling 1.10 0.95 - 1.26 0.19 
    Treatment compliance 1.36 1.01 – 1.83 0.04 
    Total insight 1.06 0.99 – 1.14 0.08 
GAP: Genetics and Psychosis Study. RR: Relative Risk. CI: Confidence Interval. IQ: Intelligence Quotient.  




Age at first presentation, which was dichotomised through the median (28 years) (RR 
2.92, 95% CI 0.96-8.86, p=0.06), living alone (RR 3.57, 95% CI 1.32-9.65, p=0.01), suicidal history 
(RR 3.95, 95% CI 1.55-10.1, p<0.01), premorbid IQ (RR 0.96, 95% CI 0.91-1.01, p=0.09), treatment 
compliance (RR 1.06, 95% CI 1.01-1.83, p=0.04), and total insight (RR 1.06, 95% CI 0.99-1.14, 
p=0.08) were most strongly related to risk of suicidal behaviour. Of note, no 
psychopathological dimension, including depression, was significantly associated with risk of 
suicidal behaviours over the follow-up. 
Therefore, young age at first presentation (<28 years), living status (i.e. living alone) 
suicidal history, premorbid IQ, treatment compliance and total insight were entered into the 
first forward stepwise Cox regression model. Living alone (RR 3.24, 95% CI 1.04-10.04, p=0.04) 




Table 4.17. GAP: Multivariate analysis: Risk factors for suicidal 
behaviour from Cox regression modelling 
Risk factor RR 95% CI p-value 
Living status Alone 3.24 1.04 – 10.04 0.04 
 Not alone 1.00   
Previous SA Present 7.36 2.25 – 24.04 <0.01 
 Absent 1.00   
Model based on n=82 GAP patients, including 13 suicide attempters, whom had complete  
data for all the variables in the model 
GAP: Genetics and Psychosis Study. RR: Relative Risk. CI: Confidence Interval 




4.6. – Discussion 
4.6.a. – Main findings 
Two major conclusions can be drawn from the results presented in this chapter. 
First, all insight dimensions except compliance were associated with a history of suicide 
attempts prior to first contact with services. However, other variables such as being white and 
unemployed, DUP, two psychopathological domains such as disorganization and mania 
symptoms severity (negatively) and a diagnosis of psychotic depression (as opposed to other 
psychoses), influenced insight levels at that time and thus mediate the above associations. 
Second, although in contrast to my expectations the bivariate Kaplan-Meier analyses 
revealed treatment compliance and total insight to be linked with risk of suicidal behaviour 
over the follow-up, the multivariable Cox regression analyses showed that only living alone 
and a previous suicidal history predicted suicide risk, hence consistent with my hypothesis H5  
concerning the role of mediating variables (see chapter 2, section 2.5). In addition, premorbid 
IQ and age at first presentation reduced suicide risk, although these variables did not survive 
the multivariable regression models.  
 
4.6.b. – Insight levels at baseline are influenced by suicidal antecedents 
As postulated, the bivariate analyses showed that all insight dimensions except 
treatment compliance were associated with suicidal history preceding first presentation with 
psychosis. However, contrary to my expectations these associations did not survive the 
multivariable regression models. A potential explanation may have been a lack of sufficient 
statistical power to test this. Alternatively, the above relationships may be mediated by other 
variables, which were related to insight and suicidal history, namely gender (female), 
unemployment, DUP and a diagnosis of psychotic depression (as opposed to other psychoses). 
Also, these variables were associated with suicidal history at a non-significant level, which 
may have been due to the limited statistical power.  
The insight dimensions awareness/recognition of disorder and relabeling did not 
emerge as distinct factors in this sample, whereas compliance was less strongly correlated with 
the other two. Nevertheless, each insight dimension was associated with different predictors 
and correlates, which provides some support for the multidimensional model of insight 
(David, 1990; Amador & David, 2004).   
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With regard to gender and insight, several previous studies do not report differences 
(Markova, 2005), although in line with our results, those that do, tend to show that females 
have greater insight than males (Wiffen et al., 2012; Mintz et al., 2003; Parellada et al., 2011; 
McEvoy et al., 2006). Other socio-demographic variables such as age and level of education did 
not predict insight in our sample, although previous studies did find significant associations 
(Markova, 2005), particularly regarding education level (Wiffen et al., 2010), although white 
people showed higher levels of recognition and compliance, which is consistent with previous 
literature (Morgan, 2003; Goldberg et al., 2001; Johnson & Orrell, 1995).  Unemployment was 
also associated with poorer ability to recall symptoms as pathological, including lower total 
insight scores, than employed patients. However, two previous studies showed no differences 
in insight according to employment status (Lysaker & Bell, 1994; David et al., 1995).   
Of relevance to my main research question, I replicated the controversial association of 
depressive symptoms severity with two insight domains (illness recognition and symptom 
relabeling), and also with total insight (Peralta et al., 1998; Mintz et al., 2003; Cooke et al., 2005; 
Lincoln et al., 2007; Nair et al., 2014; Belvederi-Murri et al., 2015). However, the cross-sectional 
design does not allow causality conclusions to be drawn from this. In addition, three further 
psychopathological domains such as positive, disorganization and mania showed an inverse 
relationship with insight levels at first contact with services, which is in full agreement with a 
previous meta-analysis (Mintz et al., 2003). Also, compliance was (inversely) related to mania. 
Of interest, a positive relationship between compliance and negative symptom severity was 
revealed by the analyses, which suggests that (passive) compliance does not necessarily equate 
to awareness of illness (for a conceptual review, see Morgan & David, 2010).  
 Interestingly, those patients without suicidal antecedents were found to present with 
more severe depressive symptoms and greater levels of insight. Hence, it seems that based on 
our cross-sectional analyses one may intuitively conclude that insight is a risk factor for 
suicidal behaviour in early psychosis. However, as alluded to in chapter 2, such a conclusion 
would be subject to selection bias since the outcome variable (suicidal history) would precede 
the cause (insight), thus not fulfilling the causality criteria, particularly that of temporality 
(Hill, 1965).     
Regarding DUP, an inverse relationship between insight and DUP was replicated (Pek 
et al., 2006; Saravanan et al., 2010; Cuesta et al., 2011), i.e. the longer the DUP, the poorer the 
insight at first presentation. However, the direction of causality remains unclear since it is 
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plausible that poor insight leads to avoidance of care and hence increases DUP (Drake et al., 
2000) as it is that as DUP increases insight levels fall. Moreover, DUP was shorter (although 
not significantly) in the suicidal group in comparison with non-suicidal patients (Table 4.13), 
which suggests that suicidal behaviour shortens DUP by bringing the patient to the attention 
of psychiatric services earlier and subsequently, suicidality might increase insight at the point 
a FEP is diagnosed by lessening the negative effect of a more prolonged DUP on insight levels.   
In contrast to previous extensive literature on ‘insight and neurocognitive deficits in 
schizophrenia’ (Amador et al., 1991; Morgan & David, 2004; Aleman et al., 2006; Ayesa-Arriola 
et al., 2011; David et al., 2012; Nair et al., 2014), the multivariate analyses failed to replicate a 
link between insight dimensions and two measures of cognition such as premorbid IQ and the 
TMT B-A, which assesses executive functions. However, these negative results were consistent 
with some previous studies (Cuesta et al., 1995; Ayesa-Arriola et al., 2014). Also, a previous 
analysis with an overlapping sample found verbal memory, which was not evaluated in this 
chapter, to predict insight above and beyond the effect of IQ (Wiffen et al., 2012).  
 
4.6.c. – Insight dimensions did not predict suicide risk over the follow-up 
Interestingly, in contrast to my hypotheses H5 and H6 (chapter 2, section 2.5.), 
awareness of the need for treatment was found to be a suicide risk factor over the 3-year 
follow-up period and total insight showed a borderline significance. However, no insight score 
predicted suicide risk over the follow-up period according to the multivariable Cox-regression 
models, consistent with my hypotheses outlined in chapter 2 (section 2.5). Therefore, there is a 
complex tautological issue here. First, suicidal history, which is the strongest predictor of 
future suicidal events in subjects with psychotic disorders (e.g. Hawton et al., 2005; Challis et 
al., 2013), affected insight levels at first presentation. Second, the bivariate analyses from the 
follow-up data found a link between insight at baseline and risk of suicidal behaviours over 
the 3-year follow-up; however, such an association did not remain significant after adjusting 
for previous suicidal history. 
These findings concerning the lack of association of insight levels with suicide risk in 
early stages of psychosis were in line with my hypotheses (Chapter 2, section 2.5), my 
literature review (Lopez-Morinigo et al., 2012) and recent studies (Yan et al., 2013; Pijnenborg 
et al., 2013; Barrett et al., 2015), although many clinicians remain concerned about the risks 
associated with improving insight in patients with early onset psychosis. 
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However, I did replicate a relationship between insight, particularly illness recognition, 
and depression, as measured by the PANSS factor. This cross-sectional association again does 
not permit me to infer the direction of causality. Thus, although it is intuitive to believe that 
gaining awareness of suffering from such a serious illness leads to a depressive state, including 
an increased suicide risk, which is known as the  ‘demoralization syndrome’ (Drake et al., 
1985; Drake & Cotton, 1986; Amador et al., 1996; Restifo et al., 2009); equally, the so-called 
‘depressive realism model’ may explain how a more depressed patient, biased by depression-
related cognitions, loses their ‘normal’ optimistic biases and sees their illness for what it is 
(Ghaemi & Rosenquist, 2004), thus displaying higher levels of insight at the time of the 
assessment. This ‘chicken and egg’ dilemma can only be solved with longitudinal intervention 
studies; for example, if it was shown that insight improving interventions reduced suicidality. 
As alluded to above, intervention studies do not appear to suggest that improving insight 
increases suicidality (Pijnenborg et al., 2013), which is discussed further in chapter 8.  
While the above overall negative results concerning the lack of association between 
insight dimensions and risk of suicidal behaviours were consistent with my hypotheses, they 
could also be attributed to the limited statistical power of these data as detailed in section 
4.4.c.1. above.  
 
4.6.d. – Predictors of suicidal behaviour over the follow-up 
In addition to treatment compliance, three further predictors of suicidal behaviour over 
the follow-up emerged from the bivariate analyses, namely age at first contact, living alone 
and a previous suicidal history. However, only living alone and suicidal history remained 
significant in the multivariable Cox-regression model. 
The inverse association of age with suicide risk in psychosis is one of the most 
consistent findings in the literature on the subject (e.g. Tsuang, 1978; Osby et al., 2000; Qin & 
Nordentoft, 2005; Palmer et al., 2005; Limosin et al., 2007; Osborn et al., 2008; Alaräisänen et al., 
2009; Dutta et al., 2010; Barrett et al., 2010a; Barrett et al., 2010b), which suggests that close 
monitoring is needed in early stages of the psychotic illness (Popovic et al., 2014; NCISH, 
2015). In keeping with this, early intervention services have been reported to reduce suicide 
risk in psychosis (Chan et al., 2014). Again, the lack of association of early age at first contact 
with services and suicide risk in the multivariate analyses may be explained by the limited 
statistical power of this study. 
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Living alone has been consistently found to be a risk factor for suicide both in 
schizophrenia (Hawton et al., 2005a) and FEP (Challis et al., 2013). A number of people with 
psychosis live alone in our catchment area (Kirkbride et al., 2006). To my knowledge, no 
previous FEP studies have examined whether transferring these patients to sheltered or 
supported accommodation, which tends to occur at late stages of the illness, in which suicide 
risk is lower than at earlier stages, although still significantly higher than in the general 
population (Dutta et al., 2010), reduces suicide risk. In keeping with this, being unmarried 
increased risk of suicidal behaviour over the follow-up period, although this difference did not 
reach significance, which was probably due to the small percentage of married patients in the 
sample (less than a quarter of the total sample). This finding is consistent with previous meta-
analyses on both schizophrenia (Hawton et al., 2005) and FEP (Challis et al., 2013) which 
reported overall inconclusive results regarding the relationship between marital status and risk 
of suicide and deliberate self-harm, respectively.  
In addition, suicidal history was replicated as the strongest predictor of future suicidal 
events in early psychosis (Hu et al., 1991; De Hert et al., 2001; Sinclair et al., 2004; Hawton et 
al., 2005; Reutfors et al., 2009; Dutta et al., 2010; Pompili et al., 2011; Björkenstam et al., 2014; 
Bakst et al., 2010a; Challis et al., 2013; Tarrier et al., 2006), including  two recent meta-analyses 
(Large et al., 2011; Challis et al., 2013). However, it should be noted that up to 42% of patients 
with schizophrenia spectrum disorders who end their own lives have no suicidal history 
(Lopez-Morinigo et al., 2014b; Lopez-Morinigo et al., 2016).  
Sadly, most of the suicidal events over occurred a few days after a face-to-face 
appointment with a member of the staff, which is consistent with previous studies (Hu et al., 
1991; Heilä et al., 1997; Tarrier et al., 2006; Lopez-Morinigo et al., 2014b; Lopez-Morinigo et al., 
2016), which appear to demonstrate the difficulties in predicting imminent suicide risk in the 
clinical setting.  
The model tested in this research and the model based on the finding from this study 




Figure 4.3. Hypothesised model to be tested in this thesis. 
Red arrows increase risk and green risk show reduced risk 
 
Figure 4.4. Model based on the GAP cohort study 




4.6.e. – Strengths and limitations 
I recruited a representative sample of FEP, which was part of a large research project 
focused on the biological aetiology of psychosis, namely the Genetics and Psychosis Study 
(GAP). Thus, a number of variables were comprehensively evaluated by trained researchers. 
Also, participants were followed-up over a minimum period of 3 years, which has been 
reported to be the highest suicide risk period in psychosis (e.g. Palmer et al., 2005).  
However, the study presented in this chapter has several limitations. Firstly, most of 
the negative results presented above should be interpreted with caution. For example, a 
potential type 2 error needs to be considered when interpreting these results since the 
statistical power for insight variables was 62.5%. As a result of this, I decided to merge this 
GAP sample with the AESOP cohort presented in chapter 5, which is detailed in chapter 6. 
Secondly, other non-tested variables might contribute to insight such as premorbid personality 
(Lysaker et al., 1999; Campos et al., 2011; Cuesta et al., 2011; Ritsner & Blumenkrantz, 2010) 
and neuroanatomical abnormalities (Morgan et al., 2010; David et al., 2012). Thirdly, examiners 
were not blind to other scales such as the PANSS, which might bias the insight assessment 
(Campos et al., 2011). Fourthly, our cross-sectional design did not allow me to capture the 
dynamics of insight (Wiffen et al., 2010; Campos et al., 2011; Cuesta et al., 2011; Ayesa-Arriola 
& Lopez-Morinigo et al., 2014) since predictors of state-insight may change over the course of 
the illness and also, these time-related insight changes may affect suicide risk differently from 
insight levels at baseline. In keeping with this, demographic variables associated with suicide 
risk (for instance, living status) may have changed over the study follow-up, which was not 
recorded.  
 
4.7. – Chapter summary 
Although I found no relationships between insight dimensions and suicide risk in this 
FEP cohort over a 3-year follow-up, which was consistent with my hypotheses formulated in 
chapter 1, a type 2 error cannot be excluded. Accordingly, I decided i) to analyse a larger FEP 
cohort (Chapter 5); and ii) to merge both cohorts (chapter 6).  
In addition, I will present the findings from a 3-year follow-up FEP study from 
Santander (Spain) in chapter 7, which I will compare with the above UK-based cohorts in the 
General Discussion (Chapter 8).   
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Chapter 5 – Suicidal behaviour in early psychosis. Findings 
from the Aetiology and Ethnicity in Schizophrenia and Other 
Psychoses (AESOP) study (UK) 
 
5.1. – Introduction 
This chapter describes the predictors of suicidal behaviour in a 10-year follow-up of a 
first-episode psychosis (FEP) cohort from the UK (London and Nottingham), which is part of 
the AESOP-10 study (Morgan et al., 2014; Reininghaus et al., 2014). In particular, I present the 
results of investigating the relationship of three insight dimensions, namely recognition of 
having a mental illness, symptom relabelling and awareness of the need for treatment, with 
suicidal acts over the follow-up, including suicide attempts (SA) and suicide completions (SC).  
I also adjusted these analyses for a set of demographic and clinical variables, which may 
mediate/confound the above relationships and therefore influence the rate of suicidal acts. 
For the purposes of this thesis I have focused on suicidal events ‘after’ first presentation 
with psychosis, which is the main outcome measure, and I am thus considering survival to a 
first suicidal event over the follow-up period in relation to insight levels at baseline.  
 
5.2. – Background 
As detailed in chapter 2 and in chapter 4 (section 4.2), the role of insight dimensions in 
suicidal behaviour in FEP patients remains unclear (Lopez-Morinigo et al., 2012), and this may 
have important clinical implications for the development of suicide prevention measures 
focused on insight management from first presentation. 
First, I will present the results from a replication study with an AESOP sample looking 
at the association of suicidal history prior to first presentation to services with multiple insight 
dimensions evaluated at that point. Second, I report the results from survival analyses aimed 
to examine the role of insight levels at first presentation in relation to time to a first suicidal act 
over the follow-up (median=10 years), whilst adjusting these analyses for a set of demographic 




5.3. – Aims and Objectives 
5.3.a. – Descriptive aims and objectives 
 To describe the distribution of insight dimensions according to the outcome of 
suicidal behaviours, including both SA and SC. 
 
5.3.b. – Analytical aims and objectives 
 To investigate whether there is an association between a history of suicidal 
behaviours before first presentation with psychosis and insight levels at that point.  
 To adjust the above analyses for a set of potential confounders in order to 
determine independent predictors of insight at baseline, including the role of 
previous suicidal history.  
 To calculate the case fatality of this FEP sample over the 10-year follow-up. 
 To identify the risk factors associated with suicidal behaviours in a FEP cohort over 
a 10-year follow-up. 
o And to determine whether there is an association of insight levels with risk 
of suicidal behaviours over the 10-year follow-up.  
 To test for potential interactions between insight dimensions and other clinical and 
demographic variables related to risk of suicidal behaviour. 
 To formulate a model, based on a multivariable Cox Regression analysis of the 
above baseline variables, including insight dimensions, for predicting suicidal 
behaviours over the 10-year follow-up. 
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5.4. – Method 
5.4.a. – Recruitment and baseline assessment 
The Aetiology and Ethnicity in Schizophrenia and Other Psychoses (AESOP) study is a 
multi-centre population based incidence and case-control study of first episode psychosis, 
conducted over a three-year period from September 1997 to August 2000. The primary aim of 
the AESOP study was to investigate the high rates of psychosis in African-Caribbean 
populations from the UK, and from this to shed light on the aetiology of psychosis in general. 
As the study progressed, the wealth of data collected and the measurement of outcomes at 10-
year follow-up, including all-cause-mortality and suicide, allowed further questions to be 
addressed such as this thesis topic, namely the role of insight in suicide risk in early psychosis.  
The inclusion criteria for cases were: a) age between 16 and 65 years; b) resident within 
tightly defined catchment areas in Nottingham or south-east London; and c) presence of a first 
episode of psychosis, namely F20-F29 and F30- F33 codes in ICD-10 within the time frame of 
the study.  
Exclusion criteria were: a) evidence of psychotic symptoms precipitated by an organic 
cause; b) transient psychotic symptoms resulting from acute intoxication as defined by ICD-10; 
and c) IQ less than 50. Case finding procedures were based on those used by the World Health 
Organization (WHO) in its multi-country studies of the incidence and outcome of 
schizophrenia (Jablensky et al., 1992). A team of researchers was involved in regularly 
checking all points of potential patient contact with secondary and tertiary health services in 
the catchment areas.  
Specifically, those potential cases who gave their written informed consent were 
screened for inclusion using the Screening Schedule for Psychosis (Jablensky et al., 1992), 
which was completed by interviewing the patient and/or using case notes and information 
provided by psychiatric staff. Each patient meeting inclusion criteria for the study was 
approached and informed consent sought. Case recruitment took place initially over two years 
in Nottingham and south-east London and nine months in Bristol. During the third year of the 
study, recruitment of African-Caribbean cases was extended in Nottingham and south-east 
London to increase the number of these patients in the case-control arm of the study. At the 
end of the period of case recruitment, a leakage study was conducted to identify further 
potential cases initially missed. For each patient included in the study, consent to interview a 
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close relative who had been in recent contact with the patient was also sought. Bristol 
participants were not followed-up and therefore, they were not included in this analysis. 
Using the data obtained from the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN 2.0, WHO, 1992), which is an instrument designed to make 
psychiatric diagnoses (Janca et al., 1994), consensus diagnoses were established for each 
patient at regular AESOP Project meetings led by senior consultant psychiatrists. Those who 
did not meet the criteria for a functional psychotic disorder were excluded from the study. 
Patients in the AESOP study were asked to participate in a large number of assessments. One 
of those assessments was the Schedule for the Assessment of Insight – Expanded version (SAI-
E) (Kemp & David, 1997). The patients who took part in the SAI-E interview formed the 
subsample for this thesis. A summary of the AESOP study methods is provided in box 4.1, 
some of which were used for this thesis. 
 
Box 5.1. – AESOP study 
Biological: Magnetic resonance imaging, DNA. 
Clinical: Schedules for Clinical Assessment in Neuropsychiatry, Personal and 
Psychiatric History Schedule, Schedule for Assessment of Insight – Expanded 
version. 
Psychosocial: MRC Sociodemographic Schedule, Culture and Identity Schedule, 
Achievements and Expectations Schedule, Employment Schedule, Significant 
Others Schedule, Childhood Experiences of Care and Abuse Questionnaire, Life 
Events and Difficulties Schedule, Mental Disorder Beliefs Schedule, Locus of 
Control, Self-Esteem, Self-Concept. 
Cognitive: neuropsychological test battery, Neurological Soft Signs, Minor Physical 







5.4.b. – Follow-up: the AESOP-10 study 
In order to collect as much information as practicable at 10 years after the study 
inception, a comprehensive tracing procedure was carried out by AESOP researchers (for 
further methodological details, see Morgan et al., 2014).  
Briefly, those patients who were in contact with mental health services at 
approximately 10 years were contacted via the clinical teams and invited to participate in the 
study.  For those who were not under mental healthcare, up to two letters were sent to their 
last known address inviting them to participate. In addition, researchers made a maximum of 
three visits to the address (morning, afternoon and evening on different days) to make initial 
contact. For those who had moved address, and for whom GP details were available, an 
invitation letter was sent to the GP. 
Either from face-to-face interviews or from clinical records, the World Health 
Organization (WHO) Life Chart (Sartorius et al., 1996) was used to collate extensive 
information on three domains – clinical (including suicide attempts), social and mental health 
service use.  
In addition, with regard to mortality data, including suicide, a person-tracing 
procedure was conducted on behalf of the AESOP team by the Office for National Statistics 
(ONS) using name, sex, date of birth and last known address. For all identified deaths, ICD-10 
codes of the official cause of death (according to the ONS certificate of death) were recorded 
(see Reininghaus et al., 2014 for further details). 
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5.4.c. – Measures 
5.4.c.1. – Premorbid, sociodemographic and clinical variables 
Information was obtained from patients, relatives and medical records. This included 
sex, age at admission, age at onset, ethnicity and duration of untreated psychosis (DUP). 
Specifically, the time from the date of the first psychotic symptom to the date of first contact 
with services was taken. 
 Other sociodemographic variables collected were: level of education, relationship 
status (“married” vs. “unmarried”), living status (“alone” vs. “other”), employment status 
(“employed” vs. “unemployed”), cannabis (‘use’ and ‘abuse/dependence’ were both 
dichotomized as present/absent, respectively) and alcohol (‘use’ and ‘abuse/dependence’ 
were both dichotomized as present/absent, respectively). 
 
5.4.c.2. – Neurocognitive tests 
The National Adult Reading Test (NART) (Nelson & Willison, 1991) was used to 
evaluate the premorbid Intelligence Quotient (IQ). Also, the short version of the Wechsler 
Adult Intelligence Scale Revised (WAIS-R, Wechsler, 1981) provided an accurate estimate of 
the current IQ (full scale). 
Executive functions were assessed by the Trail Making Test (Reitan, 1958), which 
involves connecting numbers (Trails A) or alternating numbers and letters (Trails B). The time 
(in seconds) taken to complete the task was the dependent variable. Subtracting time to 
complete Trails A from Trails B gives an overall measure of executive function, after having 
controlled for the effect of processing speed. 
 
5.4.c.3. – Psychopathological symptoms 
Symptom data in AESOP were collected using the Schedules for Clinical Assessment in 
Neuropsychiatry (SCAN; WHO, 1992). The SCAN incorporates the Present State Examination 
Version 10, which was used to elicit symptom-related data at the time of presentation. All 
SCAN interviews were conducted as soon as possible after first contact with psychiatric 
services. For the purposes of the analysis, symptom ratings were calculated according to the 
SCAN’s Item Group Checklist (IGC) algorithm. The IGC is advantageous in reducing the 
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number of symptoms and signs entering the analysis and also allows for a case-notes and 
informant-based (e.g. health professionals, close relatives) assessment of symptoms to be 
carried out when it is not possible to conduct a face-to-face patient interview. The IGC 
combines scores on 31 SCAN items specific to particular groups of symptoms. For instance, an 
IGC item, ‘special features of depressed mood’, includes loss of feeling, unremitting 
depression, morning depression, preoccupation with catastrophe, pathological guilt, guilty 
ideas of reference, loss of self-esteem and dulled perception. Scores for individual item groups 
range from 0 (absent) to 2 depending on the frequency and severity of symptoms. The choice 
of items to be included in the analysis was guided by previous studies that had used the PSE 
(Liddle, 1987; Mellers et al. 1996, Hutchinson et al. 1999). A factor analysis with an overlapping 
AESOP sample (Demjaha et al., 2009) yielded five psychopathological dimensions: reality 
distortion (or positive), negative, disorganization, mania and depression.  
 
5.4.c.4. – Insight 
The Schedule for Assessment of Insight – Expanded version (SAI-E) (Kemp & David, 
1997) was used to evaluate insight (see section 4.4.b.2 for further details). 
 
5.4.c.5. – Suicide attempts information 
Suicidal behaviours were taken from medical records and defined as ‘any potentially 
self-injurious behaviour for which the person intended to kill himself/herself’ (O'Carroll et al., 
1996), which included SA and SC both before and after first presentation to services. Those 
subjects with information on suicidal behaviour available, including censoring dates, were 
included. 
In addition, I identified all occurrences of death and emigration in the cohort over the 
follow-up via a person-tracing procedure conducted on my behalf by the Office for National 
Statistics (ONS) for England and Wales and the General Register Office (GRO) for Scotland 
using name, sex, date of birth, and last known address. For all identified deaths, principal 
underlying causes of death were determined according to the International Classification of 
Diseases, 10th revision (ICD-10), as recorded on copies of death certificates obtained from 
ONS. I classified as ‘suicides’ those subjects with the following ICD-10 codes of death 
according to the ONS: X60–X84 and Y10–Y34.  
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5.4.d. – Statistical analysis 
The Statistical Package for Social Science version 22.0 (SPSS Inc., Chicago, IL, USA) was 
used for performing the statistical analyses. Descriptive analyses and comparison of patient 
characteristics, including the aforementioned demographic and clinical variables, were 
undertaken using chi-square, t-tests and Mann-Whitney U tests as appropriate.  
First, predictors of insight dimensions at baseline were investigated through binary 
logistic regression models in order to precisely test the influence of suicidal history on insight 
levels after adjusting the analyses for potential mediating variables.  
Second, all patients were entered into a survival analysis with the end date being the 
date of first suicide attempt (or suicide completion where appropriate) or the censoring point, 
i.e. either the date on which the patient was last known to be alive or the end of the follow-up 
study period, which commenced at the time of discharge from hospital or after first contact to 
services in those patients who were not admitted at first presentation.  
Case-fatality (Palmer et al., 2005) was estimated based on the number of suicides 
identified at the end of the follow-up (numerator) and the initial sample size (denominator). 
Survival analyses (Kaplan-Meier Curves and log-rank tests) were performed to 
compare time from hospital discharge, or first appointment for those outpatients who did not 
require hospitalization, to first suicidal event or the censoring point as appropriate with insight 
levels at baseline. Participants were censored as non-attempters at the time of the last face-to-
face assessment with a member of staff.  
In addition, multivariable Mandel-Cox regression models (Cox, 1972) investigated time 
to first suicidal event in relation to baseline insight variables, whilst adjusting the analyses for 
potential mediating/confounding demographic and clinical variables. 








5.4.d.1. – Power calculations 
As explained in chapter 4 (section 4.4.c.1) I used the stpower logrank command of 
STATA 11.0 for Windows (StataCorp LP, USA) to conduct the power calculations based on the 
number of patients with information on insight and suicidal behaviour available. 
In particular, the FEP cohort presented in this chapter was followed-up over 10 years 
(median). Based on previous FEP studies, it is expected that at the end of the follow-up at least 
20% of the initial sample size will have made one suicide attempt (e.g. Robinson et al., 2010), 
including 2-5% of suicides (Dutta et al., 2010; Palmer et al., 2005).  Given that the mean SAI-E 
score for FEP patients is around 13/28 with a standard deviation of around 6 (e.g. Morgan et 
al., 2010), a difference of 2 points (e.g. 13 vs 15) between suicide attempters and non-
attempters, which is considered to be clinically meaningful (Kemp & David, 1997), is 
equivalent to an effect size of 0.33 with a two-tailed alpha set at 5%. Under these assumptions I 

















5.5. – Results 
5.5.a. – Baseline demographic and clinical characteristics of the sample 
The sample was comprised of N=181 FEP cases from the AESOP study. The 
sociodemographic and clinical characteristics of the whole sample, including the number of 
patients with information available on each variable, and differences between those 
with/without SA prior to first presentation are presented in Table 5.1. below. 
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Table 5.1. AESOP: Demographic and clinical differences between patients with/without 

















Age at first contact, years 181 (100) 30.5 ± 11.3 31.4 ± 11.5 31.4 ± 11.2 t=-0.0 0.97 
Gender, males 181 (100) 101 (55.8) 8 (50.0) 78 (53.4) Χ2=0.1 0.79 
Level of education 162 (89.5)      
    No qualifications  51 (31.5) 9 (56.2) 42 (28.8) Χ2=5.0 0.02 
    ≥GCSE  111 (68.5) 7 (43.7) 104 (71.2)   
Unmarried 162 (89.5) 111 (67.7) 9 (56.2) 99 (67.8) Χ2=0.8 0.35 
Living alone 168 (92.8) 52 (31.0) 5 (39.0) 45 (28.9) Χ2=0.4 0.53 
Unemployed 175 (96.7) 78 (44.6) 8 (50.0) 61 (41.8)   
Ethnicity 181 (100)    Χ2=0.2 0.63 
White  101 (55.8) 10 (62.5) 82 (56.2) Χ2=1.4 0.23 
Black  61 (33.7) 3 (18.7) 49 (33.6) Χ2=1.0 0.30 
Other  19 (10.5) 3 (18.7) 15 (10.3) U 0.06 
DUP: days, median 166 (91.7) 49.5 51 47   
Diagnosis (ICD-10) 181 (100)    Χ2=0.0 0.92 
    Schizophrenia spectrum  118 (65.2) 10 (62.5) 93 (63.7) Χ2=4.0 0.04 
    Mania with psychosis  31 (17.1) 0 (0) 30 (20.5) Χ2=4.6 0.03 
    Psychotic depression  32 (17.7) 6 (37.5) 23 (15.7)   
Drugs use 175 (96.7)    Χ2=0.8 0.38 
    Use  103 (58.9) 7 (46.7) 83 (58.4)   
Alcohol 180 (99.4)    Χ2=0.0 0.83 
    Use  152 (84.4) 14 (87.5) 124 (85.5)   
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
SA: Suicide attempts (before first contact).  
GCSE: General Certificate of Secondary Education 
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5.5.b. – Insight 
5.5.b.1. – Values and scores distribution 
The insight total scores and insight dimensions levels are summarised in table 5.2. In 
particular, the mean, standard deviation (SD), median and range of scores for recognition of 
illness, symptoms relabelling, treatment compliance and the total insight are presented. 
Kolmogorov-Smirnov tests confirmed normal distribution for total insight scores, while insight 
dimensions were not normally distributed. 
 
Table 5.2. Insight levels across the AESOP sample (N=181) 
 n (%) Mean ± SD Median Min - Max K-S test 
Recognition 181 (100) 6.0 ± 3.0 7.0 0 – 10 <0.01 
Relabelling 181 (100) 4.7 ± 3.6 4.0 0 – 12 <0.01 
Compliance 157 (86.7) 3.2 ± 1.5 3.0 0 – 6 0.01 
Total insight 157 (86.7) 13.6 ± 6.6 13.3 0 - 28 0.69 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
SD: Standard Deviation.  




Figure 5.1. AESOP. Distribution of insight scores 
 
 






5.5.b.2. - Correlations between insight dimensions 
All insight dimensions showed significant (p<0.01) and positive correlations between 
themselves. Specifically, symptom relabelling and treatment compliance showed the weakest 
correlation (r=0.36), while relabelling and recognition had the strongest correlation (r=0.54). 
All these correlations are presented in table 5.3. below.  
Table 5.3. AESOP. Correlation matrix* of theoretical  
insight dimensions (n=157-181) 
 Recognition Relabelling Compliance 
Recognition  0.54 0.53 
Relabelling 0.54  0.36 
Compliance 0.53 0.36  
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses  




5.5.b.3. – Factor analysis 
As conducted in chapter 4 (section 4.5.b.3.), an exploratory factor analysis with Varimax 
rotation was performed in order to assess the degree of similarity between these data and the 
3-factor model proposed by David (David, 1990). In this sample, a 3-factor solution was 
replicated (eigenvalues over 1), which explained 40.6%, 13.0% and 9.4% of the variance, 
respectively; hence 63.4% of the variance on total insight. 
However, in this 3-factor solution item 9 of the SAI-E (hypothetical contradiction) 
emerged significant within the ‘symptoms relabelling’ factor (i.e. factor 2) and item 6 
(awareness of the need for treatment) was captured by ‘illness recognition’ rather than 
‘treatment compliance’. See table 5.4 below. 
Table 5.4. AESOP. Factor loadings following a Varimax rotation on the SAI-E 
Principal Component Matrix* 
  Factors 
SAI-E item Insight 
dimensions 
1 2 3 
1  0.75 0.16 0.01 
2  0.68 0.30 0.13 
3  0.67 0.38 0.05 
4 Recognition 0.60 0.53 0.04 
5  0.59 -0.16 0.30 
6  0.69 0.18 0.17 
7  0.19 0.87 0.09 
8 Relabeling 0.24 0.85 0.15 
9  0.14 0.81 0.04 
10  0.20 -0.01 0.75 
11 Compliance 0.25 0.25 0.76 
Initial eigenvalues  4.47 1.43 1.03 
Variance explained (%)  40.6 13.0 9.4 
Extraction Method: Principal Component Analysis.  
Rotation Method: Varimax with Kaiser Normalization. 
*Rotation converged in 6 iterations. 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses  




5.5.c. – Differences between patients with/without suicidal history in insight levels, 
psychopathology and neurocognitive variables 
I replicated the associations of illness awareness and total insight with suicidal history 
as detailed in table 5.5. below. However, neither symptom relabeling nor treatment compliance 
showed such relationships. 
In addition, the severity of one psychopathological domain, namely depression, 
significantly differed across groups.   
No significant differences in neurocognitive variables emerged from the analyses. 
172 
 
Table 5.5. AESOP: Differences in insight, psychopathology and neurocognitive 











Insight scores       
    Recognition 181 (100)  n=16 n=146   
  6.0 ± 3.0 7.6 ± 1.9 5.9 ± 3.0 t=3.1 <0.01 
    Relabelling 181 (100)  n=16 n=146   
  4.7 ± 3.6 5.5 ± 3.3 4.7 ± 3.7 t=0.82 0.41 
    Compliance 157 (86.7)  n=15 n=127   
  3.2 ± 1.5 4.0 ± 1.4 3.2 ± 1.5 t=1.9 0.05 
    Total Insight 157 (86.7)  n=15 n=127   
  13.6 ± 6.6 17.2 ± 5.0 13.4 ± 6.7 t=2.1 0.03 
Psychopathology 156 (86.2)  n=16 n=133   
    Positive   4.0 4.5 4.0 U 0.26 
    Negative   1.0 2.0 0.0 U 0.05 
    Disorganization  0.0 0.0 0.0 U 0.51 
    Mania  1.0 0.0 1.0 U 0.07 
    Depression  0.0 5.0 0.0 U <0.01 
Premorbid IQ 133 (73.4)  n=35 n=127   
    Verbal  96.6 ± 13.5 96.8 ± 15.9 97.6 ± 13.0 t=-0.2 0.82 
    Performance  98.1 ± 13.0 98.3 ± 15.6 99.1 ± 12.6 t=-0.2 0.83 
    Full  97.2 ± 14.6 97.6 ± 17.5 98.3 ± 14.2 t=-0.2 0.86 
Current IQ 147 (81.2)  n=12 n=119   
  89.6 ± 16.0 89.0 ± 16.0 91.0 ± 16.5 t=-0.4 0.69 
TMT-A (seconds) 145 (80.1)  n=11 n=119   
  47.2 ± 27.0 50.0 ± 24.0 45.1 ± 24.8 t=0.6 0.53 
TMT-B (seconds) 140 (77.3)  n=11 n=114   
  107.3 ± 62.5 127.2 ± 77.3 102.7 ± 60.3 t=1.2 0.21 
TMT-B-A (seconds) 138 (76.2)  n=11 n=112   
  60.9 ± 46.4 77.2 ± 68.9 58.6 ± 45.4 t=0.9 0.40 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
IQ: Intelligence Quotient. TMT: Trail Making Test (Reitan, 1958)  
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5.5.d. – Bivariate analyses: relationships between insight dimensions and baseline 
demographic and clinical characteristics of the sample 
Exploratory analyses investigated potential relationships between insight levels (as 
dependent variable) and a wide range of baseline demographic variables. In particular, no 
significant differences in insight scores emerged from between-group comparisons with regard 
to age at first contact.  
However, symptom relabelling and total insight were significantly greater in females 
than in males.  
Also, those with ‘qualifications’ (i.e. GCSE levels or higher education) showed 
significantly higher levels of symptom relabelling than those without qualifications.  Insight 
levels did not vary in terms of marital, living and employment status. 
However, patients of White ethnicity were found to have greater levels of illness 
recognition and total insight than Black patients.  
















Table 5.6. AESOP: Baseline demographic data and insight levels 
 Recognition Relabelling Compliance Total insight 
Age at first contact n=164 n=164 n=144 n=144 
 r=-0.07 r=-0.14 r=0.04 r=-0.08 
 p=0.36 r=0.07 p=0.62 p=0.32 
Gender n=181 n=181 n=157 n=157 
    Males 5.7 ± 3.1 4.1 ± 3.1 3.1 ± 1.6 12.6 ± 6.4 
    Females 6.4 ± 3.0 5.4 ± 3.9 3.3 ± 1.4 14.9 ± 6.8 
 t=-1.5, p=0.15 t=-2.4, p=0.02 t=-1.1, p=0.28 t=-2.1, p=0.04 
Level of education n=175 n=175 n=153 n=153 
    No qualifications 5.7 ± 3.3 3.8 ± 3.5 3.1 ± 1.6 12.5 ± 7.0 
    ≥ GCSE 6.3 ± 2.9 5.1 ± 3.5 3.3 ± 1.5 14.5 ± 6.4 
 t=-1.1, p=0.29 t=-2.3, p=0.02 t=-0.9, p=0.38 t=-1.7, p=0.08 
Marital status n=169 n=169 n=148 n=148 
    Unmarried 5.8 ± 3.0 4.8 ± 3.7 3.1 ± 1.6 13.4 ± 7.1 
    Married 6.5 ± 3.0 4.6 ± 3.3 3.5 ± 1.3 14.4 ± 5.8 
 t=-1.4, p=0.15 t=-0.2, p=0.81 t=-1.7, p=0.09 t=-0.9, p=0.38 
Living status n=168 n=168 n=147 n=147 
    Alone 5.9 ± 3.1 4.5 ± 3.6 3.2 ± 1.5 13.7 ± 7.0 
    With others 6.1 ± 2.9 4.8 ± 3.6 3.3 ± 1.6 13.7 ± 6.5 
 t=-0.4, p=0.72 t=-0.5, p=0.63 t=-0.2, p=0.84 t=-0.0, p=0.99 
Employment status n=175 n=175 n=153 n=153 
    Unemployed 5.7 ± 3.3 4.3 ± 3.6 3.0 ± 1.7 12.7 ± 7.2 
    Employed 6.4 ± 2.7 5.1 ± 3.5 3.4 ± 1.4 14.7 ± 5.9 
 t=-1.6, p=0.10 t=-1.5, p=0.14 t=-1.4, p=0.16 t=-1.8, p=0.06 
Ethnicity n=181 n=181 n=157 n=157 
    White 6.6 ± 2.9 5.5 ± 3.5 3.4 ± 1.4 14.8 ± 6.2 
    Black 5.2 ± 3.3 4.0 ± 3.6 2.8 ± 1.6 11.7 ± 6.9 
    Others 5.5 ± 2.5 4.9 ± 3.3 3.1 ± 1.7 13.8 ± 7.0 
 F=4.8, p<0.01 F=1.8, p=0.16 F=2.5, p=0.08 F=3.7, p=0.03 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  





With regard to baseline clinical characteristics of the sample such as DUP, diagnosis 
and alcohol and illicit drugs use, no significant differences emerged from the bivariate 
analyses which are shown in table 5.7. below.  
 
Table 5.7. AESOP: Baseline clinical characteristics and insight dimensions 
 Recognition Relabelling Compliance Total Insight 
DUP n=166 n=166 n=146 n=146 
    <49.5 days 6.4 ± 2.9 5.1 ± 3.7 3.5 ± 1.5 14.5 ± 6.9 
    >49.5 days 5.8 ± 3.0 4.3 ± 3.4 3.1 ± 1.6 13.1 ± 6.4 
 t=1.2, p=0.23 t=1.4, p=0.15 t=1.5, p=0.13 t=1.3, p=0.20 
     
Diagnosis n=181 n=181 n=157 n=157 
    Schizophrenia 5.8 ± 3.1 4.5 ± 3.7 3.2 ± 1.6 13.3 ± 7.0 
    Mania 5.7 ± 3.2 5.3 ± 3.4 2.6 ± 1.3 12.9 ± 6.4 
    Depression 7.2 ± 2.4 4.8 ± 3.1 3.5 ± 1.3 15.2 ± 5.1 
 F=2.8, p=0.06 F=0.6, p=0.54 F=2.6, p=0.07 F=0.9, p=0.38 
     
Alcohol n=180 n=180 n=156 n=156 
    Use 6.1 ± 2.9 4.9 ± 3.6 3.2 ± 1.6 13.8 ± 6.6 
    non-use 5.8 ± 3.5 3.6 ± 3.3 3.1 ± 1.5 12.5 ± 6.7 
 t=-0.4, p=0.65 t=-1.7, p=0.08 t=-0.2, p=0.87 t=-0.9, p=0.36 
     
Drugs n=175 n=175 n=151 n=151 
    Use 6.2 ± 3.1 4.8 ± 3.6 3.2 ± 1.7 13.8 ± 6.9 
    non-use 5.9 ± 2.9 4.6 ± 3.7 3.2 ± 1.4 13.4 ± 6.4 
 t=-0.6, p=0.57 t=-0.3, p=0.79 t=-0.2, p=0.82 t=-0.4, p=0.71 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  








I also conducted correlation analyses between insight scores and psychopathological 
dimensions and neurocognitive variables, which are detailed in table 5.8. below, which 
revealed several significant differences. In terms of significant associations of 
psychopathological domains and insight dimensions, depression correlated positively with all 
insight scores, while compliance showed a negative relationship with disorganization and 
mania. In addition, the positive dimension showed an inverse association with symptoms 
relabeling.  
Regarding neurocognitive variables, the directions of the associations was that the 
worse the cognitive performance, the poorer the insight. Specifically, current IQ and TMT-A 
and TMT-B correlated with illness recognition and relabeling, which also correlated with 
premorbid IQ (including verbal, performance and full IQ). Total insight showed a relationship 









Table 5.8. AESOP: Correlations of insight dimensions with psychopathological and neurocognitive variables 
 Recognition Relabelling Compliance Total Insight 
 n r p n r p n r p n r p 
Positive 156 -0.05 0.52 156 -0.20 0.02 137 0.03 0.70 137 -0.12 0.17 
Negative 156 -0.08 0.34 156 -0.02 0.80 137 0.04 0.61 137 -0.06 0.51 
Disorganization 156 0.00 0.94 156 -0.03 0.65 137 -0.20 0.02 137 -0.03 0.72 
Mania 156 -0.06 0.46 156 -0.09 0.94 137 -0.18 0.03 137 -0.09 0.30 
Depression 156 0.23 <0.01 156 0.18 0.04 137 0.26 <0.01 137 0.18 0.04 
Premorbid IQ 199 0.05 0.30 199 0.21 0.01 172 0.04 0.62 172 0.13 0.13 
IQ (WAIS-III) 202 0.22 0.01 202 0.23 0.01 174 0.12 0.20 174 0.27 <0.01 
TMT-A (seconds) 195 -0.24 <0.01 195 -0.19 0.02 170 -0.09 0.28 170 -0.29 <0.01 
TMT-B (seconds) 190 -0.21 0.01 190 -0.18 0.03 165 -0.06 0.49 165 -0.15 0.11 
TMT B-A (seconds) 187 -0.16 0.05 187 -0.16 0.07 163 0.04 0.64 163 -0.03 0.78 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
IQ: Intelligence Quotient. WAIS: Wechsler Adult Intelligence Scale, revised (Wechsler, 1981). TMT: Trail Making Test (Reitan, 1958).  
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5.5.e. – Regression on recognition of illness 
A hierarchical linear regression model (‘enter’ method) was performed to reassess the 
association of previous SA with recognition of illness whilst adjusting for some variables 
which had also been associated with illness recognition, namely being white, neurocognition 
(current IQ and TMT-A) and depressive symptoms severity. Of note, the block of variables that 
remained significant was neurocognition. The final model accounted for 11% of the variance 
on recognition.  
  
Table 5.9. AESOP: Regression on recognition 
 B SE p R2 Change p-change 
Block 1:     0.029 0.06 
    White 0.42 0.56 0.46   
Block 2:     0.014 0.20 
    Previous SA 0.84 0.96 0.38   
Block 3:    0.052 0.04 
    Current IQ 0.02 0.02 0.22   
    TMT-A -0.02 0.01 0.14   
Block 4:    0.015 0.18 
    Depression 0.21 0.15 0.18   
GLOBAL R2    0.11  
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
SA: suicide attempts prior to first presentation 











5.5.f. – Regression on relabelling of symptoms 
A hierarchical linear regression model (‘enter’ method) was carried out to reassess the 
association of previous SA with symptoms relabelling after controlling for the effects of 
education level (no qualifications vs. higher level), gender (male vs. female), neurocognition 
(premorbid and current IQ and TMT-A to avoid multi-collinearity) and positive and 
depressive symptoms severity. Gender (p=0.04) was the only variable that remained 
significant in the final model, which explained 14% of the variance on relabelling of symptoms.  
 
Table 5.10. AESOP: Regression on relabelling 
 B SE p R2 Change p-change 
Block 1:    0.061 0.03 
    Gender (male) -1.40 0.67 0.04   
    No qualifications -0.83 0.80 0.30   
Block 2:    0.054 0.08 
    Premorbid IQ 0.00 0.03 0.84   
    Current IQ 0.03 0.03 0.33   
    TMT-A -0.02 0.01 0.13   
Block 3:    0.027 0.18 
    Positive -0.17 0.12 0.17   
    Depression      
GLOBAL R2    0.14  
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses. 










5.5.g. – Regression on treatment compliance 
Only three psychopathological dimensions, namely disorganization (negative 
association), mania (negative association) and depression (positive relationship) were related 
to compliance, none of which survived the multivariable regression model. 
 
Table 5.11. AESOP: Regression on compliance 
 B SE R2 Change p-change 
Disorganization -0.02 0.13 0.00 0.95 
Mania -0.09 0.05 0.02 0.60 
Depression -0.04 0.16 0.00 0.86 
  AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
 
5.5.h. – Regression on total insight 
A hierarchical linear regression model (‘enter’ method) was carried out to reassess the 
association of suicidal history with total insight after controlling for the effects of demographic 
variables, such as education level (no qualifications vs. higher education), gender (male) and 
being white, neurocognitive variables (current IQ and TMT-A) and depressive symptoms 
severity. Gender remained significant, while depression showed a borderline association with 
total insight. The model accounted for 14% of the variance on total insight, which is detailed in 
table 5.12. below.   
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Table 5.12. AESOP: Regression on total insight 
 B SE p R2 Change p-change 
Block 1:     0.072 0.04 
    Gender (male) -1.51 0.68 0.03   
    No qualifications -1.16 0.81 0.15   
    White 0.13 0.74 0.86   
Block 2:    0.005 0.42 
    Previous SA 1.65 1.25 0.19   
Block 3:    0.037 0.10 
    Current IQ 0.03 0.03 0.25   
    TMT-A -0.02 0.02 0.26   
Block 4:    0.023 0.09 
    Depression -0.34 0.20 0.09   
GLOBAL R2    0.14  
 AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
SA: suicide attempts prior to first presentation 




5.5.i. – Suicidal behaviours over the 10-year follow-up  
In total, 34 subjects (18.7%) made at least one suicide attempt either prior to first contact 
with services or over the follow-up, which had a median of 10 years. Specifically, 26 
individuals (14.4%) attempted to take their lives over the follow-up, 8 of whom (4.4%) were re-
attempters, i.e. they made suicidal acts before and after first contact. In total, 16 subjects had 
attempted to take their lives before first presentation. Eight patients made two suicide attempts 
over the follow-up, three individuals attempted to end their lives on three occasions and four 
patients made multiple suicide attempts (from 4 to 7). Five subjects died from suicide over the 
10-year that period, which yielded a case fatality of 5/181=2.7%. In addition, 6 more patients 
died from natural causes within the 10-year follow-up. Regarding attrition, 10 patients (5.5%) 


























AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
FEP: First-episode psychosis 
CF: Case-fatality  
 
 








NON-FATAL SUICIDAL EVENTS 








Figure 5.2. Flow chart of AESOP patients 
5 
SUICIDE COMPLETIONS 
(CF = 5/181=2.7%) 
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Thus, 26 suicide attempters, including the 5 individuals who ended their lives, and 155 
non-suicide attempters were compared through Kaplan-Meier survival analyses and Cox 
Regression models with regard to baseline insight levels, whilst adjusting the analyses for a set 
of demographic and clinical variables.  
Of note, the median of time to first suicide attempt was one year with non-significant 
(p=0.47) differences across genders (males in green and females in blue), as shown by the 
Kaplan-Meier Curve below which also (Figure 5.3.). 
 
 
Figure 5.3. AESOP. Kaplan-Meier Curve for those who attempted and/or completed 
suicide (n=26) over the 10-year follow-up 
 
 







5.5.i.1. – Suicide methods 
As detailed in figure 5.2 above, there were 56 suicidal events over the follow-up. Thus, 
poisoning (n=16) and jumping (n=9), which included both jumping off a high place and 
jumping in front of a vehicle, were the most common suicide methods. Also, there were suicide 
attempts by violent methods such as stabbing (n=1) or arson (n=1). There were no suicide 
attempts by firearms. 
Also, 5 subjects ended their lives, who were all males. In particular, two subjects 
hanged themselves, one patient jumped in front of a train, another individual stabbed himself 
to death and ‘other’ method was used by the remaining suicide completer.  
 
 
Table 5.13. AESOP. Suicide methods 
Method Events (n=56) 
Poisoning 16 








AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 




5.5.j. – Risk factors for suicidal behaviour over the follow-up 
Univariate analyses concerning demographic, clinical and symptom-related variables, 
including insight, are presented below in tables 5.14, 5.15 and 5.16, respectively.  
 
Table 5.14. AESOP: Univariate analysis: log-rank tests of equality of survival 
distributions for the demographic variables (n=166) 







Gender Male 12.8 11 0.75 0.39 
 Female 11.1 13   
Age at first contact <28 11.7 12 0.00 0.95 
 >28 12.3 12   
Education level No qualifications 2.8 2 0.22 0.64 
 ≥ GCSE 6.2 7   
Marital status Unmarried 6.0 5 0.67 0.41 
 Married 2.3 4   
Living status Alone 7.6 10 1.25 0.26 
 Not alone 16.4 14   
Employment status Unemployed 10.4 8 1.01 0.32 
 Employed 13.6 16   
Ethnicity White 13.4 16 1.84 0.40 
 Black 7.9 5   
 Other 2.6 3   
 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 










Table 5.15. AESOP: Univariate analysis: log-rank tests of equality of survival 
distributions for the clinical variables (n=166) 




Log-rank test  
(X2) 
p-value 
Previous SA Absent 21.6 16 23.11 <0.01 
 Present 2.4 8   
DUP <49.5 12.0 11 0.22 0.64 
 >49.5 12.0 13   
Diagnosis Schizophrenia 15.2 16 0.76 0.68 
 Mania 4.5 3   
 Depression 4.3 5   
Drugs non-use 10.4 9 0.38 0.54 
 Use 13.6 15   
Alcohol non-use 3.6 0 4.49 0.03 
 Use 20.4 24   
 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
SA: suicide attempts prior to first presentation 
 
 
As shown in tables 5.14, 5.15., above, and 5.16 and 5.17., below, only three variables 
emerged as significant factors associated with time to first suicidal event, namely suicidal 
history (RR 2.92, 95% CI 0.96-8.86, p=0.06), an overall measure of executive functions such as 
TMT B-A (RR 1.01, 95% CI 1.00-1.02, p=0.01) and depressive symptoms severity (RR 1.57, 95% 
CI 1.30-1.89, p<0.01), which were therefore added to a Cox regression model (enter method). 
Interestingly, only depression (RR 1.55, 95% CI 1.22-1.97, p<0.01) survived as significant risk 
factor for suicidal behaviour, although a previous suicidal history showed a borderline 
association (RR 2.78, 95% CI 0.90-8.60, p=0.07) as detailed in table 5.17. below. Although 
alcohol use was significantly associated with suicidal behaviours risk, given the lack of events 
in the non-users group, I did not include this variable in the multivariable regression model. 
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Table 5.16. AESOP: Cox regression analyses for neurocognitive,  
psychopathological and insight-related variables (n=166) 
Risk factor RR 95% CI p-value 
Neurocognition    
    Premorbid IQ 1.02 0.99 - 1.06 0.21 
    Current IQ 1.00 0.98 - 1.04 0.47 
    TMT-B-A 1.01 1.00 – 1.02 0.01 
Psychopathology    
    Positive 1.08 0.93 – 1.24 0.33 
    Negative 0.93 0.74 – 1.17 0.53 
    Disorganization 0.84 0.51 – 1.38 0.48 
    Mania 0.96 0.80 – 1.16 0.68 
    Depression 1.57 1.30 – 1.89 <0.01 
Insight    
    Illness recognition 1.14 0.98 – 1.34 0.09 
    Symptoms relabeling 1.06 0.96 - 1.18 0.25 
    Treatment compliance 1.30 0.99 – 1.71 0.06 
    Total insight 1.06 0.99 – 1.13 0.08 
 AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
RR: Relative Risk. CI: Confidence Interval 
TMT B-A: Trail Making Test B-A (Reitan, 1958) 
 
 
Table 5.17. AESOP: Cox regression model 
Risk factor RR 95% CI p-value 
Previous SA Present 2.78 0.90 – 8.60 0.07 
 Absent 1.00   
TMT B-A  1.00 0.99 – 1.01 0.13 
     
Depression  1.55 1.22 – 1.97 <0.01 
    Model based on n=116 AESOP patients, including 18 suicide attempters,  
    whom had complete data for all the variables in the model 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
SA: Suicide attempts (prior to first presentation/contact) 
RR: Relative Risk. CI: Confidence Interval 




5.6. – Discussion 
5.6.a. – Main findings 
Three main findings emerged from the above results.  
First, consistent with findings from chapter 4, I replicated the relationship between 
illness recognition and total insight at first contact with services and previous SAs. However, 
previous SA did not survive the multivariable regression models, suggesting that other 
variables, particularly depression, may explain such a relationship.  
Second, with regard to the follow-up analyses, in keeping with my postulations, 
although the three insight dimensions behaved as risk factors of suicidal behaviour (bivariate 
analyses), the associations did not reach statistical significance. However, these non-significant 
associations may have been due to insufficient statistical power (75% for insight variables), 
particularly taking into account that illness awareness, symptom relabeling and total insight 
showed trends at a borderline significance (p<0.1 but > 0.05). On the other hand, these 
negative results may be reliable and therefore confirm my hypotheses. Given this uncertainty, I 
decided to merge this cohort of FEP patients with those presented in chapter 4 from the GAP 
study, which forms the context for chapter 6.  
Third, I replicated the role of previous SA and depressive symptom severity in 
predicting further suicidal events, whilst taking into account the time to such suicidal events. 
In addition, a general measure of executive functions such as the TMT B-A was found to be 
associated with risk of suicidal behaviour in the bivariate analyses (the poorer the cognitive 
performance, the higher the risk), although this association did not survive the multivariable 









5.6.b. – Insight levels at baseline are influenced by suicidal antecedents 
Those patients who had made suicide attempts prior to first presentation to services 
were found to have significantly greater levels of illness awareness and total insight than non-
suicidal subjects. These results were in full alignment with chapter 4 and my previous first 
author publication (Lopez-Morinigo et al., 2014a).  
In addition, consistent with the multidimensionality of insight proposed by David 
(David, 1990), different predictors were found for each insight dimension which would 
provide further support for such a model (for a review, see Amador & David, 2004).   
More specifically, in line with previous (Wiffen et al., 2012; Mintz et al., 2003; Parellada 
et al., 2011; McEvoy et al., 2006), but not all (Markova, 2005) studies, I replicated the association 
of being a female with greater levels of insight, although in this sample the differences were 
only significant for symptom relabelling and total insight. Also, those patients with higher 
levels of education had higher levels of insight, particularly in terms of symptom relabelling 
and total insight, which is consistent with a previous report from our group (Wiffen et al., 
2010). This finding also links with employment since those who were unemployed scored 
lower on insight subscales, namely illness awareness and total insight, than employed people 
(although this was not statistically significant). However, previous research in this area is 
scanty (Lysaker & Bell., 1994). In addition, consistent with chapter 4, white patients had 
significantly higher levels of insight than those of a Black ethnicity, which is in line with 
previous literature (Johnson & Orrell, 1995; Goldberg et al., 2001; Morgan, 2003), although a 
previous London-based study by our group in the 90s had failed to show this association 
(David et al., 1995).   
In keeping with chapter 4, an inverse relationship between insight and DUP was 
replicated (Pek et al., 2006; Saravanan et al., 2010; Cuesta et al., 2011), i.e. the longer the DUP, 
the poorer the insight at first presentation, although these associations did not reach statistical 
significance. Again, this cross-sectional association did not allow me to infer causality 
conclusions. Indeed, both directions of causality are plausible. Thus, poor insight may delay 
receiving proper (psychiatric) care, thus increasing the DUP. Equally, a more prolonged DUP 
results in more severe psychotic symptoms at first contact with services, hence poorer insight 
levels at that point (Drake et al., 2000).  
Of relevance to the purposes of this investigation, I replicated the association of 
depressive symptoms severity with awareness of having a mental illness, treatment 
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compliance and total insight (Peralta et al., 1998; Mintz et al., 2003; Cooke et al., 2005; Lincoln 
et al., 2007; Nair et al., 2014; Belvederi et al., 2015). As detailed in chapter 4 (sections 4.6.c.), 
both directions of causality are possible. The so-called ‘demoralization syndrome’ (Drake, 
1986; Restifo et al., 2009), posits that gaining awareness of negative events such as (mental) 
illnesses leads patients to depression (and even suicidality), and the ‘depressive realism’ 
account (see Ghaemi & Rosenquist, 2004 for a review), which argues that those depressed 
patients are more likely to recall such negative events, thus showing greater insight at the time 
of the assessment. Indeed, those participants with suicidal antecedents also presented with 
more severe depressive symptoms at the study inception, while other psychopathological 
domains did not significantly differ across groups with/without suicidal history.  
In contrast to chapter 4, although consistent with previous research on ‘the cognitive 
basis of insight in psychosis’ (Amador et al., 1991; Morgan & David, 2004; Aleman et al., 2006; 
Ayesa-Arriola et al., 2011; David et al., 2012; Nair et al., 2014), both general cognition (i.e. 
‘current’ IQ as measured by the WAIS) and executive functions, which were evaluated by the 
TMT B-A, predicted insight levels at  first presentation with the exception of treatment 
compliance. These results were also in line with two previous FEP studies from our group 
(Morgan et al., 2010b; Wiffen et al., 2012) and a previous meta-analysis (Aleman et al., 2006).  
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5.6.c. – Insight dimensions did not predict suicide risk over the follow-up 
In keeping with my hypotheses, over the 10-year follow-up no insight dimension was 
significantly associated with risk of suicidal behaviors. However, the RRs (>1) suggest that 
insight may still be a risk factor for suicide, which may not have been demonstrated due to 
insufficient statistical power to investigate this. Indeed, with the exception of symptom 
relabeling, illness recognition, treatment compliance and total insight showed borderline 
associations with suicidal risk (p<0.1 but >0.05). These results replicated those from chapter 4, 
including the previously reported tautological link between suicidal history, insight levels at 
first presentation and risk of future suicidal acts, which is in full agreement with previous 
literature both on schizophrenia (Hawton et al., 2005) and FEP (Challis et al., 2013), as 
previously postulated (chapter 2, section 2.5) based on my literature review (Lopez-Morinigo 
et al., 2012) and more recent studies (Yan et al., 2013; Pijnenborg et al., 2013; Barrett et al., 
2015).   
However, given the relatively limited statistical power (75% for insight variables, see 
section 5.4.d.1), a type 2 error cannot be excluded. I addressed this limitation by merging these 
two FEP cohorts (Chapters 4 and 5), which is explained in chapter 6.  
 
5.6.d. – Predictors of suicidal behaviour over the follow-up 
In line with previous literature on suicide in psychosis (Hu et al., 1991; De Hert et al., 
2001; Sinclair et al., 2004; Hawton et al., 2005; Tarrier et al., 2006; Reutfors et al., 2009; Bakst et 
al., 2010; Dutta et al., 2010; Pompili et al., 2011; Challis et al., 2013; Björkenstam et al., 2014), 
including  two recent meta-analyses (Large et al., 2011; Challis et al., 2013) and chapter 3 of this 
thesis, suicidal history was found to be the strongest predictor of future suicidal events in early 
psychosis. In addition, alcohol use (in comparison to non-use), executive functions (as 
measured by the TMT B-A) and depressive symptoms severity predicted risk of suicidal 
behaviour over the 10-year follow-up period.  
Drinking alcohol abusively and using recreational drugs have been consistently linked 
with an increased suicide risk in the general population (see Hawton & van Heeringen., 2009). 
However, mixed results have been reported with regard to alcohol and suicide risk both in 
schizophrenia (Hawton et al., 2005) and FEP (Challis et al., 2013), while drugs use was 
consistently found to increase the risk (Hawton et al., 2005; Challis et al., 2013). The above 
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results concerning the role of alcohol use in suicide risk in this FEP cohort suggest that, given 
the high number of alcohol ‘users’, full abstinence may represent a protective factor for suicide 
in psychosis, although further replication studies are needed.  
Mixed findings have been reported with regard to neurocognition and suicide risk in 
psychosis (Andersson et al., 2008, Webb et al., 2011; Potkin et al., 2003; Barrett et al., 2011; see 
Hor & Taylor, 2010 for a general review). In line with my results, cognitive impairment has 
been reported to reduce suicide risk in patients with schizophrenia spectrum disorders (Fenton 
et al., 1997; De Hert et al., 2001). Hence, long-term studies of FEP cohorts are needed in this 
area, including the administration of comprehensive neurocognitive assessments over the 
course of the illness.  
Some negative results from this chapter deserve a comment. Thus, contrary to previous 
research (e.g. Tsuang, 1978; Osby et al., 2000; Qin & Nordentoft, 2005; Palmer et al., 2005; 
Limosin et al., 2007; Osborn et al., 2008; Dutta et al., 2010; Barrett et al., 2010a; Barrett et al., 
2010b) and the findings presented in chapter 4, I failed to replicate a significant association 
between age at first presentation and risk of suicidal behaviours, although the tendency was 
that younger subjects at first contact with mental health services had a higher risk of suicidal 
behaviours. Of concern, this non-significant association of early age at first presentation with 
increased suicide risk may be due to limited statistical power. Similarly, the association of 
living alone with an increased suicide risk in psychosis (Hawton et al., 2005; Challis et al., 
2013), although replicated in this sample, did not reach significance.  
Figures 5.4 and 5.5, below, represent the model tested in this thesis and the model 




Figure 5.4. Hypothesised model to be tested in this thesis 
Red arrows increase risk and green arrows show lower risk 
 




5.6.e. – Strengths and limitations 
While I included a large cohort of FEP patients, which was part of the AESOP study, 
including a long follow-up (median: 10 years), the statistical power calculations detailed in 
section 5.4.d.1. suggest that a potential type 2 error cannot be excluded. This led me to merging 
both London-based FEP cohorts, namely GAP (chapter 4) and AESOP (this chapter) as 
explained in chapter 6.  
In addition, further limitations should be taken into account when drawing conclusions 
from the above results. First, other non-tested variables might contribute to predicting insight 
such as premorbid personality (Lysaker et al., 1999; Campos et al., 2011; Cuesta et al., 2011; 
Ritsner & Blumenkrantz, 2010) and neuroanatomical correlates (Morgan et al., 2010; David et 
al., 2012). Second, examiners were not blind to other scales such as the PANSS, which might 
bias the insight assessment (Campos et al., 2011). Third, our cross-sectional assessment of 
insight did not permit to the investigation of insight changes over the course of the illness 
(Wiffen et al., 2010; Campos et al., 2011; Cuesta et al., 2011; Ayesa-Arriola & Lopez-Morinigo et 
al., 2014) in relation to suicide risk. Also, demographic variables related to suicide risk such as 
marital and living status may have changed over the study period. Hence, the link between 
demographic data at baseline and suicide risk over such a prolonged follow-up should be 
taken with caution.   
 
5.7. – Chapter summary 
Although the findings from this chapter suggest that, consistent with the hypotheses, 
insight levels were not significantly associated with risk of suicidal behaviors over the early 
stages of the psychotic illness; these negative results may conceivably have been due to limited 
statistical power.  
As a result, in the next chapter (Chapter 6), I will present the results from analyzing a 
merged cohort of FEP patients from the GAP (see chapter 4) and AESOP studies (the present 
chapter), which is detailed in the methods sections (Chapter 6, section 6.4).  
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Chapter 6 – Suicidal behaviour in early psychosis. Findings 
from the GAP-AESOP combined cohort of first-episode 
psychosis patients  
 
6.1. – Introduction 
This chapter describes the predictors of suicidal behaviour in a large cohort of first-
episode psychosis (FEP) subjects from two sites in the UK (London and Nottingham). More 
specifically, this cohort of FEP patients was the result of combining the samples presented in 
chapter 4 (from the GAP study) and 5 (from the AESOP study). In particular, the role of three 
insight dimensions, namely recognition of having a mental illness, symptom relabelling and 
awareness of the need for treatment, in suicidal acts, which encompasses suicide attempts and 
suicide completions, over a prolonged follow-up (7 year median), was investigated. Also, 
multivariable regression models were built in order to investigate the above associations 
whilst controlling for a range of demographic and clinical variables which may 
mediate/confound the relationship between insight dimensions and risk of suicidal 
behaviours in early psychosis.  
 
6.2. – Background 
As detailed in chapters 2, 4 (section 4.2.) and 5 (section 5.2.), the role of insight 
dimensions in suicidal behaviour in FEP patients remains unclear (Lopez-Morinigo et al., 
2012), which may have crucial clinical implications in the development of suicide prevention 
measures focused on insight management from first presentation.  
Although this research question was investigated in chapters 4 and 5 with two cohorts 
of FEP subjects, the statistical power was limited (ranging from 62.5% to 75.1%), which may 
have resulted in false negative results. Given that the main hypothesis of this thesis was that 
insight dimensions are not a risk factor for suicide in early psychosis, the fact that the above 
negative results from chapters 4 and 5 might have been due to insufficient statistical power 
would not allow me to draw definitive conclusions. In order to address this issue, I decided to 
merge both UK-based FEP cohorts and analyse the results from this larger (and statistically 
more powerful) sample concerning the above research question.  
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6.3. – Aims and Objectives 
6.3.a. – Descriptive aims and objectives 
 To describe the distribution of insight dimensions according to the outcome of 
suicidal behaviours, including both suicide attempts and suicide completions. 
 
6.3.b. – Analytical aims and objectives 
 To investigate whether there is an association between a history of suicidal 
behaviours before first presentation with psychosis and insight levels at that 
point.  
 To adjust the above analyses for a set of potential confounders in order to 
determine independent predictors of insight at baseline, including the role of 
previous suicidal history.  
 To calculate the case fatality of this FEP sample over the 7-year follow-up period. 
 To identify the risk factors associated with suicidal behaviours in a FEP cohort 
over a 7-year follow-up period. 
o And to determine whether there is an association of insight levels with 
risk of suicidal behaviours over the 7-year follow-up period.  
 To test for potential interactions between insight dimensions and other clinical 
and demographic variables related to risk of suicidal behaviour. 
 To formulate a model, based on a multivariable Cox Regression analysis of the 
above baseline variables, including insight dimensions, for predicting suicidal 





6.4. – Methods 
6.4.a. – Sample, baseline assessment and follow-up procedure 
The sample for this chapter came from two FEP studies, namely the Genetics and 
Psychosis (GAP) and the Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
(AESOP). The methodology of both studies is detailed in chapters 4 (section 4.4) and 5 (section 
5.4), respectively.  
In brief, it should be noted that both studies aimed to recruit all the incident cases 
presenting with a FEP (F10-F29 and F30- F33 in ICD-10) to the South London and Maudsley 
NHS Foundation Trust over 1997-1999 (AESOP) and 2004-2010 (GAP), although a small 
proportion of AESOP patients were recruited in Nottingham. Also, inclusion and exclusion 
criteria in AESOP and GAP studies were very similar as follows: 
Inclusion criteria:  
a) age between 16 and 65 years (both studies)  
b) resident within tightly defined catchment areas in Nottingham (only AESOP) or 
south-east London (GAP and AESOP) 
c) presence of a first episode of psychosis, namely F10-F29 and F30- F33 codes in ICD-
10 within the time frame of the study (both studies).  
 
Exclusion criteria:  
a) evidence of an organic cause of psychosis (both studies) 
b) drug-induced psychosis (both studies) 
c) IQ less than 50 (both studies) 
d) poor fluency of English (both studies)  
 
Participants in both studies provided written informed consent and both AESOP and 
GAP projects obtained ethical approval from the Local Research Ethics Committees.   
In order to ascertain suicidal behaviours over the follow-up, there were some minor 
differences between GAP and AESOP studies. In particular, GAP patients were traced by 
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contacting the patient via a phone call and/or a letter and contacting the GP. However, AESOP 
patients who were in contact with mental health services at approximately 10 years were 
contacted via the clinical teams and invited to participate in the study.  For those who were not 
under mental healthcare, up to two letters were sent to their last known address inviting them 
to participate. In addition, researchers made a maximum of three visits to the address 
(morning, afternoon and evening) to make initial contact. For those who had moved address, 
and for whom GP details were available, an invitation letter was sent to the GP. 
Clinical records were used in both studies to collect information on outcome variables, 
including suicidality where available. With regard to all-cause mortality data, including 
suicide, similar methods were used in both AESOP and GAP studies. Specifically, a person-
tracing procedure conducted on behalf of the teams by the Office for National Statistics (ONS), 
which in the UK records the official cause of death by using ICD-10 codes.  
  
6.4.b. –  Measures 
6.4.b.1. – Premorbid, sociodemographic and clinical variables 
The following sociodemographic variables collected used in this combined analysis: 
sex, age at admission (GAP) or first contact with services (AESOP), level of education, living 
status (“alone” vs. “other”), employment status (“employed”, “student” or “unemployed”), 
cannabis and alcohol use (yes/no) and abuse/dependence (yes/no). The duration of untreated 
psychosis (DUP) was measured in a slightly different manner in both studies. While GAP used 
the Nottingham Onset Schedule (Singh et al., 2005) to estimate DUP from medical records, 
which was defined as the time from the date of the first continuous psychotic symptom 
(lasting at least a week) to the date of commencing on antipsychotic medication (having taken 
75% of doses within the following month), the AESOP study considered the time from the 




6.4.b.2. – Insight 
The Schedule for Assessment of Insight – Expanded version (SAI-E) (Kemp & David, 
1997) was used to evaluate insight in both studies (see sections 4.4.b.2 and 5.4.c.4). 
Since both GAP and AESOP studies used the same insight measurement, I found it 
appropriate to merge both samples in this chapter.   
 
6.4.b.3. – Neurocognitive tests 
The same neurocognitive tests were used in both studies, namely the National Adult 
Reading Test (NART) (Nelson & Willison, 1991), the short version of the Wechsler Adult 
Intelligence Scale Revised (WAIS-R, Wechsler, 1981) and the Trail Making Test (Reitan, 1958), 
which assessed premorbid and current IQ and frontal functions, respectively. See further 
details about the neurocognitive assessments in sections 4.4.b.3. and 5.4.c.2.   
 
6.4.b.4. – Psychopathological symptoms 
In the GAP study five psychopathological dimensions were measured with the Positive 
and Negative Symptoms Scale for Schizophrenia (PANSS, Kay et al., 1987) based on a previous 
systematic review of PANSS factor analyses (Wallwork et al., 2012): positive, negative, 
disorganization, mania and depression.  
In keeping with this, five symptomatic dimensions emerged from a previous factor 
analysis with an overlapping AESOP sample (Demjaha et al., 2009), although it should be 
noted that the AESOP study used the Schedules for Clinical Assessment in Neuropsychiatry 
(SCAN; WHO, 1992), particularly the SCAN’s Item Group Checklist (IGC) algorithm, to 
evaluate psychopathological symptom severity.  
Given the different distribution of scores for these dimensions across studies, as 
expected, groups (present vs. absent) were created for each symptom dimension. In the 
AESOP subsample, for each symptom domain, scores of 0 designated absence of the symptom, 
while scores of 1 or greater values than 1 indicated presence.  For the GAP cohort, patients’ 
symptoms were rated as ‘absent’ if all the PANSS items included in each psychopathological 




6.4.b.5. – Suicide attempts information 
There were no differences in collecting information on suicidal behaviours between the 
GAP and AESOP studies (see sections 4.4.b.5 and 5.4.c.5, respectively). 
6.4.c – Statistics 
For the purposes of this chapter, I performed the same statistical analyses as in chapters 
4 and 5 (see sections 4.4.c. and 5.4.d. for further details) with the Statistical Package for Social 
Science version 22.0 (SPSS Inc., Chicago, IL, USA).  
Firstly I explored differences in demographic and clinical variables between patients 
with/without suicidal history and I explored predictors of each insight dimension through 
hierarchical linear regression models. Secondly, survival analyses were carried out to 
investigate time from first contact to the first suicide attempt (or suicide completion as 
appropriate) or the censoring point, i.e. either the date on which the patient was last known to 
be alive or the end of the follow-up study period, whichever came sooner. Specifically, 
survival in relation to baseline insight variables, whilst adjusting the analyses for potential 
mediating/confounding demographic and clinical variables through multivariable Cox-
Regression (Cox, 1972) models were built up. The analyses were two-tailed and significance 
level was set at 5%. 
 
6.4.c.1. – Power calculations 
The stpower logrank command of STATA 11.0 for Windows (StataCorp LP, USA) was 
used to carry out the power calculations 
As alluded to in chapters 4 (section 4.4.c.1) and 5 (section 5.4.d.1), based on previous 
FEP studies, it was expected that at the end of the follow-up (median=7 years in this study) at 
least 20% of the initial sample size will have made one suicide attempt (e.g. Robinson et al., 
2010), including 2-5% of suicides (Dutta et al., 2010; Palmer et al., 2005).  Given that the mean 
SAI-E score for FEP patients is around 13/28 with a standard deviation of around 6 (e.g. 
Morgan et al., 2010), a difference of 2 points (e.g. 13 vs 15) between suicide attempters and non-
attempters, which is considered to be clinically meaningful (Kemp & David, 1998), is 
equivalent to an effect size of 0.33 with a two-tailed alpha set at 5%. Under these assumptions, 




6.5. – Results 
6.5.a. – Descriptive analyses 
The demographic and clinical characteristics, including symptom-related variables, of 
the whole sample and differences between subsamples are presented in table 6.1. and table 
6.2., below. There were no significant differences in age at first contact and gender, although 
the GAP cohort included more subjects with no qualifications, of non-white origin and a 
greater proportion of patients with a diagnosis of schizophrenia spectrum disorders who also 
had a higher prevalence of lifetime drug use. 
Also, GAP patients were more likely to have suicidal antecedents prior to first 
presentation than those from the AESOP study.   
In terms of psychopathology, AESOP and GAP participants significantly differed, as 













Table 6.1. Demographic and clinical characteristics of the whole sample (N=293) and 








n = 181  
(61.8%) 
GAP 
n = 112 
(38.2%) 
Statistic p-value 
Age at first contact, years:  276 (94.2) 30.5 ± 10.5 31.3 ± 11.2 29.4 ± 9.2 t=1.5 0.13 
Gender, males 293 (100) 175 (59.4) 101 (55.8) 73 (65.2) Χ2 =2.5 0.11 
Level of education 285 (97.3)      
No qualifications  73 (25.6) 55 (31.4) 18 (16.4) Χ2 =8.0 <0.01 
GCSE  70 (24.6) 47 (26.8) 23 (20.9) Χ2 =1.3 0.26 
Further  93 (31.7) 51 (29.1) 42 (38.2) Χ2 =2.5 0.11 
University  49 (16.7) 22 (12.6) 27 (24.5) Χ2 =6.8 0.01 
Living alone 279 (95.2) 92 (32.9) 52 (30.9) 40 (36.0) Χ2 =0.8 0.38 
Unemployed 285 (97.3) 147 (51.6) 78 (44.6) 69 (62.7) Χ2 =8.9 <0.01 
Ethnicity 292 (99.7)      
White  130 (44.5) 101 (55.8) 29 (26.1) Χ2 =24.5 <0.01 
Black  110 (37.5) 61 (33.7) 49 (44.1) Χ2=3.2 0.07 
Other  52 (17.7) 19 (10.5) 33 (29.7) Χ2 =17.4 <0.01 
DUP: days, median 277 (94.5) 48 49.5 42 U 0.96 
Diagnosis (ICD-10) 292 (99.7)      
Schizophrenia  204 (69.9) 118 (65.2) 86 (77.5) Χ2=4.9 0.03 
Mania   47 (16.1) 31 (17.1) 16 (14.4) Χ2=0.4 0.54 
Depression  41 (14.0) 32 (17.7) 9 (8.1) Χ2= 0.3 0.57 
Alcohol use 270 (92.2) 220 (81.5) 152 (84.4) 68 (75.5)  Χ2=3.1 0.08 
Drugs use 287 (98.0) 184 (64.1) 103 (58.8) 81 (72.3) Χ2=5.4 0.02 
Suicidal history 274 (93.5) 38 (13.9) 16 (9.9) 22 (19.6) Χ2= 5.4 0.02 
Positive 265 (90.4) 211 (79.6) 131(83.9) 80 (73.4) Χ2=4.4 0.03 
Negative 265 (90.4) 143 (53.9) 79 (50.6) 64 (58.7) Χ2=0.5 0.19 
Disorganization 265 (90.4) 128 (48.3) 57 (36.5) 71 (65.1) Χ2=21.0 <0.01 
Mania 265 (90.4) 113 (42.6) 84 (53.8) 29 (26.6) Χ2=19.4 <0.01 
Depression 265 (90.4) 151 (56.9) 70 (44.9) 81 (74.3) Χ2=22.7 <0.01 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses. GAP: Genetics and Psychosis Study 
GCSE: General Certificate of Secondary Education 





Table 6.2., below, shows the mean scores on insight dimensions, psychopathological 
and neurocognitive variables in the whole sample and differences between both cohorts. In 
particular, although total insight scores did not significantly differ between AESOP and GAP 
samples, some dimensions, namely illness awareness and compliance were significantly 
greater in AESOP patients.  In addition, AESOP patients were found to have a higher 
premorbid IQ (verbal, performance and full), although no further neurocognitive differences 





Table 6.2. GAP-AESOP combined cohort: Insight scores and neurocognitive variables 
GAP: Genetics and Psychosis Study. AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
IQ; Intelligence Quotient. WAIS: Wechsler Adult Intelligence Scale, revised (Wechsler, 1981). 












Insight scores       
Recognition 293 (100)  n=181 n=112   
  6.2 ± 3.0 6.0 ± 3.0 5.0 ± 3.3 t=2.8 p<0.01 
Relabelling 284 (96.9)  n=181 n=103   
  4.9 ± 3.5 4.7 ± 3.6 4.9 ± 3.4 t=-0.6 p=0.57 
Compliance 265 (90.4)  n=157 n=108   
  3.2 ± 1.6 3.2 ± 1.5 3.8 ± 1.8 t=1.4 p=0.01 
Total Insight 257 (87.7)  n=157 n=100   
  14.1 ± 6.6 13.6 ± 3.6  13.6 ± 7.3 t=-0.0 p=0.99  
Premorbid IQ 237 (80.9)  n=147 n=90   
Verbal  93.3 ± 13.3  96.6 ± 13.5 87.9 ± 11.3 t=5.3 <0.01 
Performance  96.8 ± 12.3 98.1 ± 13.0 94.7 ± 10.6 t=2.1 0.03 
Full  93.8 ± 18.5 95.9 ± 21.7 90.5 ± 10.6 t=2.5 0.01 
IQ (WAIS-III) 242 (82.6)  n=150 n=92   
  86.8 ± 28.8 85.8 ± 30.8 88.4 ± 25.3 t=-0.7 0.50 
TMT-A (seconds) 239 (81.6)  n=147 n=92   
  46.0 ± 27.4 45.4 ± 30.8 46.9 ± 20.9 t=-0.4 0.67 
TMT-B (seconds) 230 (78.5)  n=144 n=86   
  108.6 ± 71.3 102.1 ± 69.2 119.5 ± 74.0 t=-1.8 0.07 
TMT-B-A (seconds) 224 (76.4)  n=138 n=86   
  65.1 ± 53.2 60.9 ± 46.4 71.8 ± 62.4 t=-1.4 0.16 
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6.5.b. – Baseline differences between subjects with/without suicidal history 
Two hundred and ninety-three subjects were included in this cohort. The 
sociodemographic and clinical characteristics of the whole sample and differences between 
those with /without suicidal history prior to first contact with services are presented in Tables 
6.3., 6.4. and 6.5., below. 
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Table 6.3. GAP-AESOP combined cohort: Demographic and clinical characteristics 
and differences between patients with/without suicidal history 







Age at first contact, years  29.3 ± 8.8 30.8 ± 10.7 t=-0.8 0.40 
Gender, males 21 (55.3) 138 (58.5) Χ2 =0.1 0.71 
Level of education     
No qualifications 13 (34.2) 56 (23.9) Χ2 =1.8 0.18 
GCSE 9 (23.7) 58 (24.8) Χ2 =0.0 0.88 
Further 9 (23.7) 78 (32.8) Χ2 =1.4 0.24 
University 7 (18.4) 42 (17.9) Χ2 =0.0 0.94 
Unmarried 22 (59.4) 165 (72.0) Χ2 =2.4 0.12 
Living alone 16 (42.1) 74 (31.5) Χ2 =1.7 0.20 
Unemployed 18 (47.3) 120 (51.3) Χ2 =0.2 0.65 
Ethnicity     
White 19 (50.0) 102 (43.4) Χ2 =0.6 0.45 
Black 9 (23.7) 92 (39.1) Χ2 =3.3 0.07 
Other 10 (26.3) 41 (17.4) Χ2 =1.7 0.19 
DUP: days, median 127.5 45 U 0.37 
Diagnosis (ICD-10)     
Schizophrenia 25 (15.7) 164 (69.5) Χ2 =0.0 0.81 
Mania  3 (8.1) 43 (18.2) Χ2 =2.3 0.13 
Depression 9 (24.3) 29 (12.3) Χ2 =3.9 0.05 
Alcohol use 28 (87.5) 178 (81.3)  Χ2 =0.7 0.39 
Drugs use 25 (67.5) 146 (62.9) Χ2 =0.3 0.59 
Positive 29 (78.4) 176 (79.6) Χ2 =0.0 0.86 
Negative 26 (70.3) 111 (50.2) Χ2 =5.1 0.02 
Disorganization 17 (45.9) 107 (48.4) Χ2 =0.1 0.78 
Mania 11 (29.7) 96 (43.4) Χ2 =2.4 0.12 
Depression 30 (81.1) 118 (53.4) Χ2 =9.9 <0.01 
GAP: Genetics and Psychosis Study. AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
SA: Suicide attempts (prior to first contact). GCSE: General Certificate of Secondary Education 
DUP: Duration of untreated psychosis 
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With regard to insight dimensions, those subjects with suicidal history before first 
presentation to services had higher insight scores than non-suicidal patients as detailed in table 
6.4., below. 
 
Table 6.4. GAP-AESOP combined cohort: mean Insight level differences between 






Awareness of illness 6.8 ± 2.5 5.4 ± 3.2 t=3.0 <0.01 
Symptoms relabeling 5.9 ± 3.2 4.6 ± 3.6 t=2.1 0.03 
Compliance 4.2 ± 1.6 3.4 ± 1.7 t=2.8 0.01 
Total insight 16.9 ± 5.8 13.1 ± 6.9 t=3.1 <0.01 
GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
SA: Suicide attempts (prior to first presentation/contact) 
 
Neurocognitive differences between those with/without suicidal history are shown in 
table 6.5. below, all of which were non-significant.  
 
Table 6.5. GAP-AESOP combined cohort: Neurocognitive differences between 






Premorbid IQ n=31 n=192   
Verbal 92.2 ± 13.7 93.9 ± 13.3 t=-0.6 0.51 
Performance 97.3 ± 11.3 97.3 ± 12.3 t=-0.0 0.99 
Full 94.3 ± 13.5 95.3 ± 13.6 t=-0.3 0.72 
Current IQ n=30 n=196   
 91.9 ± 14.8 86.6 ± 31.4 t=0.9 0.36 
Executive functions n=29 n=180-195   
TMT-A 44.8 ± 20.0 44.9 ± 26.9 t=-0.0 0.98 
TMT-B 108.9 ± 65.2 106.9 ± 72.9 t=0.1 0.89 
TMT B-A 66.7 ± 57.0 547.7 ± 54.2 t=0.2 0.85 
GAP: Genetics and Psychosis Study. AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
IQ; Intelligence Quotient. WAIS: Wechsler Adult Intelligence Scale, revised (Wechsler, 1981). 
TMT: Trail Making Test (Reitan, 1958) 
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6.5.c. – Bivariate analyses: relationships between insight dimensions and baseline 
demographic and clinical characteristics of the sample 
 
Exploratory analyses investigated potential relationships between insight (as the 
dependent variable) and a wide range of baseline demographic variables. In particular, no 
significant differences in insight scores emerged from between-group comparisons with regard 
to age at first contact, marital and living status.  
However, females were found to have higher levels of all insight dimensions than 
males, although for compliance this difference was not significant. Also, symptom relabelling 
and total insight scores were significantly greater in those with higher education levels 
compared with those with no qualifications. In addition, employed participants showed 
significantly higher levels of all insight dimensions than those who were unemployed, 
although the difference did not reach statistical significance for compliance. 
Finally, white patients had significantly greater insight scores (all dimensions and total 
insight) than black patients and ‘other’ ethnicities, although treatment compliance differences 



















Table 6.6. GAP-AESOP combined cohort: Relationships between baseline 
demographic data and insight scores 
 Recognition Relabelling Compliance Total insight 
Age at first contact n=276 n=267 n=252 n=244 
 r=-0.06 r=-0.14 r=-0.01 r =-0.09 
 p=0.30 r=0.02 p=0.85 p = 0.15 
Gender n=293 n=284 n=265 n=257 
Males 5.2 ± 3.2 4.3 ± 3.2 3.3 ± 1.7 12.5 ± 6.8 
Females 6.3 ± 3.0 5.5 ± 3.8 3.6 ± 1.6 15.2 ± 6.9 
 t=-2.9, p<0.01 t=-2.8, p=0.01 t=-1.5, p=0.14 t=-3.1, p<0.01 
Level of education n=285 n=276 n=259 n=251 
No qualifications 5.3 ± 3.3 3.9 ± 3.4 3.3 ± 1.7 12.3 ± 6.9 
≥ GCSE 5.8 ± 3.1 5.1 ± 3.5 3.5 ± 1.6 14.2 ± 6.8 
 t=-1.2, p=0.23  t=-2.5, p=0.01 t=-0.8, p=0.42 t=-2.0, p=0.04 
Marital status n=273 n=267 n=249 n=243 
Unmarried 5.5 ± 3.1 4.8 ± 3.6 3.3 ± 1.7 13.5 ± 7.2 
Married 5.9 ± 3.0 4.8 ± 3.2 3.8 ± 1.4 14.3 ± 5.8 
 t=-0.9, p=0.33  t=0.1, p=0.88 t=-2.0, p=0.04 t=-0.8, p=0.39 
Living status n=279 n=270 n=254 n=246 
Alone 5.6 ± 3.2 4.8 ± 3.5 3.4 ± 1.7 13.9 ± 7.3 
With others 5.6 ± 3.1 4.8 ± 3.5 3.5 ± 1.7 13.5 ± 6.7 
 t=0.1, p=0.93 t=0.1, p=0.94 t=-0.5, p=0.60 t=0.3, p=0.73 
Employment status n=285 n=277 n=260 n=252 
Unemployed 5.2 ± 3.3 4.3 ± 3.5 3.3 ± 1.7 12.6 ± 7.2 
Employed 6.2 ± 2.9 5.3 ± 3.5 3.6 ± 1.6 14.9 ± 6.3 
 t=-2.7, p=0.01 t=-2.3, p=0.02 t=-1.8, p=0.06 t=-2.8, p=0.01 
Ethnicity n=292 n=284 n=264 n=256 
White 6.5 ± 2.9 5.3 ± 3.5 3.7 ± 1.6 15.1 ± 6.6 
Black 4.9 ± 3.2 4.1 ± 3.4 3.1 ± 1.7 12.0 ± 6.7 
Others 5.0 ± 3.1 4.9 ± 3.5 3.4 ± 1.8 13.3 ± 7.5 
 F=9.8 p<0.01 F=3.5, p=0.03 F=2.7, p=0.06 F=5.6, p<0.01 
GAP: Genetics and Psychosis Study. AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  




With regard to baseline clinical characteristics of the sample such as DUP, diagnosis 
and alcohol and illicit drugs (use vs. non-use), several significant differences emerged from the 
bivariate analyses which are shown in table 6.7., below.  
DUP showed a negative significant association with both relabelling and total insight. 
In terms of diagnosis, those subjects with psychotic depression showed significantly 
greater levels of illness awareness than those with schizophrenia spectrum disorders and 
mania with psychosis.  
In addition, alcohol drinkers had greater levels of symptoms relabelling than those 
without a history of alcohol consumption. 
Other non-significant differences are shown in table 6.7., below.  
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Table 6.7. GAP-AESOP combined cohort: Relationships between insight dimensions and 
clinical characteristics 
 Recognition Relabelling Compliance Total Insight 
DUP n=277 n=268 n=253 n=245 
<48 days 5.2 ± 3.2 4.2 ± 3.4 3.2 ± 1.7 12.5 ± 6.8 
>48 days 6.0 ± 3.0 5.4 ± 3.6 3.7 ± 1.6 14.9 ± 6.8 
 t=-2.2 p=0.03 t=-2.7, p=0.01 t=-2.6, p=0.01 t=-2.7, p=0.01 
     
Diagnosis n=292 n=283 n=265 n=257 
Schizophrenia 5.3 ± 3.2   4.6 ± 3.5 3.5 ± 1.7 13.2 ± 7.0 
Mania 5.3 ± 3.2 4.8 ± 3.5 2.7 ± 1.5 12.4 ± 6.8 
Depression 7.5 ± 2.3 5.6 ± 3.4 3.9 ± 1.4 16.9 ± 5.3 
 F=9.1, p<0.01 F=1.5, p=0.23 F=5.4, p<0.01 F=5.03, p=0.01 
     
Alcohol n=270 n=266 n=243 n=240 
Use 5.9 ± 3.1  5.0 ± 3.6 3.5 ± 1.7 14.2 ± 6.9  
non-use 5.2 ± 3.2 3.9 ± 3.0 3.3 ± 1.7 12.2 ± 6.3 
 t=1.5, p=0.13 t=2.1, p=0.04 t=0.5, p=0.62 t=1.7, p=0.09 
     
Drugs n=287 n=278 n=259 n=251 
Use 5.8 ± 3.2  5.0 ± 3.5 3.5 ± 1.8 14.1 ± 7.2  
non-use 5.3 ± 3.1 4.4 ± 3.5 3.3 ± 1.5 12.9 ± 6.5 
 t=1.4, p=0.17 t=1.5, p=0.14 t=0.9, p=0.36 t=1.4, p=0.16 
GAP: Genetics and Psychosis Study. AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
















In addition, I compared insight levels across groups of psychopathological dimensions 
(presence vs. absence) as explained in section 6.4.b.3., above. Illness awareness and compliance 
were significantly higher in those with depression compared with non-depressed patients. 
Also, compliance was significantly higher in those affected by negative symptoms and lower 
in manic patients than in non-manic subjects. Symptom relabelling score was significantly 
lower in those with positive symptoms, while total insight differences across groups did not 
reach significance.  
 
Table 6.8. GAP-AESOP cohort: Insight dimensions and psychopathological domains 
 Recognition Relabelling Compliance Total Insight 
 n=265 n=257 n=242 n=235 
Positive     
Presence 5.2 ± 3.2 4.5 ± 3.2 3.5 ± 1.6 13.4 ± 6.8 
Absence 5.9 ± 3.0 5.9 ± 4.0 3.3 ± 1.7 14.5 ± 7.5 
 t=-0.9 p=0.36 t=-2.3, p=0.03 t=1.1, p=0.29 t=-0.9, p=0.35 
Negative     
Presence 5.5 ± 3.1   4.8 ± 3.3 3.7 ± 1.6 13.9 ± 6.7 
Absence 5.7 ± 3.3 4.7 ± 3.8 3.2 ± 1.7 13.2 ± 7.3 
 t=-0.5, p=0.59 t=0.1, p=0.94 t=2.8, p=0.01 t=0.7, p=0.45 
Disorganization     
Presence 5.2 ± 3.2  4.7 ± 3.4 3.4 ± 1.7 13.0 ± 6.9  
Absence 5.9 ± 3.1 4.8 ± 3.7 3.6 ± 1.6 14.2 ± 6.9 
 t=-1.9, p=0.06 t=0.4, p=0.67 t=-1.2, p=0.22 t=-1.3, p=0.20 
Mania     
Presence 5.4 ± 3.2  4.5 ± 3.5 3.2 ± 1.6 12.9 ± 6.5  
Absence 5.7 ± 3.2 4.9 ± 3.6 3.7 ± 1.7 14.1 ± 7.2 
 t=-0.8, p=0.44 t=-1.1, p=0.29 t=-2.0, p=0.04 t=-1.4, p=0.17 
Depression     
Presence 6.0 ± 3.1  4.8 ± 3.4 3.8 ± 1.6 14.7 ± 6.6  
Absence 5.0 ± 3.2 4.6 ± 3.7 3.0 ± 1.6 12.0 ± 7.2 
 t=2.7, p=0.01 t=0.5, p=0.61 t=3.9, p<0.01 t=2.9, p=0.16 




In line with chapters 4 and 5, I explored bivariate correlations of insight levels with 
neurocognitive variables, which are shown in table 6.9., below, which revealed several 
significant differences. In particular, illness recognition and symptom relabeling significantly 
correlated with current IQ and two measures of executive functions such as TMT-A and TMT-
B, while no significant associations of compliance with neurocognitive variables emerged from 





Table 6.9. GAP-AESOP combined cohort: Correlations of insight dimensions with neurocognitive variables 
 Recognition Relabeling Compliance Total Insight 
 n r p n r p n r p n r p 
Premorbid Verbal IQ 237 0.15 0.02 232 0.16 0.01 212 -0.03 0.61 208 0.12 0.09 
Premorbid Performance IQ 237 0.10 0.12 232 0.16 0.01 212 0.02 0.77 208 0.11 0.10 
Full Premorbid IQ 237 0.10 0.11 232 0.11 0.11 212 0.04 0.60 208 0.09 0.21 
IQ (WAIS-III) 242 0.17 0.01 236 0.15 0.02 216 0.09 0.52 211 0.15 0.02 
TMT-A (seconds) 239 -0.25 <0.01 233 -0.19 <0.01 215 -0.10 0.12 210 -0.24 <0.01 
TMT-B (seconds) 230 -0.18 <0.01 225 -0.14 0.03 205 0.02 0.81 201 -0.14 0.05 
TMT B-A (seconds) 224 -0.12 0.07 219 -0.11 0.11 200 0.04 0.56 196 -0.08 0.27 
GAP: Genetics and Psychosis Study. AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses.  
IQ: Intelligence Quotient. WAIS: Wechsler Adult Intelligence Scale, revised (Wechsler, 1981). 
TMT: Trail Making Test (Reitan, 1958) 
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6.5.d – Regression on recognition of illness 
A hierarchical linear regression model (‘enter’ method) was performed to reassess the 
association of suicidal history with recognition of illness, whilst adjusting for some variables 
which had also been associated with illness recognition, such as gender, unemployment, being 
white, DUP, a diagnosis of depression with psychotic symptoms,  two neurocognitive 
measures (i.e., current IQ and TMT-A) and depressive symptoms severity. As a result, only 
DUP and depressive symptom severity remained significant predictors of recognition of 
mental illness in the final model, which accounted for 11% of the variance on illness 
recognition.   
 
Table 6.10. GAP-AESOP combined cohort: Regression on recognition 
 B SE p R2 Change p-change 
Block 1:     0.032 0.10 
Gender (male) -0.04 0.25 0.86   
Unemployed -0.25 0.25 0.33   
White 0.30 0.25 0.23   
Block 2:     0.031 0.01 
DUP -0.65 0.24 0.01   
Block 3:    0.017 0.07 
Previous SA 0.48 0.35 0.17   
Block 4:    0.004 0.37 
Depression (dx) 0.09 0.38 0.81   
Block 4:    0.003 0.74 
Current IQ 0.00 0.00 0.55   
TMT-A 0.00 0.00 0.97   
Block 5:    0.026 0.02 
Depressive sym. 0.58 0.25 0.02   
GLOBAL R2    0.11  
GAP: Genetics and Psychosis Study. AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
DUP: Duration of untreated psychosis. SA: Suicide attempts (prior to first presentation) 
dx: diagnosis IQ: Intelligence Quotient. WAIS: Wechsler Adult Intelligence Scale, revised (Wechsler, 1981) 
TMT-A: Trail Making Test, task A (Reitan, 1958) 




6.5.e – Regression on relabelling of symptoms 
A hierarchical linear regression model (‘enter’ method) was carried out to reassess the 
association of suicidal history with symptoms relabelling after controlling for the effects of a 
set of demographic variables (age at first contact, gender, education level, employment and 
being white), DUP, alcohol use, two neurocognitive measures such as IQ and TMT-A and 
positive symptoms severity. Thus, only gender and DUP predicted symptoms relabelling and 
the model, as a whole, explained up to 18% of the variance on relabelling of symptoms.   
 
 
Table 6.11. GAP-AESOP combined cohort: Regression on relabelling 
 B SE p R2 Change p-change 
Block 1:     0.105 <0.01 
Age -0.05 0.03 0.08   
Gender (male) -1.48 0.54 <0.01   
No qualifications  -1.12 0.65 0.08   
Unemployed 0.24 0.53 0.65   
White 0.31 0.55 0.57   
Block 2:    0.021 0.04 
DUP (>48days) -1.10 0.52 0.04   
Block 3:     0.016 0.07 
Alcohol use 1.12 0.71 0.12   
Block 4:    0.008 0.19 
Previous SA 0.92 0.76 0.26   
Block 5:    0.015 0.20 
Current IQ 0.01 0.01 0.39   
TMT-A -0.01 0.01 0.17   
Block 6:    0.016 0.06 
Positive -1.14 0.60 0.06   
GLOBAL R2    0.18  
GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
DUP: Duration of untreated psychosis 
SA: Suicide attempts (prior to first presentation) 
dx: diagnosis 
IQ: Intelligence Quotient. WAIS: Wechsler Adult Intelligence Scale, revised (Wechsler, 1981) 
TMT-A: Trail Making Test, task A (Reitan, 1958) 
sym: symptoms severity 
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6.5.f. – Regression on treatment compliance 
DUP, suicidal history, a diagnosis of depression with psychotic features and three 
psychopathological domains such as negative symptoms, mania and depression were added to 
the multivariable regression model. Of note, only DUP and two psychopathological domains 
such as negative and depressive symptom severity remained significant predictors of 
compliance in the final model, which accounted for just 12% of the variance on treatment 
compliance (table 6.12 below).  
 
 
Table 6.12. GAP-AESOP combined cohort: Regression on treatment compliance 
 B SE p R2 Change p-change 
Block 1:    0.016 0.06 
Unmarried -0.28 0.23 0.23   
Block 2:    0.018 0.04 
DUP -0.56 0.21 <0.01   
Block 3:    0.022 0.02 
Previous SA 0.45 0.30 0.14   
Block 4:    0.005 0.30 
Depression (dx) 0.03 0.33 0.94   
Block 4:    0.062 <0.01 
Negative 0.47 0.21 0.03   
Mania -0.30 0.22 0.17   
Depression 0.57 0.23 0.01   
GLOBAL R2    0.12  
GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
DUP: Duration of untreated psychosis 








6.5.g. – Regression on total insight 
A hierarchical linear regression model (‘enter’ method) was carried out to reassess the 
association of suicidal history with total insight after controlling for the effects of demographic 
variables, such as gender, education level (no qualifications vs. higher education), 
unemployment and being white, a diagnosis of depression with psychotic symptoms (as 
opposed to all other diagnoses) and two neurocognitive variables (current IQ and TMT-A). 
Interestingly, only education level (no qualifications), DUP and suicidal history survived the 
multivariable regression model, which accounted for 19% of the variance on total insight, 
which is detailed in table 6.13., below.   
 
 
Table 6.13. GAP-AESOP combined cohort: Regression on total insight 
 B SE p R2 Change p-change 
Block 1:     0.112 <0.01 
Gender -2.00 0.99 0.04   
No qualifications -2.80 1.17 0.02   
Unemployment -0.47 0.99 0.64   
White 1.48 1.02 0.15   
Block 2:    0.024 0.02 
DUP -2.27 0.96 0.02   
Block 3:    0.026 0.02 
Previous SA 3.23 1.37 0.02   
Block 4:    0.010 0.14 
Depression (dx) 2.03 1.46 0.17   
Block 4:    0.017 0.14 
Current IQ 0.01 0.02 0.72   
TMT-A -0.03 0.02 0.07   
GLOBAL R2    0.19  
GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
DUP: Duration of untreated psychosis 
SA: Suicide attempts (prior to first presentation/contact) 
dx: diagnosis 
IQ: Intelligence Quotient 




6.5.h. – Suicidal behaviour over the follow-up 
Of the 293 FEP cases included in this chapter, 64 subjects (21.8%) made at least one 
suicide attempt. Thirty-eight individuals (12.9%) had suicidal antecedents prior to first contact 
with psychiatric services. Eighteen of these subjects (6.1%) also attempted to take their lives 
over the 7-year follow-up, during which 26 subjects without suicidal antecedents (8.9%) made 
at least one suicidal act. Eight subjects died from suicide over the 7-year period, which results 
in an overall case fatality of 2.7% (8/293). Also, 10 more patients died from natural causes, 
which represents an overall proportionate mortality of 6.1% (18/293) at the end of the follow-
up (median=7 years). In terms of attrition, 32 patients (10.9%) could not be traced or they were 
abroad at the time of suicide-related variables assessment as explained above. Figure 6.1., 



























GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses  
FEP: First-episode psychosis 
293 
FEP PATIENTS 
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(CF = 8/293 = 2.7%) 










Figure 6.1. GAP-AESOP combined cohort. Flow chart of suicidal events over the study period 
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6.5.h.1. – Suicide methods 
As shown in figure 6.1. above, over the follow-up 44 subjects attempted to end their 
lives on at least one occasion and in total there were 80 suicidal events. In terms of methods 
(see table 6.14., below), poisoning (n=31) and jumping (n=12), which encompasses both 
jumping off a height and jumping in front of a vehicle, were the most common suicide 
methods. Also, there were suicide attempts by violent methods such as stabbing (n=3) or fire-
setting (n=2). There were no suicide attempts by firearms. 
With regard to those subjects who took their lives (n=8), hanging (n=2) and jumping 
(n=2) were the most common means of suicide. One patient died from taking an overdose, 
another subject set a fire at home and one patient stabbed himself to death. No specific method 
was recorded in the remaining (n=16) suicide completers. See Table 6.14, below.   
 
 
Table 6.14. GAP-AESOP combined cohort:   
 Suicide methods 
Method Events (n=80) 
Poisoning* 26 








GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and 
Other Psychoses 
*at least one suicide completion by this mean 
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6.5.i. – Risk factors for suicidal behaviour over the follow-up 
Univariate analyses concerning demographic, clinical and symptom-related variables, 
including insight, are presented below in tables 6.15, 6.16 and 6.17, respectively.  
 
 
Table 6.15. GAP-AESOP combined cohort (n=293): Univariate analysis: log-rank 
tests of equality of survival distributions for the demographic variables 







Gender Male 24.5 23 0.18 0.67 
 Female 17.5 19   
Age at first contact <28 21.1 26 2.36 0.12 
 >28 19.9 15   
Education level No qualifications 10.2 14 3.79 0.28 
 GCSE 10.1 6   
 Higher 13.4 14   
 University 7.3 7   
Living status Alone 13.7 21 7.04 0.01 
 Not alone 27.3 20   
Employment status Unemployed 20.9 17 1.49 0.22 
 Employed 20.0 24   
Ethnicity White 18.0 23 2.38 0.30 
 Black 15.4 11   
 Other 7.5 7   




Table 6.16. GAP-AESOP combined cohort (n=293): Univariate analysis: log-rank tests of 
equality of survival distributions for the clinical and demographic variables 




Log-rank test (X2) p-value 
Previous SA Absent 36.2 26 33.11 <0.01 
 Present 5.8 16   
DUP <48 20.6 21 0.02 0.89 
 >48 20.4 20   
Diagnosis Schizophrenia 28.9 33 2.63 0.27 
 Mania 7.1 4   
 Depression 5.9 5   
Alcohol non-use 6.8 2 4.38 0.04 
 Use 30.2 35   
Drugs non-use 15.5 12 1.61 0.20 
 Use 26.5 30   
Positive Absent 8.0 8 0.02 0.89 
 Present 30.9 31   
Negative Absent 18.2 13 3.19 0.07 
 Present 20.8 26   
Disorganization Absent 20.2 24 1.16 0.28 
 Present 18.7 15   
Mania Absent 22.6 27 2.85 0.09 
 Present 16.4 12   
Depression Absent 16.7 9 8.01 <0.01 
 Present 22.3 30   
GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 








Table 6.17. GAP-AESOP combined cohort: Cox regression analyses for 
neurocognitive, psychopathological and insight-related variables 
Risk factor RR 95% CI p-value 
Neurocognition    
Full premorbid IQ 0.99 0.97 - 1.02 0.84 
Current IQ 0.99 0.99 - 1.00 0.81 
TMT-B-A 1.00 1.00 – 1.01 0.03 
Insight    
Recognition of illness 1.10 0.99 – 1.23 0.06 
Symptoms relabeling 1.08 0.99 - 1.17 0.08 
Treatment compliance 1.35 1.10 – 1.64 <0.01 
Total insight 1.06 1.01 – 1.11 0.01 
GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
RR: Relative risk. CI: Confidence Interval.  
IQ: Intelligence Quotient. TMT: Trail Making Test (Reitan, 1958) 
 
From the bivariate analyses shown in tables 6.15, 6.16. and 6.17 above, the following 
factors were found to be associated with time to first suicidal event:, living alone (RR 2.21, 95% 
CI 1.20-4.08, p=0.01), suicidal history (RR 5.10, 95% CI 2.72-9.56, p<0.01), alcohol use (RR 3.99, 
95% CI 0.96-16.58, p=0.06), depression (RR 2.76, 95% CI 1.31-5.82, p=0.01), TMT B-A (RR 1.00, 
95% CI 1.00-1.01, p=0.03) and two insight-related variables such as treatment compliance (RR 
1.35, 95% CI 1.10-1.64, p<0.01) and total insight score (RR 1.06, 95% CI 1.01-1.11, p=0.01). 
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As a result, living status, suicidal history, depression, TMT B-A, compliance and total 
insight were included in a multivariable Cox regression model (enter method) detailed in table 
6.18., below.  In particular, suicidal antecedents (RR 5.00, 95% CI 2.26-11.04, p<0.01) emerged 
as the only significant predictor of suicidal behaviour over the follow-up.   
 
Table 6.18. GAP-AESOP combined cohort: Multivariate analysis of risk factors for 
suicidal behaviour from Cox regression modelling (n=174) 
Risk factor RR 95% CI p-value 
Living status Alone 2.09 0.84 – 3.84 0.13 
 Not alone 1.00   
Previous SA Present 5.00 2.26 – 11.04 <0.01 
 Absent 1.00   
Depression Present 1.70 0.69 – 4.17 0.24 
 Absent 1.00   
TMT B-A  1.00 0.99 – 1.01 0.09 
Compliance  1.19 0.88 – 1.60 0.26 
Total insight  1.01 0.94 – 1.08 0.82 
GAP: Genetics and Psychosis Study 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses 
RR: Relative Risk. CI: Confidence Interval 
SA: Suicide attempts (prior to first presentation) 





6.6. – Discussion 
6.6.a. – Main findings 
In this chapter, I merged two FEP cohorts in order to investigate the relationship 
between insight levels shortly after first presentation with psychosis and risk of suicidal 
behaviour over a prolonged follow-up period (median=7 years), which resulted in greater 
statistical power (over 90%) to detect differences in insight levels equivalent to an effect size of 
0.33 with a two-tailed alpha set at 5%. 
In the light of the above results, I can draw three conclusions. First, suicidal antecedents 
prior to first presentation to psychiatric services influence insight levels at that point. Second, 
depressive symptom severity is related to both suicidal antecedents and insight levels at first 
presentation. Third, although those subjects who showed suicidal behaviours over the follow-
up had higher levels of insight at baseline, these relationships appear to be mediated by other 
variables such as depression, DUP, and, more importantly, the influence of suicidal history on 
both insight levels at baseline and future suicidal events.  
First, in full agreement with the findings from chapters 4 and 5, as expected, an 
association of all insight dimensions at first presentation and previous history of suicide 
attempts was replicated. Unlike chapter 4 and 5, in this cohort such a relationship was also 
significant for treatment compliance. Moreover, after performing multivariable regression 
models, previous suicidal history remained an independent significant predictor of total 
insight score. In addition, further predictors of insight dimensions emerged from the analyses 
such as DUP (the longer the DUP, the poorer the insight) and gender (females presenting with 
greater scores on symptoms relabeling) and low education level, which was linked with 
impaired total insight. Second, in keeping with the above, depressive symptom severity was 
significantly associated with two insight dimensions: illness recognition and treatment 
compliance. Interestingly, those patients with suicidal antecedents presented with both higher 
levels of all insight dimensions and more severe depressive symptomatology.   
Third, in contrast to my fifth hypothesis (H5) and chapter 2 (section 2.5), treatment 
compliance emerged as significant risk factor for suicidal behaviour from the bivariate 
analyses, although the strength of the association was weak (RR=1.35). However, consistent 
with my hypothesis H6 (chapter 2, section 2.5), total insight score, although significantly 
associated with suicidality in the bivariate analyses, did not survive the multivariable 
regression models, which revealed suicidal history to predict risk of suicidal behaviour over 
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the follow-up. Further predictors of suicidal behaviour from the bivariate analyses, which did 
not remain significant in the multivariable regression models, were living status and 
depression. Hence, it seems that, relatively in line with my hypotheses, SAs prior to first 
contact, which was also associated with insight levels at that point, behaved as a risk factor for 
suicidal behaviour over the follow-up. In other words, based on these findings, previous SA 
may explain, in part, the apparent relationship between insight and future suicide risk in early 
psychosis, which is consistent with my hypotheses (Chapter 2, section 2.5). 
 
6.6.b. – Suicidal history influences insight levels at first presentation 
In keeping with findings from chapters 4 and 5, including a data-based peer-reviewed 
publication presented in chapter 4, of which I was first author (Lopez-Morinigo et al., 2014a), 
those subjects with suicidal antecedents were found to have greater insight levels at first 
presentation than those patients without suicidal history. Of note, unlike chapters 4 and 5, in 
this chapter the score on treatment compliance was also significantly higher in those subjects 
with previous suicide attempts than in non-suicide attempters, which was against my 
expectations. In addition, further predictors of each insight dimension were revealed by the 
analyses, which would provide further support for the multidimensional model (David, 1990; 
Amador & David, 2004).   
Interestingly, in this chapter (see table 6.9.) I replicated the ‘neurocognitive basis of 
insight in psychosis’ (Amador et al., 1991; Morgan & David, 2004; Aleman et al., 2006; Ayesa-
Arriola et al., 2011; David et al., 2012; Nair et al., 2014) since I found IQ and some measures of 
executive function to be associated with all insight dimensions except compliance, which is 
consistent with previous literature (see Nair et al., 2014 for an up-to-date meta-analysis).     
With regard to demographic variables, females, employed people and those of white 
ethnicity presented with significantly higher insight levels except for compliance. In terms of 
gender, these findings are in full agreement with previous reports (Wiffen et al., 2012; 
Parellada et al., 2011; McEvoy et al., 2006) and a meta-analysis (Mintz et al., 2003), although 
some groups failed to replicate such an association (e.g. Markova, 2005). As alluded to in 
chapters 4 and 5, white patients had significantly higher levels of insight than those of a Black 
ethnic origin, consistent with previous literature (Morgan, 2003; Goldberg et al., 2005; Johnson 
& Orrell, 1995), although a London-based study had reported no differences in insight levels 
across ethnicities (David et al., 1995).  Also, as reported in chapter 4, symptom relabelling and 
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total insight scores were higher in those with some form of certificated education, i.e. GCSE or 
higher levels, which is in line with a previous study from our group (Wiffen et al., 2010). In 
keeping with this, unemployment was linked with poorer insight, although differences in 
treatment compliance did not reach statistical significance, which was in line with previous, 
although limited, literature (Lysaker & Bell, 1994).  
In line with chapters 3 and 4, I replicated the inverse relationship between insight and 
DUP (Pek et al., 2006; Saravanan et al., 2010; Cuesta et al., 2011), i.e. the longer the DUP, the 
poorer the insight at first presentation, which also remained significant in the multivariable 
regression models for the four insight scores. However, the cross-sectional association did not 
allow me to draw conclusions in terms of the direction of causality. On the one hand, it can be 
postulated that lacking insight delays seeking attention and receiving treatment, thus 
increasing the DUP. On the other hand, it can be argued that a more prolonged DUP results in 
a more symptomatically severe first presentation, hence with poorer insight (Drake et al., 
2000).  
Several significant associations of psychopathological symptoms and insight levels 
were revealed by the analyses. Thus, relabelling was negatively associated with positive 
symptom severity, in keeping with previous studies (e.g. Mintz et al., 2003; Cuesta et al., 2011), 
while compliance was linked with negative symptoms, mania and depression. Specifically, 
those with more severe negative and depressive symptoms were more compliant than those 
with less severe presentations in those domains. Interestingly, those patients with lower mood 
scored higher on the compliance item. Of note, depression (rather than psychotic symptoms) 
showed more significant correlations with insight scores, particularly illness recognition and 
treatment compliance, which is in full agreement with previous literature (Peralta et al., 1998; 
Mintz et al., 2003; Cooke et al., 2005; Lincoln et al., 2007; Nair et al., 2014; Belvederi et al., 2015). 
As detailed in chapter 4 (sections 4.6.c. and 4.6.d.) and chapter 5 (section 4.6.b.), the direction of 
causality remains unclear, as illustrated by the so-called ‘demoralization syndrome’ (Drake, 
1986; Restifo et al., 2009) and ‘depressive realism’ (see Ghaemi & Rosenquist, 2004 for a 
review), respectively.  
Of interest to this investigation, it is worth noting that those subjects with suicidal 
antecedents had more severe depressive symptoms at the time of the assessment, including the 
evaluation of insight (indeed, those subjects had significantly higher insight levels). Hence, 
while there is strong evidence to support the existence of a ‘depressive-insightful-suicidal’ 
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group of FEP patients, the direction of causality of the above variables requires prospective 
investigation, which forms the context for the next two sections.  
  
6.6.c. – Insight dimensions and risk of suicidal behaviour over the follow-up 
As postulated in chapter 2 (section 2.5., hypotheses H1 and H2), illness awareness and 
symptom relabeling behaved as risk factors for suicide, although the differences did not reach 
statistical significance. However, in contrast to my expectations (see hypothesis H5 in chapter 
2, section 2.5.), better compliance with treatment was a significant risk factor in the bivariate 
analyses, as well as total insight score.  
In addition, a set of variables were linked with risk of suicidal behaviour from the 
bivariate analyses, namely living alone, alcohol use, suicidal history, more severe depressive 
symptoms and a measure of executive functions such as the TMT B-A. These variables were 
therefore added to a multivariable regression model which revealed suicidal history to predict 
risk of suicidal behaviour over the follow-up, as explained in section 6.6.d. below.  
Hence, these results suggest that insight is not a direct risk factor for suicide in early 
psychosis. Certainly, in the light of my results, it seems that if there was an association of any 
insight dimension with risk of suicidal behaviours in early psychosis, such an association 
would be confounded by other variables, namely suicidal history and depression, both of 
which were significantly associated with insight levels (at baseline) and suicidality over the 
follow-up. These findings are in line with the seminal paper by Hawton and colleagues 
(Hawton et al., 2005), which demonstrated insight to be a non-significant risk factor for suicide 
in schizophrenia, while poor compliance was significantly associated with an increased risk; 
and a recent meta-analysis of FEP studies (Challis et al., 2013), which reported an overall 
significant OR of 1.64 (95% CI 1.23-2.56) for insight as risk factor for suicide, but with 
important exceptions. In particular, treatment compliance was a risk factor in this research, 
which suggests that being aware of the ‘need’ for treatment may contribute, to a certain 
degree, to suicidal behaviour in some, but not all, patients with psychosis from South-East 
London. The complexity of these relationships is discussed in more detail in chapter 8.      
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6.6.d. – Predictors of suicidal behaviour over the follow-up 
Consistent with chapters 4 and 5, suicidal history emerged as the strongest predictor of 
future suicidal events, which was in full agreement with previous literature on ‘suicide and 
psychosis’ (Hu et al., 1991; De Hert et al., 2001; Sinclair et al., 2004; Hawton et al., 2005; 
Reutfors et al., 2009; Dutta et al., 2010; Pompili et al., 2011; Björkenstam et al., 2014; Bakst et al., 
2010a; Challis et al., 2013; Tarrier et al., 2006), including  two recent meta-analyses (Large et al., 
2011; Challis et al., 2013). In addition, living alone at baseline, depressive symptom severity 
and executive functions (as measured by the TMT B-A) were significantly associated with risk 
of suicidal behaviour over the 7-year follow-up. However, only suicidal history remained 
significant predictors of suicidal behaviour in the multivariable Cox-regression models, 
although TMT B-A showed a borderline trend.  
In keeping with this, living alone was found to be a significant risk factor for suicidal 
behaviour, consistent with previous literature (Hawton et al., 2005a; Challis et al., 2013), 
although this relationship did not survive the multivariable regression models. It should be 
noted that the living status may have changed over the follow-up, i.e. from the time of the 
study inception and assessment to the time of the first suicidal event.  
As discussed in chapter 5 (section 5.6.d), the relationship between cognitive 
performance and suicide risk in psychosis remains far from clear (Andersson et al., 2008, Webb 
et al., 2011; Potkin et al., 2003; Barrett et al., 2011; see Hor & Taylor, 2010 for a general review), 
although it seems that the stage of the illness may play a relevant part in these conflicting 
results. In particular, in this sample of FEP patients more impaired executive function, as 
measured by the TMT B-A, was associated with an increased suicide risk. Although this 
finding is consistent with previous studies of schizophrenia patients (Fenton et al., 1997; De 
Hert et al., 2001), the strength of the association (RR=1.01) was too weak for it to be considered 
as a relevant risk factor for suicide in early psychosis. Hence, further research is warranted in 
this area, including following cohorts of FEP subjects from first presentation over a prolonged 
period of time, during which comprehensive cognitive assessments should be carried out.  
Of note, in keeping with previous research (e.g. Tsuang, 1978; Osby et al., 2000; Qin & 
Nordentoft, 2005; Palmer et al., 2005; Limosin et al., 2007; Osborn et al., 2008; Alaräisänen et al., 
2009; Dutta et al., 2010; Barrett et al., 2010a; Barrett et al., 2010b), risk of suicidal behaviour was 
linked with younger age; however, at a non-significant level in this study.   
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Finally, the link between depression and suicidality was replicated in this FEP sample 
(Altamura et al., 2003; Hawton et al., 2005; Barrett et al., 2010; Bertelsen et al., 2007; Upthegrove 
et al., 2010; Flanagan and Compton, 2012; Harvey et al., 2008; Kontaxakis et al., 2004; Barrett et 
al., 2010a; Barrett et al., 2010b; Pompili et al., 2011), although it did not survive the 
multivariable regression models. Indeed, as detailed above, depression appears to mediate the 
potential relationship between insight, particularly treatment compliance, and risk of suicidal 
behaviours in this FEP cohort.  
The results from this chapter are shown in figures 6.2 and 6.3, below, which present the 
model hypothesised in this investigation (figure 6.2) and the model based on this chapter 




Figure 6.2. Hypothesised model to be tested in this thesis 
 




6.6.e. – Strengths and limitations 
The above findings come from a very large cohort of FEP patients who were followed-
up over a prolonged period of time (median=7 years). In addition, this cohort comes from two 
FEP studies which aimed to recruit ‘all incident cases’ in NHS-funded hospitals from South-
East London (the vast majority of participants) and Nottingham, both settings based in the UK. 
Since most people with psychosis in these two catchment areas receive NHS-funded mental 
health care, the sample is likely to be representative of the local populations. In addition to the 
‘sufficient’ statistical power, as detailed in section 6.4.c.1., due to using a large sample size and 
a long follow-up period, a number of variables were comprehensively assessed using validated 
instruments, including demographic data, clinical antecedents, psychopathological, insight-
related and neurocognitive variables.     
However, this chapter has several limitations. First, other non-tested variables might 
affect insight such as premorbid personality (Lysaker et al., 1999; Campos et al., 2011; Cuesta et 
al., 2011; Ritsner & Blumenkrantz, 2010) and neuroanatomical correlates (Morgan et al., 2010; 
David et al., 2012). Second, examiners were not blind to other scales such as the PANSS, which 
might bias the insight assessment (Campos et al., 2011). Third, our cross-sectional assessment 
of insight did not permit the investigation of insight changes over the course of the illness 
(Wiffen et al., 2010; Campos et al., 2011; Cuesta et al., 2011; Ayesa-Arriola & Lopez-Morinigo et 
al., 2014) in relation to suicide risk. Also, demographic variables such as living status may have 
changed over the follow-up period. Moreover, psychopathology and insight have been 
reported to improve over the early stages of the psychotic illness (e.g. Cuesta et al., 2011; 
Ayesa-Arriola & Lopez-Morinigo, 2015). Hence, these potential insight changes are likely to 
have affected suicide risk differently, which requires further studies with several insight 
assessments over time, which is challenging in the real-world, particularly in terms of 
reassessing patients with psychosis on a face-to-face basis.   
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6.7. – Summary of the chapter 
In the light of these results, there is no evidence to support a direct association of 
insight levels with risk of suicidal behaviours in early psychosis, which in this sample was 
predicted by previous SAs.  
With regard to insight, in contrast to my expectations, better treatment compliance 
emerged as the main insight dimension linked with suicide risk, although all insight 
dimensions behaved as risk factors in the bivariate analyses. However, depressive symptom 
severity and suicidal history appeared to confound the above relationships, and this is 




Chapter 7 – Suicidal behaviour in early psychosis. Findings 
from a 3-year follow-up first-episode cohort from Santander 
(Spain) 
 
7.1. – Introduction 
This chapter describes the predictors of suicidal behaviour in a 3-year follow-up first-
episode psychosis (FEP) study from Santander (Spain). The role of three insight dimensions - 
namely insight into mental illness (IMI), insight into the social consequences of the illness (ISC) 
and insight into the need for treatment (INT) - in suicidal behaviours over the follow-up period 
was investigated.  Suicidal behaviours included both suicide attempts (SA) and completions 
(SC).  The analyses were adjusted for demographic and clinical variables, which may mediate 
or confound the above relationships and therefore influence the rate of suicidal acts. 
Parts of the analyses presented in this chapter were published as a peer-reviewed 
article which I co-authored (Ayesa-Arriola et al., 2015). However, for the purposes of this 
thesis, I have only considered suicidal events ‘after’ first presentation with psychosis and I 
have taken a different statistical approach by conducting Cox regression analyses, thus 
considering survival to a first suicide attempt over the follow-up in relation to insight levels at 
baseline. This constitutes a substantial expansion of the content of the aforementioned paper. 
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7.2. – Background 
As explained in chapters 2, chapter 4 (section 4.2.), chapter 5 (section 5.2.) and chapter 6 
(section 6.2.), the role of insight dimensions in suicidal behaviour in FEP patients remains 
unclear (Lopez-Morinigo et al., 2012), which may have crucial clinical implications for suicide 
prevention in early psychosis.  
Although this research question was investigated in chapters 4, 5 and 6 with two 
cohorts of FEP subjects from two sites in the UK (mainly, London), the statistical power was 
limited in some of these studies (62.5% in the GAP cohort presented in chapter 4 and 75.1% in 
the AESOP study, see chapter 5), which may have been resulted in false negative results. 
Although merging these two FEP cohorts increased the power to 90% (Chapter 6, section 
6.4.c.1.), given that the main hypothesis of this thesis was that insight is not a direct risk factor 
for suicide in early psychosis, I also decided to analyse data from a large cohort of FEP patients 
from a different country (Santander, Spain) in order to compare the findings from both cohorts 
(UK and Spain), which forms the context for chapter 8 (General Discussion).   
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7.3. – Aims and Objectives 
7.3.a. – Descriptive aims and objectives 
 To describe the distribution of insight dimensions according to the outcome of 
suicidal behaviours, including both suicide attempts and suicide completions. 
 
7.3.b. – Analytical aims and objectives 
 To investigate whether there is an association between a history of suicidal 
behaviours before first presentation with psychosis and insight levels at that point.  
 To adjust the above analyses for potential confounders in order to determine 
independent predictors of insight at baseline, including the role of previous suicidal 
history.  
 To calculate the case fatality of this FEP sample over the 3-year follow-up. 
 To identify the risk factors associated with suicidal behaviours in a FEP cohort over 
a 3-year follow-up. 
o And to determine whether there is an association of insight levels with risk 
of suicidal behaviours over the 3-year follow-up.  
 To test for potential interactions between insight dimensions and other clinical and 
demographic variables related to risk of suicidal behaviour. 
 To formulate a model, based on a multivariable Cox Regression analysis of the 
above baseline variables, including insight dimensions, for predicting suicidal 
behaviours over the 3-year follow-up.  
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7.4. – Method 
7.4.a. – Participants, study design and setting  
Data for this chapter came from a large epidemiological and 3-year longitudinal study 
of first-episode psychosis (PAFIP) conducted at the out- and inpatient services of University 
Hospital Marques de Valdecilla, Santander, Spain. This study was approved by the local 
institutional review board and informed consent from participants was obtained. A more 
detailed description of the program has been previously reported (Pelayo-Teran et al., 2008). 
Briefly, all referrals to PAFIP over 2001-2010 were screened with the following 
inclusion criteria: age 15-60 years; living in the catchment area; experiencing their first episode 
of psychosis; no prior treatment with antipsychotic medication or, if previously treated, a total 
life time of adequate antipsychotic treatment of less than 6 weeks; meeting DSM-IV criteria for 
brief psychotic disorder, schizophreniform disorder, schizophrenia, or schizoaffective 
disorder. DSM-IV criteria for drug dependence and mental retardation and having a history of 
neurological disease or head injury were exclusion criteria.  
Three hundred and ninety seven patients who met inclusion criteria were included in 
the PAFIP program during this time interval. Diagnoses were made using the Structured 
Clinical Interview for DSM-IV (SCID-I) (First et al., 1996), which was carried out by an 
experienced psychiatrist 6 months after the baseline visit. The diagnoses (DSM-IV) of 
participants are presented in table 7.1. below. Two diagnostic categories - ‘schizophrenia’ and 
‘other psychoses’ - were created for the analyses. 
 
Table 7.1. Santander: Diagnoses of participants 
Diagnoses N (%) 
Schizophrenia 224 (56.4) 
Schizophreniform disorder 96 (24.2) 
Schizoaffective disorder 5 (1.2) 
Brief psychotic disorder 41 (10.3) 
Psychosis NOS 29 (7.3) 
Delusional Disorder 2 (0.5) 
   NOS: Not otherwise specified  
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7.4.b. – Measures 
7.4.b.1. – Premorbid and sociodemographic variables 
Information was obtained from patients, relatives and medical records. This included 
sex, age at admission, age at illness onset and duration of untreated psychosis (DUP). Other 
sociodemographic variables collected were: years of education, relationship status 
(“married/cohabiting” vs. “single/divorced/separate or widowed”), living status (“alone” vs. 
“other”), socio-economic status derived from the parents’ occupation (“low” vs. “other”), 
employment status (“employed” vs. “unemployed”), living area (“urban” vs. “rural”, which 
included those living in areas with less than 10,000 inhabitants), cannabis and alcohol use (self-
reported as yes/no) and first degree family history of psychosis (yes/no). Premorbid social 
adjustment (PAS) (Cannon-Spoor et al., 1982) and hospitalization (yes/no), and days in 
hospital where appropriate, were considered. 
 
7.4.b.2. – Baseline clinical and neuropsychological measures 
Clinical symptoms of psychosis at study entry were assessed with the Scale for the 
Assessment of Negative Symptoms (SANS) (Andreasen, 1983) and the Scale for the 
Assessment of Positive Symptoms (SAPS) (Andreasen, 1983). Global scores were used to 
generate three symptomatic dimensions: positive, disorganized and negative (Grube et al., 
1998). Depressive symptoms were evaluated using the Calgary Depression Scale for 
Schizophrenia (CDSS) (Addington et al., 1992). 
The neuropsychological assessment was carried out when patient clinical status 
permitted good cooperation, which occurred at a mean of 10.5 weeks after intake. A detailed 
description of the neuropsychological assessment has been reported elsewhere (Gonzalez-
Blanch et al., 2007). Specifically, a measure of overall cognition such as the premorbid IQ, 
which was estimated by the Wechsler Adult Intelligence Scale III vocabulary test (Lezak, 1995), 
and executive functioning, which was evaluated with the Trail Making Test (Reitan , 1958), 
particularly the time to complete task B minus time to complete task A, were considered for 




7.4.b.3. – Insight assessment 
The shortened version of the Scale to Assess Unawareness of Mental Disorder (SUMD) 
(Amador et al., 1994) was used to measure three insight dimensions: insight into mental illness 
(IMI), insight into need for treatment (INT), and insight into social consequences of the illness 
(ISC). ‘Poor’ insight was defined as SUMD scores greater than 1, and a score of 1 designated 
‘good insight’. Patients were classified in two groups (good and poor insight). Of note, the 
SUMD was found to strongly correlate with other insight scales, including the SAI-E (Sanz et 
al., 1998). Hence, the results were deemed appropriate for cross-comparisons with the findings 
from the UK cohorts (Chapters 4, 5 and 6), which forms the context for the general discussion 
(Chapter 8).   
 
7.4.b.4. – Suicide attempts information 
Suicidal behaviours, i.e. potentially self-injurious behaviour for which the person 
intended to kill himself/herself (O’Carroll et al., 1996), were taken from medical records. In 
particular, any SA before first contact with psychiatric services and any further SAs were 
registered, which included suicide attempts and suicide completions. Information on suicidal 
behaviour was available for the entire sample, N=397 patients. SAs methods were 
dichotomized according to Asberg et al.’s criteria (Asberg et al., 1976) into ‘violent’ (hanging, 
jumping from a height, jumping in front of a vehicle, cutting him/herself, setting a fire) and 
‘non-violent’ (i.e. self-poisoning). 
241 
 
7.4.c. – Statistical analysis 
The Statistical Package for Social Science version 22.0 (SPSS Inc., Chicago, IL, USA) was 
used for performing the statistical analyses.  
Descriptive analyses and comparison of patient characteristics, including the 
aforementioned demographic and clinical variables, were undertaken using chi-square, t-tests 
and Mann-Whitney U tests as appropriate.  
First, predictors of insight dimensions at baseline were investigated through binary 
logistic regression models in order to precisely test the influence of suicidal history on insight 
levels after adjusting the analyses for potential mediating variables.  
Second, all patients were entered into a survival analysis with the end date being the 
date of first suicide attempt (or suicide completion where appropriate) or the censoring point, 
i.e. either the date on which the patient was last known to be alive or the end of the 3-year 
follow-up study period, which commenced at the time of discharge from hospital or after first 
contact to services in those patients who were not admitted at first presentation.  
Risk of suicide over the 3-year follow-up was calculated by considering the proportion 
of patients who died from suicide of the total initial sample size (i.e. those who were lost to 
follow-up were included in the denominator), which is known as case-fatality (Palmer et al., 
2005). 
Survival analyses (Kaplan-Meier Curves and log-rank tests) were performed to 
compare time from hospital discharge or first appointment for those outpatients who did not 
require hospitalization to first suicidal event or the censoring point as appropriate across 
insight groups (good vs. poor insight) for each insight dimension. Participants were censored 
as non-attempters at the time of the last face-to-face assessment or at 3-year follow-up, 
whichever came sooner.   
In addition, multivariable Mandel-Cox regression models (Cox, 1972) were built up in 
order to investigate survival in relation to baseline insight variables, whilst adjusting the 
analyses for potential mediating/confounding demographic and clinical variables. 




7.4.b.6. – Power calculations 
Given the variable amount of missing data for each variable, a range of power 
calculations was performed for suicide risk using the stpower logrank command of STATA 11.0 
for Windows (StataCorp LP, USA). 
Under the assumption of a 20% risk of suicidal behaviour based on previous studies 
(e.g. Robinson et al., 2010) and given that insight variables, which were dichotomized (see 
section 7.4.b.3, above) were available on n=352 (i.e. 352/397=88.7%), there was 96.7% power to 
detect a difference of 2% in risk between groups, which is equivalent with an effect size of 0.5.  
  
7.5. – Results 
7.5.a. – Sociodemographic and clinical characteristics of the sample 
The sample was comprised of 397 individuals. The sociodemographic and clinical 
characteristics of the whole sample and differences across patients with/without SA preceding 
first presentation to services are presented in Table 7.2. below. 
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Table 7.2. Santander: Sociodemographic and clinical characteristics of the whole sample 
and differences across patients with/without previous suicide attempts 










Gender, males 226 (56.9%) 20 (80%) 202 (54.3%) Χ2 = 5.87 0.01 
Age, years:  29.9 ± 9.5 30.6 ± 9.8 29.8 ± 9.5 t = 0.44 0.66 
DUP: days, median 90 75 90 U 0.97 
Schizophrenia 224 (56.4%) 18 203 Χ2 = 2.60 0.11 
Years of education 10.2 ± 3.3 9.9 ± 3.5 10.2 ± 3.3 t = -0.42 0.67 
Unmarried 313 (78.8%) 21 (84%) 288 (77.4%) Χ2 = 0.37 0.54 
Living alone 57 (14.4%) 2 (8%) 53 (14.2%) Χ2 = 0.82 0.36 
Unemployed 176 (44.3%) 14 (56%) 159 (42.7%) Χ2 = 0.15 0.23 
Urban area 293 (73.8%) 22 (88%) 267 (71.8%) Χ2 = 2.69 0.10 
Cannabis 171 (43.1%) 15 (60%) 153 (41.1%) Χ2 = 3.16 0.07 
Alcohol 215 (54.2%) 14 (56%) 198 (53.2%) Χ2 = 0.03 0.86 
Family history 88 (22.2%) 2 (8%) 83 (22.3%) Χ2 = 2.72 0.09 
Poor Premorbid Adjustment 117 (29.5%) 11 (44%) 106 (28.5%) Χ2 = 2.77 0.09 
Premorbid IQ 9.1 ± 2.8 8.8 ± 2.9 9.1 ± 2.8 U 0.55 
TMT B-A 62.0 ± 50.4 51.1 ± 38.4 62.7 ± 51.2 U 0.67 
SAPS-Positive 13.5 ± 4.3 13.1 ± 4.2 13.5 ± 4.3 U 0.63 
SANS-Negative 7.0 ± 6.2 8.2 ± 2.8 7.0 ± 6.1 U 0.77 
CDSS  2.3 ± 3.3 3.5 ± 3.6 2.3 ± 3.6 t = 1.74 0.08 
Insight Mental Illness 125 (31.5%) 9 (36%) 115 (30.9%) Χ2 = 0.04 0.83 
Insight Social Consequences 218 (54.9%) 13 (52%) 202 (54.3%) Χ2 = 0.60 0.44 
Insight Need for Treatment 188 (47.4%) 7 (28%) 179 (48.1%) Χ2 = 6.03 0.01 
Hospitalization 256 (64.5%) 23 (92%) 227 (61.0%) Χ2 = 9.12 0.01 
Length of admission (days) 21.5 ± 16.1 28.1 ± 25.6 20.8 ± 14.8 t = 1.35 0.19 
SA: Suicide attempts prior to first presentation/contact. DUP: Duration of untreated psychosis. IQ: Intelligence Quotient. TMT B-
A: Trail Making Test, time to complete task B minus time to complete task A (Reitan, 1958).  
SAPS: Scale for the Assessment of Negative Symptoms (Andreasen, 1983) SANS: Scale for the Assessment of Positive Symptoms 
(Andreasen, 1983). CDSS: Calgary Depression Scale for Schizophrenia (Addington et al., 1992). 
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7.5.b. – Suicidal behaviours 
Sixty patients (15.1%) made (at least) one suicide attempt. Twenty-five individuals 
(6.3%) had made a suicidal act before first presentation. Also, 35 subjects (8.8%) attempted 
suicide on at least one occasion over the 3-year follow-up, including 12 patients (3%) who 
made two suicide attempts and 5 cases who attempted to take their lives three times after first 
contact with psychiatric services. Eight patients (2.1%) showed suicidal behaviour both before 
and after first presentation to services.  In addition, 6 subjects (CF=6/397=1.51%) completed 
suicide over the 3-year follow-up period, which equates to a suicide rate of 603.06 
suicides/100,000 persons-year. According to population data from the Instituto Cántabro de 
Estadística (www.icane.es), the suicide rate in Cantabria in 2010 was 4.48 suicides/100,000 
persons-year, which meant the SMR was estimated at approximately 134.6. See Figure 7.1. 
below. 
 
7.5.b.1. – Suicide methods 
Six individuals (25%) took an overdose, while the remaining 19 suicide attempts before 
first presentation (75%) were categorized as ‘violent’. Fifty-seven suicidal events occurred over 
the follow-up period, with ‘non-violent’ methods significantly more common (41, 71.9%) than 











FEP: First-episode psychosis. CF: Case-fatality. 
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Figure 7.1. Flow chart of suicidal events over the study period 
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7.5.c. – The influence of previous suicide attempts on insight into having a mental 
illness  
IMI was not found to significantly vary between those patients with and without 
suicidal acts before first presentation with psychosis, although the proportion of ‘suicidal’ 
patients was slightly higher in the ‘good IMI’ group (7.3%) than in those with poor IMI (6.6%). 
However, good insight (when compared with poor insight) was significantly associated 
with shorter DUP (60 days vs. 120 days, p=0.04), executive functions as evaluated by the TMT 
B-A (p=0.03), i.e. those with good insight performed better than the poor insight group who 
took longer to complete the task (53 vs. 66 seconds, respectively, p=0.03), unemployment (36% 
in good IMI patients vs. 49.8% in poor IMI, p=0.01) and length of hospital admission (16.5 vs. 
24.3 days, respectively, p<0.01). The percentage of patients requiring hospitalization did not 
vary across insight groups. In addition, a diagnosis of schizophrenia (in comparison to ‘all 
other psychoses’) was significantly (p=0.01) more common in the poor insight group (62.9%) 
than in those subjects with good awareness of having a mental illness (46.4%). 
Further non-significant differences were revealed in the analyses which are detailed in 
Table 7.3 below. 
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Table 7.3. Santander: Comparison of pre-morbid, socio-demographic, clinical and 
cognitive variables between patients with good and poor insight into having a mental 
illness 
 Good IMI 
n = 125 (35.5%) 
Poor IMI 
n = 227 (64.5%) 
  
 n (%) Mean ± SD n (%) Mean ± SD Statistic p-value 
Age  30.7 ± 8.9  29.8 ± 10.1 t = 0.90 0.37 
DUP (median, days)  60  120 U 0.04 
Education (years)  10.7 ± 3.5  9.9 ± 3.2 t = 1.89 0.06 
Premorbid IQ  9.2 ± 2.7  9.1 ± 2.8 t = 0.15 0.88 
TMT B-A  53.6 ± 39.3  66.1 ± 53.5 t = - 2.22 0.03 
SAPS  13.3 ± 3.9  13.8 ± 4.4 t = - 0.98 0.32 
SANS  6.6 ± 5.5  7.2 ± 6.2 t = - 1.54 0.11 
CDSS  2.6 ± 3.6  2.1 ± 2.9 t = 1.58 0.11 
Length of stay  16.5 ± 10.7  24.3 ± 17.1 t = -4.22 <0.01 
Gender (males) 69 (56.5)  132 (58.1)  Χ2 = 0.29 0.59 
Previous SA 9 (7.3)  15 (6.6)  Χ2 = 0.04 0.83 
Schizophrenia 58 (46.4)  143 (62.9)  Χ2 = 9.06 0.01 
Unmarried 94 (77.0)  188 (82.8)  Χ2 = 3.25 0.07 
Living alone 13 (10.6)  39 (17.1)  Χ2 = 2.99 0.08 
Unemployed 44 (36.0)  113 (49.8)  Χ2 = 7.13 0.01 
Urban area 96 (78.7)  165 (72.7)  Χ2 = 0.60 0.44 
Cannabis 48 (39.3)  103 (45.4)  Χ2 = 1.60 0.21 
Alcohol 68 (55.7)  124 (54.6)  Χ2 = 0.01 0.93 
Family history 22 (18.0)  54 (23.8)  Χ2 = 1.82 0.18 
Poor premorbid adjust. 40 (32.8)  73 (32.1)  Χ2 = 0.52 0.47 
Hospitalization 75 (61.4)  152 (66.9)  Χ2 = 1.70 0.19 
IMI: Insight into mental illness. DUP: Duration of untreated psychosis. IQ: Intelligence Quotient. TMT B-A: Trail Making Test, 
time to complete task minus time to complete task A (Reitan, 1958). SAPS: Scale for the Assessment of Negative Symptoms 
(Andreasen, 1983) SANS: Scale for the Assessment of Positive Symptoms (Andreasen, 1983). CDSS: Calgary Depression Scale for 




In the light of the above bivariate analyses, DUP, TMT B-A, unemployment, having 
been diagnosed with schizophrenia (in comparison to ‘all other psychoses’) and length of 
hospital admission, which emerged as significant predictors of IMI, were entered into a 
multivariable binary logistic regression model. Since suicidal history had not been found to be 
significantly associated with IMI, I did not include this variable in the regression model.   
Only length of stay (OR=1.03, 95%CI 1.00-1.06, p=0.02) remained as a significant 
predictor of IMI (Table 7.4). The model (χ2=13.49, df=5, p=0.02) explained 9.8% (Nagelkerke R2) 
of the variance on IMI and overall classified correctly 65.7% of the cases, particularly 27.9% of 
‘good IMI’ patients and 88.5% of those with ‘poor IMI’. 
 
Table 7.4. Santander: Predictors of poor insight into having a mental illness 
 B SE Wald p OR 95% CI 
DUP binary -0.02 0.35 0.01 0.96 0.98 0.49 – 1.96 
Unemployment 0.26 0.34 0.58 0.45 1.30 0.66 – 2.53 
Schizophrenia -0.42 0.34 1.55 0.21 0.66 0.34 – 1.27 
Hospital stay 0.03 0.01 5.18 0.02 1.03 1.00 – 1.06 
TMT B-A 0.01 0.01 1.23 0.27 1.00 1.00 – 1.01 
DUP: Duration of untreated psychosis.  




7.5.d. – The influence of suicidal history on insight into the social consequences of the 
illness  
Suicidal history was not significantly associated with ISC (p=0.83), although the 
proportion of patients with such antecedents was marginally higher in the ‘poor insight’ group 
(8.2%) than in the good insight group (6.0%). 
However, good insight (when compared with poor insight) was significantly (p<0.01) 
associated with shorter DUP (60 days vs. 180 days), executive functions as evaluated by the 
TMT B, i.e. those with good insight performed better than the poor insight group who took 
longer to complete the task (53.8 vs. 69.9 seconds, respectively), years of education (10.5 vs. 9.7, 
p=0.04), negative symptoms severity as measured by the SANS (6.2 vs. 7.8, p=0.02), depressive 
severity evaluated by the CDSS scores (2.6 vs. 1.7, respectively, p=0.01), poor premorbid 
adjustment (p=0.01) and length of hospital admission (17.9 vs. 27.1 days, respectively, p<0.01), 
although the percentage of patients requiring hospitalization did not vary across insight 
groups. Again, the percentage of patients diagnosed with schizophrenia was significantly 
(p<0.01) greater in the poor insight group (75.4%) than in those with good ISC (45.9%).  




Table 7.5. Santander: Comparison of pre-morbid, socio-demographic, clinical and 
cognitive variables between patients with good and poor insight into the social 
consequences of the illness  
 Good ISC 
n = 218 (61.9%) 
Poor ISC 
n = 134 (38.1%) 
  
 n (%) Mean ± SD n (%) Mean ± SD Statistic p-value 
Age  30.1 ± 8.9  30.1 ± 10.8 t = 0.05 0.96 
DUP (median)  60  180 U <0.01 
Education (years)  10.5 ± 3.3  9.7 ± 3.3 t = 2.10 0.04 
Premorbid IQ  9.3 ± 2.6  8.7 ± 2.9 t = 1.62 0.10 
TMT B-A  53.8 ± 45.3  69.9 ± 54.3 t = - 2.03 0.04 
SAPS  13.3 ± 3.9  14.1 ± 4.7 t = - 1.65 0.10 
SANS  6.2 ± 5.7  7.8 ± 6.3 t = - 2.31 0.02 
CDSS  2.6 ± 3.4  1.7 ± 2.8 t = 2.79 0.01 
Length of stay  17.9 ± 12.1  27.1 ± 18.6 t = -4.11 <0.01 
Gender (males) 121 (55.5)  80 (59.7)  Χ2 = 0.60 0.44 
Previous SA 13 (6.0)  11 (8.2)  Χ2 = 0.60 0.44 
Schizophrenia 100 (45.9)  101 (75.4)  Χ2 = 29.49 <0.01 
Unmarried 168 (77.0)  114 (85.0)  Χ2 = 3.07 0.08 
Living alone 26 (11.9)  26 (19.4)  Χ2 = 3.62 0.06 
Unemployed 89 (40.8)  68 (50.7)  Χ2 = 3.17 0.07 
Urban area 167 (76.6)  94 (70.1)  Χ2 = 2.01 0.16 
Cannabis 93 (42.7)  58 (43.2)  Χ2 = 0.01 0.91 
Alcohol 121 (55.5)  71 (52.9)  Χ2 = 0.26 0.61 
Family history 48 (22.0)  28 (20.9)  Χ2 = 0.06 0.80 
Poor premorbid adjust. 59 (27.0)  54 (40.3)  Χ2 = 10.86 <0.01 
Hospitalization 134 (61.4)  93 (69.4)  Χ2 = 2.28 0.13 
ISC: Insight the social consequences. DUP: Duration of untreated psychosis. IQ: Intelligence Quotient. TMT B-A: Trail Making 
Test, time to complete task minus time to complete task A (Reitan, 1958). SAPS: Scale for the Assessment of Negative Symptoms 
(Andreasen, 1983) SANS: Scale for the Assessment of Positive Symptoms (Andreasen, 1983). CDSS: Calgary Depression Scale for 




DUP, years of education, a diagnosis of schizophrenia, TMT B-A, SANSS, CDSS, 
premorbid adjustment and length of hospital admission, which emerged as significant 
predictors of ISC from the bivariate analyses, were entered into a multivariable binary logistic 
regression model. Since suicidal history had not been found to be significantly associated with 
IMI, this variable was not added to the model.   
Only a diagnosis of schizophrenia (OR=0.38, 95% CI 0.17-0.84, p=0.02) and severity of 
depressive symptomatology as measured by the CDSS (OR=0.790, 95% CI 0.671-0.93, p<0.01) 
predicted ‘poor’ ISC (Table 7.6). The model (χ2=38.50, df=8, p<0.01) explained 27.7% 
(Nagelkerke R2) of the variance on ISC and overall classified correctly 72.7% of the cases, 
namely 85.8% of ‘good insight’ patients and 47.5% of the ‘poor insight’ subjects. 
 
Table 7.6. Santander: Predictors of poor insight into the social consequences of the illness 
 B SE Wald p OR 95% CI 
DUP binary -0.56 0.38 2.09 0.15 1.75 0.82 – 3.71 
Education (y) -0.01 0.06 0.03 0.87 0.99 0.89 – 1.11 
Schizophrenia -0.96 0.40 5.72 0.02 0.38 0.17 – 0.84 
Days in hospital 0.02 0.01 2.83 0.09 1.06 1.00 – 1.06 
TMT B-A 0.01 0.00 0.72 0.40 1.06 1.00 – 1.06 
Premorbid ad. 0.34 0.39 0.75 0.39 1.40 0.65 – 3.03 
SANS 0.05 0.03 2.56 0.11 1.05 0.99 – 1.12 
CDSS -0.23 0.08 8.19 <0.01 0.79 0.67 – 0.93 
DUP: Duration of untreated psychosis. TMT B-A: Trail Making Test, time to complete task minus time to complete task A (Reitan, 
1958). SANS: Scale for the Assessment of Positive Symptoms (Andreasen, 1983). CDSS: Calgary Depression Scale for 








7.5.e. – The influence of suicidal history on insight into the need for treatment 
Those individuals with ‘good’ insight were less likely to have made suicidal acts before 
first contact with mental health services than ‘poor’ insight patients as follows: 3.7% vs. 10.3%, 
p=0.01. 
However, good insight (when compared with poor insight) was significantly associated 
with shorter DUP (67.5 days vs. 150 days, p=0.02), years of education (10.6 vs. 9.7, p=0.01), 
positive symptoms severity as measured by the SAPS (13.1 vs. 14.2, p=0.01), depressive 
severity which was assessed by the CDSS scores (2.7 vs. 1.8, respectively, p=0.02), 
unemployment (39.9% vs. 50.0%, p=0.05), poor premorbid adjustment (p=0.01) and length of 
hospital admission (16.9 vs. 26.4 days, respectively, p<0.01), although the percentage of 
patients requiring hospitalization did not vary across insight groups. There were significantly 
(p=0.01) more patients with schizophrenia who had poor INT (64%) than subjects with this 
diagnosis and good INT (51.1%). 
Further non-significant differences were found which are shown in Table 7.7. 
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Table 7.7. Santander: Comparison of pre-morbid, socio-demographic, clinical and 
cognitive variables between patients with good and poor insight into the need for 
treatment 
 Good INT 
n = 188 (53.4%) 
Poor INT 
n = 164 (46.6%) 
  
 n (%) Mean ± SD n (%) Mean ± SD Statistic p-value 
Age  30.8 ± 9.4  29.3 ± 9.8 t = 1.54 0.12 
DUP (median)  67.5  150 U 0.02 
Education (years)  10.6 ± 3.4  9.7 ± 3.2 t = 2.49 0.01 
Premorbid IQ  9.4 ± 2.7  8.9 ± 2.7 t = 1.45 0.15 
TMT B-A  57.8 ± 45.3  65.9 ± 53.0 t = - 1.37 0.17 
SAPS  13.1 ± 3.8  14.2 ± 4.7 t = - 2.47 0.01 
SANS  6.5 ± 5.8  7.2 ± 6.3 t = - 1.05 0.30 
CDSS  2.7 ± 3.4  1.8 ± 2.9 t = 2.40 0.02 
Length of stay  16.9 ± 10.3  26.4 ± 18.4 t = -4.83 <0.01 
Gender (males) 105 (55.8)  96 (58.5)  Χ2 = 0.26 0.61 
Previous SA 7 (3.7)  17 (10.3)  Χ2 = 6.03 0.01 
Schizophrenia 96 (51.1)  105 (64.0)  Χ2 = 6.01 0.01 
Unmarried 145 (77.1)  137 (83.5)  Χ2 = 2.65 0.10 
Living alone 28 (14.9)  24 (14.6)  Χ2 = 0.01 0.96 
Unemployed 75 (39.9)  82 (50.0)  Χ2 = 3.83 0.05 
Urban area 146 (77.6)  115 (70.1)  Χ2 = 2.31 0.12 
Cannabis 75 (39.9)  76 (46.3)  Χ2 = 1.49 0.22 
Alcohol 102 (54.2)  90 (54.9)  Χ2 = 0.01 0.95 
Family history 42 (22.3)  34 (20.7)  Χ2 = 0.13 0.71 
Poor premorbid adjust. 52 (27.6)  61 (37.2)  Χ2 = 6.60 0.01 
Hospitalization 134 (71.3)  93 (56.7)  Χ2 = 2.28 0.13 
INT: Insight the need for treatment.  DUP: Duration of untreated psychosis. IQ: Intelligence Quotient. TMT B-A: Trail Making test, 
time to complete task minus time to complete task A (Reitan, 1958). SAPS: Scale for the Assessment of Negative Symptoms 
(Andreasen, 1983) SANS: Scale for the Assessment of Positive Symptoms (Andreasen, 1983). CDSS: Calgary Depression Scale for 




DUP, years of education, a diagnosis of schizophrenia, SAPSS, CDSS, suicidal history, 
unemployment, poor premorbid adjustment and length of hospital admission, which emerged 
as significant predictors of insight into the need for treatment from the bivariate analyses, were 
entered into a multivariable binary logistic regression model. 
Only suicidal history (OR=3.72, 95% CI 1.17-11.80, p=0.02), length of stay (OR=1.04, 
95% CI 1.01-1.07, p=0.01) and depressive severity as evaluated by the CDSS total score 
(OR=0.86, 95% CI 0.77-0.96, p=0.01), which showed an inverse relationship (i.e. ‘poor’ insight 
was linked to more severe depressive symptomatology) remained as independent significant 
predictors of INT (Table 7.8). The model (χ2=38.10, df=9, p<0.01) explained 23.5% (Nagelkerke 
R2) of the variance on INT and overall classified correctly 66.5% of the cases. Specifically, 69% 
of ‘good insight’ patients and 63.9% of the ‘poor insight’ subjects were correctly identified by 
the model. 
 
Table 7.8. Santander: Predictors of poor insight into the need for treatment 
 B SE Wald p OR 95% CI 
DUP (binary) -0.41 0.35 1.40 0.23 1.51 0.76 – 3.01 
Education (y) -0.08 0.05 2.30 0.08 0.92 0.83 – 1.01 
Schizophrenia -0.10 0.34 0.01 0.76 0.90 0.46 – 1.76 
Previous SA 1.31 0.59 4.99 0.02 3.72 1.17 – 11.80 
Days in hospital 0.04 0.01 6.69 0.01 1.04 1.01 – 1.07 
Unemployment -0.32 0.34 0.90 0.34 0.72 0.37 – 1.41 
Premorbid ad. 0.30 0.35 0.76 0.38 1.35 0.69 – 2.67 
SAPS 0.05 0.04 1.56 0.21 1.06 0.97 – 1.15 
CDSS -0.15 0.06 6.92 0.01 0.86 0.77 – 0.96 
DUP: Duration of untreated psychosis. TMT B-A: Trail Making Test, time to complete task minus time to complete task A (Reitan, 
1958). SAPS: Scale for the Assessment of Positive Symptoms (Andreasen, 1983). CDSS: Calgary Depression Scale for Schizophrenia 
(Addington et al., 1992). SA: Suicide attempts prior to first presentation/contact 
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7.5.f. – Risk factors for suicidal behaviour over the 3-year follow-up  
As detailed in section 7.5.b., 35 follow-up suicide attempters, including 6 suicide 
completers, and 362 non-suicide attempters were compared through Kaplan-Meier survival 
analyses and Cox Regression models with regard to baseline insight levels, whilst adjusting 
the analyses for demographic and clinical mediating/confounding variables. The first suicide 
attempt was more likely to occur within the first year (20/35=57%) than in the remaining two 
years (15/35=43%), which was statistically significant (p<0.01). Specifically, the first suicide 
attempt (n=35) occurred within a median follow-up time of 261 days, as shown by the Kaplan-
Meier Curve below (Figure 7.2.).   
 
Figure 7.2. Santander: Kaplan-Meier Survival Curve showing time to first suicidal 
event over the follow-up in suicide attempters and completers, n=35 (Median: 0.71 




In total, there were 57 suicidal events over the 3-year follow-up, including 6 suicide 
completions. 35 attempters made just one suicidal act over the follow-up, 11 individuals made 
two suicide attempts over the 3-year follow-up and 5 patients attempted to take their life on 3 
occasions over the 3-year follow-up. 
The date of the last face-to-face review before the 57 suicidal events over the 3-year 
follow-up was recorded in 45 cases (78.9%). The median for this time was 9 days for the first 
suicide attempt, 23 days for the second suicide attempt and 3 days for the third suicidal act.  15 
suicidal events occurred within the first week after a face-to-face contact with a PAFIP member 
of the staff. Figure 7.3. below shows the Kaplan-Meier Survival Curves for time from last face-
to-face contact to first suicide attempt (n=35):   
 
Figure 7.3. Santander: Kaplan-Meier Survival Curve showing time (days) from last 
face-to-face contact to first suicidal event over the follow-up in suicide attempters 





With regard to suicide method, poisoning (n=23) and cutting (n=13) were the most 
common suicide methods. Also, there were suicide attempts by violent methods such as 
hanging (n=3) and jumping (n=5), which included jumping from a height or in front of a train. 
There were no suicide attempts by firearms.   
In terms of attrition, the 362 non-suicide attempters were censored at a mean follow-up 
time of 1095 days. Only 63 non-suicidal subjects (63/362=17.4%) did not complete the 3-year 
follow-up.   
Univariate analyses concerning demographic, clinical and symptom-related variables, 
including insight, are presented below in tables 7.9, 7.10 and 7.11, respectively. 
 
Table 7.9. Santander: Survival analyses of demographic variables 







Gender Male 19.9 22 0.72 0.40 
 Female 15.1 13   
Age <27.7 17.2 22 2.85 0.09 
 >27.7 17.7 13   
Years of education <10 19.3 22 1.37 0.24 
 >10 15.6 13   
Unmarried Unmarried 27.7 29 0.26 0.61 
 Married 7.3 6   
Living alone Alone 5.2 4 0.29 0.59 
 Not alone 29.9 31   
Urban area Urban area 25.9 28 0.86 0.35 




Table 7.10. Santander: Univariate analysis: log-rank tests of equality of survival 
distributions for the clinical variables 




Log-rank test  
(X2) 
p-value 
Suicidal history Absent 35.7 22 16.33 <0.01 
 Present 2.2 7   
DUP <90 17.9 15 0.61 0.43 
 >90 17.0 19   
Schizophrenia Absent 15.2 13 0.59 0.44 
 Present 19.7 22   
Cannabis Absent 19.9 19 0.33 0.56 
 Present 15.1 16   
Alcohol Absent 9.7 9 0.56 0.75 
 Present 5.8 12   
Family history psychosis Absent 26.4 22 4.04 0.04 
 Present 7.5 12   
Hospitalization Absent 12.4 10 0.81 0.37 
 Present 22.5 25   
Length of stay, days <18 13.1 15 0.52 0.43 
 >18 11.9 10   
 








Table 7.11. Santander: Univariate analysis: log-rank tests of equality of survival 
distributions for the neuropsychological and symptom-related variables 







Premorbid adjustment Good 16.8 11 5.81 0.02 
 Poor 9.2 15   
Premorbid IQ Low 10.3 14 3.34 0.07 
 High 8.7 5   
Executive functions Preserved 5.2 5 0.04 0.85 
 Impaired 15.8 16   
Positive symptoms Absent 17.5 17 0.02 0.88 
 Present 17.4 18   
Negative symptoms Absent 18.4 17 0.32 0.57 
 Present 16.6 18   
Depression Absent 29.6 23 11.91 0.01 
 Present 4.4 11   
Insight mental illness Absent 16.7 17 0.07 0.79 
 Present 9.2 9   
Insight social consequences Absent 9.9 9 0.04 0.84 
 Present 16.1 17   
Insight need for treatment Absent 12.1 12 0.02 0.96 
 Present 13.9 14   
 
 
Young age (<27.7 years, which was the median) at first presentation (RR 1.79, 95% CI 
0.90-3.55, p=0.09), suicidal history (RR 4.87, 95% CI 2.08-11.4, p=0.02), family history of 
psychosis (RR 2.03, 95% CI 1.00-4.09, p=0.05), poor premorbid adjustment (RR 2.52, 95% CI 
1.16-5.48, p=0.02), and depression (RR 3.30, 95% CI 1.61-6.76, p<0.01) were most strongly 
related to risk of suicidal behaviour.   




Most of suicidal acts occurred shortly after the last appointment with a PAFIP member 
of the staff. The median of this time was 18 days for the first attempts (n=35), 22 days for the 
second attempt (n=12) and 3 days for the third attempt (n=3). However, 16 suicidal events 
(35.5%) were made over a month after the last appointment.  
Young age at first presentation (<27.7 years), suicidal history, family history of 
psychosis, poor premorbid adjustment and depression were entered into the first forward 
stepwise Cox regression model. Age at first contact (RR 2.61, 95% CI 1.07-6.32, p=0.03), suicidal 
history (RR 4.35, 95% CI 1.50-12.62, p<0.01), poor premorbid adjustment (RR 2.34, 95% CI 1.00-
5.45, p=0.05) and depression (RR 4.39, 95% CI 1.91-10.10, p<0.01) remained significant as 
shown in table 7.12. below. 
 
Table 7.12. Santander: Multivariate analysis: Risk factors for suicidal behaviour from Cox 
regression modelling – sociodemographic, clinical and symptom-related variables 
Risk factor RR 95% CI p-value 
Age at first presentation <27.7 2.61 1.07 – 6.32 0.03 
 >27.7    
Suicidal history Present 4.35 1.50 – 12.62 <0.01 
 Absent    
Family history psychosis Present 0.47 0.19 – 1.17 0.11 
 Absent    
Poor premorbid adjustment Present 2.34 1.00 – 5.45 0.04 
 Absent    
Depression Present 4.39 1.91 - 10.10 <0.01 
 Absent    
Model based on n=326 first episode psychosis cases (including 24 suicide attempters) which had complete data for all the variables 
in the model. 
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7.6. – Discussion 
7.6.a. – Main findings 
Four main findings emerged from the analyses, which provide support for my 
hypotheses.  
First, in a cohort of all patients presenting with a first-episode of psychosis in the 
Cantabria catchment area over 2001-2010 and followed-up over 3 years, I identified a high 
number of patients who attempted to end their lives over that period, including six people 
who died by suicide. When compared with the general population of Cantabria, I also found 
this cohort to have a significantly higher risk of suicide completion, thus reflecting the 
importance of suicide prevention in early psychosis. Moreover, the use of violent methods was 
relatively common despite the non-fatal outcome in most cases. 
Second, no relationships between suicidal history and insight dimensions at first 
presentation were revealed by the analyses except for INT. Specifically, those patients who 
lacked INT at first presentation were more likely to have a suicidal history before first contact 
with psychiatric services than those subjects with good INT; hence suggesting that awareness 
of the need for treatment may reduce suicide risk in early psychosis.  
Third, no insight dimensions at baseline were associated with an increased risk of 
suicidal behaviours over the 3-year follow-up despite having sufficient statistical power 
(96.7%) to investigate these relationships.  
Fourth, poor premorbid adjustment, previous SAs, depression and young age at first 
contact with services were the main risk factors in those individuals who were more likely to 
make suicide attempts over the 3-year follow-up. 
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7.6.b. – Epidemiology and suicide methods in the sample 
Despite the commonly quoted figure of a “10%” lifetime suicide risk in schizophrenia 
based on previous research (Miles, 1977; Caldwell & Gottesman, 1990), I replicated the more 
recently findings from FEP cohorts (Bertelsen et al., 2007; Robinson et al., 2010; Dutta el al., 
2010), which reported a case-fatality between 1.3-1.9% (1.5% in this FEP sample from 
Santander).  
In keeping with the seminal meta-analysis by Brown (1997), I found a very significant 
increased suicide risk in the first three years of the psychotic illness in this cohort in 
comparison with the general population of this catchment area (Cantabria, Spain); thus 
replicating previous studies that reported suicide to be the largest single cause of death in 
psychotic disorders (Brown et al., 1997; Dutta et al., 2010). It remains unclear, however, what is 
the rate of suicide in people with undiagnosed psychosis (Nielssen & Large, 2009). It should be 
noted that almost half of suicide attempters prior to first presentation to services made suicidal 
acts before the onset of psychosis as rated by the DUP, which is consistent with recent research 
showing that having psychotic experiences predicts future suicidality in adolescents at a 
population level (Kelleher et al., 2013) and in clinical samples (Kelleher et al., 2014).   
In addition, given the non-fatal outcome of most of suicide attempts, taking an 
overdose was the most common suicide method, which was in line with previous samples of 
suicide attempters with schizophrenia spectrum disorders (Altamura et al., 2003; Baca-Garcia 
et al., 2005) and FEP (Fedyszyn et al., 2011). In spite of the non-fatal outcome in most cases, a 
number of attempters used violent methods such as jumping in front of a vehicle or from a 
high place, in line with previous reports (e.g. Nielssen et al., 2010; Lopez-Morinigo et al., 
2014b). However, patients with schizophrenia and related disorders were reported to kill 
themselves by taking overdoses in Finland (Heilä et al., 1997). Of note, no suicide attempts by 
firearms were identified in our study, which is in line with previous reports from Europe (e.g. 
De Hert et al., 2001; Dutta et al., 2010), reflecting the legal restrictions to access firearms 
compared to the USA.  
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7.6.c. – Previous suicide attempts and insight dimensions at first presentation 
In spite of previous findings from our group (Lopez-Morinigo et al., 2014a) and other 
FEP studies (e.g. Barrett et al., 2010a) suggesting that previous suicidal events before first 
presentation with psychosis may affect insight levels at that point, I failed to replicate these 
associations in this cohort from Santander (Spain) except for INT. Although these negative 
results may have been due to insufficient statistical power, this seems to be very unlikely. An 
alternative explanation is that most of these suicidal events occurred shortly before first contact 
with services (within the previous month) and therefore, they cannot be considered to be, in 
reality, ‘previous’ suicide attempts (i.e. they actually occurred during the ‘acute’ phase of the 
illness).  
With regard to IMI, it should be noted that the proportion of ‘good IMI’ patients was, 
however, slightly higher in the suicidal group. A negative relationship between insight and 
DUP was replicated (Pek et al., 2006; Cuesta et al., 2011; Saravanan et al., 2010; Lopez-Morinigo 
et al., 2014a), i.e. the longer the DUP, the poorer the insight at first presentation. However, the 
direction of causality remains unclear since it is at least as likely that poor insight leads to 
avoidance of care and hence increases DUP (Drake et al., 2000). Similar findings were found 
with regard to ISC and INT in relation to DUP in the bivariate analyses, although these 
associations did not survive the multivariable regression models. Moreover, the risk of suicidal 
events over the follow-up was lower in those with a short DUP (<90 days). Hence, it seems that 
shortening DUP, for instance through early detection programmes, may improve insight and 
reduce suicide risk in patients with schizophrenia spectrum disorders (Altamura et al., 2003; 
Nielssen & Large, 2009; Chan et al., 2014). However, a randomised controlled trial from 
Denmark, which compared patients with a FEP receiving an ‘integrated treatment’ with those 
subjects under ‘treatment as usual’ over a 5-year follow-up, failed to demonstrate that such a 
specific intervention on early psychosis reduced suicidality (Bertelsen et al., 2008).   
In addition, impaired frontal lobe functions were linked with poor IMI in this cohort, 
which was consistent with previous literature (Ayesa-Arriola et al., 2010; Wiffen et al., 2012; 
David et al., 2012). However, cognition does not seem to determine long-term insight (Ayesa-
Arriola & Morinigo, 2014). Also, unemployment and a diagnosis of schizophrenia were found 
to be associated with lack of IMI, which was also linked to length of hospital stay, i.e. the 
poorer the insight, the longer the admission. Although only length of stay survived the 
multivariable regression models, no causality conclusions can be drawn from these cross-
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sectional analyses. Also, for those patients requiring hospitalization, it should be noted that 
insight was assessed over the admission period. 
Although it is intuitive to think that being aware of the social consequences of the 
illness such as becoming unemployed or partnership breakup may lead to feelings of 
hopelessness, including suicidal ideation, I did not find suicidal history to be associated with 
insight into the social consequences of the illness (ISC) at first presentation. However, the 
multivariable regression analyses found ISC to be determined by having schizophrenia (as 
opposed to ‘other psychoses’) and depression at baseline, which was consistent with previous 
research (Amador et al., 1994; Ayesa-Arriola et al., 2011; Ayesa-Arriola & Morinigo, 2014). Of 
note, those patients with suicidal antecedents presented with more severe depression at 
baseline.  
A problem here is recall bias - where patients are relied upon to give previous instances 
of suicide attempts. Thus, a more insightful patient may be more likely to remember and 
report such events, which of course are likely to be distressing,  and they may also be more 
readily recalled if the current mood state is low (Harvey et al., 2008; Gonzalez, 2008; 
Schennach-Wolff et al., 2009). Also, on the basis of so-called depressive realism (Ghaemi & 
Rosenquist, 2004), I may postulate that depressive patients tend to think more pessimistically, 
thus being more likely to recall true negative events such as having a mental illness, which 
may result in higher insight scores. This source of bias does not only represent a challenge to 
researchers in determining the true association between insight and suicidality but also 
highlights the need for more theoretical discussion about the direction of causality between 
insight and ‘depression’ (Beck et al., 1990; Belvederi-Murri et al., 2015). 
Finally, INT was found to be related to suicidal history. Those individuals with good 
INT at baseline were less likely to have suicidal antecedents than those subjects unaware of the 
need for treatment. In keeping with this, DUP was found to be significantly shorter in patients 
with good insight, including the three insight dimensions evaluated in this cohort: IMI, ISC 
and INT. Hence, insight, particularly INT, may reduce suicide risk in early psychosis by 
leading the individual to seeking psychiatric attention earlier and  via shortening DUP and 
subsequently, decreasing the likelihood of suicidal events before first presentation, which is 
also the strongest predictor of future suicidal acts in schizophrenia (Hawton et al., 2005) and 
FEP (Pompili et al., 2011). In keeping with this, the multivariable regression models revealed 
that length of stay and depression were the only predictors of INT at baseline. Hence, 
depression seems to be linked with INT, although this cross-sectional association does not 
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allow me to infer causality conclusions. Regardless of the direction of causality, this ‘insightful-
depressive’ subgroup of FEP patients appeared to have a lower suicide risk before first 
presentation with psychosis in this cohort. However, this finding should be taken cautiously 
since in this cohort suicidal ‘history’ included only very recent suicidal events (within the last 
month). Indeed, in the London FEP sample this ‘insightful-depressive’ subgroup of patients 
was found to be at higher risk of suicidal behaviours before first contact with services, 
including lifetime suicidal events (Lopez-Morinigo et al., 2014a; Chapter 4).  Nonetheless, our 
results were in line with previous FEP studies (Barrett et al., 2010b), which also showed that 
insight, as measured unidimensionally through the PANNS (Kay et al., 1987) item, was 
associated with suicidality independently of negative beliefs about psychosis and depression 
(Barrett et al., 2010b). However, no causality conclusions can be drawn from these two cross-
sectional studies (Barrett et al., 2010b; Lopez-Morinigo et al., 2014a), which forms the context 
for the next section focused on the relationship between insight levels at baseline and 
suicidality over the 3-year follow-up. 
 
7.6.d. – Insight dimensions did not increase risk of suicidal behaviours 
In line with the specific hypotheses of this PhD (Chapter 2, section 2.5) concerning the 
role of insight in suicidal behaviours in early psychosis, the results presented in this chapter 
suggest that insight dimensions at baseline did not seem to predict risk of suicidal behaviours 
in this FEP cohort over a 3-year follow-up, consistently with the findings from the UK-based 
cohorts (Chapters 4, 5 and 6). Although it could be argued that these relationships were not 
found due to insufficient statistical power, there was 97.6% power to test for these associations, 
as detailed in section 7.4.b.6. Hence, this explanation appears to be unlikely. As a result, I may 
conclude that, indeed, insight does not behave as a risk factor for suicidal behaviours in early 
psychosis despite common assertions to the contrary, which deserves further discussion below.  
In Chapter 2 I summarized the findings from my MEDLINE-based systematic review 
concerning studies related to ‘insight and suicide risk in schizophrenia’ (Lopez-Morinigo et al., 
2012). In particular, 5 (Bakst et al., 2009; Bourgeois et al., 2004; Acosta et al., 2009; Robinson et 
al., 2010; Yen et al., 2002) out of the 7 follow-up selected studies (Bakst et al., 2009; Bourgeois et 
al., 2004; Acosta et al., 2009; Robinson et al., 2010; Yen et al., 2002; Robinson et al., 2009, 
Crumlish et al., 2005) failed to find such an association. Therefore, the negative results 
presented in this chapter appear to be in full agreement with the findings from this systematic 
review (Lopez-Morinigo et al., 2012), which have been replicated more recently (Fedyszyn et 
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al., 2011). Moreover, a recent 1-year follow-up FEP study suggests that the relationship 
between insight and suicide risk may change over the course of the illness. Thus, insight at 
baseline was found to be associated with increased risk of suicidality at 1-year, whilst the gain 
of insight over the 1-year follow up reduced the risk at that point (Barrett et al., 2015). 
In addition, I demonstrated that those studies reporting a positive association between 
IMI and suicide risk, particularly those with a cross-sectional design, appear to be subject to 
both selection and recall bias (Lopez-Morinigo et al., 2012).  
Hence, a direct link between insight and suicide in psychosis remains unproven but 
may be mediated by other variables such as depression, which is consistent with the results 
from this cohort concerning the role of depression in risk of suicidal behaviours. A correlation 
between level of insight and depression has been consistently demonstrated (Belvederi et al., 
2015), although some inconsistencies were reported in adolescents with early-onset FEP 
(Parellada et al., 2011). Specifically, this recent meta-analysis reported a significant association 
of awareness of mental illness and awareness of social consequences with depression, while no 
such relationship was replicated between depression and compliance (Belvederi et al., 2015). 
However, the direction of causality remains poorly understood and both directions can be 
currently supported. First, some insight dimensions (i.e. awareness of the social consequences 
of the illness) may lead the patient with a psychotic disorder to a more depressive state 
(Amador et al., 1996), which has been called the ‘demoralization syndrome’ (Drake et al., 1985; 
Drake & Cotton, 1986; Amador et al., 1996; Restifo et al., 2009). And second, the so-called 
‘depressive realism model’ may provide the pathway through which a more depressed patient 
would tend to confront difficult issues such as illness, disability and so on (Ghaemi & 
Rosenquist, 2004). Thus, this hypothetically more depressed patient would express higher 
levels of insight. There is thus a ‘chicken and egg’ dilemma here that can only be solved with 
longitudinal intervention studies; for example, if it was shown that insight improving 
interventions reduced suicidality. Certainly, there is no evidence that insight improving 
interventions worsen suicidality (Pijnenborg et al., 2013). 
In contrast to our expectations based on the aforementioned meta-analysis (Belvederi et 
al., 2015), which linked ISC with depression, I failed to replicate this association in this cohort. 
Although this negative result may be attributed to limited statistical power, the power 
calculations presented in section 7.4.c.1 suggest that this is unlikely. However, a genuine 
smaller effect cannot be excluded. An alternative explanation is the focus of PAFIP on meeting 
patient’s social needs from first contact. For instance, all PAFIP patients are encouraged and 
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supported to enroll vocational courses in order to get employed. Also, almost half of 
participants were living in rural areas, where social cohesion may minimize the impact of 
potentially unmet social needs on suicidality, consistently with the Durkheim’s sociological 
theories of suicide (Durkheim, 1897).  
Interestingly, half of the suicidal events over the follow-up occurred shortly after 
(within 9 days) the last face-to-face contact with a member of the staff, which is in keeping 
with previous studies showing the relative inability of clinicians to predict, and prevent, 
imminent suicide risk in individuals with SSD under their care (Hu et al., 1991; Heilä et al., 




7.6.e. – Predictors of suicidal behaviour over the follow-up 
The bivariate analyses revealed that young age at first presentation (<27.7 years), 
suicidal history, family history of psychosis, poor premorbid adjustment and depression were 
related to risk of suicidal behaviours over the follow-up. Also, poor premorbid adjustment, 
previous SAs, depression and age at first presentation survived the multivariable regression 
models. 
Thus, I replicated an increased risk in early stages of the psychotic illness as measured 
by age at first contact (e.g. Tsuang, 1978; Osby et al., 2000; Qin & Nordentoft, 2005; Palmer et 
al., 2005; Limosin et al., 2007; Osborn et al., 2008; Alaräisänen et al., 2009; Dutta et al., 2010; 
Barrett et al., 2010a; Barrett et al., 2010b), although a large nation-wide population-based study 
from Finland reported late first contact (>30 years) to reduce suicide risk (Hëila et al., 1997). In 
keeping with this, late illness onset reduced suicide risk in an epidemiological study from 
Taiwan (Kuo et al., 2005). Nevertheless, close monitoring in early psychosis has been strongly 
recommended by recently reviewed guidelines (Popovic et al., 2014; NCISH, 2015), which is in 
line with real-world data from the South London and Maudsley NHS Foundation Trust case 
register (Lopez-Morinigo et al., 2014b; Lopez-Morinigo et al., 2016; Chapter 3). Moreover, 
findings from our London cohort (Lopez-Morinigo et al., 2014a) suggest that a number of 
suicidal events occur even before the onset of psychosis as rated by the DUP. It could be 
therefore speculated that a number of very young individuals with undiagnosed psychosis end 
their lives before first presentation to psychiatric services (Nielssen & Large, 2009; 
Andriopoulos et al., 2011). Prospective studies are required for this, including cohort studies 
which follow individuals from a point prior to their first illness presentation; for instance, by 
recruiting participants from the so-called ‘at-high-risk’ or ‘prodromal’ services. 
Regarding gender, although I replicated an association of being male with risk of 
suicide (Hawton et al., 2005; Limosin et al., 2007; Hor and Taylor, 2010; Dutta et al., 2011; 
Pompili et al., 2011), the differences did not reach significance, which was in line with previous 
similar case-control studies with samples of both schizophrenia (Reutfors et al., 2009) and FEP 
(Björkenstam et al., 2014) patients. Moreover, some of  these studies revealed similar suicidal 
risk across genders (Large et al., 2011) or even a greater risk for females (Thorup et al., 2007). 
Also, I found no association of level of education with suicide risk despite previous 
positive studies in both schizophrenia (e.g. Reutfors et al., 2009) and FEP (Björkenstam et al., 
2014). Furthermore, education level was linked with insight levels in patients with 
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schizophrenia and related disorders in a previous report from our group (Wiffen et al., 2010), 
i.e. the higher the education level, the greater the insight.  
In terms of area of residence, no differences emerged from the analyses between living 
in rural or urban areas. However, it has been reported that living in rural areas increases the 
risk of suicide due the availability of firearms and more limited access to mental healthcare 
(Searles et al., 2013), which is consistent with another study that found lower levels of 
urbanicity to be associated with higher risk of suicide by firearms (Burros et al., 2013). 
However, living in urban areas was also linked with an increased suicide risk by jumping. 
Hence, urbanicity, as opposed to living in rural areas, may have different associations with 
suicide risk across countries. Specifically, I may speculate that living in rural areas in Cantabria 
behaved as a protective factor due to increased social cohesion, which is, to some extent, 
related to the Durkheim’s sociological theories of suicide (Durkheim et al., 1897).  
Interestingly, the risk of suicidal events over the follow-up was lower in those with a 
short duration of untreated psychosis (DUP) (<90 days), although this difference did not reach 
significance. Hence, it seems that shortening DUP, for instance through early detection 
programmes, may reduce suicide risk in patients with schizophrenia spectrum disorders 
(Altamura et al., 2003; Barrett et al., 2010a).   
I replicated the role of suicidal history in future suicidal events in early psychosis (Hu 
et al., 1991; De Hert et al., 2001; Sinclair et al., 2004; Hawton et al., 2005; Reutfors et al., 2009; 
Dutta et al., 2010; Björkenstam et al., 2014; Bakst et al., 2010a; Challis et al., 2013; Tarrier et al., 
2006), including  a recent meta-analysis (Large et al., 2011). Specifically, 6.3% of our FEP 
attempters over the 3-year follow-up had made suicide attempts prior to the study inception, 
which was also a predictor of future suicide attempts in the bivariate analyses, consistently 
with previous research (eg. Hawton et al., 2005; Pompili et al., 2011). These results were 
therefore consistent with previous FEP studies (e.g. Robinson et al., 2009, Harvey et al., 2008), 
including the UK-based cohorts used in this investigation (Lopez-Morinigo et al., 2014a; 
Chapters 4, 5 and 6). Although most of these ‘previous’ suicidal acts occurred within the 
month before first presentation and therefore further suicidal events may have happened at 
earlier stages, it should be noted that up to 42% of patients with schizophrenia spectrum 
disorders who end their own lives have no suicidal history (Lopez-Morinigo et al., 2014b; 
Lopez-Morinigo et al., 2016).  
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Of note, my findings concerning the relationship between having a family history of 
psychosis and risk of suicide were in line with a recent national register-based cohort study 
with FEP patients admitted in Sweden (Björkenstam et al., 2014). 
In addition, I replicated the high risk of suicide during the immediate period after 
hospitalization (Hu et al., 1991; Sinclair et al., 2004; Heilä et al., 1997; De Hert et al., 2001; 
Alaräisänen et al., 2009; NCISH, 2015). Half of suicides occurred in the 6-month period after 
being discharged from a psychiatric ward. Hence, close monitoring over that period of time 
should be strongly recommended (Popovic et al., 2014; NCISH, 2015). Moreover, this study 
showed that the highest self-harm rates occurred shortly before and after psychiatric 
hospitalization, which is in full agreement with a literature review about suicide risk factors in 
FEP (Pompili et al., 2011). Therefore, earlier intervention, including hospitalization as 
appropriate, appears to be needed to better manage the high risk of suicide in the prodromal 
stages of psychosis. Also, a high level of support should be provided on discharge from 
hospital, although recent findings from the 2015 UK national Confidential Inquiry into Suicide 
and Homicide suggest that Crisis and Resolution Home Treatment Teams do not seem to 
safely manage the high risk of suicide over that period, which is of particular concern for those 
patients who live alone (NCISH, 2015).  
Of note, while in the past inpatient suicides in schizophrenia were relatively common 
(Caldwell et al., 1990; Heilä et al., 1997), in today’s psychiatry hospital appears to provide a 
safe environment to patients (NCISH, 2015). On the other hand, a high level of support is 
required to safely manage FEP patients who have been recently discharged from hospital 
(Popovic et al., 2014; NCISH, 2015). In this regard, it remains unclear the extent to which Crisis 
and Resolution Home Treatment Teams (NCISH, 2015) and early intervention services 
(Bertelsen et al., 2007; Castle & Singh, 2015) may reduce suicide risk in patients recently 
discharged from hospital after a first episode of psychosis.  
In contrast to previous literature, neither alcohol (Potkin et al., 2003; Limosin et al., 
2007) nor drugs (Hawton et al., 2005; Limosin et al., 2007) were associated with an increased 
risk of suicidal behaviours in this FEP sample. 
The relationship between cognition and suicide risk remains unclear. Thus, three 
previous large nation-wide studies (Andersson et al., 2008, Webb et al., 2011) found high IQ to 
be a risk factor for suicide in schizophrenia, while in the general population high IQ reduces 
this risk (Andersson et al., 2008). The results concerning the lack of association between 
premorbid IQ and suicide risk over the 3-year follow-up in this FEP cohort were consistent 
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with some (Potkin et al., 2003; Barrett et al., 2011), but not all, previous studies in this area (see 
Hor & Taylor, 2010 for a general review). However, cognitive decline may prevent patients 
with schizophrenia and related disorders from dying by suicide (Fenton et al., 1997; De Hert et 
al., 2001). Thus, further research is warranted to clarify whether or not cognitive impairment 
may prevent patients with schizophrenia and related disorders from suicide. In particular, it 
seems that while cognitive impairment may behave as risk factor in early psychosis, those 
patients with poorer cognitive performance in later stages of the illness may have a lower 
suicide risk. Hence, FEP cohorts should be followed-up over a long period of time to 
investigate this matter. More recently (Martinez-Aran & Vieta, 2015), it has been suggested that 
cognitive reserve and cognitive enhancement may mediate the relationships between cognition 
and clinical outcomes, including suicide, which deserves future research. However, poor 
premorbid adjustment identified suicide attempters independently of other variables, which 
was consistent with a previous systematic review (Hor & Taylor, 2010).  
Interestingly, I found no associations of psychotic symptom severity with suicide risk. 
Previous studies have yielded mixed results. In particular, replication studies conducted in the 
90s (Fenton et al., 1997; Fenton, 2000) reported negative symptoms to prevent suicide in 
patients with schizophrenia spectrum disorders. In addition, these reports (Fenton et al., 1997; 
Fenton, 2000) found suicide completers to present with more severe positive symptoms than 
those who did not take their lives. It should be noted, however, that participants in these 
studies were long-term inpatients who were discharged from hospital between 1950 and 1975. 
Hence, these patients were not treated with atypical antipsychotics, which have been reported 
to reduce suicide risk in schizophrenia (Reutfors et al., 2013), particularly clozapine (Meltzer et 
al., 2003; Bourgeois et al., 2004). On the other hand, positive symptoms, particularly 
hallucinations, may reduce suicide risk in schizophrenia (Hawton et al., 2005).   
The role of depression in suicidality was replicated in this FEP cohort, which is 
consistent with previous literature (Altamura et al., 2003; Hawton et al., 2005; Barrett et al., 
2010; Bertelsen et al., 2007; Flanagan and Compton, 2012; Harvey et al., 2008; Kontaxakis et al., 
2004; Barrett et al., 2010a; Barrett et al., 2010b; Pompili et al., 2011). 
In my literature review summarised in chapter 2 (Lopez-Morinigo et al., 2012), three 
‘negative’ selected studies (i.e. they failed to link insight with suicidality) did find depression 
to be a significant risk factor for suicide, even after adjusting the analyses for potential 
confounders (Bakst et al., 2009; Barrett et al., 2010; Restifo et al., 2009). More precisely, 
hopelessness behaved as the strongest predictive factor for suicidality among patients with 
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schizophrenia in three selected studies (Kim et al., 2003; Bourgeois et al., 2004; Acosta et al., 
2009), consistent with Hawton et al’s findings (Hawton et al., 2005). This symptom, rather than 
depression per se, may therefore represent the main clinical target for the management of 
patients with schizophrenia spectrum disorders to reduce the risk of them developing a 
suicidal behaviour (Pompili et al., 2004).  
Hence, while hopelessness appears to be one of the main risk factors for suicide in early 
psychosis, the case register-based case-control study with suicide completers with 
schizophrenia presented in chapter 3 showed that hopelessness was relatively uncommon 
amongst those who ended their lives. In other words, the impact of hopelessness, and probably 
depression in a broad sense, appears to be more relevant in early stages of the illness, 
consistent with the previous literature (Pompili et al., 2011; Ayesa-Arriola et al., 2015).   
However, it remains unclear whether ‘depression’ in early psychosis represents a 
symptomatic domain in its own right (Peralta et al., 2013) or a psychological consequence of 
the social consequences of the psychotic illness onset (Drake & Cotton, 1986). Thus, a recent 12-
month follow-up first-episode psychosis study found that while malevolent voices, use of 
safety behaviour and subordination to persecutors were associated with depression in the 
acute FEP, post-psychotic depression was linked to loss, shame, low level continuing positive 
symptoms and longer duration of untreated psychosis (Upthegrove et al.,2014). In line with the 
results from this Santander cohort, a previous first episode study from our group found an 
association between suicidal behaviour preceding first contact with services and depression at 
that point (Lopez-Morinigo et al., 2014a; Chapter 4), which was also replicated by the study 
presented in chapter 5. Also, depression in the prodromal stage was reported to predict both 
suicidality at first presentation and further depressive episodes both in the acute and recovery 
stages of FEP (Upthegrove et al., 2010). This association seems to challenge, to some extent, the 
so-called demoralization syndrome (Drake and Cotton, 1986) since depression in early 
psychosis appears to behave as a trait-like phenomenon (Upthegrove et al., 2010) rather than a 
psychological reaction to the social consequences of such a devastating illness. Overall, 
depression seems to play a crucial role in suicide risk in schizophrenia (Hawton et al., 2005) 
and FEP (Pompili et al., 2011). However, there is little guideline in the management of 
depression in schizophrenia and related disorders (Siris, 2000; NICE, 2015). 
One clinically relevant aspect to mention concerns the difficulties that clinicians so 
frequently find in distinguishing negative and depressive symptoms (Siris, 2000; Siris, 2001). In 
terms of suicidality, this distinction may play a crucial role. While depression in schizophrenia 
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behaves as a risk factor for suicide, the presence of negative symptoms may make this fatal 
outcome much less likely (Fenton et al., 1997), which may have resulted in depressive 
symptoms in psychotic patients being undertreated, or even untreated (Addington et al., 2002).  
A recent meta-analysis (Belvederi et al., 2015) reported insight, particularly IMI and 
ISC, to be significantly associated with depression. Interestingly, this meta-analysis (Belvederi 
et al., 2015) failed to link compliance with depression, on which I had based my hypothesis H5, 
i.e. compliance as a protective factor for suicidality. Although no insight dimension was 
associated with an increased risk of suicidal behaviours over the follow-up, I found that those 
patients with good insight into the need for treatment were less likely to have suicidal 
background before first presentation. Hence, based on this finding I may hypothesize that 
awareness of the need for treatment reduces suicide risk in (very) early psychosis. Thus, the 
lack of associations of baseline INT with suicidal behaviours over the follow-up may be due to 
insight changes over time (Saeedi et al., 2007; Wiffen et al., 2010; Campos et al., 2011; Cuesta et 
al., 2011; Ayesa-Arriola et al., 2015). In other words, I speculate that those non-suicide 
attempters over the follow-up may have greater levels of INT at a later point rather than at 
baseline, which was not evaluated by this study. Indeed, this is consistent with a recent 12-
month follow-up first-episode study from Norway (Barrett et al., 2015), which demonstrated 
that those subjects who gained insight (which was measured by the PANSS (Kay et al., 1987) 
item) over the follow-up had lower levels of suicidality at that point, which was assessed by 
the item 8 of the Calgary Depression Scale for Schizophrenia (CDSS) (Addington et al., 1992).   
In summary, while depression at first presentation predicted risk of suicidal behaviours 
over the follow-up, as expected, and depression was linked with two insight dimensions at 
that point, namely ISC and INT, no insight dimension was associated with an increased risk of 
suicidal behaviours over the 3-year follow-up. In other words, it seems that although insight 
may lead to an immediate state of low mood or depression, including increased suicidality, 
consistent with the so-called demoralization syndrome (Drake & Cotton, 1986) or the ‘insight 
paradox’ (Lysaker et al., 2007), in the longer-term these insightful patients may present with 
better mood and reduced suicide risk (Pijnenborg et al., 2013). Thus, figure 7.4, below, shows 




Figure 7.4. Hypothesised model to be tested in this thesis 
Red arrows increase risk and green arrows reduce risk 
 
Figure 7.5. Model based on the Santander cohort results 




7.6.f. – Strengths and weaknesses 
Of note, I included a relatively large sample (n=397) of FEP patients who were 
followed-up over a 3-year period. This allowed sufficient statistical power (from 71.1% to 
84.4% depending on the amount of missing data for each variable) to investigate between-
groups differences. Moreover, our sample included both in- and outpatients from urban and 
rural areas, which was therefore very likely representative of the catchment area population 
(Cantabria, Spain). In addition, a wide range of potential contributing variables was analyzed 
through Cox-Mandel regression models, thus taking into account the effect of time on 
variables, i.e. survival.   
However, several study limitations should be borne in mind when interpreting the 
results. First, follow-up information on suicidal behaviour was taken retrospectively from the 
medical records, which might have resulted in underestimating suicide attempts. In addition, 
some FEP patients may have completed suicide before contacting psychiatric services, thus 
also increasing the risk of underestimation. Second, a lack of sufficient statistical power to test 
for certain interactions cannot be excluded, although this seems to be unlikely based on the 
power calculations. Third, other non-tested variables may contribute to suicide risk in FEP. 
Fourth, several variables were dichotomized due to little variability of scores across patients, 
which may have increased the risk of false positives. Finally, ‘baseline’ predictors, including 
insight variables, may have changed over the follow-up period and therefore their associations 
with suicide risk should be taken cautiously, particularly regarding late stages of the follow-up 
period.  
 
7.7. – Summary of the chapter 
In summary, our results suggest that  young age at first presentation with psychosis, 
suicidal history, family history of psychosis, poor premorbid adjustment and depression are 
useful markers to identify those patients with a first episode psychosis at higher risk of suicide. 
Of note, no insight dimensions at baseline, including IMI, ISC and INT, were linked with 
increased suicide risk over the 3-year follow-up period. Therefore, depression seems to emerge 




Chapter 8 – General Discussion 
 
8.1. – Summary of thesis findings 
The main aim of this thesis was to investigate the role of three insight dimensions in 
risk of suicidal behaviour in early psychosis. First, I provided some general background to the 
topic (Chapter 1), including an up-to-date systematic literature review (Chapter 2), which was 
also peer-reviewed and later published (Lopez-Morinigo et al., 2012). Then, I provided real-
world data on suicide by patients with schizophrenia and related disorders from the South 
London and Maudsley NHS Foundation Trust (SLaM) (Chapter 3), which also resulted in two 
peer-reviewed publications of which I was first author (Lopez-Morinigo et al., 2014b; Lopez-
Morinigo et al., 2016). Finally, I analysed comprehensive data pertaining to my research 
question from three cohorts of patients with a first-episode psychosis (FEP), which was 
presented in Chapters 4, 5, 6 and 7. This chapter therefore aims to summarise and integrate all 
the above findings, including a reflection on their clinical implications, the methodological 
strengths and limitations and some suggestions for future research. 
 
8.2. – Literature review 
As detailed in chapter 2, I conducted a systematic review of previous studies, by using 
three major databases namely MEDLINE, PsychInfo and EMBASE, which looked at the 
association of insight with risk of suicidal behaviour in samples of patients with schizophrenia 
and related disorders. Twenty studies met the predetermined selection criteria. A meta-
analysis could not be conducted due to significant methodological differences between the 
studies, such as the insight assessment tool, participants’ illness stage, study design (cross-
sectional vs. prospective) and the lack of consistent quantitative data required for meta-
analysis. 
In contrast to the commonly held view among clinicians, fourteen out of the twenty 
selected studies failed to find a direct association between insight into having a mental illness 
and an increased risk of suicidal behaviour, which was also consistent with my first hypothesis 
H1 (see chapter 2, section 2.5, for further details). 
In addition, I postulated up to four reasons underlying the above mixed results, namely 
selection and recall bias, to which cross-sectional studies are particularly subject, the scale used 
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to assess insight (unidimensional vs. multidimensional) and the extent to which other 
contributory factors such as depression-related variables had been taken into account. This led 
me to formulating the hypotheses listed in chapter 2 (section 2.5), i.e. the confounding role of 
depression in the relationship between insight dimensions and suicidality, and it also provided 
me with additional information on the methodological aspects to be considered when 
conducting my own research (Chapters 4, 5, 6 and 7).  
 
8.3. – Suicide by patients with schizophrenia under secondary mental healthcare 
In chapter 3 I used a large database from the South London and Maudsley NHS 
Foundation Trust (SLaM), which is known as the Case Records Interactive Search (CRIS) 
(Stewart et al., 2009; Perera et al., 2016). Thus, of 242,227 SLaM service users until 31st 
December 2013, 635 suicides were identified, which included 96 subjects with a primary 
diagnosis of schizophrenia spectrum disorder (SSD) (F2-ICD10) who took their lives, although 
25 individuals were removed from the analyses due to poor quality of data as they had died 
prior to 2007, leaving a sample of n=71 patients with SSD who ended their lives.  
Hence, nearly one in five of the suicide completers had a diagnosis of psychosis, which 
was almost double that in a previous meta-analysis of psychological autopsy studies 
(Cavanagh et al., 2003; Arsenault-Lapierre et al., 2004). While this finding probably reflects the 
high prevalence of psychotic disorders in South-East London (Fearon et al., 2006), it may also 
highlight the importance of suicide prevention in patients with psychosis residing in our 
catchment area, which supports further the need for this investigation (Chapters 4-7). 
In particular, by using the above sample of suicide completers with SSD I conducted 
two case-control studies (see chapter 3 for further details). First, I compared those suicide 
completers with SSD with those suicide completers with all other diagnoses and I found that 
most of the classic suicide risk factors (for instance, suicidal ideation/plans, hopelessness, 
impulsivity and significant loss) were more common in the non-SSD group (Lopez-Morinigo et 
al., 2014b). Disengagement, which links with impaired insight in psychosis (Amador & David, 
2004), was more frequent in the SSD patients, although the difference (p=0.06) was not 
statistically significant (Lopez-Morinigo et al., 2014b).  
The above results led me to speculating that the classic suicide risk assessment model 
may be of little relevance for patients with SSD (Lopez-Morinigo et al., 2014b). In order to test 
this hypothesis I compared the above suicide completers with SSD with a control group of 
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patients with SSD under SLaM teams who did not end their lives. This work resulted in a peer-
reviewed publication, of which I am first author (Lopez-Morinigo et al., 2016).  
Although older age at first contact with mental health services and lack of both suicidal 
history and suicidal ideation emerged as useful protective markers, the overall performance of 
the model, which was based on widely recognized risk assessment factors, was very poor, with 
a very low positive predictive value of 6%, although the negative predictive value was 96% 
(Lopez-Morinigo et al., 2016). This discouraging finding was, however, in full agreement with 
recent literature reporting on the limited positive predictive value of suicide risk assessment 
scales irrespective of diagnosis (Quinlivan et al., 2016) and the NICE guidelines, which no 
longer recommend risk assessment tools (NICE, 2011). Moreover, concerns have been voiced 
about the futility of risk assessment in schizophrenia (Large & Ryan, 2014), which is consistent 
with my observational finding that most SSD patients who took their lives did so shortly after 
(even within a few days of) their last face-to-face contact with a staff member. One may think 
that these suicidal patients were engaged with the teams, which may therefore lead to 
speculation that insight, which is related to engagement, increases suicide risk. However, no 
insight assessment was recorded in this study, which was based on data from a large case 
register, and therefore, such a conclusion cannot be drawn from these results. Also, I postulate 
that attending the appointment is not conceptually the same as having insight; for instance, 
many patients with schizophrenia who lack insight do attend their appointments due to legal 
restrictions (i.e. the UK Community Treatment Order, DoH (2008)), or just as part of a routine 
or in order to address social needs (for example, benefits or housing issues), yet they deny 
having a mental illness. 
Also, it is noteworthy that insight was not part of the above risk assessment and 
therefore, these data, while providing further support for the importance of suicide research in 
schizophrenia and related disorders, did not allow me to answer my main research question. 
However, a history of disengagement was more common (although at a non-significant level, 
p=0.33) in the suicide completers group than in controls (i.e. those patients with SSD who did 




8.4. – Previous suicide attempts affect insight levels at first presentation 
It should be noted that the two UK-based FEP cohorts included in this investigation 
(from the GAP and AESOP studies) found illness recognition and total insight to be affected by 
SA prior to first presentation to services. This adds a relevant confounder to my research 
project since previous suicide attempts are the strongest predictor of future suicidal acts both 
in schizophrenia (Hawton et al., 2005) and FEP patients (Challis et al., 2013). Consistent with 
this, the Santander-based study (Chapter 7), which did not include an overall measure of 
insight, revealed treatment compliance to be associated with suicidal history and this 
relationship also survived the multivariable regression models. However, it is noteworthy that 
those FEP patients with suicidal antecedents were more likely to have poor insight into the 
need for treatment, which suggests that these patients have a tendency to try and deal with 
problems themselves. Also, the FEP studies presented in Chapters 4-7 reported other variables 
such as DUP, cognitive deficits and depression to contribute to insight at first presentation, 
thus mediating the relationships between suicidal history and insight levels at that point, 
which did not survive the multivariable models except treatment compliance in the Santander-
based study.  Table 8.1. below provides a summary of the studies’ findings regarding the 
influence of suicidal history on insight dimensions at first presentation (bivariate analyses).  
 
Table 8.1. Previous suicide attempts and insight dimensions in FEP 
 GAP AESOP GAP-AESOP SANTANDER 
Recognition + + + - 
Relabelling + - + n/a 
Compliance - - + + 
Social consequences n/a n/a n/a - 
Total insight + + + n/a 
GAP: Genetics and Psychosis Study (Chapter 4) 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses (Chapter 5) 
+: There was a significant association. -: There was no significant association. n/a: Not applicable  
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8.5. – The role of insight in suicidal behaviour in early psychosis 
With regard to the role of insight at baseline in predicting suicidal behaviour over the 
follow-up, contrary to my expectations, the study presented in chapter 4, which was based on 
data from the GAP study, found awareness of the need for treatment to be associated with an 
increased suicide risk over the 3-year follow-up study period, while total insight showed a 
borderline relationship. However, no insight score survived the multivariable Cox-regression 
models, which was relatively in line with my postulations, particularly regarding the role of 
mediating/confounding variables such as suicidal history and depression in the relationship 
between insight dimensions and suicide risk.  
In keeping with this, chapter 5 (AESOP data-based) reported no associations of insight 
scores with risk of suicidal behaviour over the 10-year follow-up, although illness recognition, 
treatment compliance and total insight showed some trends (p-value<0.1 but >0.05). Hence, 
these results may suggest that insight behaves as a risk factor for suicide, which may have not 
been detected by the analyses owing to insufficient power (75%). In order to increase this 
power, I decided to merge both GAP and AESOP FEP cohorts, as shown in chapter 6, reaching 
over 90% power to detect an effect size of 0.33 in differences across groups on the SAI-E, which 
is considered to be clinically meaningful (Kemp & David, 1997). Yet, no significant 
relationships between insight levels and risk of suicidal behaviour over the follow-up 
(median=7 years) emerged from the analyses, which was also in full agreement with the 
negative findings from the Santander cohort (chapter 7), with n=397 subjects followed-up over 
3 years and 97% power.  
Hence, the principal finding from this research work, which is consistent with my 
hypotheses listed in chapter 2 (section 2.5), is the lack of evidence to support a direct 
relationship between insight levels at first presentation with psychosis and risk of suicidal 
behaviour in the early stages of the illness, when precisely such risk is significantly higher (e.g. 
Palmer et al., 2005).  
However, three points deserve further discussion. First, suicidal history, which was 
replicated as the strongest predictor of future suicidal events, including suicides (Chapter 3), in 
the four FEP studies presented in this thesis (Chapter 4-7), affects insight levels at first 
presentation. Second, the bivariate analyses from the combined UK FEP cohort (GAP and 
AESOP, chapter 6), which was sufficiently powered (90%), revealed treatment compliance and 
total insight to behave as significant predictors of suicidal behaviour, although such an 
association did not remain significant when multivariable analyses were carried out. Third, 
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depression was linked with both suicidal history and insight levels in the three FEP cohorts. 
And depression was also related to risk of suicidal behaviour in the AESOP sample (Chapter 5) 
and in the Santander cohort (Chapter 7), which is in full agreement with previous FEP studies 
(see Pompili et al., 2011; Challis et al., 2013). Table 8.2. below shows the associations of insight 
dimensions with depression across the studies included in this thesis.  
 
Table 8.2. Depression and insight dimensions in FEP 








Recognition + + - - 
Relabelling + + - n/a 
Compliance - + - + 
Social consequences n/a n/a n/a + 
Total insight + + - n/a 
GAP: Genetics and Psychosis Study (Chapter 4) 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses (Chapter 5) 
+: There was a significant association. -: There was no significant association. n/a: Not applicable 
 
Several questions arise. First, does suicidal history influence insight or is it actually a 
consequence of gaining insight in early psychosis? Second, why do some, but not all, patients 
who gain insight become depressed, which can also lead to suicidality? In other words, what 
underlies the relationship between insight and depression in psychosis? Third, how do insight 
changes in the early stages of psychosis affect risk of suicidal behaviour?  
Indeed, insight has been consistently associated with depression (Mintz et al., 2003; 
Belvederi et al., 2015), which is known as the ‘Insight Paradox’ (Lysaker et al., 2007), i.e. better 
insight, worse depression despite the general positive associations of insight with outcome 
(McEvoy, 2004; Lincoln et al., 2007). However, no causality conclusions can be drawn from 
such a ‘cross-sectional’ association. Thus, although it is intuitive to think that becoming aware 
of having such a devastating mental illness should lead to a depressive state, including 
increased suicidality, which is known as the  ‘demoralization syndrome’ (Drake et al., 1985; 
Drake & Cotton, 1986; Amador et al., 1996; Restifo et al., 2009); the so-called ‘depressive 
realism model’ explains how depression, which is linked with disturbed cognitions (i.e. 
depressed patients tend to think more pessimistically, thus being able to more easily recall 
negative events such as an illness, i.e. better insight), can result in greater levels of insight 
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(Ghaemi & Rosenquist, 2004). Furthermore, longitudinal studies suggest that insight 
improving is associated with better mood (Pijnenborg et al., 2013).  
A different approach to better understand what underlies the relationship between 
insight and depression in psychosis is to examine its mediators and moderators. Previous 
research on this topic is limited, however. Lysaker et al. (2007) found internalized stigma to 
mediate such an association in a sample of schizophrenia patients, particularly in terms of 
functioning (Lysaker et al., 2007). More recently, Belvederi et al. (2016) tested the ‘insight 
paradox’ (Lysaker et al., 2007) in a sample of (n=89) outpatients with stable schizophrenia. 
Interestingly, amongst multiple insight domains, which were measured with the SUMD 
(Amador, 1993), only unawareness of symptoms was linked with depression, which was 
evaluated by the CDSS (Addington et al., 1992). Of note, low socioeconomic status, 
disengagement and illness severity were found to moderate the relationship between this 
insight domain (unawareness of symptoms) and depression, i.e. the lower the socioeconomic 
status and/or the lower the engagement and/or the more severe the illness, the stronger the 
association of insight with depression (Belvederi et al., 2016).  
Based on my findings concerning the association of suicidal history, depression, insight 
and further suicidal events and my clinical experience, the phenomenological model of acute 
psychosis proposed by Conrad (1958) may shed some light on this matter. Conrad described 
the stages of psychosis onset in relation to the degree of insight, i.e. psychotic symptoms 
become more severe as insight levels decrease, which usually results in first presentation to 
services, when the patient is diagnosed and receives treatment. This results in symptom 
remission, after which insight is developed. In other words, patients first present with 
symptoms, which result in a diagnosis (illness) and the subsequent treatment onset with some 
degree of compliance. Interestingly, my results mirror this medical model of insight dimensions 
gain (symptoms  illness  treatment) with regard to suicidality. Thus, while the subject 
presents with more and more severe psychotic symptoms (i.e. the prodromal stage), if this 
psychotic state also impacts on mood leading to depression, which was linked with the content 
of these psychotic experiences (Upthegrove et al., 2014), such a patient is at a higher risk of 
attempting suicide. Indeed, those who made suicide attempts, when asked about the reasons 
underlying such acts, tended to describe them as coping mechanisms (e.g. Acosta et al., 2006; 
Harvey et al., 2008; Andriopoulos et al., 2011). As a result, the suicidal patient receives medical 
attention earlier, thus shortening the DUP and presenting with greater levels of insight than 
non-suicidal subjects (Lopez-Morinigo et al., 2014a). In keeping with this, awareness of 
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symptoms was found to be the more strongly associated insight domain with depression 
(Belvederi et al., 2016) and suicidality (Amador et al., 1996; Lopez-Morinigo et al., 2014a). After 
psychosis remission and completion of the diagnostic process, during which the patient is 
exposed to some degree of ‘psychoeducation’ (i.e. ‘your diagnosis is that of first-episode 
psychosis’) with a focus on treatment compliance (‘you should continue taking this 
antipsychotic’), the depressive patient will develop insight into aspects linked with the ‘need’ 
for treatment, which also perpetuates such a depressive state (awareness of the ‘need’ for 
treatment is not the same as awareness of the ‘benefits’ from treatment) and the subsequent 
negative thinking style, thus leading to a self-perpetuating vicious circle. This is in full 
agreement with my findings from the three FEP studies presented in this thesis except the 
GAP cohort (chapter 4), which may be related to its limited statistical power (62%). Hence, 
these depressive-insightful patients, who are ‘at risk’ of suicidal behaviour at first contact with 
services, particularly those with previous suicide attempts, should be carefully provided with 
coping mechanisms in order to make different narrative judgments of the illness (Lysaker et 
al., 2007), i.e. to improve insight qualitatively rather than quantitatively.    
Insight has been reported to evolve over the course of the illness with a tendency to 
improve in the early stages (Wiffen et al., 2010; Campos et al., 2011; Cuesta et al., 2011), 
although these improvements appear to be less relevant in the longer-term (Ayesa-Arriola & 
Morinigo et al., 2014). Although my research did not evaluate insight over the follow-up (see 
section 8.8.b.6, below), previous literature (Bourgeois et al., 2004; Pijnenborg et al., 2013; Barrett 
et al., 2015) suggests that insight improvement is associated with less depression and 




8.6. – Predictors of suicidal behaviour in psychosis  
Chapter 3 presented the findings from a large dataset of patients with SSD under 
secondary mental healthcare in SLaM. Interestingly, young age at first contact, suicidal history 
and suicidal ideation emerged as the main predictors of suicide. 
Chapter 4, which was based on data from the GAP FEP study, reported four predictors 
of suicidal behaviour over the follow-up, namely treatment compliance, age at first contact, 
living alone and a previous suicidal history. However, only living alone and suicidal history 
remained significant in the multivariable Cox-regression model. Chapter 5, which described 
the findings from the AESOP study, revealed previous suicide attempts, alcohol use, executive 
dysfunction and depression to be associated with an increased risk of suicidal behaviour over 
the 10-year follow-up, although only suicidal history and depression survived the 
multivariable regression models. Unsurprisingly, chapter 6, which presented the analyses from 
the GAP-AESOP combined cohort of FEP patients revealed suicidal history and executive 
dysfunction to be linked with suicidal behaviour risk.  
Finally, regarding the Santander cohort detailed in chapter 7, the bivariate analyses 
reported younger age at first presentation, suicidal history, family history of psychosis, poor 
premorbid adjustment and depression to be related to risk of suicidal behaviours over the 
follow-up. Of note, poor premorbid adjustment, suicidal history, depression and age at first 
presentation survived the multivariable regression models. 
A summary of the above predictors of suicidal behaviour in early psychosis is shown in 
table 8.3., below. In brief, younger age at first presentation, suicidal history and depression 
were replicated to be the strongest predictors of suicidal behaviour in early psychosis, which is 
consistent with previous literature (e.g. Hawton et al., 2005; Challis et al., 2013).  
Of relevance, no insight dimension at baseline predicted risk of suicidal behaviour in 
the multivariable analyses based on data from these FEP samples, although the Santander 
study found insight into the social consequences of the illness and insight into the need for 
treatment to be associated with an increased risk of suicidal behaviour over the 3-year follow-
up period.     
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Table 8.3. Predictors of suicidal behaviour in psychosis 
 CRIS GAP AESOP GAP-AESOP SANTANDER 
 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 
Age (young) + - - - + 
Living alone - + - - - 
Marital status - - - + - 
Suicidal history + + + + + 
Suicidal ideation + n/a n/a n/a n/a 
Poor premorbid adjustment n/a n/a n/a n/a + 
Cognition - - - + - 
Depression - - + - + 
CRIS: Clinical Record Interactive Search (Chapter 3) 
GAP: Genetics and Psychosis Study (Chapter 4) 
AESOP: Aetiology and Ethnicity in Schizophrenia and Other Psychoses (Chapter 5) 




8.7. – Integration of findings 
In summary, Chapter 3 showed that older age at first contact with services and lack of 
suicidal ideation and suicidal history identified those patients with schizophrenia and related 
disorders who are less likely to take their lives, bearing in mind that the lifetime suicide risk in 
a high-risk group of patients with psychosis is still very low (2-5%) (Dutta et al., 2010; Palmer 
et al., 2005).  The fortunate rarity of the outcome is what limits the predictive potential of any 
modelling. 
However, in the light of the multivariable Cox regression analyses from the 
experimental chapters (4-7) concerning the role of insight dimensions in risk of suicidal 
behaviour in early psychosis, two major conclusions can be drawn. First, I found no evidence 
to suggest that there is a direct link between insight levels in FEP and risk of suicidal behaviour 
in the immediate years ahead. Second, suicidal history and depression were the strongest 
predictors of suicidal behaviour, which was in line with previous literature. Given that both 
suicidal history and depression correlated with insight levels at baseline, this may explain, in 
large part, the apparent relationship between insight dimensions and suicide risk. How may 
we integrate these findings? Figure 8.1. below illustrates the hypothesised model (see Chapter 
2, section 2.5) of the relationship between insight dimensions and risk of suicide behaviour in 
FEP which has been tested in this thesis. Figure 8.2 shows, however, the model based on the 
investigation results.    
The development of psychotic symptoms from the prodromal stage is associated with 
an impact on mood in some, but not all, patients, which has been related to the content of the 
psychotic phenomena (Upthegrove et al., 2016). These patients would therefore be at a higher 
risk of making suicidal acts, which was replicated to be the strongest predictor of future 
suicidal events. Suicidal antecedents help to gain awareness of illness and symptoms 
relabelling (‘that is why I attempted to take my life, I was hearing voices, I must be ill’), which 
is consistent with the results from the GAP-AESOP combined cohort. Thus, during the 
recovery phase this depressive state would lead these patients to thinking more 
pessimistically, consistent with the so-called depressive realism model (Ghaemi & Rosenquist, 
2004), thus becoming more aware of the negative aspects of the illness such as its social 
consequences and the ‘need’ for treatment, which also perpetuate the depressive cycle. In other 
words, as postulated, depression or at least low mood, and suicidal history explain, in large 
part, the apparent association of insight with suicide risk in psychosis. Of course, other factors 
play a part in such a complex phenomenon.  
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Figure 8.1. Hypothesised model to be tested in this thesis. 
Red arrows indicate increased risk and green arrows show reduced risk. 
 
Figure 8.2. Model based on the thesis findings  




8.8. – Strengths and limitations 
8.8.a. – Strengths  
Chapter 3 provided information on real-world data concerning suicide by patients with 
schizophrenia and related disorders receiving secondary mental health care in our catchment 
area. In particular, a large case register (currently accessing records on over 250,000 patients) 
linked to national mortality data was used. Also, the sample was very likely to be 
representative since only a tiny proportion of patients living in South-East London receive 
private mental health care and a wide range of demographic and clinical variables, including 
service use-related factors and specific scales such as HoNOS and ‘risk assessment’, were 
analysed. More specifically, the use of a large case register allowed the investigation of a rare 
phenomenon such as suicide completion in patients with schizophrenia spectrum disorders. In 
particular, up to 96 of such subjects were identified. 
With regard to my main research question, i.e. the role of multiple insight dimensions 
at first presentation of psychosis, I used up to three different FEP cohorts, including long 
follow-up periods (up to 10 years in the AESOP sample) in order to capture a sufficient 
number of suicidal events. It is noteworthy that these FEP samples formed part of large scale 
FEP studies, involving recruitment from many wards across a large catchment area, conducted 
by many research workers and encompassing an intensive study battery, which used validated 
scales to measure a wide range of baseline variables, including insight. Before discussing the 
disadvantages of this type of project in the next section, it is important to acknowledge that it 
would have been unfeasible to collect this amount of data within the context of a smaller 
study. The increased resources of the studies made it possible to reach the widest possible 
range of patients and complete a large number of assessments on each of them, thus increasing 
statistical power and external validity. 
Indeed, the statistical power of the above samples ranged from 62.5% to 96.7%, thus 
suggesting that the lack of associations between insight levels and risk of suicidal behaviours 
was not due to insufficient power (Type II error), or at least this was unlikely. Furthermore, the 
recruitment of FEP samples from two different countries such as Spain and the UK permitted 
me to address potential cultural issues associated with suicide risk in psychosis, thus 
increasing further the generalisability of the findings from this research. In particular, the 
consistency between the findings regarding my research question suggests that the 
confounding role of depression and previous suicide attempts in the apparent relationship 
between insight and suicide risk in psychosis cannot be attributed to cultural factors.  
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8.8.b. – Limitations 
This investigation, though both consistent with much previous work and delivering 
several novel findings, has some limitations. Some of these have been addressed throughout 
the thesis. However, some more general limitations shall be discussed here. 
 
8.8.b.1. – Bias and confounding 
All the individuals who took part in the above studies, including cases and controls, 
received mental health care from publicly-funded secondary services, which introduces a 
potential selection bias since those patients with psychosis who received care from the general 
practitioner or in the private sector were not recruited. However, the number of these cases is 
likely to be small both in Spain and in the UK. Of note, the potential hospital bias was avoided 
by including both out- and inpatients in the above studies, although most of the participants 
were inpatients, which applies to the vast majority of research in FEP.   
Another potential systematic error concerns those suicidal behaviours, including 
deaths from suicide, outside the UK (or Spain in the case of the Santander patients) or simply 
unreported (e.g. homeless people), which therefore were not captured. Given the attrition rates 
at the end of the studies (around 15-20%), which were consistent with previous prospective 
FEP studies (e.g. Robinson et al., 2010), this limitation should not have affected the findings 
significantly.  
 
8.8.b.2. – Generalisability  
 This research work included three cohorts of FEP patients from two different countries 
(Spain and the UK) which were followed-up over prolonged periods of time (from 3 to 10 
years). While this methodology made the overall findings more generalizable, some caution 
should be taken when comparing results between the included studies; for instance, the level 
of urbanicity differed significantly between the Santander cohort and the UK samples. In 
addition, procedures for case ascertainment vary between these two countries, which may also 
reflect preferences in suicide recording. Of course, the findings from this investigation cannot 
generalise to all countries and settings across the world.   
In addition, it remains a matter of debate whether suicide attempters and completers 
represent similar or different populations. In particular, based on some differences between 
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these two groups, particularly in terms of personality-related variables (Giner et al., 2013), 
some authors have suggested that, statistically speaking, suicide completers may represent the 
‘outliers’ of suicidal groups (mainly formed of suicide attempters), which may also partially 
explain the limited ability to predict suicide completion both in research and in the clinical 
setting (de Leon et al., 2015). However, no such differences were replicated in psychotic 
patients (Innamorati et al., 2008; Giner et al., 2013), which provides further support to the 
methodology used in this thesis.  
 
8.8.b.3. – Sample size and power 
The power calculations detailed in chapters 4, 5, 6 and 7 showed that while the GAP 
(62%) and AESOP (75%) cohorts were underpowered to detect clinically meaningful 
differences in insight variables (with an effect size of 0.33) across groups (suicide attempters 
vs. non-attempters), provided such differences exist, the combined FEP cohort resulting from 
merging GAP and AESOP samples and the Santander cohort were both sufficiently powered 
(over 90 and 98%, respectively), thus making a Type 2 error unlikely. In this investigation, a 
Type 2 Error would be of particular concern since I aimed to demonstrate the ‘null’ hypothesis, 
i.e. the lack of direct associations of insight levels with suicide risk.    
 
8.8.b.4. – Missing data 
The length of the battery administered to patients (often well over 10 hours) meant that 
many were unable to complete all tasks. One problem this caused was patchy data, where 
completion rates were different between measures. Consequently, whilst a high number of 
recruited patients completed at least one insight measure (main inclusion criterion), a smaller 
number completed all the assessments. This meant that statistical power was considerably 
reduced because in the final models only those patients with all the variables tested were 
included. As a result, bias may have been introduced if the tendency to have a particular 
missing variable was related to insight and the link between insight and suicide risk. 
Intuitively, one may expect that those with a lower number of missing variables were more 
‘compliant’ with the study procedure, which clearly links with insight.  
This also raises a general limitation to all studies on insight, which is the ethical 
requirement of providing informed consent. In particular, it should be noted that generally 
speaking all study participants consented to take part. Hence, those who declined probably 
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had poorer insight levels and findings cannot apply to these subjects. For instance, 
approximately 44% of patients approached to participate in the GAP project declined our 
invitation, and it is possible that they were systematically different from those who did take 
part. However, schizophrenia patients’ willingness to participate in research was not found to 
be influenced by insight according to one survey (Kim et al., 2009). 
 
8.8.b.5. – Insight assessment 
Although insight assessments were conducted as early as practicable during the 
admission (most of the participants were inpatients), in some cases there were some delays 
between completion of insight assessment and other measures, hence adding statistical noise 
to the data. Symptom measures in particular may be affected by this, as they may change 
significantly over the course of assessments. However, symptoms severity (PANSS, SCAN, 
SAPS, SANS) and insight tended to be evaluated at the same time in most cases. Also, insight 
may well change over time, although there is evidence to suggest that longer-term insight 
tends to be relatively stable (Ayesa-Arriola & Lopez-Morinigo et al., 2014). For example, a 
patient who had very little insight when completing the SAI-E, may have had better insight  
Furthermore, there were multiple investigators administering and scoring assessments. 
Whilst every care was taken to ensure that researchers were thoroughly trained in each 
assessment, with ‘top-ups’ of training regularly provided, and relevant experts always 
available to advise as appropriate, it is possible that differences between investigators existed, 
particularly for less structured assessments such as the SAI-E and the PANSS. Although this is 
unlikely to have had any systematic effect, it may have weakened the size of any genuine 
effects that existed in the data. Also, researchers were not blind to other measures. For 
example, a researcher rating the PANSS very high (i.e. the patient is severely psychotic) may 
have a tendency to underscore insight. 
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8.8.b.6. – Changes of insight and other variables 
Baseline predictors, including insight variables, may have changed over the follow-up 
period. Hence, their associations with suicide risk should be taken cautiously, particularly 
regarding late suicidal events, which in some cases occurred up to 10 years after the study 
inception. However, it should be noted that my research interest here, which was driven by 
my clinical experience, was investigating whether insight levels at the time of first presentation 
to services with psychosis (i.e. when FEP patients are more comprehensively evaluated in the 
clinical setting) predicted suicide risk given the clinical implications on insight development / 
management if such an association was demonstrated, which is discussed further in section 
8.9., below. Also, by conducting survival analyses instead of logistic regression, not only was 
the likelihood of the event taken into account, but also the time to event (and time to non-event 
or end of the study as appropriate), thus lessening the above potential limitation.   
 
8.8.b.7. – Non-evaluated variables 
Other non-tested factors might contribute to both insight and suicide risk in psychosis, 
such as premorbid personality (Lysaker et al., 1999; Ritsner et al., 2007; Campos et al., 2011), 
neurobiological variables (David et al., 2012; Mann et al., 2003) and medication effects 
(Pijnenborg et al., 2015; Meltzer et al., 2003; Bourgeois et al., 2004), which are discussed further 




8.9. – Clinical implications of this investigation 
This research work would be completely theoretical if the findings could not contribute 
to improving patient’s outcomes, which in this case would equate to preventing suicide in 
patients with psychotic disorders, or at least reducing this risk. Although thankfully suicide is 
an uncommon outcome in psychosis, with a lifetime risk currently estimated at approximately 
2-5% (Dutta et al., 2010; Palmer et al., 2005), even in high-risk patients such as those receiving 
secondary mental healthcare, it is worth considering that these fatal events tend to occur early 
in the course of the illness, thus representing a high number of life years lost. In other words, 
preventing just one patient with psychosis from suicide may result in him/her living for up to 
30 more years (Lopez-Morinigo et al., 2016). 
 
8.9.a. – Suicide prevention in psychosis 
First of all, it is worth making a point on what we mean by suicide risk. In the very first 
paragraph of this thesis (Chapter 1), I stated that ‘suicides are preventable’ (WHO, 2016), 
which is indeed an assumption prerequisite for this type of research. 
In short, suicide prevention means reducing risk. According to the English Oxford 
Dictionary, risk can be defined in terms of ‘possibility’ or ‘probability’, but also regarding 
the consequences of the occurrence. In other words, risk should be conceptualised as the 
inverse relationship between ‘likelihood of the event’ and ‘severity of the consequences of 
the event’. For instance, the ‘suicidal spectrum’ encompasses from suicidal ideation (high 
risk in terms of likelihood, low risk given its consequences) to suicide completion (low 
risk in terms of likelihood, high risk given the irreversible consequences) (Bebbington et 
al., 2010).  
According to the WHO, there are a number of measures that can be taken at 
population, sub-population and individual levels to prevent suicide and suicide attempts 
(WHO, 2016): 
  Reducing access to the means of suicide (population-level). 
  Reporting by media in a responsible way (population-level). 




  Early identification, treatment and care of people with mental health and 
substance use disorders, chronic pain and acute emotional distress 
(subpopulation-level). 
  Training of non-specialized health workers in the assessment and management 
of suicidal behaviour (subpopulation-level). 
  Follow-up care for people who attempted suicide and provision of community 
support (individual-level). 
Although this investigation focused on a high-risk group (patients with a FEP), the 
overall low positive predictive value of a combination of suicide risk factors reported in 
chapter 3 (Lopez-Morinigo et al., 2016) suggests that population-level strategies may be 
more useful. In particular, I replicated that hanging and jumping (from a height or in 
front of a vehicle) were the most common suicide methods in this SSD sample. In keeping 
with a recent Lancet review of suicide prevention measures (Zalsman et al., 2016), I 
suggest that installation of physical barriers on bridges, tall buildings and railway 
stations, particularly those near psychiatric hospitals, may prevent patients with SSD 
from suicide as well as the general population (Lopez-Morinigo et al., 2014b; Lopez-
Morinigo et al., 2016). 
A more challenging issue is suicide prevention at an individual level in the clinical 
setting (Lopez-Morinigo et al., 2016). In this regard, the main implication of this 
investigation is that insight, which is strongly linked with better outcomes in psychosis 
(McEvoy et al., 2004; Lincoln et al., 2007), does not increase suicide risk despite common 
assertions to the contrary. Hence, these results, although pending independent 
replication, should help clinicians to focus on insight improvement strategies, which 
indeed warrants further research (see section 8.10.a. below).     
In addition, the role of previous suicide attempts and depression in the risk of 
further suicidal events in early psychosis was replicated, particularly amongst those 
younger patients at first contact with services.  
In particular, the presence of suicidal antecedents appears to be a useful marker to 
identify those ‘at-high-risk’ patients, who should therefore be more closely monitored 
after first presentation with psychosis (i.e. individual-level prevention). Furthermore, as 
alluded to above, I speculate that such suicidal history informs us about the patient’s 
personality and coping mechanisms. Specifically, I demonstrated that these suicidal 
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patients tended to be less aware of the need for treatment (see chapter 7, Santander-
based). In other words, these individuals seem to deal with problems themselves, which 
links to the general tendency of psychotic patients not to report suicidal ideation (Bakst et 
al., 2009). Hence, suicide prevention at an individual level seems to be about predicting 
how our patients will react to specific potential (i.e. unpredictable) stressors, such as a 
relationship breakup, which is related to measurable factors such as current mental state 
or premorbid personality (i.e. coping mechanisms style), about which suicidal history tells 
us much. More specifically, being depressed (current mental state) or having a tendency 
to becoming depressed (i.e. personality) appears to play a major role in suicide risk in 
psychosis. Accordingly, a more detailed discussion about suicide in psychosis is provided 
below.   
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8.9.b. – Depression and insight in psychosis   
The role of depression in suicidality in psychosis was replicated in this investigation, 
which is in full agreement with previous literature (Altamura et al., 2003; Hawton et al., 2005; 
Bertelsen et al., 2007; Flanagan and Compton, 2012; Harvey et al., 2008; Kontaxakis et al., 2004; 
Barrett et al., 2010a; Barrett et al., 2010b; Pompili et al., 2011; Challis et al., 2013). 
Specifically, in my literature review summarised in chapter 2 and published (Lopez-
Morinigo et al., 2012), I found hopelessness to be associated with suicidality, particularly in 
FEP samples. On the other hand, Chapter 3 (based on data from CRIS) showed that 
hopelessness was relatively uncommon amongst those patients with SSD who ended their 
lives, which led me to speculate that the impact of hopelessness, and probably depression in a 
broader sense, on suicide risk, appears to be stage-related, i.e. more relevant in early phases of 
psychosis, consistent with previous literature (Pompili et al., 2011; Ayesa-Arriola et al., 2015).   
However, it remains unclear whether ‘depression’ in early psychosis represents a 
symptomatic domain in its own right (Peralta et al., 2013) or a psychological reaction to the 
social consequences of the psychotic illness onset (Drake & Cotton, 1986). Thus, a recent 12-
month follow-up first-episode psychosis study found that while malevolent voices, use of 
safety behaviours and subordination to persecutors were associated with depression in the 
acute FEP, post-psychotic depression was linked to loss, shame, low level continuing positive 
symptoms and longer duration of untreated psychosis (Upthegrove et al.,2014).  
In line with the results from this Santander cohort, a previous first episode study from 
our group found an association between suicidal behaviour preceding first contact with 
services and depression at that point (Lopez-Morinigo et al., 2014a; Chapter 4). Also, 
depression in the prodromal stage was reported to predict both suicidality at first presentation 
and further depressive episodes both in the acute and recovery stages of FEP (Upthegrove et 
al., 2010). This association seems to challenge, to some extent, the so-called demoralization 
syndrome (Drake and Cotton, 1986) since depression in early psychosis appears to behave as a 
trait-like phenomenon (Upthegrove et al., 2010) rather than a psychological reaction to the 
social consequences of such a devastating illness. Overall, depression seems to play a crucial 
role in suicide risk in schizophrenia (Hawton et al., 2005) and FEP (Pompili et al., 2011). 
However, there are few guidelines on the management of depression in schizophrenia and 
related disorders (Siris, 2000; Siris, 2001; NICE, 2015). 
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With regard to the theoretical conceptualisation of depression in schizophrenia, 
Birchwood postulated up to three distinct pathways: depression which is intrinsic to 
psychosis, depression which is a psychological reaction to the diagnosis and depression as 
“smoking gun evidence” of childhood trauma (Birchwood et al., 2005). Specifically, the second 
pathway received stronger support from research, which can be summarised as, ‘it is the way a 
person appraises the meaning and significance of their psychotic experience, including their subordinate 
relationship to voices, or persecutors and the impact of the diagnosis on social status that underlies the 
development of depression’ (Upthegrove et al., 2016).   
One clinically relevant aspect to mention concerns the difficulties that clinicians so 
frequently find in distinguishing negative and depressive symptoms (Siris, 2001; Upthegrove 
et al., 2016). 
In 2003, a classic meta-analysis of 40 studies examining associations of insight with 
psychopathology found depression to have a positive correlation with insight, although the 
effect size was rather small (r=0.18) (Mintz et al., 2003). Interestingly, a more recent meta-
analysis (Belvederi et al., 2015) looking at the association of depression with insight from a 
multidimensional approach failed to link compliance with depression, which led me to 
formulating the hypothesis (H5) (Chapter 2, section 2.5) that compliance would reduce suicide 
risk.  
However, prospective studies do tend to show that depression improves as insight 
levels increase (Bourgeois et al., 2004; Pijnenborg et al., 2013; Barrett et al., 2015), which 
suggests that this complex association appears to be dynamic in nature, which is intuitive. 
More specifically, time is needed for the patient to make different judgments of the nature of 
their mental illness, from being made aware of the ‘need’ for medication to acknowledging the 
‘benefits’ from a treatment plan (in the broadest sense), in which patients with psychosis 




8.9.c. – Implications on services provision 
Organisational factors and service provision changes were demonstrated to affect 
suicide rates at a national level in the UK (Kapur et al., 2016). For instance, it is noteworthy the 
reduction in inpatient suicides, which was mainly due to the focus on ligature risk 
assessment/management, may have occurred at the price of an increase in post-discharge 
suicides (Kapur et al., 2013). Nevertheless, there has been an increase in the number of suicides 
by patients with schizophrenia in the UK since 2008 (NCISH, 2015).  
With regard to psychosis, based on preliminary research showing the detrimental 
effects of delaying treatment (Johnstone et al., 1986) on outcome, over the last two decades 
there has been a growing interest in the implementation of early intervention services (EIS) for 
patients with psychosis (McGorry et al., 1996).  
In the UK the first EIS started in Birmingham in 1990. Since 2001 the development of 
EIS has become a priority across the UK as a result of several reasons, including the rise of 
community care, the move towards control as well as care in the community, user and carer 
concerns, the increasing evidence of unacceptably long durations of untreated psychosis (DUP) 
and the benefits from early diagnosis and treatment (DoH, 2001). Specifically, the Policy 
Implementation Guidance on Early Intervention (DoH, 2001) suggested that EIS should be able 
to:  
• Reduce the stigma associated with psychosis and improve professional and lay 
awareness of the symptoms of psychosis and the need for early assessment  
• Reduce the length of time young people remain undiagnosed and untreated.  
• Develop meaningful engagement, provide evidence-based interventions and aid 
recovery during the early phase of illness.  
• Facilitate development and provide opportunities for personal fulfilment including 
social life and employment and training opportunities.  
• Provide a user-centred service that is a seamless service available for those from 14– 
35 years of age. 
• At the end of the treatment period (up to 3 years), ensure that the care is transferred 
thoughtfully and effectively.  
Overall, mixed results have been reported regarding the effect of EIS on suicide rates. 
In particular, it seems that the initial protective effect disappears once the early intervention 
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period ends, which has been particularly examined in Scandinavian countries such as 
Denmark (Nordentoft et al., 2002; Bertelsen et al., 2008) and Norway (Melle et al., 2006; Melle 
et al., 2010), and in Canada (Goldberg et al., 2006) and Australia (Harris et al., 2008).  However, 
extending the treatment period has been shown to reduce suicide rates in Hong Kong when 
compared with standard care (Chan et al., 2014). Not only UK-based studies are needed in this 
area but also, a meta-analysis in order to get a better understanding of the real effect of EIS on 
suicide rates. While the above negative results may have been due to insufficient statistical 
power given the very low number of suicides identified in the studies, suicide attempts are a 
more frequent measurable outcome for more powered studies.   
Of relevance, the case-fatality estimated in the FEP studies presented in this thesis 
ranged from 1.5% (Santander cohort) to 2.7% (GAP and AESOP studies), which were 
considerably lower than that reported by Palmer and colleagues in their 2005 seminal meta-
analysis, which was 4.9% (Palmer et al., 2005). While participants in these FEP studies, all of 
whom were receiving care from EIS, were followed-up for up to 10 years and some suicides 
may occur at later stages (Dutta et al., 2010), based on these findings there are grounds to 
consider that EIS may reduce suicide rates in psychosis patients, although more prolonged 
follow-up periods are needed.   
However, a number of suicide attempts in the FEP samples presented in this thesis 
occurred before the onset of psychosis as rated by the so-called DUP (for instance, up to 43% in 
the GAP study), thus supporting the role of ‘at-ultra-high-risk’ services in suicide prevention. 
In this regard, it should be noted that in such a prodromal state depression behaves as the only 
significant predictor of suicidal behaviour (Nielssen & Large, 2009; Andriopoulos et al., 2011), 
which is consistent with a previous FEP study which demonstrated that indeed depression 
appears to precede the onset of psychosis (Upthegrove et al., 2010). Nevertheless, the benefits 
from EIS are yet to be established (Castle & Singh, 2015), particularly taking into account the 




8.10. – Directions for future research 
Throughout this research work, I have become aware of a range of putative factors 
associated with suicidal behaviour in psychosis which were not evaluated in this study, such 
as insight changes, suicidal behaviour in prodromal stages of psychosis and premorbid 
variables, stigma, neurobiological variables, metacognition and the use of new technologies. 
 
8.10.a. – Insight changes  
Insight has been reported to be a dynamic phenomenon, which improves over the early 
stages of the psychotic illness (Wiffen et al., 2010; Campos et al., 2011; Cuesta et al., 2011; 
Parellada et al., 2011), although longer-term studies appear to suggest a ceiling effect, i.e. poor 
insight in psychosis patients appears to be a ‘trait’ rather than a state associated with acute 
psychosis (Ayesa-Arriola & Lopez-Morinigo et al., 2014). Nevertheless, longitudinal studies 
found no evidence to link insight improvement with increased suicidality (Bourgeois et al., 
2004; Pijnenborg et al., 2013), which is in full agreement with the findings from this 
investigation.  
Regretfully, I could not re-evaluate insight in participants over the follow-up periods, 
which would require face-to-face interviews given the limitations associated with self-rated 
scales such as the Birchwood Insight Scale (Birchwood et al., 1994), namely a tendency to recall 
bias.  
Certainly, intervention studies are needed to clarify the real associations of insight 
levels with risk of suicide; for instance, if an insight improving intervention was shown to 
reduce suicidality. In particular, antipsychotic treatment has been demonstrated to increase 
insight levels (Pijnenborg et al., 2015) and reduce suicide rates at a population-level 
(Torniainen et al., 2015), while as far as I know, no ‘cognitive-behaviour therapy for psychosis’ 




8.10.b. – Suicidal behaviour in prodromal stages  
I found a high number of suicidal events prior to first presentation to services. 
However, little research has been conducted in this stage of the illness with suicidal behaviour 
as an outcome (see Andriopoulos, 2011). Hence, there are grounds to consider that a number of 
people with undiagnosed psychosis die from suicide before first contact with services. 
Psychological autopsy studies of deceased adolescents with a focus on psychosis screening are 
warranted for this.  
 
8.10.c. – Stigma 
Stigma, which prevents patients from receiving proper care (Alonso et al., 2007), may 
contribute to suicide risk in patients with SSD who disengage from secondary mental health 
services (Thornicroft & Mansella, 2013). Nevertheless, more research is needed to test whether 
anti-stigma campaigns, such as the England-based ‘Time to Change’ (Henderson & 
Thornicroft, 2009) or the worldwide ‘Depression: Let’s talk’ (WHO, 2016), can reduce suicide 
rates both at a population level and in high-risk groups such as mental health service users 
with SSD (Rüsch et al., 2014). 
 
8.10.d. – Neurobiological variables and medication 
After the seminal contribution by Mann et al. (1999), who proposed a diathesis-stress 
model of suicide detailed in chapter 1 (section 1.2.b), a number of studies have investigated the 
role of different neurobiological mechanisms with a focus on serotoninergic systems (Mann et 
al., 2003; Oquendo et al., 2014). However, overall results have been inconclusive, which led to a 
2015 editorial warning against the limitations of Mann’s original model and highlighting the 
role of non-medical psychosocial factors in suicide, which cannot be predicted (de Leon et al., 
2015).   
To the best of my knowledge, no study has specifically investigated the neurobiology 
of suicidal behaviour in psychosis to date. In this regard, it may be worth looking at the 
neurobiological mechanism of action underlying the well-demonstrated anti-suicidal effects of 
clozapine on patients with schizophrenia (Meltzer et al., 2003; Bourgeois et al., 2004), including 
a Cochrane meta-analysis (Asenjo et al., 2010). Interestingly, clozapine was also reported to 
improve insight when compared with classic antipsychotics in a non-randomized trial of 
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(n=22) schizophrenia patients (Pallanti et al., 1999). Moreover, data from the InterSePT study 
showed that over the 2-year follow-up, insight improved while risk of suicide decreased 
(Bourgeois et al., 2004). Generally speaking, antipsychotic exposure has been associated with 
reduced suicide rates in a nation-wide study from Sweden (Torniainen et al., 2015), which 
provides additional support for the role of engagement in reducing suicide risk. However, 
more modest results were reported on the benefits of medication on insight (Pijnenborg et al., 
2015). Furthermore, as alluded to above (section 8.10.a), the main research question 
investigated in this work might be properly answered if a specific antipsychotic (but also any 
non-pharmacological intervention) was demonstrated to improve insight and reduce 
suicidality. To the best of my knowledge, this study is yet to be carried out.    
 
8.10.e. – Premorbid variables 
Some aspects of premorbid personality have been linked with insight levels in 
schizophrenia (Lysaker et al., 1999; Ritsner et al. 2007) and FEP (Campos et al., 2011). More 
specifically, sociopathic and schizoid personalities were associated with lack of insight at 6 
months after FEP (Campos et al., 2011). Also, passive-dependant personality traits predicted 
suicide attempts at 6-month follow-up in a FEP sample (Canal-Rivero et al., 2016). Hence, 
further studies looking at the mediating effects of premorbid personality on the relationship 
between insight and suicide risk in early psychosis are needed.  
Moreover, premorbid variables should be carefully assessed as they appear to mediate 
the association of insight with suicide risk; for instance, the higher the premorbid functioning, 
the more demoralizing insight will be and therefore, more strongly linked with suicidality 




8.10.f. – Metacognition 
In Chapter 1 (section 1.3.f.) I commented on the different theories proposed to explain 
what underlies poor insight in psychosis. Despite much attention being paid to neurocognitive 
deficits on the basis of its similarities with anosognosia observed in neurological disorders 
(Babinski, 1914), a meta-analysis of 35 studies in 2006 reported overall modest results (Aleman 
et al., 2006). This meta-analysis’ authors suggested in the very last paragraph of the article 
(Aleman et al., 2006) that other variables may contribute to insight, such as metacognition, 
which has attracted much research attention since, particularly so-called cognitive insight 
(Beck et al., 2004), which is linked with outcome in FEP (e.g. O’Connor et al., 2013).  
This focus on metacognition also resulted in promising results from non-randomized 
metacognitive therapy clinical trials, which showed an improvement in both insight and 
depression (e.g. Favrod et al., 2011). Further intervention studies testing metacognitive 
therapies should also include suicidal behaviour as an outcome measure. Indeed, cognitive 
insight appears to mediate the relationship between clinical insight and depression (Palmer et 
al., 2015), which based on my findings explains the apparent association of insight with suicide 




8.10.g. – New technologies  
According to the International Communication Union (ICU), in 2016 there are over 7 
billion mobile phone subscriptions worldwide and approximately half of these are mobile-
broadband subscriptions, i.e. smartphones with Internet access (ICU, 2016). 
The use of communication technologies in health care and public health is known as 
Mobile health (mHealth) (Free et al., 2010), which has been the subject of extensive research on 
a wide range of topics, including suicide (Vahabzadeh et al., 2016). However, the legal 
regulations are far from clear (Armontrout et al., 2016) and evidence on suicide prevention is 
still limited (Zalsman et al., 2016). Moreover, concerns have been voiced regarding the 
potential effect of the Internet on increased suicide risk (Aboujaoude, 2016), although this has 
not been confirmed yet.  
From a research point of view, web-based datasets integrating data from different sites 
and countries appear to be promising tools to investigate suicide, particularly given its rare 
occurrence, and its risk and protective factors (Lopez-Castroman et al., 2015b). In addition, 
mobile phone and web-based text messaging may represent a useful tool to monitor suicide 
risk (Berrouiguet et al., 2016), particularly to follow-up suicide attempters (Berrouiguet et al., 
2014). For instance, the classic suicide note may have been substituted by a message left on this 
new media, which clinicians should discuss with patients and carers when assessing self-harm 
in the emergency department (Barrett et al., 2016).   
However, I have my reservations about the use of new technologies in patients with 
psychosis due to the potential increased paranoid thoughts associated with such a close 
monitoring, which may also raise ethical issues.  
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8.11. – Concluding remarks 
Suicide is an uncommon outcome even in a high-risk group such as patients with 
psychosis receiving secondary mental healthcare (Lopez-Morinigo et al., 2016). As a result, a 
successful approach for suicide prevention in early psychosis is likely to require a combination 
of population-level measures such as means restriction with interventions on such a high-risk 
group (Dutta et al., 2010; Lopez-Morinigo et al., 2014b; Lopez-Morinigo et al., 2016), including 
improving insight measures based on this research.  
For instance, EIS appear to play a crucial role in reducing suicide rates in such a high-
risk period (Fedyszyn et al., 2014; Chan et al., 2015). However, the onset of psychosis may be 
‘too late’ to prevent some suicidal events. Alternatively, universal school-based interventions 
appear to be a promising strategy to tackle suicide both in young adolescents at high-risk of 
psychosis and in the general population (e.g. Kelleher et al., 2012). These findings appear to 
provide further support for my assertion, which is now evidence-based (Lopez-Morinigo et al., 
2016), that suicide, although unpredictable at an individual-level, particularly in those suffering 
from psychosis, seems to be preventable at a population-level.  
In particular, this research does not support the commonly held view among clinicians 
that insight, which is linked with positive outcomes in psychosis, increases suicide risk. 
Moreover, based on my findings it seems that suicidal history and depression explain the 
apparent association of insight with suicide risk, which may prevent patients with psychosis 
from insight improving interventions and the subsequent positive outcomes associated with 
insight such as reduced rehospitalisations and better psychosocial functioning. Also, insight 
improving interventions appear to reduce suicidality (Pijnenborg et al., 2013), which requires 
further research. Hence, I hope that all this work can have a positive impact on patients’ 
outcomes, particularly in terms of suicide prevention.  
Insight in psychosis is strongly linked with better outcomes (Amador & David, 2004; 
Lincoln et al., 2007) and this need not occur at the price of increased suicidality as previously 
thought, which is the main contribution of this work. In short, it seems that ‘painful truth is 
better than a pleasant lie’ (McGill, 2015). And as it is commonly said in the UK: ‘the sooner (the 
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Appendix 3 – GAP informed consent 
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Email: r .murray@iop.kcl.ac.uk 
 





University of London 
www.kcl.ac.uk 
at The Maudsley 
Division of Psychological Medicine,  




INFORMATION AND CONSENT FORM  
You have been asked to take part in a study being conducted in the South 
London and Maudsley NHS Trust.  Before you decide whether to enter the study, it is 
important that you understand why the research is being done and what it will 
involve. 
 
Please take time to read the following information and ask any questions 
if something it is not clear or you wish to know more. 
 
Title :   Genetics and Psychiatric illness (GAP)  
 
 What are the aims of the study? 
 
In our research project we are interested in identifying what the main risk 
factors that predispose to psychotis are. In particular, we want to know whether there 
are any genes that increase the risk of developing a psychotic disorder, either alone 
or by interacting with environmental factors such as stress, cannabis, and infections. 
Part of the reason why some people become ill may lay in genetic differences 
between people, in the same way that we are different in the colour of our eyes, hair 
etc. To achieve this, we will compare the genetic make-up of people with a diagnosis 
of psychosis with the make-up of people with similar characteristics but no history of 
mental health problems.            
 
We also aim to establish whether some genes might influence the course of 
the illness and response to medication. Some patients experience an improvement of 
their psychiatric symptoms when they are treated with medications, whereas others 
do not do so well and/or experience severe side-effects. Therefore we aim to look at 
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how genes can influence individual differences in response to drug treatment so that 
we may be able to choose better drugs for each person. 
In conclusion, the type of genetic analysis that we carry out is only for 
research purposes and does not at present produce clinically relevant results. 
                                                                                                                                                                                                                                                                                
      Why are we asking for your help? 
 You have been invited to take part in this study because of the nature of the 
symptoms that you appear to have been experiencing. During the course of the 
study approximately 1000 people who have had symptoms like yours will be 
asked to take part. 
  
  What will we ask of you if you take part in the study?  
 For this project we will ask from you a small sample of blood, about 20 mls (a few 
tablespoons full) or cheek swab and saliva samples for metabolic and genetic 
analysis.  We may also use your blood and saliva sample to : 
  
1) Measure the level of hormones and proteins contained in the blood 
serum and in the saliva. 
2) Look at the expression of some genes of interest in the white cells 
contained in the blood. 
  
A medically trained researcher will take the blood sample using disposable 
sterile equipment. It will only take few minutes as for any routine blood sample. If you 
are unable or unwilling to give a blood sample it is also possible to perform genetic 
analysis from cheek swab samples, a simple procedure that (we can show you the kit 
and illustrate the procedure) collects dead cells present in your saliva and in your 
mouth. From the cheek swab sample we cannot measure level of medication or look 
at expression of genes, we can only extract a small amount of DNA. Therefore we 
prefer to ask for a blood sample to guarantee a better quality of our results and make 
the most out of your generous help. 
 
A researcher will demonstrate how to collect the saliva sample and will provide 
you with the tubes required. The level of some proteins contained in the saliva can 
give us an indication of differences in the level of stress experienced by healthy 
volunteers and people suffering from mental illnesses.         
 
 We will also ask for some of your time to collect clinical and socio-demographic 
information using standardised research instruments: diagnostic interview, 
symptoms rating scale, socio-demographic interview and neuropsychological 
tests. 
 
 If you have already taken part in other research projects at the Institute of 
Psychiatry, London that involved some of the assessment we are interested in, 
we will not ask you to undergo them again but we request your permission to use 
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the existing data.  
  
 Some people within the study will be invited to undergo an MRI scan of the head 
and of another region of the body (the adrenal gland, a small gland above the 
kidney). They will be presented with separate information and consent forms for 
this procedure. 
 
 The sample collection and the clinical assessment will require approximately 3 
hours of your time. 
 
 Moreover we would like to contact you again for follow up (up to 24 months) to 
repeat the above assessments to investigate changes over time. 
 
 We will also reimburse any travel expense related to your participation into the 
study. 
 
What are the risks? 
 The risks involved are those of ordinary blood tests such as small pain and 
occasionally a small bruise around the area from where the sample has 
been taken. There is no risk involved in the collection of saliva. 
        
 Is Confidentiality guaranteed? 
 All personal information about you is regarded as strictly confidential; only 
researchers belonging to the study team, and not external collaborators, 
know which sample belongs to whom. All the information about you will be 
coded; you will not be identifiable in any research outcome. 
   
1) The blood samples first and the DNA samples after extraction will be 
stored in the Institute of Psychiatry secured laboratory for 5 years. 
2) The samples will be coded using bar codes (numbers and letters not 
referring to your name or date of birth) that will be entered on a secure 
computerized data base. 
3) The clinical information collected on the sample will be securely held in 
the Institute of Psychiatry building.  
 
The access to the samples and the related information will be restricted to the 
researchers involved in the study. In case of commercial collaborations only the 
coded data will be shared, therefore no researcher external to the study team will 
ever have access to personal data concerning participants.  
 
Any future work will pursue aims related to the topic of this project and any 




You are free to withdraw from this study at any point without giving a reason by 
contacting the researcher whose details are at bottom of the consent form. 
Withdrawal will not affect any of the care and treatment you receive. 
 
 What are the benefits for you of taking part? 
This is a research project, looking at comparing a group of healthy volunteers with 
people experiencing their first psychotic episode. As mentioned before, this study will 
not produce individual test results for any of the data collected. Therefore we cannot 
offer direct benefits for you. We will be able to provide to all the participants with a 
general summary of our research, when the project is complete, through a project 
newsletter. Our research study is also described on the Institute of Psychiatry 
general website (www.iop.kcl.ac.uk), under the division of Psychological Medicine, 
Department of General Psychiatry. 
 
Who is funding this project? 
 
 This study is funded by the Maudsley Charitable Fund and the Department of 
Health. 
 
Thank you very much for your time and once again please ask for more 
information on both the project and or your illness/symptoms if it is still 
unclear.  
 
Contact name and telephone number: Dr Marta Di Forti. Tel 0207 848 5352 
e.mail :m.diforti@iop.kcl.ac.uk 
 
CONSENT FORM  
If you have come to the decision of entering the study after carefully weighting 




Title of project: Genetics and Psychiatric illness (GAP) 
Researcher: Dr Marta Di Forti, Institute of Psychiatry  
 
1.  I have read the information sheet and I have been given a copy. I was 
given the opportunity to ask questions. I understand why the research is being done and 
the risks involved. 
2.  I agree to give a sample of blood/cheek swab and saliva samples for 
research in the above project. I understand how the sample will be collected, that 
giving the sample is voluntary and that I am free to withdraw at any time without giving a 
reason, and without my medical treatment or legal rights being affected. I understand 
that I will be contacted in the future to repeat part of the assessment. 
3.  I understand that research using the sample I give will involve genetic 
analysis aimed at understanding the role of genes in disease and response to drugs,  
that the data produced are for research  rather than clinical purposes, and that these 
results will have no implications for me personally.  
4. I understand I will not receive any 'test' results from this study, because 
the assessment I will undergo, does not produce clinically relevant information but just 
research data. The project newsletter will describe the general importance of any 
research results obtained.   
5.  I give permission for my previous research records to be looked at,  
and information from them to be analysed in strict confidence by responsible 
professional staff from the research team. Researchers external to the study team, 
collaborating in the project (including commercial collaborations) will only access my 
coded data. 
6. I agree that the samples I have given and the information gathered about 
me can be examined and stored (for 5 years) at the Institute of Psychiatry.  I 
understand that future research may be performed by researchers other than those who 
conducted the first project, including researchers from commercial organisations. To 
guarantee confidentiality, I agree that researchers external to the study team, including 
those from commercial collaborators, will only have access to coded data and not to 
personal details. Any future research will only persue aims related to the topic of this 
project,and any extension of the project beyond 5 years, will be subjected to review by a 
research ethics committee. 
7.  I consent to the input of coded data obtained from my blood sample and 
from the information gathered about me into a computer, to be used for statistical 
analysis and research. I understand I have the right to request, via the study co-
ordinator, to review data concerning me, and to have such data modified if inaccurate, or 
deleted.   
8.  I understand I will not benefit financially if this research leads to the 
development of a new treatment or medical test but my travel expenses will be 
reimbursed. 
 
..................................  .....................  .............................. 
  Name of subject  Date   Signature 
 
..................................  ......................  .............................. 




































Please tick boxes 
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Appendix  5 – SAI-E (Kemp & David, 1997) 
1. “Do you think you have 
been experiencing any emotional 
or psychological changes or 
difficulties?” 
Often   
(thought present most of 






Never  (ask why 




2. “Do you think this means 
there is something wrong with you?” 
(For example, a nervous condition).  
If previous answer was “never” or “no”  ask ;  
“If the doctor(s) and/or others think you have been 
experiencing emotional or psychological changes 
or difficulties do you think there must be something 
wrong with you even though you don’t feel it 
yourself?” 
Often   (thought 
present most of the day, most 
days) 
2 
Sometimes  (thought 
present occasionally) 
1 
Never  (ask why 
doctors / others think so) 0 
Notes/Comments: 
 
3. “Do you think your condition 
amounts to a mental illness or mental 
disorder?” 
Often   (thought 
present most of the day, most 
days) 
2 
Sometimes  (thought 
present occasionally) 
1 
Never  (ask why 









4. “How do you explain 
your condition / disorder / 
illness?” 
Reasonable account given 
based on plausible mechanisms 
(appropriate given social, cultural 
and educational background, e.g. 
excess stress, chemical imbalance, 
family history, etc) 
2 
Confused account, or 
overheard explanation without 
adequate  
understanding or “don’t 
know”  
1 





If score ‘0’ on items 1, 2 and 3 proceed straight to item 6 and score item 5 as 
‘0’. 
 
5. “Has your nervous/emotional 
/psychological /mental /psychiatric 
condition (use patient’s term) led to 
adverse consequences or problems in 
your life?” 
(For example, conflict with others, neglect, 
financial or accommodation difficulties, irrational, 
impulsive or dangerous behaviour). 
Yes (with example) 2 
Unsure  (cannot give 







6. “Do you think your … 
condition (use patient’s term) or the 
problem resulting from it warrants 
(needs) treatment?” 
 
Yes (with example) 2 
Unsure  (cannot give 







7. Pick the most prominent symptoms up to a maximum of 4.  
Then rate awareness of each symptom out of 4 as below.   
(Interviewer to assess which symptoms to rate from previous 
interviews e.g. highest scoring on PANSS and/or from patient’s 
current presentation). 
Examples: 
“Do you think that the belief ... is not really / happening (could you be imagining 
things)?” 
“Do you think the ‘voices’ you hear are actually real people talking, or is it 
something arising from your own mind?” 
“Have you been able 
to think clearly, or do your 
thoughts seem mixed up / 
confused?  Is your speech 
jumbled?” 
“Would you say you 
have been more agitated / 
overactive / speeded up / 
withdrawn than usual?” 
“Are you aware of any 
problem with attention / 
concentration / memory / motivation?” 
 
4 = Definitely  (full awareness) 
3 = Probably (moderate awareness) 
2 = Unsure (sometimes yes, sometimes no) 
1 = Possibly (slight awareness) 
0 = Absolutely not (no awareness) 
 
 
Symptom 1:  
Symptom 2:  
Symptom 3:  
Symptom 4:  






9. “How do you feel when 
people do not believe you? 
(when you talk about ... 
delusions or hallucinations).” 
That’s when I know 
I’m sick  
4 
I wonder whether 
something’s wrong with me 
3 
I’m confused and I 
don’t know what to think  
2 
I’m still sure despite 
what others say 
1 











Mean Score:  
8. For each symptom rated above (up to a maximum of 4), 
ask patient ...  “How do you explain ... (false beliefs, hearing 
voices, thoughts muddled, lack of drive etc.)?” 
 
 
4 = Part of my illness 
3 = Due to nervous 
condition 
2 = Reaction to stress / 
fatigue 
1 = Unsure, maybe one of 
the above 
0 = Can’t say, or 







Compliance to treatment/therapy/medication 
NOTE: 
Patient’s primary nurse to rate following three items (A C). 
 
A. How does patient accept 
treatment (includes passive 
acceptance)? 
Often (may rarely 
question need for treatment) 
2 
Sometimes (may 
occasionally question need 
for treatment) 
1 
Never  (ask why) 0 
Notes/Comments: 
 
B. Does patient ask for 
treatment unprompted? 
Often (excludes 
inappropriate request for 
medication etc.) 
2 
Sometimes (rate here 
if forgetfulness / 
disorganization leads to 
occasional requests only) 
1 
Never  (ask why 




C. Summary of compliance to 
treatment/therapy/medication. 
Complete refusal      
         
      
1 




Reluctant acceptance (accepting only because treatment is 




Occasional reluctance about treatment (questioning the need 





Passive acceptance 5 
Moderate participation  (some knowledge of and interest in 
treatment and no prompting needed to take the drugs) 
    
6 
Active participation (ready acceptance, and taking some 
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